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Abstract
ii
The main aim of this thesis is to investigate the role of computerised record linkage in 
clinical trial and epidemiological follow-up. This is illustrated using the West of 
Scotland Coronary Prevention Study (WOSCOPS). This study is placed in context by 
reviewing the results of previous clinical trials and epidemiological studies. Details of 
the probabilistic basis for record linkage techniques and the practical methods used to 
set up a computerised record linkage system are also given. The above ideas are brought 
together in the application of record linkage techniques, as employed in the Scottish 
Record Linkage System, to link the WOSCOPS subjects to their morbidity and mortality 
records on the Scottish national databases. The data resulting from the linkages are 
considered in various ways. A comparative study was carried out for the subjects 
randomised into WOSCOPS. The availability of two separate adverse event databases, 
one produced by routine subject follow-up and the other derived by computerised record 
linkage, provided a unique opportunity to assess the completeness and accuracy of each 
of the follow-up methods, and the benefits of a system incorporating both methods. This 
study found that record linkage compared well with traditional methods of follow-up in 
terms of completeness, accuracy, speed and cost. Record linkage provided the only 
feasible method by which adverse event records could be obtained for the large cohort 
of subjects screened for WOSCOPS. The data for the screened cohort were analysed in 
relation to categories of baseline risk factors. Data were categorised to maintain subject 
anonymity since informed consent was not available for all screenees. Analysis of this 
large cohort provided results which were in agreement with the previous studies. The 
mortality rates observed for the screened cohort using record linkage were finally 
compared to the mortality rates for the general population in the screening area. This 
provides an assessment of how representative the screened cohort is of the general 
population. It was found that the general population in the screening area tended to have 
higher mortality rates than the screened cohort.
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Chapter 1 
Introduction
1
1.1 Risk factors for coronary heart disease
1.1.1 Overview
Coronary heart disease (CHD) became a disease of epidemic proportions in the West as 
economic development progressed and deaths due to infectious diseases decreased 
(Marmot, 1992). In the UK this transition occurred in the 1920s. CHD and cancer 
combined caused approximately the same number of deaths as infectious diseases in 
1921, but by 1931 they had become the major causes of death in both men and women. 
However, in the West, coronary heart disease is now in decline (Figure 1.1), particularly 
in higher socio-economic groups, while it is on the increase in developing countries, 
with Eastern Europe now showing the same decline in life expectancy that Western 
Europe did until the 1950s and 1960s (Marmot, 1992). The observed decrease in CHD 
in the higher socio-economic groups in Western Europe is thought to be mainly due to 
decreases in dietary cholesterol and saturated fat intake, decreases in cigarette smoking, 
decreases in blood pressure levels due to increased use of antihypertensive drug 
treatment, and increased leisure time physical activity in the more educated population 
strata.
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Figure 1.1 Trend in coronary heart disease deaths in Scotland for Males and Females age 45-64  
from 1980 to 1993 (Data from Annual Reports o f the Registrar General for Scotland).
Risk factors for coronary heart disease which are unmodifiable include age, sex and a 
family history of CHD. Older men with a family history of CHD are at greater risk. 
Diabetes is also a risk factor although it is of much lower prevalence in the population 
than the other risk factors. Other coronary heart disease risk factors are modifiable. 
These include cigarette smoking, hypertension, obesity and elevated blood cholesterol. 
Hypertension, obesity and serum cholesterol are all influenced by ‘rich diet’. Experience 
in Japan has shown that in the absence of ‘rich diet’ there is no CHD epidemic, even 
with high rates of smoking. The risk of coronary heart disease increases substantially 
when several factors are present. It is now acknowledged that coronary heart disease is a 
multifactorial process, with no one factor strictly determinative, essential or sufficient 
alone to produce the disease. In every instance, the risk associated with any factor has 
been found to vary according to the combination of other risk factors present. Thus a 
combined approach to the risk factors would seem to be sensible since they are 
frequently found clustered together. The major risk factors appear to be aetiological 
because they are strong and dose-related, predictive in a variety of population samples, 
independent of other risk factors, pathogenetically plausible and supported by clinical 
investigations (Inter-Society Commission for Heart Disease Resources, 1984). For 
example, the strength, consistency and graded nature of the relation between plasma
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cholesterol and mortality from CHD make any explanation of the link other than a 
causal one extremely unlikely (Marmot, 1994). The size of the association between 
cholesterol and CHD mortality becomes even larger after correction for regression 
dilution bias, which arises from the random fluctuation of serum cholesterol 
concentration in subjects over time, and the surrogate dilution effect, which arises from 
the close relationship between total cholesterol concentration and low-density 
lipoprotein (LDL) cholesterol concentration (Law, Wald, Wu et al, 1994). The following 
sections will discuss each of the main CHD risk factors in greater detail.
1.1.2 Cholesterol
At all ages, the atherogenic potential of serum total cholesterol has been shown to derive 
from the LDL cholesterol fraction which is positively related to CHD incidence 
(Kannel, 1983). LDL cholesterol and high-density lipoprotein (HDL) cholesterol are the 
2 main components of total serum cholesterol. LDL normally accounts for between 60 
and 80 per cent of total serum cholesterol. It picks up cholesterol in the gut and dumps it 
in tissue, leading to a build-up of deposits. LDL cholesterol is known to transfer from 
plasma to the arterial wall at a rate which is directly related to its plasma concentration 
(Lewis, 1992). LDL cholesterol can be lowered slightly by diet, but large decreases 
require drug intervention. HDL normally accounts for between 15 and 25 per cent of 
total serum cholesterol, and it’s role is to pick up cholesterol and transport it to the liver, 
so that it is flushed out of the body. HDL cholesterol has been shown to be inversely 
related to CHD incidence, which is consistent with it’s metabolic role in removing 
cholesterol from the tissues (Kannel, 1983). HDL levels can be increased by exercise 
(Goldberg, 1989). Reflecting this 2-way traffic in cholesterol, the ratio of total to HDL 
cholesterol has been shown to be an efficient and convenient measure of lipid risk 
profile (Kannel, 1983) and a strong predictor of mortality (Goldbourt et al, 1985). The 
remaining component of total serum cholesterol is very-low-density lipoprotein (VLDL) 
cholesterol. Triglyceride is another important lipoprotein. It makes up most of the 
dietary fat consumed in industrial nations, and has been shown to be an independent risk 
factor for CHD in women, although it is not such a powerful predictor in men,
4
particularly after adjustment for HDL cholesterol levels with which it is correlated 
(Thelle, 1991).
Total serum cholesterol levels also rise with age. For women, the gradient of this rise 
increases sharply around age 35, while for men the slope levels off around age 45, as 
can be seen from Figure 1.2.
250
women% 240 
O)
E 230
oL_ 220 menCD
co0
oszo
210
200
CO 190
180
20-24 25-34 35-44 45-54 55-64 65-74
age group
Figure 1.2 Mean total cholesterol levels according to age and gender (Data from the National Health and 
Nutrition Examination Survey II (Fulwood et al ,1986)).
In general, women have higher concentrations of HDL cholesterol than men (10 mg/dl 
or 0.26 mmol/1 higher on average) which change little with age (Harlan and Manolio, 
1992), and lower concentrations of LDL cholesterol until the menopause. This leads to 
women being exposed to cholesterol risk later in life than men, with coronary heart 
disease occurring an average of 7-10 years later in women than in men (Hulley et al, 
1992) (see also the death rates for 45-64 year old men and women in Figure 1.1). After 
the menopause, the combination of rising LDL cholesterol and unchanging HDL 
cholesterol creates a less favourable risk profile for women. Post-menopausal oestrogen
5
replacement therapy has been shown (in the Lipid Research Clinics Program Follow-up 
Study) to increase HDL cholesterol and lower LDL cholesterol, leading to 40-50% 
fewer CHD events and lower overall mortality (Bush et al, 1987) but there may be other 
risks associated with this therapy.
Published studies vary in their units of cholesterol measurement. For reference:
1 mg/dl = 0.026 mmol/1
The British Hyperlipidaemia Association has issued guidelines on strategies for 
reducing coronary heart disease, and desirable limits for blood lipid concentrations 
(Shepherd et al, 1987). The recommended total cholesterol concentration is one below
5.2 mmol/1 (200 mg/dl). Any subject in the general population with cholesterol level >
5.2 mmol/1 should receive dietary advice, >6.5 mmol/1 (250 mg/dl) should receive 
clinical supervision and possibly drug intervention, although drugs will be required 
mainly by patients with cholesterol level >7.8 mmol/1 (300 mg/dl), most of whom will 
suffer from familial hypercholesterolaemia.
Cholesterol measurement alone would not make an optimal screening test to detect 
those at high risk of CHD because of the substantial overlap between the relative 
frequency distributions of cholesterol levels for those who do and do not develop CHD 
(Pooling Project Research Group, 1978). Stress, dietary variation, acute illness, seasonal 
effects, posture and aspects of the blood sampling technique can all cause changes in 
cholesterol levels (Gordon et al, 1987; Hegsted and Nicolosi, 1987). It has been 
estimated that for cholesterol measurements taken one year apart, with no concurrent 
lipid intervention, the within-person coefficient of variation is 7%, compared with a 
between-person coefficient of variation of 15% (Thompson and Pocock, 1990).
1.1.3 Smoking
Cigarette smoking is also a major risk factor for coronary heart disease although it may 
be of less primary importance than dietary factors. The Seven Countries Study (Keys, 
1980) found that smoking was a strong risk factor for CHD mortality and incidence in 
the USA, but only a weak risk factor in Japan. The strength of smoking as a risk factor
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may be related to the background level of risk as determined by diet and levels of 
plasma lipids. Cigarette smoking has a greater influence in men than women and it’s 
effects appear to be reversible on cessation (Kannel et al, 1984).
1.1.4 Fibrinogen
It is said that about half of the risk associated with cigarette smoking could be attributed 
to higher levels of plasma fibrinogen. Each standard deviation increase in fibrinogen has 
been found to be associated with a 1.6-fold increase in CHD incidence, a risk ratio close 
to that observed for cholesterol (Kannel, 1992). Fibrinogen and factor VII are two of the 
main determinants of the formation of clots, and thus influence thrombosis. They have 
been shown to be strong and independent risk factors for CHD in middle-aged 
populations (Harlan and Manolio, 1992; Kannel et al, 1987). High fibrinogen levels 
increase viscosity, enhance platelet aggregability and contribute to the development of 
atheroma, at least in its more advanced stages (Meade, 1987). The main environmental 
determinant of fibrinogen levels is smoking, with which there is a dose-response 
relationship (Wilkes et al, 1988), although fibrinogen levels are also associated with 
increased CHD risk in non-smokers (Meade et al, 1986). Thrombosis-related 
mechanisms can also be favourably influenced by dietary intake of fish oil. Fish oil also 
affects serum lipids, with the greatest changes occurring in the lowering of triglyceride 
levels (Elwood, Burr and Sweetman, 1992).
1.1.5 Diabetes
The relative risk of CHD incidence in diabetics compared to non-diabetics has been 
found to be higher in women than in men (Kannel, 1985), so that, for diabetics, the sex 
differences in CHD risk are virtually abolished. In men, this relative risk of CHD for 
diabetics compared to non-diabetics has been estimated as 2.4, while in women it was 
5.1. Risk levels become even higher if the diabetes is insulin-dependent.
1.1.6 Obesity
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Obesity, defined as an excess of body fat, frequently results in a significant impairment 
to health. The most simply measured and widely used index of body fat is Body Mass
Index, BMI = we*&kj- . This is also known as Quetelet’s index and is strongly 
height2
correlated with more direct estimates of body fatness such as body density (Keys et al, 
1972) or total body potassium (Larsson et al, 1981). Studies of large cohorts have found 
a U-shaped relationship between obesity and all-cause mortality (Larsson, 1992) with 
the optimum BMI being between 22 and 29 kg/m2 for middle-aged subjects. Thinness is 
associated with mortality from obstructive lung disease, tuberculosis and stomach and 
lung cancer (Waaler, 1983), while the association between obesity and longevity has 
shown conflicting results due to short follow-up and small studies (Manson et al, 1987). 
Most larger studies have found general obesity to be an independent risk factor for CHD 
in both men and women (Rissanen et al 1989; Manson et al 1990), although obesity is 
also important through its close links with the development of other risk factors over 
time, including an association between obesity and smoking, and the obvious 
relationship between obesity and cholesterol levels via diet. Some recent studies have 
suggested that abdominal obesity (sometimes estimated by abdominal skinfold 
thickness) may be more closely related to CHD than general obesity (Hartz et al, 1990), 
with relative risks for abdominal obesity indicating almost as strong a risk as for the 
major CHD risk factors.
1.1.7 Lack of Exercise
Vigorous physical activity, especially aerobic exercise, has been associated with lower 
CHD incidence in a wide variety of populations (Morris et al 1980; Donahue et al 1988; 
Leon et al 1987). Adequate, habitual aerobic exercise in leisure time improves cardio­
respiratory fitness and performance and thus confers protection against the occurrence of 
CHD. Its effect mainly relates to the acute phases of the disease, such as thrombosis,
although it is also of some benefit in counteracting standard risk factors (Morris, 1992), 
for example its role in raising HDL cholesterol levels. (Goldberg, 1989)
1.1.8 Blood Pressure
Despite the strong independent effects of blood pressure on CHD incidence, controlled 
trials have been inconclusive (MacMahon et al, 1986). This may be due to the 
antihypertensive agents used having adverse effects on other CHD risk factors, which 
cancel out the benefits of reduced blood pressure (Poulter, 1991). Exposure to blood 
pressure risk can also be influenced by salt intake, obesity and alcohol intake. It is 
thought that diastolic blood pressure is more closely related to cardiovascular disease 
before age 45, while systolic blood pressure is a better predictor after age 45 (Dame et 
al, 1989).
1.1.9 Alcohol
There has been some evidence from recent studies that alcohol consumption may have a 
‘protective’ effect in lowering coronary heart disease risk. Hartung et al, (1983), 
suggested that this effect may be due to higher levels of high density lipoprotein in 
drinkers. This must however be balanced against the increased risk of death from other 
causes with high alcohol consumption. Alcohol raises HDL cholesterol, but this benefit 
may be offset by induced rises in blood pressure and triglyceride. There are problems 
with the measurement of alcohol consumption in that it may vary considerably from one 
point in time to another, which may have an effect on the predictive relevance of 
recorded consumption at any given point in time. The ‘non-drinkers’ group may also 
include people who have recently stopped drinking because of health problems, which 
will lead to bias and difficulty in interpreting associations.
1.1.10 Social Class
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Social class has also shown interesting relationships with coronary heart disease. The 
Black Report (Black et al, 1988) concluded that social class differences in health are due 
to material conditions of life that are correlated with income levels, for example, 
nutrition and smoking. Further investigation is needed into risk factors which may 
account for socio-economic differences in health.
1.1.11 A look forward
This thesis will focus on the West of Scotland Coronary Prevention Study (WOSCOPS), 
(see Chapter 2). WOSCOPS has measured all of the above mentioned risk factors, 
although it’s primary interest is in serum cholesterol. Cigarette smoking is an important 
risk factor which should always be considered, and alcohol has become of increasing 
interest in recent years. WOSCOPS also included a measurement of fibrinogen, 
currently emerging as a potentially important risk factor. Investigation into relationships 
among the above risk factors and various disease outcomes will be carried out primarily 
using the large cohort of subjects screened for WOSCOPS.
1.2 Evidence from epidemiology
1.2.1 The Framingham Heart Study
The Framingham Heart Study, one of the longest-running epidemiological studies, 
began in 1948 and has followed up a cohort of 5070 men and women, age 35-64 and 
living in the area of Framingham, Massachusetts, for over 30 years, with participants 
being examined every two years. It found (Stokes et al, 1987) that hypertension, total 
cholesterol, smoking and obesity are the major risk factors for cardiovascular disease.
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Consideration of 3 sub-cohorts of the Framingham population, men age 50-59 at each of 
1st January 1950, 1960 and 1970, showed (Sytkowski et al, 1990) that there has been a 
decline in the mortality from cardiovascular disease over the past 30 years. Comparison 
of the 1950 cohort with the 1970 cohort, for men who were free from cardiovascular 
disease at baseline, indicates that this decrease may be due to an improvement in the 
cardiovascular risk factors, with the 1970 cohort displaying lower serum cholesterol and 
systolic blood pressure, and reduced cigarette smoking. Analysis of 24 years of follow- 
up of the Framingham cohort (Friedman and Kimball, 1986) found a negative 
relationship between alcohol consumption and coronary heart disease for all males, and 
for female smokers, with no relationship for female non-smokers. In non-smokers, beer 
and wine consumption showed greater reductions in coronary heart disease mortality 
than consumption of spirits.
1.2.2 The Whitehall Study
The Whitehall Study examined mortality in 10 years of follow-up from initial screening 
between 1967 and 1969, for 17,530 office-based male civil servants in London. This 
study found a steep inverse relation between civil service employment grade and 
mortality. Men in the lowest employment grade had 3 times the mortality rate from 
CHD as men in the highest grade (Marmot et al, 1984). Smoking and other coronary risk 
factors are more common in the lower grades, but they account for only part of the 
difference in mortality. Consideration of the 1422 men in this study who had completed 
dietary records, revealed a U-shaped relationship between alcohol consumption and 
mortality (Marmot et al, 1981). This relationship was just as strong after excluding the 
first 2 years of follow-up, making it less likely that the high mortality among 
‘abstainers’ was due to people giving up alcohol because they were already sick. 
Exclusion of the first two years of follow-up removed the U-shaped relationship 
between total mortality and plasma cholesterol, and left a positive relationship between 
them (Rose and Shipley, 1980).
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1.2.3 The Multiple Risk Factor Intervention Trial
The Multiple Risk Factor Intervention Trial (MRFIT) required a large screening 
exercise, which involved over 300,000 men aged between 35 and 57 at baseline in 1973- 
1975, from 18 US cities (Kannel et al, 1986). Analysis of this large cohort confirmed the 
independent effects of serum cholesterol concentration, blood pressure and cigarette 
smoking as risk factors for coronary heart disease and all-cause mortality, although the 
strength of the associations diminished with increasing age. The relationships between 
age-adjusted CHD mortality and quintiles of serum cholesterol and systolic blood 
pressure (SBP) and baseline cigarette smoking are shown in Table 1.1. These indicate 
that CHD increases with serum cholesterol for both smokers and non-smokers, and 
CHD increases with SBP quintile at every level of cholesterol for both smokers and 
non-smokers. A similar pattern appears with diastolic pressure (Stamler et al, 1989).
Serum Total Choi (mg/dl) <118
Systolic
118-124
Pressure
125-131 132-141 >142
Non-smokers
<182 3.09 3.72 5.13 5.35 13.66
182-202 4.39 5.79 8.35 7.66 15.80
203-220 5.20 6.08 8.56 10.72 17.75
221-244 6.34 9.37 8.66 12.21 22.69
>244 12.36 12.68 16.31 20.68 33.40
Smokers
<182 10.37 10.69 13.21 13.99 27.04
182-202 10.03 11.76 19.05 20.67 33.69
203-220 14.90 16.09 21.07 28.87 42.91
221-244 19.83 22.69 23.61 31.98 55.50
>244 25.24 30.50 35.26 41.47 62.11
Table 1.1 Baseline cigarette smoking, quintiles o f serum cholesterol, systolic pressure and age-adjusted 
CHD mortality per 10,000 person-years for men screened for the MRFIT.
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A distinct escalation of risk was noted for combinations of these three risk factors. It 
was estimated that elimination of these risk factors had the potential for reducing the 
coronary heart disease mortality rate by two thirds in 35-45 year old men, and by half in 
46-57 year old men. The relationship between coronary heart disease death and serum 
cholesterol quintile observed in the MRFIT study is illustrated in Figure 1.3 (Kannel et 
al, 1986), which also shows that risk increases with age.
25 age 55-57
20
/  age 50-54
15
age 45-49
10
age 40-44
5 age 35-39
0
<182 >244182-202 203-220 221-244
quintiles of serum cholesterol distribution (mg/dl)
Figure 1.3 Relationship between coronary heart disease death and serum cholesterol quintile for various 
age bands observed in the MRFIT.
Further analysis of the MRFIT screening data (Martin et al, 1986) showed that above the 
20th percentile for serum cholesterol (>181 mg/dl, or >4.68 mmol/1), coronary heart 
disease mortality increased progressively. Using men below the 20th percentile as a 
baseline risk group, half of all coronary heart disease deaths were associated with raised 
serum cholesterol concentrations, and half of these excess deaths occurred in men with 
cholesterol levels above the 85th percentile (>253 mg/dl, or >6.54 mmol/1). Diastolic 
blood pressure had a risk curve shaped similarly to cholesterol, for both coronary heart 
disease and total mortality (that is, a positive slope for the relationship with CHD and a 
J-shaped relationship with total mortality).
1.2.4 The British Regional Heart Study
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HDL cholesterol and triglycerides were examined in relation to total serum cholesterol 
in the British Regional Heart Study (BRHS) (Pocock et al, 1989). This risk factor survey 
involved 7735 men aged 40-59, between 1978 and 1980, selected from general practices 
in 24 British towns chosen to reflect regional variations in CHD, including 3 in Scotland 
(Ayr, Dunfermline and Falkirk). 99% of these men were traced to their current GP 
between 9.5 and 11 years after screening, for follow-up purposes. Data collected 
included a standard questionnaire, physical measurements, blood samples, ECGs and 
measurements of respiratory function (Shaper and Elford, 1992). The BRHS found that, 
after adjusting for HDL and other risk factors, men in the highest quintile of the total 
cholesterol distribution were at 3.5 times the risk of ischaemic heart disease as men in 
the lowest quintile. Conversely, men in the lowest quintile of HDL concentration were 
at twice the risk of men in the highest quintile after adjusting for total cholesterol 
concentration and other risk factors. Triglycerides did not have a predictive importance 
once other risk factors had been taken into account. Consideration of place of birth 
information revealed that geographic zone of examination was a more important risk 
factor for CHD than zone of birth (Elford et al, 1989). Inter-town variation in CHD 
mortality was found to be associated with mean blood pressure, % of men with 
hypertension, current cigarette smoking, heavy drinking and the % of manual workers 
(Shaper and Elford, 1992). This study also found that ischaemic heart disease mortality 
rates were higher in manual than in non-manual workers (Pocock et al, 1987), with 
much of this increased risk being due to differences in cigarette smoking. Manual 
workers also had higher blood pressure, were more obese and took much less physical 
activity in leisure time. Although adjustment for these factors narrowed the gap between 
the two groups, manual workers still had a 24% excess of ischaemic heart disease 
events.
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1.2.5 The Scottish Heart Health and Scottish 
MONICA Studies
Scotland has a reputation for very high coronary heart disease mortality rates. Data from 
the World Health Organisation (WHO), on coronary heart disease mortality from 1969 
until 1981 in North America, Japan, Europe and Australasia, showed (Figure 1.4) that 
Scottish rates were among the highest, although the rate for males has been falling 
(Tunstall-Pedoe et al, 1986; and Figure 1.1). It also showed that, in the 40-69 year old 
age band, female rates correlate very strongly with male rates for the same country, 
although they are only 20-30% of the male rates (see Figure 1.1).
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Figure 1.4 Age-standardised coronary heart disease mortality rates (per 100,000) for males age 40-69  
(from Tunstall-Pedoe et al, 1986).
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The Scottish Heart Health Study (SHHS) (Smith et al, 1989), a study of lifestyle and 
coronary heart disease risk factors measured between 1984 and 1986, in 10,359 men and 
women aged 40-59 in 22 of the 56 local government districts of Scotland, found that 
high cholesterol and cigarette smoking provided a classical explanation for the excess of 
coronary deaths in Scotland, but other factors such as dietary deficiencies merited 
further investigation. Considering one of the less frequently studied CHD risk factors, 
the SHHS observed that fibrinogen levels in men and women increased with age and 
were slightly higher in women than in men at each age group as shown in Table 1.2 
(Smith et al, 1989). There was a weak association observed between fibrinogen levels 
and district smoking levels (Tunstall-Pedoe et al, 1989).
Age (years) Mean values g/1 (s.d.)
Men Women
40-44 2.18(0.62) 2.22 (0.64)
45-49 2.27 (0.66) 2.30 (0.62)
50-54 2.35 (0.73) 2.46 (0.69)
55-59 2.43 (0.71) 2.52 (0.74)
Table 1.2 Fibrinogen levels in the Scottish Heart Health Study
The main objectives of the SHHS were (Smith et al, 1987) to establish levels of 
coronary heart disease risk factors, explain geographical variation and assess the relative 
contribution of the risk factors, in the Scottish context, as well as to explain why 
Scotland as a whole has such a high coronary heart disease mortality rate. The SHHS 
found (Tunstall-Pedoe et al, 1989) that coronary mortality rates over 5 years varied 
between districts in Scotland by a factor of 2 in men and 3 in women, with lower rates 
generally being in the East, and higher rates in the West of Scotland. The SHHS 
observed an association between coronary heart disease mortality and % male 
unemployment, % in social class 3-5 and rainfall, explaining 73% of the geographical 
variation in mortality (Crombie et al, 1989). The SHHS followed the WHO protocol and
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also included subjects in the age range of 40-59 from the WHO MONICA study, from 
Edinburgh and Glasgow, bringing the cohort size to approximately 12,000.
The aim of the MONICA Project was to measure the trends in and determinants of 
cardiovascular disease over 10 years in many different populations (WHO MONICA 
Project Principal Investigators, 1988). It’s original design placed more emphasis on 
longitudinal measurement within each centre than on the comparability among centres. 
It involved 41 collaborating centres world-wide, resulting in a population of around 15 
million men and women aged 25-64. In the Scottish branch of the MONICA Project, 
population surveys of coronary risk factors took place simultaneously in Edinburgh and 
north Glasgow in 1986. Comparison of these cohorts found that Glasgow in the west 
had a much higher cardiovascular mortality rate than Edinburgh in the east. This was 
related to the fact that major coronary risk factors were higher in north Glasgow than in 
Edinburgh, with the exception of serum lipids which were not significantly different 
(Smith et al, 1990). Again, with the exception of serum lipids, the risk factors were 
related to socio-economic status, so that most of the differences between the two cities 
disappeared after adjustment for housing tenure. So the socio-economic differences in 
coronary heart disease and its major risk factors may explain the apparent differences in 
CHD mortality rates between east and west Scotland.
1.2.6 Other studies looking at alcohol consumption
The findings in the Framingham cohort (see section 1.2.1) and the Whitehall study (see 
section 1.2.2) were in agreement with a review of ischaemic heart disease deaths in 18 
developed countries (St Leger et al, 1979) which found a strong negative association 
between ischaemic heart disease deaths and alcohol consumption which was wholly 
attributable to consumption of wine. This effect may be due to trace components found 
in wine.
However, examination of the Malmo birth cohort of 4571 men bom between 1926 and 
1929 and screened between 1974 and 1978 (Petersen et al, 1980) found that heavy 
alcohol consumption was the single most important risk factor associated with
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premature death from any cause in these middle-aged Swedish men, with serum 
cholesterol being an inverse risk factor.
In Britain, this relationship was examined via a postal questionnaire, sent to surviving 
male doctors (12,321 of whom replied) in 1978, with mortality follow-up until 1991. 
These men had originally been involved in the study into the effects of smoking which 
began in 1951. This study considered 7 categories of alcohol consumption and found a 
U-shaped relationship between alcohol consumption and all-cause mortality, with the 
lowest risk group being consumption of 8-14 units/week (Doll et al, 1994). However, 
all-cause mortality increases with amount drunk above 21 units per week.
The Albany Study (Gordon and Doyle, 1986) carried out in 1971-72 on 1910 civil 
service employees who had been enrolled into an earlier study in 1953-55 found that 
alcohol consumption was positively related to cigarette consumption, blood pressure 
and HDL cholesterol (although cigarette consumption was negatively related to HDL 
cholesterol). Thus the apparent alcohol effect may depend on other concurrent 
behaviour.
1.2.7 Overview Studies
Simons (1986) examined the coronary artery disease mortality rates for 19 countries, 
whose rates had previously been published by WHO. He found that, for men, 45% of the 
interpopulation variation in coronary artery disease mortality could be explained by 
interpopulation differences in total serum cholesterol levels, 32% by the variation in 
HDL cholesterol, and 55% by variation in the ratio total cholesterol/HDL cholesterol. 
For women, total cholesterol/HDL cholesterol was the only significant correlate of the 
coronary artery disease mortality rate, and explained 31 % of the variation.
A more recent analysis of prospective cohort studies (Law, Wald and Thompson, 1994) 
showed that the size of the decrease in coronary heart disease incidence as cholesterol 
decreased was related to age. There have been at least 60 cohort studies of serum 
cholesterol and CHD, but this analysis has been restricted to the 10 largest published 
studies, which together involved 494,804 men. 7 of these studies considered only CHD
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mortality, but 3 also considered non-fatal infarcts. A 0.6 mmol/1 decrease in cholesterol 
(approximately 10% decrease) resulted in a decrease in coronary heart disease incidence 
of 54% on average, at age 40, but an average decrease of only 39% at age 50 and 27% at 
age 60. A cholesterol decrease of up to 0.6 mmol/1 could be achieved by moderate 
dietary change without resorting to drug intervention which could reduce serum 
cholesterol by up to 1.2 mmol/1 (approximately 20%).
1.2.8 Summary
These epidemiological studies support the relationships between CHD and the various 
risk factors described in section 1.1. They show that CHD risk is greater with raised 
cholesterol levels, high blood pressure and cigarette smoking, and have conflicting 
results with regard to the association between CHD and alcohol consumption. The 
Whitehall Study, the BRHS and the WHO MONICA Study have revealed interesting 
associations between socio-economic status and CHD which merit further investigation. 
The WOSCOPS study, which will be dealt with in this thesis will address these 
epidemiological issues through analysis of the cohort of subjects who came for initial 
screening.
1.3 Evidence from clinical trials
1.3.1 The Multiple Risk Factor Intervention Trial
The Multiple Risk Factor Intervention Trial (MRFIT) was a randomised primary 
prevention trial, involving approximately 12,000 35-57 year old men who were in the 
upper 10-15% of CHD risk. Screening for this study took place between 1973 and 1975, 
and it was designed to test the effect of a multifactor intervention program on mortality 
from coronary heart disease (MRFIT Research Group, 1982). The MRFIT was special in 
that it took a multiple factor approach, while the vast majority of clinical trials involve
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only unifactor intervention. The ‘special intervention’ group received counselling for 
cigarette smoking, treatment for hypertension and dietary advice for lowering blood 
cholesterol. The control group relied on their usual sources of health care in the 
community. Follow-up was for an average of 7 years, but the difference in CHD 
mortality between the two groups was not statistically significant (there were 17.9 
deaths per 1000 in the intervention group and 19.3 deaths per 1000 in the control 
group). It has been suggested that this may have been due to the decline of risk factor 
levels in both groups, resulting in a lower than expected mortality in the control group, 
or to unfavourable responses to antihypertensive drugs in some subjects in the treatment 
group.
1.3.2 Primary Prevention Trials of Cholesterol 
Lowering drugs
The three largest primary prevention trials of cholesterol reducing agents are described 
below.
The WHO Clofibrate Trial was started in 1965 to test the hypothesis that ischaemic 
heart disease incidence in middle-aged men could be reduced by lowering raised serum 
cholesterol levels. It involved 15,745 men from 3 European centres - Edinburgh, 
Budapest and Prague, approximately 10,000 of whom fell in the upper third of the 
cholesterol distribution determined from the 30,000 screened volunteers, and 
approximately 5000 from the lower third to be used as a second control group. The men 
with raised cholesterol were randomised to either clofibrate or placebo (Committee of 
Principal Investigators, 1978). A mean reduction of approximately 9% of the initial 
serum cholesterol values was achieved in the treatment group, resulting in a 20% 
decrease in the incidence of ischaemic heart disease, compared to the high cholesterol 
controls. The low cholesterol group showed substantially lower rates of ischaemic heart 
disease than either of the high cholesterol groups. The trial thus supported the 
hypothesis that lowering high serum cholesterol could reduce the incidence of ischaemic 
heart disease. However, this drug was not recommended for community-wide primary
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prevention because of concerns regarding adverse reactions to the drug clofibrate. A 
further four years of follow-up until the end of 1982, giving a total mean follow-up of 
13.2 years with a mean of 5.3 years in the trial and 7.9 years beyond the end of the trial 
revealed that the excess mortality in the clofibrate treated group did not continue after 
the end of treatment. There was an excess mortality of 47% during treatment, but only 
5% after treatment ended. The authors were unable to explain the substantial excess of 
non-coronary mortality during the trial (Committee of Principal Investigators, 1984).
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a 
multi-centre randomised trial of the cholesterol lowering drug cholestyramine vs. 
placebo. Screening took place from 1973 to 1976 in 12 lipid research clinics across the 
US, to identify 3806 middle-aged men with primary hypercholesterolaemia, who also 
followed a moderate cholesterol lowering diet over the average of 7.4 years follow-up 
for the trial. The treatment group showed a 24% reduction in definite coronary heart 
disease death and a 19% reduction in non-fatal myocardial infarction in conjunction 
with an average 13.4% reduction in plasma total cholesterol and a 20.3% reduction in 
LDL cholesterol. These reductions were 8.5% (for total cholesterol) and 12.6% (for 
LDL cholesterol) greater than those obtained in the placebo group, which was also on 
the cholesterol lowering diet (Lipid Research Clinics Program, 1984, Part I). The 
cumulative seven year incidence of coronary heart disease death or non-fatal myocardial 
infarction was 7% in the cholestyramine group and 8.6% in the placebo group. The 
active treatment group also had lower rates of new positive exercise tests, angina and 
coronary bypass surgery. Small increases in HDL cholesterol which also accompanied 
cholestyramine treatment independently accounted for a 2% reduction in CHD risk 
(Lipid Research Clinics program, 1984, Part II). The risk of death from all causes was 
not however significantly reduced in the treatment group, which had a greater number of 
violent and accidental deaths which were not thought to be related to cholestyramine 
therapy.
The Helsinki Heart Study was a randomised 5 year trial of the safety and efficacy of the 
cholesterol lowering drug gemfibrozil in dyslipidemic middle-aged men. It involved 
4081 Finnish men aged 40-55 with high levels of cholesterol. The study began in 1980 
and was completed in 1987. A reduction of 34% was observed in the incidence of
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coronary heart disease events in men on gemfibrozil treatment. Compared with placebo, 
gemfibrozil produced average decreases of 10% in total serum cholesterol, 11% in LDL 
cholesterol and 35% in triglycerides, and a mean increase of 11% in HDL cholesterol 
over the 5 years of follow-up, with the lipid changes being related to lipid levels prior to 
treatment and compliance with the medication regime. The changes in HDL and LDL 
cholesterol levels were both significantly associated with the reduction in CHD 
incidence rates in the gemfibrozil group after correction for other CHD risk factors 
including age, blood pressure, smoking and drinking habits, baseline lipid levels, 
exercise and relative weight. This study suggested that elevating HDL cholesterol and 
lowering LDL cholesterol are both effective strategies in the primary prevention of CHD 
(Manninen et al, 1988). This study also found (Manninen et al, 1992) that in the placebo
, , , , LDL cholesterol Tgroup the best single predictor of cardiac events was the ratio o f ---------------------- . In
HDL cholesterol
combination with the serum triglyceride level, this ratio revealed a high risk group of 
subjects (representing approximately 10% of the trial population) with ratio > 5 and 
triglycerides > 2.3 mmol/1, which had a relative risk of cardiac events of 3.8 compared 
to all the other subjects. This high risk group received most benefit from treatment with 
gemfibrozil, with a 71% lower incidence of cardiac events in the subgroup at high risk 
and on gemfibrozil than in the corresponding high risk subgroup on placebo.
1.3.3 Secondary Prevention Trials
A review of published studies carried out by Silberberg and Henry (1991) indicated that 
cholesterol lowering to prevent CHD death is of far greater benefit in secondary 
prevention than in primary prevention. The authors calculated that the risk reduction 
achieved by drug therapy in secondary prevention studies of cholesterol lowering was 
3.2%, while in primary prevention studies it was only 0.1%.
One of the most recent secondary prevention trials was the Scandinavian Simvastatin 
Survival Study (4S). This study involved 4444 men and women aged 35-70 with a 
history of angina pectoris or acute myocardial infarction and a serum cholesterol level
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between 5.5 and 8.0 mmol/1. These subjects were randomised to treatment with either 
placebo or simvastatin, an HMG-CoA reductase inhibitor, between May 1988 and 
August 1989. Follow-up was for an average of 5.4 years, ending on 1 August 1994. 
Simvastatin therapy produced mean decreases of 25% in total cholesterol and 35% in 
LDL cholesterol, and a mean increase of 8% in HDL cholesterol. The relative risk of 
coronary death in the simvastatin group relative to the placebo group was 0.58, while for 
all-cause mortality the relative risk was 0.7. There were no significant differences 
between the two groups in terms of non-cardiovascular deaths. The study thus shows 
that treatment with simvastatin is safe, and improves survival in CHD patients post 
myocardial infarction (Scandinavian Simvastatin Survival Study Group, 1994).
1.3.4 Overviews
A meta-analysis by Yusuf et al (1988), of 22 randomised trials (9 primary and 13 
secondary prevention) found a highly significant 23% reduction in risk of non-fatal 
myocardial infarction and CHD death with cholesterol lowering. The authors also 
reported that this reduction was directly related to both the degree and duration of the 
intervention to lower cholesterol levels.
Gordon et al (1989) examined, in American subjects, the inverse relation between HDL 
cholesterol and coronary heart disease as reported in the BRHS (Pocock et al, 1986). 
They looked at four prospective American studies. Two of these studies, the 
Framingham Heart Study and the Lipid Research Clinics Program Mortality Follow-up 
Study, were population based studies, while the other two, the Lipid Research Clinics 
Coronary Primary Prevention Trial and the Multiple Risk Factor Intervention Trial, were 
randomised trials of middle-aged men at high coronary heart disease risk (only the 
control groups were analysed here). On adjusting for age, blood pressure, smoking, body 
mass index and LDL cholesterol there was found to be a consistent inverse relation 
between HDL cholesterol levels and coronary heart disease incidence rates in each of 
these 4 studies with, for example, a 1 mg/dl increment in HDL cholesterol being 
associated with a decrease in cardiovascular mortality of 3.7% in men and 4.7% in
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women in the Lipid Research Clinics Program Mortality Follow-up Study. HDL 
cholesterol levels were found to be unrelated to non-cardiovascular mortality.
In an overview analysis of 16 randomised clinical intervention trials (a mixture of 
primary and secondary prevention, diet and drug trials) of cholesterol reduction (Holme, 
1990) it was found that for every 1% decrease in cholesterol level, there was an 
estimated 2.5% decrease in coronary heart disease incidence. It was also found, 
predictably, that drug trials tended to more efficacy at cholesterol lowering than dietary 
trials, that efficacy was higher in secondary than in primary prevention trials, and that 
efficacy depended on the baseline cholesterol level. This review also showed that while 
a 1% decrease in cholesterol was effective in lowering CHD incidence, the reduction 
must be at least 8-9% to be effective in lowering total mortality.
1.3.5 Summary
Evidence from controlled clinical trials shows convincingly that reducing serum 
cholesterol levels by diet or drug treatment reduces the incidence of coronary heart 
disease (Katan, 1990). Some of these trials have found that while coronary heart disease 
death rates were lower, there was no significant difference in all-cause mortality 
between the treatment and control groups. In the LRC-CPPT this was thought to be due 
to the larger number of violent and accidental deaths in the treatment group. However, 
the actual numbers of violent deaths in the LRC-CPPT was small (11 in the treatment 
group and 4 in the placebo group) so the study had very low power to address this 
outcome. The 4S study is of particular relevance to the WOSCOPS study, which will be 
dealt with later, as it involves a drug belonging to the same family - the HMG CoA 
reductase inhibitors. This study indicated that there may be substantial benefit to 
coronary mortality from this cholesterol lowering therapy, and some benefit for all-cause 
mortality.
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1.4 Concerns about Reduction in 
Cholesterol Levels
While the relationship between high cholesterol levels and coronary heart disease is well 
established, there has been much controversy about a possible relationship between low 
cholesterol levels and cancer. Some epidemiological studies and meta-analyses of 
clinical trials have detected this relationship, but others have found no significant 
relationship, leading to results which, overall, are conflicting and unclear. Although 
previous clinical trials have indicated a decrease in cardiovascular disease with 
cholesterol lowering, meta-analysis has indicated no decrease in total deaths in the 
treatment groups, with an increase in deaths due to suicide and other violence as well as 
to cancers. Evidence relating to these non-cardiac outcomes will now be considered.
1.4.1 Cancer and Cholesterol
I AAA  Epidemiological Evidence
In 1981, Feinleib observed a fairly consistent inverse relationship between baseline 
cholesterol and subsequent cancer mortality in the Framingham Study. For all-cause 
mortality there was a U-shaped relationship (as illustrated in Figure 1.5), indicating that 
there was an optimal range of cholesterol values for which total morbidity and mortality 
might be minimised. He observed these relationships only for men, with no significant 
trends appearing for women.
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Figure 1.5 Age-adjusted mortality rates by serum cholesterol measured at examination 4 o f the 
Framingham Study for men age 35-64.
A cohort of 5209 men and women from the Framingham study had repeat measurements 
of serum cholesterol made biennially, up to 18 years prior to cancer diagnosis (Sorlie 
and Feinleib, 1982). There was a significant inverse relationship, with the principal 
elevation in risk being for men with serum cholesterol less than 190 mg/dl. The 
hypothesis of pre-clinical cancer is refuted by the fact that an association of low 
cholesterol with incident cases occurred up to 18 years after baseline - most oncologists 
would be reluctant to accept that a metabolically active lesion would remain pre-clinical 
for 10 or more years, and the lack of a relationship between cholesterol and cancer in 
women - since it is reasonable to assume that once the cancer process has begun, the 
metabolic consequences for men and women would be similar. An analysis of time 
trends did not yield consistent results for all age groups. In some age groups, cholesterol 
levels were depressed 18 years before diagnosis, while in other age groups, the 
cholesterol level reduced further as the time of diagnosis approached. So low cholesterol 
may be both a precursor and a response to the cancer process.
The Lipid Research Clinics Program Mortality Follow-up Study involving 2753 men 
and 2476 women aged 40-79 at baseline between 1972 and 1976 and followed up until 
1984 found that total cholesterol and LDL cholesterol were significantly inversely
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associated with overall cancer mortality in men but observed no relation for women 
(Cowan et al, 1990). The relatively small numbers of cancer deaths restricted the site- 
specific analysis possible, but for colon cancer the relative risk of men in the lowest 
quartile of cholesterol levels (< 187 mg/dl) compared to the other three quartiles of 
cholesterol was 5.20, after correcting for age, body mass index, cigarette smoking and 
alcohol consumption. From consideration of the survival curves, the authors felt that the 
inverse relation observed in men was not due to pre-existing disease.
Salmond et al (1985) carried out a prospective epidemiological study on New Zealand 
Maoris with 17 years follow-up from first examination in 1962-63, and found a 
significant inverse relationship between serum cholesterol and cancer mortality for both 
men and women, after adjusting for age, systolic blood pressure and body mass index. 
This relationship remained significant after excluding deaths occurring in the first five 
years, indicating that the apparent relationship could not be explained by undetected 
illness.
Tomberg et al (1989) followed up 9217 Swedish men identified by screening between 
1963 and 1965 for 18-20 years and also found a significant relationship between 
cholesterol and cancer incidence and mortality. However, in contrast to Salmond et al, 
they found that this relationship was strongest in the first two years of follow-up, 
consistent with the effect being due, at least in part, to preclinical cancer.
In the Honolulu Heart Program it was possible to consider several cancer sites 
separately. The Honolulu Heart Program examined the relationship between baseline 
serum cholesterol level and subsequent 9 year mortality in a cohort of around 8000 
Japanese-American men age 46-65 who lived on the island of Oahu in 1965 (Kagan et 
al, 1981). There was a strong inverse relationship between serum cholesterol level and 
the subsequent risk of dying from cancer. This association persisted after excluding 
patients with evidence of disease at baseline, excluding deaths occurring in the first 6 
years of follow-up, and adjusting for age, systolic blood pressure, smoking, alcohol 
consumption and relative weight. The only specific site which remained significant after 
these adjustments was cancer of the colon. The risk of death from cancer was nearly
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four times greater in men with serum cholesterol less than 180 mg/dl than in men with 
serum cholesterol greater than 269 mg/dl. In contradiction, a further study on these 
Japanese-American men using 22 years of follow-up (Chyou et al, 1992) found that a 
significant negative association between serum cholesterol and smoking related cancers 
(lung, mouth, larynx, oesophagus, pancreas, bladder) did not persist after adjustment for 
cigarette smoking and alcohol consumption. The Honolulu Heart Program also found 
evidence of a U-shaped relationship between alcohol consumption and all-cause 
mortality (Blackwelder et al, 1980). While coronary heart disease decreased with 
increasing alcohol consumption, other disease outcomes such as cancer and stroke 
increased giving a total mortality picture as in Figure 1.6.
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A retrospective case-control study involving cancer patients, heart patients and controls, 
stratified for gender, age and smoking habit, and followed up for fourteen and a half
per 1000
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years for the Stockholm Prospective Study, with screening between 1970 and 1973 and 
follow-up back to 1963 and forward to 1982 (Gerhardsson et al, 1986), found an 
association between low serum cholesterol and cancer of the large intestine and rectum. 
However, this association was only apparent for a six-year period prior to death. Since 
this paper considers mortality rather than incidence, the low serum cholesterol levels are 
more likely to reflect an effect of preclinical cancer.
For the cohort of 300,000 men screened for the MRFIT between 1973 and 1975, 
mortality follow-up revealed a significant excess of cancer in the lowest decile of serum 
cholesterol level during the early years of follow-up, which decreased over time but had 
not disappeared after an average 7 years of follow-up (Sherwin et al, 1987). This finding 
is consistent with the inference that the association between low serum cholesterol and 
cancer is at least in part due to an effect of preclinical cancer.
During the same time period, a case-control study was carried out in Iowa with 
screening between 1973 and 1975 and follow-up until 1980 (Wallace et al, 1982). 
Controls were matched to cancer cases on age, sex, screening centre and date of 
screening, and the authors found that plasma cholesterol levels were lower among male 
cases and higher among female cases than among controls. The higher cholesterol levels 
in women were mainly for hormone-related cancers, while the lower levels in men were 
mainly for smoking-related cancers.
Meanwhile, in Scotland, the Renfrew and Paisley Survey (Isles et al, 1989), with 
screening from 1972 to 1976 and an average of 12 years of follow-up, found that the 
inverse association between cholesterol and cancer in men was strongest for lung 
cancer, unrelated to age, present for incidence as well as mortality, and persisted even 
when the first 4 years of follow-up were excluded. This study found no consistent 
relationship between cholesterol and smoking, counteracting another possible 
explanation. Out of 21 previous reports on cholesterol and cancer, examined by Isles et 
al, 8 showed no relationship, 12 found an inverse association and 1 found a positive 
association, which was with colorectal cancer.
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A slightly different angle on the question was to consider a population with naturally 
low cholesterol levels. The mean cholesterol level in China is much lower than that 
usually observed in Western populations. A study of 9021 Chinese men and women age 
35-64 in 2 screening cohorts (1972-73 and 1977-78) (Chen et al, 1991) revealed no 
significant association between baseline cholesterol and total mortality from cancer. 
There was however an inverse trend for liver cancer, excluding patients who died in the 
first three years of follow-up. There was also a significant inverse relationship between 
cholesterol and other chronic liver diseases for this population. The authors suggest that 
the lowered cholesterol levels were probably due to the fact that many Chinese suffer 
from long-term chronic hepatitis-B.
In the United States, a case-control study was carried out at the Mount Sinai hospital in 
New York City between 1978 and 1980 to examine cholesterol levels in relation to 
colon cancer (one of the more common cancers in the US). Controls were subjects who 
had entered the hospital for elective surgery. Comparison of 133 case-control pairs, 
matched by age and sex, revealed that colon cancer patients had significantly lower 
serum cholesterol levels than controls (Miller et al, 1981). However, examination of 130 
case-case pairs in which early tumours were matched with advanced tumours found that 
women, although not men, had significantly lower cholesterol levels with advancing 
disease. This supports the idea that, in women at least, low serum cholesterol levels in 
cancer patients may be the result of metabolic influences of tumours.
The National Health and Nutrition Survey Epidemiologic Follow-up Study 
(Kritchevsky, 1992), which was conducted during 1981-84 using subjects who had 
previously been in the probability sample of US civilians used in the National Health 
and Nutrition Examination Survey from 1971-75, found that in females, the 
relationship between low cholesterol and cancer varied according to the amount of fat 
on the body. This suggests that, in women, a hormonal/metabolic basis may underlie the 
low cholesterol-cancer association. Diet could not, however, explain the low 
cholesterol-cancer association in men. In this study, the exclusion of early cancers 
strengthened the low cholesterol-cancer association, for males. This study also revealed 
(Schatzkin et al, 1988) that the inverse relationship was especially prominent for 
smoking related cancers, for which the association persisted 6 years after baseline
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measurements, suggesting that the relationship cannot simply be dismissed as a pre­
clinical cancer effect. There was no appreciable difference when analysis was carried 
out within strata of various risk factors such as age, education, poverty index, body mass 
index, smoking, alcohol consumption, race, dietary fat, fibre intake, and also, for 
women, age at first birth, age at menarche, parity and menopausal status.
1.4.1.2 Evidence from clinical trials
In the LRC-CPPT, it was observed (Kritchevsky et al, 1991) that the cholesterol levels 
of men diagnosed with non-localised cancer began to drop about 2 years prior to 
diagnosis. This decrease was not observed for men with localised malignancies. The 
decrease was 9.3 mg/dl on average, and weight also decreased by an average of 1.2 kg. 
Within eight months of diagnosis, both weight and cholesterol were significantly lower 
than expected. Kritchevsky et al recommended that analysis should exclude incidence 
within two years and deaths within three and a half years of baseline.
In the clinical trial branch of the MRFIT, it was found that the numbers of cancer deaths 
in the intervention and control groups were similar (81 in the intervention group and 69 
in the control group) (MRFIT Research Group, 1982), suggesting that cholesterol 
lowering may not lead to excess cancer risk in subjects who start with high cholesterol 
levels.
Similarly to these primary prevention studies, the secondary prevention 4S study found 
no significant difference between the drug and placebo groups in terms of cancer deaths. 
There were 33 cancer deaths in the simvastatin treatment group, and 35 in the placebo 
group. In addition, there were 57 non-fatal cases of cancer in the simvastatin group and 
61 in the placebo group (Scandinavian Simvastatin Survival Study Group, 1994).
1.4.1.3 Evidence from Overviews
In 1982, an International Collaborative Group examined 11 population studies from 8 
countries, including the Renfrew and Paisley Survey in Scotland, and found a strong
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inverse association between cancer and cholesterol in the first year of follow-up which 
diminished and disappeared in later years, consistent with the hypothesis that lower 
cholesterol levels were due to an effect of undetected disease.
This is consistent with an examination of 20 published cardiovascular disease studies, 
(McMichael et al, 1984), which afforded substantial evidence that preclinical cancer 
causes a lowering of blood cholesterol, and limited evidence that males with naturally 
low blood cholesterol levels are at increased risk of colon cancer. Deliberate lowering of 
blood cholesterol did not appear to alter the risk of cancer. It is possible that an 
individual’s innate lipoprotein cholesterol profile is statistically associated with his/her 
predisposition to develop cancer, and the cholesterol-cancer relationship is thus not 
causal.
Law and Thompson (1991) analysed 33 prospective studies and discovered lower 
cholesterol levels in subjects diagnosed with cancer within 2 years of the baseline 
measurements. After this interval, the average differences in cholesterol levels were 
smaller, but still statistically significant, and could not be attributed to preclinical 
cancer. They concluded that the long-term association between low cholesterol and lung 
cancer is probably due to smoking, which may also explain how this association varied 
between studies according to the predominant socio-economic status of the subjects 
recruited. Law and Thompson found that the long term association was absent in studies 
of professional men, moderate in studies of mixed populations and strong in studies of 
manual workers. The association was confined to the first few years of follow-up in 
some of these 33 studies, but persisted despite many years of follow-up in others. There 
was an apparent association between high cholesterol and primary brain tumours. 
Cancer does act to lower serum cholesterol, to a certain extent, as does oestrogen, and 
the inverse association between cholesterol and cancer is much smaller than the direct 
association between cholesterol and coronary heart disease. So, overall, the authors 
argue that the data do not suggest that serum cholesterol reduction causes cancer.
The conference on low blood cholesterol (Jacobs et al, 1992), considered 19 cohort 
studies in a pooled epidemiologic study. The formal statistical overview adjusted for 
age, diastolic blood pressure, cigarette smoking, body mass index and alcohol intake as
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available. Once again, they found a U-shaped relationship between cholesterol and all­
cause mortality for men, reflecting the positive association with coronary heart disease 
and the negative relationship with cancer. There was no clear relationship for women 
due to the lack of power caused by the few numbers of women in the studies, and the 
results were unaltered by the exclusion of deaths occurring in the first 5 years of follow- 
up. It is suggested that the relationship between cholesterol and cancer may be due to 
some other confounding factor, although several factors were adjusted for in the 
analysis. It appears that the cholesterol-cancer relationship may be strongest in the 
lowest socio-economic group, but the authors felt that more research is needed in this 
area.
1.4.1.4 Discussion
From the above papers, it can be seen that there is much conflict in the findings of 
different studies regarding low cholesterol and cancer. Although some of the findings 
are from large studies, most come from smaller studies which have relatively little 
power on their own, or from meta-analyses. Also, most of the studies concentrate on 
middle-aged men, leading to an even less clear picture for women.
To summarise, some studies have found no relationship between cholesterol and cancer 
(for example, Chen et al 1991), some studies have found an inverse relationship which 
disappeared after the removal of deaths in the first few years of follow-up suggesting an 
effect of pre-clinical cancer (for example, Gerhardsson et al 1986), some studies found 
an inverse relationship which persisted after the removal of early deaths (for example, 
Sorlie and Feinleib 1982) [although there is considerable inter-study variation on how 
many years should be excluded from analysis], and some studies found a direct 
relationship, although this was mainly for hormone-related cancers in women (Wallace 
et al 1982).
It is plausible that the apparent relationship between cancer and low cholesterol may be 
due to preclinical cancer causing cholesterol lowering. A biological explanation for 
cholesterol lowering with pre-clinical cancer has been given in terms of an activation of
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the membrane low density lipoprotein receptors of the cancer cells, so that cholesterol is 
incorporated into these cells, with a consequent reduction of its serum level (Budd and 
Ginsberg, 1986).
Buchwald hypothesised in 1992 that since cancer cells seem to demand an increase in 
cholesterol concentrations in themselves, cholesterol inhibition, either by decreased 
cholesterol availability or by decreased intracellular cholesterol synthesis, could inhibit 
tumour cell growth, act as an adjuvant to cancer chemotherapy and possibly prevent 
carcinogenesis. There are two sources of cellular cholesterol - synthesis within the cell 
and incorporation of extracellular cholesterol via receptor-mediated uptake of plasma 
LDL cholesterol. The cholesterol requirements of tumour cells exceed their total 
endogenous synthesis, so the tumour cells must use more cholesterol from the cell 
environment for their survival and growth. Buchwald (1992) found that, in rats, tumour 
weight was positively correlated with plasma cholesterol concentrations, and that, in 
mice, restriction of cholesterol synthesis using the HMG CoA reductase inhibitor 
lovastatin resulted in suppressed tumour growth. Buchwald’s tissue-culture experiments 
point to an additive effect of cholesterol inhibition and chemotherapy on tumour cell 
growth, although this has yet to be tested in humans.
An alternative explanation of this relationship could be competing risks. Cancers 
comprise the most common contribution to non-cardiovascular mortality, and would 
thus be expected to show higher incidence at lower cholesterol levels where the 
cardiovascular risk is less (Williams et al, 1981). This argument of competing risks 
could be valid for elderly people who are followed up till death, but not for middle-aged 
subjects who are followed up for only a few years and most of whom are still alive.
This apparent relationship may also be due to confounding with other risk factors (such 
as smoking as a major risk factor for lung cancer), while some studies have suggested 
that the association between low cholesterol concentrations and cancer may be 
secondary to a relationship between low retinol (vitamin A) concentrations and cancer 
(Marenah et al, 1983).
However, there is a fear that it may be the act of cholesterol lowering which leads to 
increased risk of cancer, while indigenously low cholesterol has no adverse effects. The
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possible relationship between low cholesterol and cancer is apparent in populations with 
high mean cholesterol levels, but there is little convincing evidence of high cancer rates 
in populations with naturally low cholesterol concentrations in countries where the diet 
is low in saturated fat and cholesterol, for example Japan (Katan, 1990). A further piece 
of evidence against cancer risk with indigenously low cholesterol is the lack of excess 
cancer mortality among people suffering from genetic conditions which cause LDL 
cholesterol levels of zero (although these conditions are relatively rare) (Katan, 1990). 
In the case of clinical trials, it is also possible that the cholesterol lowering drug used 
may be carcinogenic, although this is unlikely in general since the inverse trend between 
cholesterol and cancer has appeared with several different drugs (Oliver, 1992). There 
is, however, suspicion that the increase in cancer deaths was due to the particular drug 
involved in the large WHO clofibrate trial (Committee of Principal Investigators, 1984), 
which may, in turn, bias some of the meta-analyses carried out.
1.4.2 Suicide and other deaths
As mentioned earlier, the LRC-CPPT found a greater number of violent and accidental 
deaths in the treatment group compared to the controls, leading to no significant 
reduction in all-cause mortality for the treatment group, although there was a 24% 
decrease in definite coronary heart disease deaths (Lipid Research Clinics Program, 
1984). However, the actual numbers involved were fairly small and the study was 
designed to look at coronary deaths, so it had insufficient power to address the endpoint 
of all-cause mortality.
The LRC-CPPT was considered with the Helsinki Heart Study (Wysowski and Gross,
1990), which also had higher rates of homicides, suicides and accidents in the treatment 
group than the placebo group. A detailed review of the individual case histories for each 
of these deaths provided little evidence to support the hypothesis that the cholesterol 
lowering drugs, gemfibrozil and cholestyramine, could be causally related to these 
deaths. The higher rates were not statistically significant in either study due to the small 
number of deaths involved.
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In secondary prevention, the 4S study revealed no suggestion of a higher rate of violent 
deaths in the simvastatin treatment group. There were 6 violent deaths in the simvastatin 
group compared with 7 in the placebo group (Scandinavian Simvastatin Survival Study 
Group, 1994). Once more, there were very few events in this category of deaths.
The association between low cholesterol and violent deaths has appeared consistently in 
several primary prevention studies, whether cholesterol lowering was achieved by drugs 
or diet (Ryman, 1994). But this finding is not restricted to intervention trials. A 
significant association between low cholesterol and death from non-medical causes was 
also found in a population with naturally low cholesterol concentrations (Chen et al,
1991), suggesting that the association is due to the cholesterol level itself, and is not just 
a treatment effect (Ryman, 1994).
However, in contrast, a study carried out in Finland on two independent cohorts (one 
with baseline measurements carried out in 1972, and the other in 1977) with 10-15 years 
mortality follow-up, found no significant relationship between cholesterol levels and 
deaths from accidents, suicides and other violence (Vartiainen et al, 1994). This result 
may have been influenced by the relatively high cut-off point used for a ‘low’ 
cholesterol value in this study (< 5.0 mmol/1) (Ryman, 1994).
Examination of 25 years of follow-up for the two Finnish cohorts of the Seven 
Countries Study found a statistically non-significant negative association between 
cholesterol and mortality due to accidents and violence for one cohort, and a statistically 
significant positive association for the other cohort (Pekkanen et al, 1989). It is 
suggested that the observed associations between serum cholesterol and violent deaths 
are probably due to other, presently unknown, factors or to chance.
A meta-analysis of 6 primary prevention trials, including LRC-CPPT and HHS as 
above, found that while cholesterol lowering intervention reduced CHD mortality, it had 
no effect on total mortality (Muldoon et al, 1990). No consistent relation was found 
between reduction in cholesterol and mortality from cancer, but there was a significant 
increase in deaths not related to illness. In contrast to the group on cholesterol lowering 
therapy, mortality from suicides, accidents and other violent deaths in the control group 
was similar to the American national average. The near doubling of mortality from
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violent causes observed in the group on cholesterol lowering therapy compared to the 
control group is inconsistent with the hypothesis of competing risks. The authors state 
that there is some evidence that modifying fat in the diet has both neurochemical and 
behavioural consequences, which may cause these excess deaths.
Considering these consequences of low cholesterol, a study of male mental hospital 
patients (Sletten et al, 1964) observed that low cholesterol subjects were more regressed 
and withdrawn, with less evidence of initiative and positive mental health than subjects 
with higher cholesterol levels. However, this gives no indication of whether low 
cholesterol is a precursor or a result. The California Psychological Inventory (Jenkins et 
al, 1969) found that impulsive behaviour traits were associated with low cholesterol 
levels. A study of 280 male homicidal offenders, carried out in Finland from 1974-1981 
(Virkkunen, 1983), found that there was a clear relationship between low cholesterol 
and a habitually violent tendency under the influence of alcohol, and suggested that this 
may be due to an enhanced insulin secretion underlying both aspects. A smaller study, 
involving 47 adolescent boys (Virkkunen and Penttinen, 1984) found significantly lower 
cholesterol in boys with aggressive conduct disorder than in controls. It was again 
proposed that this may be due to the effects of active insulin in regulating LDL 
cholesterol.
An alternative biological explanation may come from an effect of lowering cholesterol 
on cerebral cell metabolism, leading to bizarre behaviour and poor co-ordination. In the 
central nervous system, serotonin suppresses harmful behavioural impulses (Engelberg,
1992). Low membrane cholesterol decreases the number of serotonin receptors, which 
may contribute to a decrease in brain serotonin and poorer suppression of aggressive 
behaviour. Abnormalities in cerebral serotonin systems are associated with poor impulse 
control, which may manifest itself either as suicidal behaviour or as aggression towards 
others. Long-term follow-up of middle-aged men may not show this relationship so 
clearly since those with a naturally low cholesterol may have already died in 
adolescence. A subsequent lowering would then be needed to trigger violence or suicide 
in older men, but this triggering may not be related to the magnitude of the reduction. It 
is not unreasonable that anything which affects the balance of central lipid metabolism 
could have profound effects on brain function.
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Possible confounding variables which may influence the proposed relationship between 
cholesterol and violent death include alcohol consumption, blood pressure and social 
class. For example, in clinical trials, people may react differently to their usual alcohol 
intake, while taking drugs. Analysis of the Italian cohorts of the Seven Countries Study 
(Menotti et al, 1980 and 1987) revealed a direct relationship between blood pressure and 
violent death. Indeed, a review of specific cases found that some fatal accidents were 
preceded by minor cardio-circulatory events. These possible confounding variables may 
be worthy of further investigation.
A review of 10 cohort studies, 2 international studies and 28 randomised trials (Law, 
Thompson and Wald, 1994) found an excess in mortality with low or lowered serum 
cholesterol. The main cause of death attributable to low cholesterol was haemorrhagic 
stroke, with the excess risk being for cholesterol concentration less than 5 mmol/1. 
However, stroke affects only about 6% of Western populations, so this excess risk will 
be outweighed by the benefits from the low risk of ischaemic heart disease. Employed 
cohorts showed no excess non-circulatory mortality, while community cohorts showed 
cholesterol associations with suicide, chronic bronchitis and chronic liver and bowel 
diseases, as well as lung and haemopoietic cancers. These excess deaths can mostly be 
explained by early disease, or by other factors, such as depression leading to suicide, and 
also causing cholesterol lowering. This suggests that the lowering of cholesterol 
concentrations causes an increase of deaths only in a population more vulnerable to 
factors such as psychiatric disorder, and that employed cohorts are protected from this 
effect (Ryman, 1994). It is argued that for a relationship to be causal, it must also be 
reversible. Treating depression leads to an increase in serum cholesterol, suggesting that 
it is the depression which causes the low cholesterol. (Similarly, cholesterol increases 
when chemotherapy induces remission of cancer, backing the pre-clinical cancer 
argument.) Low cholesterol seems to be associated with suicide only for the first 5 years 
after measurement. Cholesterol can predict ischaemic heart disease deaths 30-40 years 
later and should do the same if it were a cause of suicide. Alcoholism is also associated 
with depression and other mental illness, causes deaths through accidents and suicides, 
and lowers serum cholesterol. So there appears to be some evidence for the safety of 
lowering serum cholesterol, as the adverse effects may be explained by confounding 
factors, or as having a cholesterol lowering effect themselves.
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Excess stroke deaths with low cholesterol concentrations were found in an analysis of 
the MRFIT screening exercise, which involved 6 years of follow-up on 350,977 men 
age 35-57 (Iso et al, 1989). Deaths from intracranial haemorrhage were three times 
higher in men with serum cholesterol levels under 4.14 mmol/1 than in those with higher 
levels, but there was also a positive association between serum cholesterol and deaths 
from non-haemorrhagic stroke. The deaths from intracranial haemorrhage were confined 
to men with diastolic blood pressure > 90 mmHg, among whom death from intracranial 
haemorrhage is relatively common. The risk of haemorrhagic stroke death with low 
cholesterol is thus overwhelmed by the risks of non-haemorrhagic stroke and coronary 
heart disease with high cholesterol levels.
Analysis of 17 years of follow-up in the Honolulu Heart Program also found significant 
inverse trends between cholesterol and deaths due to haemorrhagic stroke, all cancer, 
benign liver disease and chronic obstructive lung disease (Frank et al, 1992). Only the 
inverse trends for all cancer and benign liver disease flattened when deaths in the first 
five years of follow-up were excluded.
1.5 Summary and Proposed Investigation
As has been seen above, while cholesterol is well established as a risk factor for 
coronary heart disease, it’s effects on cancer, suicide and other violence are much less 
clear. The studies have conflicting results, making this a controversial area of medical 
research.
Differences in study design - whether it is prospective or retrospective, the cancer 
outcome used (incidence or mortality), the sample size involved in the study, the 
average cholesterol levels in the different population groups used, the age of patients at 
the end of the study and the ethnic composition of the study subjects could all contribute 
to some of the inconsistent findings between studies. The selection of the population 
entering the study has the potential to be a major source of bias. It is also important to 
note the length of follow-up in the different studies, especially when considering the
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possible relationship between cancer and cholesterol, where preclinical disease could 
bias results in the first few years of follow-up. A further problem is that the studies 
described above were designed to examine cardiac endpoints and do not have sufficient 
power to address alternative outcomes. This is particularly relevant for the outcome of 
‘violent deaths’ where the actual numbers of deaths observed is small. Differences in 
results may also be due to differences in the methods of analysis employed (Salmond et 
al, 1985). The studies also vary with respect to which covariables are adjusted for in the 
analysis. In meta-analyses, drug and dietary trials with varying periods of follow-up and 
degrees of success are often considered together. Amidst the conflicting findings it is 
difficult to discern whether the observed trends relate to cholesterol lowering in general, 
to specific drugs for cholesterol lowering, to naturally low cholesterol or are simply a 
statistical artefact.
Lowering of plasma cholesterol should be achieved by diet alone, where possible, with 
drug intervention being reserved only for those at very high risk of coronary heart 
disease. Cholesterol reduction should be desirable only for those with raised cholesterol 
concentrations, and not as a general population measure.
An argument against a causal link between low cholesterol and disease is the fact that 
the levels of cholesterol and diseases vary among different populations. The relationship 
is not consistent (Marmot, 1994). If mortality from other causes increases with 
cholesterol lowering then intervention would be of doubtful value. Falling cholesterol 
concentrations could have different biological effects than consistently low 
concentrations. If cholesterol lowering itself is not harmful, and diet is safe, then 
attention must focus on the side effects of particular drugs. Drugs will be appropriate for 
those at higher risk only when the benefits outweigh the hazards.
Following on from this review of previous studies of coronary heart disease, the next 
chapter will consider the West of Scotland Coronary Prevention Study (WOSCOPS) in 
more detail. This is a randomised clinical trial of the safety and efficacy of the 
cholesterol lowering drug pravastatin, for the primary prevention of CHD.
Chapter 3 will then examine an alternative method of adverse event follow-up for 
clinical trials using record linkage techniques, and chapter 4 will consider how record 
linkage techniques have been applied to WOSCOPS.
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Chapter 5 will compare this alternative method of follow-up using record linkage with 
the more traditional follow-up methods routinely applied in WOSCOPS, in order to 
assess the quality of the follow-up achieved by each of these methods in the context of a 
clinical trial.
Having thus assessed the quality of adverse event data obtained by record linkage for the 
clinical trial branch of WOSCOPS, chapter 6 gives an analysis of the data acquired for 
the WOSCOPS screened cohort by this technique, in relation to baseline risk factors. 
Analysis of this large cohort will address some of the issues raised in this chapter. The 
outcomes of all-cause mortality, coronary heart disease deaths, cancer deaths and trauma 
deaths will be examined, as well as cancer incidence. Analysis will consider the 
coronary heart disease risk factors discussed above, with primary emphasis on 
cholesterol, alcohol consumption and a measure of socio-economic status.
Chapter 7 will compare the event rates observed in the screened cohort (via record 
linkage) to the event rates for the population in the area of screening, in order to assess 
how representative of the general population a screened cohort is.
Finally, chapter 8 will give a review of the conclusions which can be drawn from this 
thesis, and suggestions for future work to be undertaken.
Chapter 2 
The West of Scotland Coronary 
Prevention Study
2.1 Background to the study
Previous epidemiological studies have consistently supported the link between raised 
plasma cholesterol levels and increased rates of coronary heart disease mortality, both 
individually and combined (Stokes et al, 1987; Law, Wald and Thompson, 1994). The 
three largest of the previous clinical trials of cholesterol lowering agents, the WHO 
clofibrate study (Committee of Principal Investigators, 1978), the Lipid Research 
Clinics Coronary Primary Prevention Trial (Lipid Research Clinics Program, 1984) and 
the Helsinki Heart Study (Manninen et al, 1988) have also supported this causative link, 
although their results have been disappointing due to low statistical power. These and 
other studies have been discussed in Chapter 1.
The West of Scotland Coronary Prevention Study (WOSCOPS) was the fourth large 
clinical trial to be carried out on the use of cholesterol lowering drugs for the primary 
prevention of coronary heart disease. WOSCOPS was a double-blind, randomised, 
placebo-controlled primary prevention trial in middle-aged men (45-64 years) with 
raised cholesterol levels. It was designed to test the long-term safety and efficacy of the 
cholesterol lowering drug pravastatin, a competitive inhibitor of 3-hydroxy-3- 
methylglutaryl coenzyme A (HMG CoA) reductase, in the primary prevention of 
coronary heart disease morbidity and mortality. The HMG CoA reductase inhibitors 
have been shown to be potent reducers of LDL cholesterol with reductions of 30% being 
readily achievable with once per day treatment. Early experience with this class of drugs 
has shown good compliance and a low incidence of adverse events. Active treatment
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should result in reductions of up to 34% in LDL cholesterol, as much as 25% in plasma 
triglyceride, and mean increases of up to 14% in HDL cholesterol, thus significantly 
improving the whole lipoprotein profile (La Rosa, 1989).
The design and administration of WOSCOPS are described in more detail elsewhere 
(West of Scotland Coronary Prevention Study Group, 1992). The major trial endpoint 
was coronary heart disease death plus non-fatal myocardial infarction. The study also 
reported on the incidence of coronary mortality, all-cause mortality, coronary artery 
bypass graft, angioplasty, coronary arteriography and cerebrovascular disease. 90% of 
the subjects lived within a 30 mile radius of the Data Centre in the University of 
Glasgow, with the remaining 10% coming from the area of Dumfries and Galloway 
approximately 90 miles to the south of the city. All randomised subjects gave informed 
consent including written permission for the follow-up of their medical records. 
Participants were monitored for an average of 5 years to obtain long-term efficacy and 
safety information. By the end of the study, WOSCOPS had accumulated approximately 
32,000 patient years of follow-up.
The progress of the trial was reviewed regularly by an external Data and Safety 
Monitoring Committee, which was responsible for recommending the continuation or 
termination of the trial in the light of any observed treatment effects (whether 
pronounced adverse effects or significant benefits). This external committee was the 
only body with access to unblinded information during the course of the trial.
In WOSCOPS, the statistical power was improved, as compared to the Lipid Research 
Clinics Coronary Primary Prevention Trial (LRC-CPPT) and the Helsinki Heart Study 
(the 2 more recent large clinical trials of cholesterol lowering drugs), by
1) using a larger sample size, with 6595 men randomised to either pravastatin or placebo 
(an increase of 50% compared to the LRC-CPPT (3806 men) and the Helsinki Heart 
Study (4081 men)).
2) recruiting older men, age 45-64, with a corresponding higher cardiac event rate (mean 
age=55.2 in WOSCOPS, mean age=47.8 in LRC-CPPT and mean age=47.3 in Helsinki 
Heart Study).
3) recruiting men in a high risk area (the West of Scotland has among the highest rates 
in the world).
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4) using a powerful new cholesterol reducing agent, pravastatin, which has the potential 
for reducing the cardiac events in the active treatment group by at least 30% over the 
average 5 years of follow-up. This drug is substantially more palatable than the drugs 
used in the previous studies, easy to take and with few apparent side effects, and should 
thus ensure a higher compliance with the study protocol (West of Scotland Coronary 
Prevention Study Group, 1992).
In addition to the clinical trial side of WOSCOPS, the population screening programme 
provided important epidemiological information on coronary heart disease risk factors 
in the West of Scotland. There has been substantial scientific and health board interest 
in following these people up, to study relationships between baseline risk factors and 
incidence of heart disease, cancer and other illnesses.
The process of recruitment involved the initial population screening programme 
followed by two filtering visits and a randomisation visit. This led to different levels of 
data being available for subjects who reached each stage.
2.2 Screening visit 1
In order to randomise 6595 men into the study, it was necessary to carry out a large 
population screening exercise, which ran from October 1988 until March 1991. Initially, 
screening was open to all adults, but as time went on, more emphasis was placed on 
screening men in the targeted age range of 45-64, who were identified from doctor’s 
age-sex registers or local health centre computerised databases (GPASS), and invited by 
mail to come for screening. Screening took place in four health board areas, Greater 
Glasgow Health Board, Lanarkshire Health Board, Argyll and Clyde Health Board, and 
Dumfries and Galloway Health Board, all of whom gave ethical permission for the 
study.
Of the 105,383 subjects who attended an initial screening visit, 16776 were women, and 
88,607 were men, of whom 81,161 were age eligible. At this first screening visit,
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subject identifying information was collected, as well as information on risk parameters, 
personal history, clinical findings and demographic variables. While baseline 
measurements of risk factors are available for all of these 105,383 subjects, only 97,165 
subjects had complete name, address and date of birth information recorded.
The full list of variables measured can be seen in Table 2.1. At this first screening visit, 
data were entered directly into a computer database by the screening centre nurses and 
no case report forms were completed.
Identification Name 
Address 
Date of birth 
Sex
Marital status (see below) 
Date of screening visit 1
Demography Educational level (see below) 
Occupational category (see below)
Risk parameters Height (cms)
Weight (kg)
Aerobic exercise (hours per week) 
Diastolic blood pressure (mmHg) 
Systolic blood pressure (mmHg) 
Cholesterol (mmol/1)
Smoking habit (see below)
Number of cigarettes smoked per day 
Number of years smoked 
Number of years stopped smoking 
Alcohol intake (units per week)
History / clinical findings Personal history of CHD (yes/no)
Personal history of diabetes (yes/no)
Personal history of hyperlipidaemia (yes/no) 
Personal history of hypertension (yes/no) 
Number of first degree relatives dead from CHD 
Presence of xanthomata (yes/no)
Presence of comeal arcus (yes/no)
Table 2.1 Data recorded at screening visit 1
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The categorical variables are classified as:-
Marital status: single 
married 
widowed 
divorced 
separated
Education: left school <16 
highers
technical college
university
other
Occupation: unemployed
unskilled 
skilled 
managerial 
professional 
other
Smoking: never smoked
ex-smoker
current cigarette smoker 
current pipe / cigar smoker
At this stage, the cholesterol measurement related to Total Cholesterol as measured 
using a Reflotron bench-top analyser. The obvious physical signs of xanthomata and 
comeal arcus, possibly indicating hypercholesterolaemia, were also noted at this visit.
Two derived variables were calculated from this recorded information:
Age = Date of screening visit 1 - Date of birth, and Body mass index =
height
Men in the targeted age range who had a total cholesterol level >6 . 5  mmol/1, no 
knowledge of a previous myocardial infarction and who were willing to participate were 
given dietary advice on cholesterol reduction and invited to return for a further 
screening visit in 4 weeks time, as a potential recruit.
2.3 Screening visit 2
From the second screening visit onwards, all data collected at the screening centres were 
recorded on standard case report forms. Approximately 20,800 men with high 
cholesterol returned for a second screening visit, when they underwent a fasting 
lipoprotein analysis, in which total plasma cholesterol, triglyceride, very low density
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lipoprotein (VLDL), low density lipoprotein (LDL) and high density lipoprotein (HDL) 
cholesterol were determined. If the LDL cholesterol level was > 4.0 mmol/1 then the 
subject was asked to return in another 4 weeks for a further screening visit. Blood 
samples were sent to Glasgow Royal Infirmary for analysis accompanied by a form 
containing the patient’s name, address, GP information, centre number and subject 
number (this form, containing patient identifying information, is given in Appendix A). 
All subsequent screening forms identified the patient only by a patient number and the 
patient’s initials. At this second screening visit, patients were also asked about their past 
and current general health and family history, with particular emphasis on coronary 
events, and the Rose Questionnaire for detection of angina pectoris and intermittent 
claudication was administered.
2.4 Screening visit 3
Approximately 13,600 subjects with moderately raised LDL cholesterol and no reported 
history of CHD returned for a third screening visit at which a further fasting sample was 
taken for lipoprotein analysis, together with blood for a full biochemical and 
haematological profile and measurement of fibrinogen and plasma viscosity. The 
biochemical and haematological variables measured are given in Table 2.2. A 12 lead 
resting ECG was performed at this visit. More detailed information on the subject’s 
current health, alcohol consumption, smoking habits (past and present), and 
demographic details such as education and employment status were also recorded.
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Biochemical Tests Haematological Tests
AST (u/1)
ALT (u/1)
ALP (u/1)
CK (u/1) 
Calcium (mmol/1) 
Total protein (g/1) 
Creatinine (umol/1) 
Glucose (mmol/1) 
Sodium (mmol/1) 
Potassium (mmol/1) 
Bilirubin (mmol/1) 
Triglyceride (mmol/1)
MCV (fl) 
Haemoglobin (g/1) 
White cell count (cell/1) 
Red cell count (cell/1)
Table 2.2 Biochemical and Haematological Tests carried out at Visit 3
The main inclusion criteria for the trial were based on LDL cholesterol levels as 
follows:
- LDL cholesterol > 4.0 mmol/1 (154 mg/dl) at both screening visits 2 and 3
- LDL cholesterol > 4.5 mmol/1 (174 mg/dl) at either screening visits 2 or 3
- LDL cholesterol <6.0 mmol/1 at either screening visits 2 and 3
This requirement of a raised LDL cholesterol level on 2 occasions, measured several 
weeks apart, meant that subjects whose cholesterol level became acceptable simply by 
following the dietary advice given were not randomised to study treatment. These 
requirements also excluded subjects who consistently showed a very high LDL 
cholesterol level possibly requiring overt therapy.
Patients with any evidence of previous myocardial infarction (including evidence from 
their screening visit 3 ECG), other life threatening illnesses or any physical or mental 
disability which might interfere with completion of the study, were excluded, as were 
patients with hypertension despite treatment or who were already on lipid lowering 
therapy. Subjects with a positive Rose Questionnaire were only excluded if they had 
been hospitalised for treatment or investigation of angina within the previous 1 2  
months. There were further exclusion criteria based on the biochemical and 
haematological tests carried out at screening visit 3 (West of Scotland Coronary
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Prevention Study Group, 1992). Biochemical tests provided a general screening to try 
to exclude patients with possible concurrent disease. The tests of liver function (in 
particular AST and ALT (serum transaminases)) and the muscle enzyme creatine kinase 
were carefully monitored throughout the study for safety reasons, so a baseline level 
within normal limits had to be established.
2.5 Screening visit 4
The above screening procedures resulted in 6595 subjects being randomised to treatment 
with either placebo or pravastatin at their fourth screening visit. These randomisation 
visits took place between February 1989 and September 1991.
At the randomisation visit (visit 4), a trial physician conducted a general physical 
examination and an opthalmoscopic examination for lens opacities and visual acuity, 
and further details were collected on blood pressure, heart rate, height, weight and 
concurrent medication. If the subject was willing to take part in the study, then written, 
informed consent was obtained and the subject was randomised. All screening case 
report forms were then transmitted to the Data Centre where the data was entered, 
verified and stored in a central computer database.
The baseline characteristics of the 6595 randomised subjects as recorded at screening 
visit 1 are presented in Table 2.3, along with the corresponding data for the screened 
population of men in the same age range.
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All Screenees Randomised Subjects
Continuous variables
Age at visit 1 (years) 54.8 (5.7) 54.8 (5.5)
Systolic BP (mmHg) 137.4(19.2) 138.2(18.5)
Diastolic BP (mmHg) 84.9 (10.8) 85.4 (10.5)
Weight (kg) 77.5 (12.4) 78.5(11.0)
Body mass index (kg/m2) 25.8 (3.7) 26.1 (3.2)
Total cholesterol (mmol/1) 5.9 (1.2) 7.3 (0.7)
Categorical variables
History of hypertension 16.1 14.7
History of hyperlipidaemia 2 . 6 4.0
History of CHD 1 1 . 6 4.6
Current cigarette smoker 36.5 36.7
Alcohol (units per week)
< 2 1  units 80.4 82.0
>= 2 1  units 19.6 17.8
Table 2.3 Comparison o f data recorded for all age eligible men (81,161 subjects) and the randomised 
subjects (6595 subjects). Continuous variables are presented as mean (standard deviation). Data for 
categorical variables are given as percentages o f all subjects in the ‘All Screenees’ group or ‘Randomised 
Subjects’ group as appropriate.
The above data suggest that the screening process has not resulted in the selection of a 
particular subgroup which is substantially different from the screened population other 
than with respect to cholesterol level and previous history of coronary heart disease 
(West of Scotland Coronary Prevention Study Group, 1995).
2.6 Subject follow-up during the trial
Patients were followed up in the community, and attended trial centres set up either in 
GP’s surgeries, local health centres or other public buildings at 3 monthly intervals, for 
monitoring of adverse events (including potential side-effects) or endpoint events, 
recording of concurrent medication, re-testing of lipid levels and monitoring of clinical
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and laboratory safety parameters, as well as receiving a new supply of tablets and 
returning unused tablets to be counted for compliance assessment. The data on the lipid 
levels (post-baseline) were not available to the investigators, in order to maintain 
blinding, and were used only for safety purposes. The information collected at each visit 
was as in Table 2.4 with patients being required to fast overnight prior to 6  monthly and 
annual visits. Participants were also given regular dietary advice and actively 
encouraged to stop smoking.
Procedure 3 /9  monthly 
visits
6 monthly 
visits
12 monthly 
visits
Compliance pill count X X X
Concurrent medication X X X
Adverse event check list X X X
Record hospitalisations 
or other endpoints
X X X
Intercurrent illness X X X
Physical examination X
BP, smoking record X X
Full lipoprotein profile X X
Biochemical profile X X
Haematology X
ECG X
Angina questionnaire X
Opthalmic tests X
Table 2.4 Procedures performed at follow-up visits
At 3, 6  and 9 monthly visits, the subject was seen by a nurse and the documentation 
checked by a trial physician, while annual ( 1 2  monthly) visits were conducted by the 
trial physician. The trial physician may have interviewed the patient at any visit or at 
times between visits however, if they reported an adverse event. Opthalmic tests were 
carried out on an annual basis to check for visual acuity and lens opacity (initially 
thought to be possible side-effects of the cholesterol lowering therapy). Any patient 
displaying lens opacity was followed up closely by an opthalmologist. At the first 
annual visit, a second measurement of fibrinogen and plasma viscosity was made.
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All data entry and validation of case report forms was carried out at the Robertson 
Centre for Biostatistics at Glasgow University and central biochemical and 
haematological analyses of blood samples took place at Glasgow Royal Infirmary. 
Automated ECG analysis was also undertaken at Glasgow Royal Infirmary using the 
Glasgow program (MacFarlane, Devine et al, 1990) to generate Minnesota codes, a 
scheme for classifying ECG abnormalities (MacFarlane, Latif et al, 1990).
Documentation of adverse events relied primarily on patients’ self-reporting. 
WOSCOPS personnel had no direct access to a patient’s medical records even when 
trial visits took place at the subject’s own health centre. This process was supplemented 
through manual flagging with the National Health Service Central Register (NHSCR) 
for deaths and incident cancers.
Information on adverse events was recorded by the medical staff based at each trial 
centre, and reviewed by an Adverse Events Committee. Support documentation was 
obtained by a clinical researcher from Glasgow Royal Infirmary for all serious adverse 
events, including deaths, cardiac events and cancers. The Adverse Events Committee 
consisted of three consultant physicians who examined all serious or cardiac adverse 
events and allocated an ICD code to them. They also indicated whether an event should 
be passed to the Endpoints Committee or not. Possible study endpoints were classified 
by the Endpoints Committee, who reviewed all deaths, possible myocardial infarctions 
and annual study ECGs which showed serial changes. The Endpoints Committee was 
staffed by two cardiologists and an ECG specialist who decided whether or not a given 
adverse event met the criteria of an endpoint. Both the Adverse Events Committee and 
the Endpoints Committee remained blinded throughout the study. Safety monitoring of 
abnormal bloods and general adverse events was carried out at Glasgow Royal Infirmary 
by Clinical Co-ordinators.
Subjects who withdrew from taking study medication were encouraged to attend for an 
annual visit so that information on adverse events could be obtained, along with a blood 
sample and ECG. This was important, as final analysis was carried out on an intention- 
to-treat basis, with an outcome being sought for every patient.
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Adverse events were all documented on an adverse event report form. Serious adverse 
events, however, triggered specific additional forms depending on the nature of the 
event. More than one additional form could be completed for events as required. The 
documentation structure is illustrated in Figure 2.1 and examples of some of these forms 
are given in Appendix B. Separate forms were completed for a hospitalisation, death, 
possible myocardial infarction, coronary arteriography, angioplasty, coronary artery 
bypass graft, cerebrovascular accident (stroke) or cancer. A form confirming the event 
to be a trial endpoint was also completed by the Endpoints Committee where 
appropriate.
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H o s p i t a l i s a t i o n  
r e p o r t
De a t h  for m
C a n c e r  for m
A n g i o p l a s t y
form
C e r e b r o - v a s c u l a r  
a c c i d e n t  for m
C o r o n a r y  
a r t e r i o g r a p h y  form
P o s s i b l e  m y o c a r d i a l  
i n f a r c t i on  form
C o r o n a r y  a r t e r y  
b y p a s s  g r a f t i ng  for m
De a t h  a n d  e n d p o i n t  
c l a s s i f i c a t i o n  form 
( c o m p l e t e d  by  E n d p o i n t s  
C o m m  i t t ee)
B a s i c  a d v e r s e  
e v e n t  for m 
( c o d e d  by A d v e r s e  
E v e n t s  C o m m i t t e e )
Figure 2.1 Structure of Adverse Event Documentation
Follow-up was completed at visits scheduled between January and May 1995, at which a 
final study ECG was recorded. The vital status of all subjects (including those who 
failed to attend their visit) was ascertained during this period.
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2.7 Discussion of the Adverse Event 
Reporting System
WOSCOPS adverse event follow-up by patient self-reporting has been supplemented by 
flagging the WOSCOPS subjects with NHSCR. Since 1948, NHSCR has contained 
brief particulars of every person registered with a GP, updated for deaths and emigration 
where known. In the 1970s, information from the National Cancer Register was added, 
providing a system by which study subjects can be flagged for all deaths and incident 
cancers, by comparing the identifying particulars of study subjects with those known to 
NHSCR. Currently, this matching is done clerically, although moves are being made to 
automate this system (Acheson, 1987).
A study was carried out in Oxford to assess the efficiency of NHSCR notification of 
breast cancers which had been verified as part of a cohort study of women taking HRT 
(Hunt and Coleman, 1987). 28 out of the 50 cases observed in the study had not been 
notified by NHSCR two and a half years after the diagnosis of the most recent case. Of 
these 28 cases, 14 had not been registered (a problem arising from the fact that in the 
UK, cancer registration is voluntary), 8  had been registered but had not yet arrived at 
NHSCR, 5 were in the process of being notified, and 1 registration could not be linked 
to the individual’s record. It was not uncommon for there to be a year between receipt of 
a batch of registrations at the central registry and processing at NHSCR, on top of the 
delay between diagnosis and registration (median delay was 1 year). This study took 
place in England, where 12 cancer registries send data to the Office of Population 
Censuses and Surveys (OPCS) centrally, but there is no reason to expect that the 
situation is any better in Scotland, where 5 registries send data to the Information and 
Statistics Division (ISD) of the Scottish Health Services Common Services Agency for 
central processing. Notification of deaths is regarded as being reliable and complete, but 
there is concern about the completeness and timeliness of cancer notifications.
Concerns over the completeness of adverse event information derived from patient 
reporting and NHSCR, have led to the consideration of an alternative method of patient 
follow-up using record linkage techniques.
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Scotland is fortunate in having national databases covering all deaths, incident cancers, 
hospitalisations, psychiatric hospitalisations and cardiac surgical procedures. These 
databases are all held in Edinburgh within the Scottish Record Linkage System 
(Kendrick and Clarke, 1993). Record linkage techniques, which will be described in 
chapter 3, made it possible to obtain details of adverse events for the WOSCOPS 
subjects from these national databases, as described in chapter 4, using the patient 
identifying information recorded at screening visits 1 and 2 (see Appendix A). The more 
traditional methods of subject follow-up for clinical trials could thus be validated and 
supplemented, as discussed in chapter 5. Record linkage also provided a cost effective 
manner in which prospective epidemiological follow-up could be carried out for the 
large cohort of subjects who attended screening visit 1 .
Chapter 3 
Record Linkage Methodology
3.1 What is record linkage?
'Record Linkage' is simply the bringing together of information from two records believed 
to relate to the same individual. When this is based on the calculation of the likelihood of a 
correct linkage (that is, that the individuals represented on the two records are really the 
same person), the process is said to be 'probabilistic'. Probabilistic record linkage is 
appropriate where the identifying particulars used for searching and 'linking' records are 
prone to change or are less than reliably reported, or when different subjects may have the 
same identifiers. Record linkage techniques are used subconsciously by everyone on a 
daily basis, for example, when looking up a number in a phone book. In this example, the 
name of the person whose phone number is required is compared to a ‘file’ of names until 
a ‘match’ is found. Record matching algorithms are at the heart of all automatic 
information retrieval systems. The use of record linkage systems in the context of clinical 
trials and cohort studies will be described in Chapter 4.
Although there are a few early references to the problems of record matching (Farr, 1861; 
Stocks, 1944), the main stimulus to research in this area came in the 1960s with attempts 
to store medical and vital status records on a computer system. As ever more data are 
stored in this way, the scope for record matching and, in particular, matching with a 
probabilistic element increases correspondingly. The statistician has a role to play in the 
production of matching algorithms, assessment of evidence for matching, and evaluation 
of the accuracy of results from statistical matching, where there is any uncertainty over the 
choice of matched pairs.
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3.2 Standard Methodology for Record 
Linkage
3.2.1 Empirical concepts
Much of the early development of record linkage techniques was carried out by Howard 
Newcombe and colleagues in Canada (Newcombe et al, 1959). He describes the 
probabilistic basis of record linkage and a practical plan for setting up a record linkage 
system in his book, the Handbook of Record Linkage (Newcombe, 1988). This section 
gives Newcombe’s suggestions on how record linkage may be carried out in practice.
The degree of certainty of a correct linkage obviously depends on the outcomes from the 
comparisons of individual identifiers. If all the identifiers agree and are unlikely to have 
done so by accident, then the level of assurance of a correct link will be high, but if they all 
disagree and are unlikely to have done so in records truly belonging to the same person, 
then there is little doubt that the pair are wrongly matched. Partial similarities and 
dissimilarities may argue in either direction. Probabilistic record linkage quantifies this 
comparison process and decides where the balance lies for intermediate situations where 
some of the identifying information points to a link and other information does not. Often 
an identifier may fail to agree precisely on a pair of records but be obviously similar 
nevertheless. The levels of agreement and disagreement can be subdivided into 
appropriate categories of partial match/mismatch, and frequency ratios calculated 
accordingly.
The basic question for each comparison is 'How typical is that comparison outcome 
among pairs of records relating to the same person (“linked”), as compared with pairs of 
records brought together at random (“unlinkable”)?' The first step to addressing this 
question is the calculation of frequency ratios. The frequency ratio represents the 'betting 
odds' in favour of a correct match, associated with the particular comparison and its 
outcome.
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Frequency Ratio -  frecluency °f outcome (x, y) among linked pairs 
frequency of outcome (x, y) among unlinkable pairs
x = value of identifier on file initiating search 
y = value of identifier on file being searched
The combined frequency ratios pertaining to a given record pair (that is, their product) 
constitute the information on which the overall 'betting odds' in favour of a correct match 
are based.
In order to calculate these frequency ratios, one first needs to manually produce a file of a
few hundred correctly matched pairs of records, in order to calculate the frequencies of the
various comparison outcomes in this file of linked pairs. A larger file of record pairs 
brought together randomly will provide the frequencies of the outcomes for unlinkable 
pairs.
The simplest comparisons use 'global' discriminating powers where the frequency ratios 
are derived from the files of linked and unlinkable pairs, but are non-specific for the value 
of an identifier. For example, where the surname is the same on both records, but no 
account is taken of the rarity of that surname in the population under consideration. Thus, 
global treatments under-exploit the discriminating power of the information available.
In practice, global frequency ratios are routinely converted to their 'value-specific' 
counterparts wherever this would result in better use being made of the discriminating 
power of the identifiers. The frequencies of specific values for such identifiers may be 
stored in look-up tables.
„ T , . _ _ . freq of agreement in linked pairs (A has specified value)Value-specific freq ratio = ------------- - --------------------------------------------------------------
freq of agreement in unlinkable pairs (A has specified value)
where record A is from the file that initiates the search.
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Both the numerator and the denominator of the value-specific ratio are usually estimated 
rather than observed. For disagreements, it is assumed that the particular value of the 
identifier on record A does not influence the chance of a disagreement. The global odds 
for a given disagreement now provides an estimate for the value-specific odds for the 
disagreement. For full agreements, it is assumed that in the linked pairs, the particular 
value of the identifier on record A does not influence the chance of an agreement. The 
global numerator for a given agreement thus provides an estimate for the value-specific 
numerator. It is also assumed that the frequency, in the unlinkable pairs, of a chance 
agreement of the particular value of the identifier on record A will be identical to the 
frequency of that particular value in the file being searched, thus providing an estimate of 
the value-specific denominator for full agreement. However, this simple approach is 
inappropriate for partial agreements, due to difficulties calculating the value-specific 
denominator.
While the ideal method of obtaining the denominator of these outcome frequencies is from 
an actual file of unlinkable pairs, in practice it is often possible to calculate 
approximations to them based on various assumptions. For example,
a) Comparison of month and day of birth - Births are assumed to be uniformly distributed 
over the months of the year, and over the days of the month. The general formula to obtain 
the frequencies of various outcome levels, when the records are matched randomly is
Frequency of discrepancy x =
n
where n is the number of months in a year, or days in a month and x is the magnitude of 
the positive or negative difference between the two months, or days. If both positive and 
negative differences are to be included together, then (n-x) must be multiplied by 2. Slight 
seasonal variation in the birth pattern has little effect on the accuracy of this calculation, 
which yields outcome frequencies almost exactly the same as those found in an actual file 
of unlinkable pairs.
b) Comparison of year of birth - For years of birth, it is not reasonable to assume a uniform 
distribution. However, for a particular calendar year, the frequency with which there will 
be an exact agreement by pure chance, for randomly matched pairs, will be equal to the
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frequency of that year in the search file times the corresponding frequency in the file being 
searched. Where the year itself is unimportant, a value non-specific frequency over all 
years of birth can be found by summing the frequencies for individual years. Levels of 
disagreement can be dealt with in a similar manner.
A simplified, empirical approach to calculating value-specific frequency ratios is to 
convert the global ratio to it’s value-specific counterpart using an adjustment factor, rather 
than calculating a new ratio. The adjustment factor will depend on whether the agreement 
portion of the specific identifier is rare or common in comparison with the general 
frequency for that portion of the identifier. The general frequency for an identifier is a 
weighted mean of all the specific frequencies in the file being searched.
General frequency = ^(frequency of value x) 2
X
Adjustment factor =  general frequency  ^
value - specific frequency
For convenience, the ratios of the two frequencies are often expressed logarithmically and 
called weights. Value-specific weights (or adjustment weights) are usually stored in look­
up tables, while non-specific global weights are written directly into the comparison rules.
It is often simpler to regard a missing comparison as indicating nothing. But the 
assumption that blank fields are essentially neutral may not be true. For example, a blank 
middle initial may indicate that the subject has no middle name, rather than that an 
existing middle name has been missed out. If blanks could be significant, they should be 
treated as another specific value option when calculating frequency ratios.
Identifiers that are logically related may appear on records as separate identifiers or as a 
single identifier (for example, first initial plus remainder of first name, or home postcode 
plus health board of treatment). The two parts may be compared separately, with the 
second comparison being conditional on the outcome of the first, or they may be combined 
and concatenated, with recognition of a number of possible comparison outcomes. But
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care must be taken in the calculation of frequency ratios for these conditional comparisons, 
and they should not be considered as separate, independent comparisons.
Finding appropriate discriminating rules is a trial-and-error process, requiring repeated 
refinements, with the ultimate purpose being for the computer to adopt the strategies of 
the human mind in order to keep expensive clerical resolutions to a minimum. More 
sophistication in the comparison procedures, possibly involving unconventional 
comparisons or more levels of similarity, are necessary if the numbers of false-positive 
and missed linkages are important, and manual checking is to be kept to a minimum. 
Much time must initially be spent resolving borderline links, to get clues as to how they 
are resolved, and thus develop the comparisons. However, there is a point beyond which 
the cost of refining rules outweighs the advantages of applying them, particularly if the 
refinement requires an extensive amount of manual review.
The overall odds in favour of a correct link is found by multiplying together all of the 
frequency ratios for the comparison pair. This is usually done by converting each of the 
frequency ratios into its logarithm, called a weight, and adding the weights to produce a 
total weight. This assumes that the various agreements and disagreements are independent 
of each other. For a single-step multiple-outcome procedure, the combined frequencies of 
all outcomes should add to 100%, among both the linked and unlinkable pairs. Total 
weight is a relative measure of the assurance of a correct link, not an absolute measure. It 
chiefly serves to rank the matched pairs in order of assurance, but does not indicate what 
the actual 'betting odds' would be. A threshold weight at which the records will be linked 
is set by clerical checking. Strictly speaking, total weights reflect only the likelihood or 
unlikelihood that the observed similarity of identifying information has arisen other than 
by chance. But the ruling out of chance does not necessarily establish that the same person 
is involved (Newcombe et al, 1983). For example, the similarity could be due to twins.
The accumulated frequency ratios take no account of the probability that a search record is 
in the file being searched, or the size of that file. For example, you might expect only 10% 
of your study population to have died, and thus appear in a death file. When relative odds 
only are used, a subjective threshold is set in the transition region from good to bad links. 
It would also be possible to subjectively set two thresholds to separate good, doubtful and
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bad links. The problem of establishing thresholds is a function of the far greater size of the 
nonlinks relative to the links.
, the more objective method of assessing the absolute odds (in Newcombe’s terminology) 
has distinct advantages, such as making it easier to detect unexpected sources of bias, and 
giving the true ‘betting odds’ that the record pair is correctly matched. Using absolute odds 
rescales the odds, and thus brings the subjective threshold closer to the odds point required 
(for example, 50:50).
The conversion formula is:
, i ^ , ,  „  . . ^ , # linked search records 1AbsoluteOdds=RelativeOdds x ------------------------------x ---------------------------------------
total # search records total # records being searched
where the search records are from the file initiating the search (for example, study 
subjects) and the records being searched are from the master file of information (for 
example, Registrar General Death records).
So the absolute odds in favour of a correct linkage, and its logarithm the absolute total 
weight, are determined by the prior probability that a search record will find a correctly 
matching record in a single random draw from the file being searched (made up of the 
probability that a correct match exists, and the number of records in the file) and reflect the 
relative odds of the combined frequency ratios. A further possible adjustment would be to 
make the absolute odds age-specific. For example, considering death records, a young 
person would be far less likely to appear in a death file than an old person, so year of birth 
agreement for a young person would carry more discriminating power than for an old 
person, in a given year.
When relative odds have been converted to absolute odds, the single optimum threshold 
(minimising linkage errors) is likely to be near the 50:50 odds point, although a different 
balance of false positive to false negative may be desirable. Thus, a conscious decision 
must be taken concerning the desired ratio of the two types of error (false match or missed 
link). However, a 50:50 absolute odds ratio serves only as a rough guide to placing an 
optimum threshold.
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The primary personal identifiers for linkage are sex, names, date of birth and geographical 
information. To avoid the problem of different spellings of surname, a phonetic code is 
used. There are two common phonetic coding systems, the New York State Intelligence 
Information System (NYSES) and the Soundex, of which the NYSIIS is considered to 
have more discriminating power. These codes suppress vowel information (with Soundex 
losing vowels completely, while NYSES at least retains a marker of where the vowels 
were) and replace certain consonants by a standard character representing that sound. Both 
the phonetically coded version and the alphabetical name should be compared, with the 
alphabetical comparison being conditional on an agreement on the phonetic code. An ‘ill- 
spelled name routine’ will detect levels of similarity between phonetic codes which are not 
exactly the same (for example, if there has been an insertion or deletion in a name), but the 
benefits of this must be balanced against the increased complication in calculating an 
appropriate frequency ratio. Cross-comparisons should also be used for initials as people 
may reverse the order of their given names. Adjustment factors should be applied for 
initials that agree so that rare initials raise the frequency ratio by more than common 
initials. E  there is reason to suspect that they could have been inverted, cross-comparisons 
could also be used for day and month of birth.
The comparison of given names was considered in more detail in a recent paper 
(Newcombe, Fair and Lalonde, 1992). Not all variations on given names are necessarily 
truncations which can be recognised simply by the computer. A human checker can 
recognise nicknames, ethnic variants, diminutives or misspellings, for example, Anthony - 
Tony, Joseph - Joe, William - Bill. If a machine is to acquire a similar ability, it must learn 
from past experience, in the same way as humans do. Some kind of grouping of possible 
synonyms is inevitable, but this must be exceedingly flexible if discriminating power is 
not to be wasted. Informal versions of names are more likely to be used on ‘alive’ records 
than on death records. For example, Statistics Canada has created a composite file of 
64,937 linked pairs of male given names derived from 26 different linkage projects 
involving the Canadian mortality database which gives the frequency of combinations of 
names which were correctly linked. The chief problem with this file is the high number of 
possible value pairs which are rare, or as yet unobserved in the available links. Grouping is 
necessary to bring rare synonyms into the same group as common forms, an unavoidably
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subjective process except that variants yielding widely different odds on their own should 
not be put into the same group.
There are various possible shortcuts to calculating the odds in favour of a match (each 
with corresponding refinements). For example, pooling of first and second given names - 
reducing the number of look-up tables for value-specific frequencies, recognising the 
specificities of only the agreement portion of names which partially agree, or pooling 
complementary partial agreements. However, these shortcuts result in slightly increased 
error rates (to extents which vary according to the specific values of the given names), so 
their merit must be balanced against the time and effort which they save. Only when the 
full specificities are taken into account does the discriminating power get efficiently 
exploited.
The emphasis in this paper (Newcombe, Fair, Lalonde, 1992) differs from that of 
procedures based on degrees of phonetic similarity plus lists of exceptions, in that both 
similarities and dissimilarities are recognised, and necessary data are drawn from large 
accumulations of linked pairs of records. Archiving empirical data from past linkage 
studies allows comparison of the performances of different systems, and facilitates 
semiautomated ‘learning’ from past experience. The approach described here follows a 
general trend in statistics to develop empirical reference distributions using computers, 
rather then rely mainly on theoretical distributions. The complexity of the procedures 
involved need not be a barrier, since once they have been developed, they can be used 
repeatedly for many different linkage jobs. However, Arellano warns (Arellano, 1992) that 
the data accumulated from previous linkages must represent the same population as the 
new linkage, for the ‘past experience’ to be of relevance. He also warned that routine 
cross-comparisons can be very wasteful of resources if the nature of the data does not call 
for them, since in most linkage evaluations, 85-90 per cent of correct linkages have exact 
agreement on name and birthdate. Before one can leam from past experience, there must 
also be a rigorous definition of a successful linkage exercise.
3.2.2 Formal theory
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While Newcombe and others at Statistics Canada focused on the more practical aspects of 
setting up a record linkage system, Fellegi and Sunter developed a mathematical theory to 
provide a framework for a computer-oriented solution to the problem of recognising those 
records in 2 separate files which represent identical persons, objects or events (Fellegi and 
Sunter, 1969). The theory leads to a linkage rule which is similar to Newcombe’s intuitive 
approach.
Notation
There are 2 populations, A and B, giving two files to be linked, La and Lb. Let a and b 
denote arbitrary elements of A and B respectively. It is assumed that some elements will 
be common to both populations.
The set of ordered pairs A x B = {(a,b);a e A,b e B} is the union of the matched pairs 
M = {(a,b);a = b,a e A,b e B} and the unmatched pairs U = {(a,b);a * b,a e A,b e B}.
The files for comparison, L A and L B , are produced by applying the record generating 
process to random samples from populations A and B. This process introduces some 
errors and incompleteness into the records, for example, from misrecording or data entry 
error.
The first step in attempting to link the records of the two files, LA and Lb, is the 
comparison of the records, which results in a set of comparison outcomes, consisting of 
an outcome for each individual comparison made between the two files.
The comparison vector is:y[a(a),/3(b)] = {y1 [ct(a),/5(b)],...... , y k[cc(a.),p(b)]} where
a(a) is the record for element a, (3(b) is the record for element b, and the Y may take the 
values ‘agree’ or ‘disagree’. For example, y1 could compare surname and y2  could 
compare year of birth. The set of all possible realisations of y is called the comparison 
space, and denoted T.
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In the course of linkage we observe y(a,b) and decide that either:
- (a,b) is a matched pair, (a,b)e M decision D j positive link
- (a,b) is an unmatched pair, (a,b)e U decision D 3 positive non-link
decision cannot be made at the )
> decision D 2 possible link
specified levels of error J
The Linkage Rule, L, is defined as a mapping from the comparison space T onto a set of 
random decision functions d={d(y)}
d(y)= (P(D  i ly),P(D2lY),P(D3ly)} y e T  f p ( D ; l T)= l
i= l
The conditional probability of y given that (a,b)e M, denoted by m(y), is 
P(y[ot(a),p(b)]l(a,b)sM)= £  P{y[a(a),|5(b)]}.P[(a,b)IM]
(a,b)eM
The conditional probability of y given that (a,b)eU is denoted as u(y) similarly.
The first type of error occurs when an unmatched comparison is linked (false match), 
and has probability
P(D,IU)=X u(y).P(D,ly)
y e  r
The second type of error occurs when a matched comparison is not linked (missed link), 
and has probability
P(D3 IM )=X rn(y).P(D3 ly)
ysr
A linkage rule on the space T  is said to be a linkage rule at the (error) levels 
(0<|I<1,0<X<1), denoted by L(|ii,A,,r) if P(DilU)=p, and P(D3 IM)=X.
The linkage rule L(|ii,X,r) is the optimal linkage rule if the relation P(D2 IL)<P(D2 IL') 
holds for every L'(|ii,A,,r). This optimal linkage rule minimises the probability of failing 
to make a positive decision.
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Main Theorem
A linkage rule Lo, defined on T with the ordered set {y} indexed by subscript i 
(Ui=u(yi),mi=m(Yi)) is the best linkage rule on T at the levels (p,,X) if Lo(|H,X,r) is 
defined as:
Take action Di if i<n-l
Take action D2 if n<i<n'-l
Take action D3 if i>n'+l
Take a random decision if i=n or i=n'
l<n<n'<Nr, ensuring that are an admissible pair of errors, and n, n' are chosen 
such that
n-l n Nr Nr
Xui</iSZui £mi>A>£
i-1 i= l  i=n' i= n '+ l
r a i
d(ri)=
(1 ,0 ,0 ) i < n - 1
1 0 i = n
(0 ,1 ,0 ) when «n < i < nv-l
(0,1- P „ P , ) i = n
(0 ,0 ,1 ) i > n '+ l
n-l
where U n .P ^ -^ U j and mn,.Px=A,- m ;
i= l i= n '+ l
" 1^; m (yn)
If n = y  u ; , X = /  m ; and we define the threshold levels T„ = —7 — f  andtt ' &  ' " u(yn)
ni f yn )
T, = —7 — 7 - then this leads to
»r.-
'(1,0,0) < m(r)/u(r)
d(y) = • (0,1,0) if • TA < m(y)/u(y) < 
(0,0,1) m (y)/u (y)< T A
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The use of threshold values and Tx makes it unnecessary to explicitly order the values 
of y in order to make decisions. Simply compare m(y)/u(y) to the threshold values. 
Since, in practical situations, the number of total configurations is usually very large, 
and Tx are estimated from a random sample of configurations.
This sample (size s) may be ordered by decreasing values of w(y)=log(m(y))-log(u(y)), 
and the hth member of the ordered listing denoted by yj,. Then P(w(y)<w(yh)lye M) is
probabilities that element are selected for the random sample and P '(w(Y)<w(Yh)lyeU) is 
h u (y
estimated by jiih = ^  h . The threshold values T(^h') and T(|UhO are simply the 
h = i n(y )
weights w(yh') and w(yh).
If error levels sufficiently high to preclude action D2  can be tolerated then n and n can 
be chosen so that the middle set of y is empty. Every record pair (a,b) will then be 
allocated to either M or U. So allocation of observations to one of two mutually 
exclusive populations by setting a single threshold level is thus a special case of the 
above theory.
The theory assumes that all possible record comparisons will be attempted, but in 
practice, to make the numbers feasible, comparisons will be made only within 
corresponding blocks. If the number of comparisons examined explicitly is thus 
restricted to a subspace T* then the probabilities in the theory above should be replaced 
with proportions. The subspace T* is then the set of y for which the blocking component 
has the agreement status, and all other y are implicit positive non-links.
In choosing the error levels (jx,A.) we may want to be guided by consideration of the 
losses incurred by the different actions.
G M ( D j )  and G u ( D j )  are non-negative loss functions which give the loss associated with 
decision Dj. Set Gm(Di)=Gu(D3 )=0.
estimated by where II(yh)=s/2 x z'(yh) and zv are the
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We seek the subspace T which minimises the total expected loss (when using a 
blocking procedure)
= C{P(M)[P* (D 2 |M)Gm (D2) + X*Gm (D3 )] + P(U)[|i*Gu (D ,) + P* (D2 |U)Gu (D2)]}
+  G r , ( L a x L b )
where c is the number of comparisons in LaXLb.
If the processing cost of comparison under any blocking T* is proportional to the 
number of comparisons c*, that is Gf. (La x  L b ) = ac , then we can minimise
*
P(M)[p’ (D 2 |M)Gm(D2 )A,*Gm(D3)] + P(U)[|1 *Gu (D1) + P*(D2 |U)Gu (D2)] + — .
0
No explicit solution to this is possible under general conditions, but it can be used to 
compare two different choices of T*. Once T* has been chosen, the ‘theoretical’ error 
levels jli,A, can be chosen so that the actual levels ji ,  X* meet the error specifications.
The basic Fellegi-Sunter model assumes conditional independence of comparisons, in 
order to allow estimation of the probabilities. Fellegi and Sunter believed that their 
model was reasonably robust to departures from independence, but methods have now 
been developed to adjust for lack of independence, as described elsewhere (Winkler, 
1989).
Recent advances in methodology include the use of an EM algorithm for parameter 
estimation (which is not sensitive to starting values), optimisation of matches by means 
of a linear sum assignment program, and a probability model that addresses both m and 
u probabilities for all value states of a field (Jaro, 1995).
3.2.3 A practical approach
The standard approach to starting a new linkage job is to initially make use of frequency 
ratios obtained in a previous job. After running the matching algorithm, a clerical check of 
borderline links is carried out, and then numerators (based on the file of linked pairs), and 
denominators (based on the file of randomly matched unlinkable pairs) are updated.
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Updating for each new job would not be necessary if we could assume that the quality of 
the data in the file initiating the search was essentially the same as that in the file being 
searched. However, this is rarely the case, so a file of randomly matched unlinkable pairs 
should be created routinely as part of each linkage job.
Full comparison of every record in the file initiating the search against every record in the 
file being searched would render linkage impractical for all but very small files. To avoid 
such unnecessary work, crude methods of comparison are used first, to exclude the 
majority of candidate pairs for linkage.
A common strategy is:
(i) Block file on phonetic code of surname and date of birth (to avoid creating most 
of the potential pairs)
(ii) Examine key identifiers, for example initials or date of birth and exclude pairs 
where there is no agreement
(iii) Examine all available identifiers for remaining pairs
(iv) Use clerical checking for pairs with borderline overall odds in favour of a link.
Blocking involves partitioning both files into mutually exclusive and exhaustive subsets, 
and only looking for matches within each subset. To avoid missing links because of errors 
in a blocking variable, it is necessary to make two blocking searches [for example, block 
on Soundex and block separately on date of birth]. Comparison of all identifiers can be 
cut-off when a record pair is seen to be unlinkable. A fixed threshold is implied for the 
complete accumulated frequency ratio. Less favourable accumulated ratios are tolerated 
until the remaining steps cease to hold any prospect of restoring the balance to an 
acceptable level at the end. For comparisons with a small number of outcomes, it is 
logically simpler to make the comparisons value-specific from the beginning rather than 
carrying out a conversion step later.
When there may be several records relating to the same person, problems of competing 
linkages may be lessened by carrying out internal linkages within the two files prior to the 
external linkage of the two files, and then linking the whole patient group to the external 
search record.
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There are 6  main sources of linkage error:
1) Disagreements on the blocking identifiers, for genuinely linkable pairs.
2) Inappropriately placed thresholds resulting in unnecessarily high numbers of errors.
3) Lack of discriminating power in the identifiers common to a record pair.
4) Underuse of the discriminating power - too few outcome levels.
5) Correlation between identifiers.
6 ) Imbalance between false positives and failures to achieve potential good links.
It has been suggested that where linkage results are to be used only for statistical purposes, 
false positive and false negative links are tolerable so long as they balance out one another. 
Thus, it may be adequate to simply place the threshold in the middle of the doubtful links. 
The problem arises in actually implementing this suggestion, since the only way to ensure 
that the false positives and false negatives are balanced is to verify the borderline links. 
While a balance may be sufficient when looking at counts of events, it is not appropriate 
when outcome records are to be related to external variables. An alternative approach is to 
carry out statistical analyses on results using three different thresholds. The middle one 
will be the likely best threshold with the other two being deliberately set too high and too 
low. If the same statistical associations hold for all three thresholds, then they are unlikely 
to be due to an imbalance between the false positives and false negatives.
3.3 Alternative models
The Tepping model for record linkage (Tepping, 1968) uses the same underlying 
framework as the Fellegi-Sunter model, but has no restriction on the number of possible 
decisions and makes ‘cost’ an explicit element of the model. ‘Cost’ here relates to both the 
costs incurred by decision D2 leading to more clerical checking being required, and the 
cost of losses associated with matching errors. For each decision Dj, cost is assumed to be 
a function of the conditional probability of a match, and the linkage rule is: For any 
P(matchly), choose the Dj with the smallest cost. The main consideration in choosing 
between the Tepping and Fellegi-Sunter models would be the feasibility of estimating
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the parameters, which are different for the two models (Jabine and Scheuren, 1986). The 
idea of a model involving minimisation of a cost function was first introduced by Nathan 
in 1967, but the simple model he proposed assumed that the information used for 
matching was complete and invariant, which is rarely the case.
Some other alternatives to the subjective probability model described by Fellegi and 
Sunter in 1969 were discussed by Copas and Hilton in their 1990 paper. Their work was 
based around the linkage of information on non-EEC citizens arriving in the UK with 
information on those leaving the UK, as part of a project for the Home Office.
The hit-miss model (Copas and Hilton, 1990) envisages a binary trial which results in a hit 
(where identifying information agrees exactly) with probability 1 -a and a miss with
probability a. For a given true record T, a hit results in X=T, but for a miss, the observed
record X is randomly distributed over all possible values in proportions similar to the 
overall incidence of true values (a miss may by chance lead to the record being correct).
a P i  i *  j
l - b - a ( l - p i )  i = j
b i o r j  = blank
P(X=ilT=j)= Ojj=
where pi =Xjpij, estimated by the overall relative frequency of value i among non-blank 
records, and b=probability that T is recorded as blank.
The model asserts that the off-diagonal cells in the nxn contingency table for matched 
pairs show a pattern of independence.
The log-likelihood ratio for the pair (i,j) under the hit-miss model is 
Tog c + 2 1 og(l-b) i *  j
• log{l - c(l - b ) “ 2 ( 1  -  /3j)} -  log i = j
[ 0  i o r j  = blank
where c=a(2-a-2b). Therefore, a pair with one or both records missing gives no matching 
information, and all discordant pairs give the same likelihood ratio. In practice, double 
blanks should often be thought of as ‘agreements’ since a person may genuinely not know 
an item of information. This can be modelled by taking b as a random effect, which results 
in double blanks giving evidence for a match, and single blanks giving evidence against a 
match. The levels of agreement approach, as described earlier, which is most closely
73
related to the hit-miss model is simply to note whether the pair of records agree or 
disagree. The use of adjustment factors to update global frequency ratios to value-specific 
frequency ratios (see section 3.2.1 and Newcombe, 1988) gives likelihood ratios which are 
similar, although not identical, to the ratios achieved by fitting a hit-miss model.
Use of extended models allows the strong assumptions of symmetry to be relaxed, but, if 
they are to be useful, they should only involve a relatively small number of extra 
parameters. Further examples of more specific models are discussed in Copas and Hilton 
(1990), including models which address the problems of highly correlated identifiers.
An alternative to a subjective probability model would be to use an expert system, 
although the added complication is unlikely to improve the accuracy of record linkage to 
any significant degree, in practice. Research into the use of neural networks in this area is 
currently being carried out by Gill and colleagues at the Oxford Record Linkage Study.
3.4 Medical record linkage in Scotland
For many years, Scotland has held sets of computerised medical records at a national level. 
In 1968, Heasman first outlined the potential for bringing these records together into 
patient groups using sex, surname, initials and date of birth (Heasman, 1968). He proposed 
linking intra-hospital and death records first, but thought it might be possible to 
incorporate cancer registrations and mental hospital records at a later date. The problems 
he anticipated at this stage included variation in identifying details on the records relating 
to the same person (leading to possibly 1 in 2 0  matches, or failures to match being 
incorrect) and issues of medical confidentiality. The potential for mismatches meant that 
this system could not be used to access records for use in the clinical care of a patient or 
for administrative decisions concerning individuals.
Throughout the next decade a system was set up to collect together medical records for an 
individual, and to enable the linked data to be used for epidemiological and health services 
research (Heasman and Clarke, 1979). The Scottish Record Linkage System (SRL), which
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is based at the Information and Statistics Division (ISD) of the National Health Service in 
Scotland, uses only records which are required for routine health statistical purposes. 
There is no extra data collection involved. The patient matching depends on the fact that 
less than one per cent of individuals have the same surname, initials, sex and date of birth, 
out of the Scottish population of approximately five million. At this stage, a new linked 
file was specially created for each project, making the procedure expensive and time 
consuming.
In 1989, development began of a new system in which all records for individual patients 
would be permanently held together in a linked data set (Kendrick and Clarke, 1993). At 
present, the morbidity data set holds hospital discharge (SMR1) records since 1981 
together with Scottish Cancer Registry records (SMR6) and Registrar General’s death 
records - over 12 million records in total. Another linked data set holds patient groups of 
psychiatric hospital admission (SMR4) records since 1970. Other records are not on a 
linked database, but are available for ad hoc linkage to other files.
3.4.1 Scottish national data sets
The national data sets which will be used in this thesis are now described.
SMR6
The Scottish Cancer Registration Scheme had its origins in a system set up in 1936 by the 
National Radium Commission to record the progress of radiotherapy patients. It is now 
one of a number of Scottish Morbidity Record (SMR) Schemes, and information is 
collected on a standard form known as an SMR6 (see Appendix C). The scheme registers 
individual primary tumours, which must be registered separately even when they occur on 
the same individual (Common Services Agency, 1990). Scotland is divided into 5 regional 
registries, which submit data to the Information and Statistics Division (ISD) of the 
Common Services Agency of the Scottish Health Service, in Edinburgh. Notification 
comes to the registries from pathology departments, haematology departments,
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radiotherapy departments, hospital medical records departments, the General Register 
Office (post-mortem information) and nursing homes.
An attempt has been made to validate central registration data on all childhood leukaemia 
cases in Scotland between 1968 and 1981 (Glass et al, 1987). It was found that 44% of 
these registrations contained minor errors, including 41 minor diagnosis differences out of 
the 629 records on the cancer registry. A further 6 records had wrong diagnoses and 8 
leukaemia cases identified from hospital notes did not appear on the cancer registry.
SMR1
Scottish Hospital Inpatient statistics come from SMR1 forms (see Appendix C) which 
have been completed since 1961 for all inpatient and day case discharges, deaths or 
transfers from Scottish non-psychiatric, non-obstetric wards. Since 1989, information from 
the SMRls has been used to plan the financial management of hospitals, but their 
completion is often delegated to clerical staff and unsupervised by clinicians.
An audit of the accuracy of recorded SMR1 data for a single ENT operation (Denholm et 
al, 1993), taking the theatre book completed twice daily by the sister-in-charge to be the 
gold standard, found that the SMR1 had the correct operation code for 88% of these 
operations performed, although the coding errors mainly related to other ENT procedures 
and were not too serious. A review of a sample of discharges in Greater Glasgow Health 
Board in 1987 for gastrointestinal diagnoses (Kohli and Knill-Jones, 1992) identified 
minor disease coding errors for 3.8% of cases, intermediate errors for 0.8% and major 
errors for 0.8%.
SMR4
Scottish Psychiatric Inpatient statistics come from SMR4 forms (see Appendix C). The 
current version of the form came into effect in 1986. These forms are in two parts. The 
first part is submitted to ISD on a patient’s admission, and the second part is completed on 
discharge.
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SMR20
In 1981, the SMR20 (see Appendix C) scheme was set up to provide accurate information 
on the position of cardiac surgery in Scotland. The Scottish Cardiac Surgery Register 
collects information on patients who are on the waiting list for cardiac surgery, as well as 
those actually admitted to hospital, and enables quarterly checks to be carried out on the 
extent of cardiac surgery waiting lists. Consultants in Public Health Medicine in each 
Health Board area are responsible for the local collection of data for the Register 
(Common Services Agency, 1990).
Other records
ISD also holds a file of death records which can be used in linkages. This data does not 
‘belong’ to ISD however, but to the Registrar General for Scotland. ISD receives an 
update file from the General Register Office (GRO) at 3-monthly intervals.
3.4.2 Methods in use in the SRL system
The basis of forming a linked data set is the comparison of 2 records, and the decision as 
to whether or not they relate to the same individual. For each of the main items of 
identifying information used to link records there may be a discrepancy rate of up to three 
per cent in pairs of records belonging to the same person due to errors in recording, so 
exact matching could miss many true links. To allow for imperfections in the data, the 
Scottish Record Linkage System uses methods of probability matching (Kendrick and 
Clarke, 1993) which have been developed over the past 30 years in Canada (Newcombe, 
1988), Oxford (Acheson, 1987) and in Scotland itself (Heasman and Clarke, 1979). 
Probability matching is useful as all computer records are liable to error or variability - 
people move house, and women change their surname when they get married, in addition 
to differences in spelling of names and errors in writing down data, deciphering hand­
writing and at data-entry. In the medical context, errors may occur through misrecording of 
information due to conditions of stress. These errors mean that two records for the same 
person may not agree, while two records which do agree may relate to different people.
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As well as maintaining the linked datasets described earlier, the Scottish Record Linkage 
System provides facilities for ad hoc linkages with other data sets available at ISD, or the 
linkage of external files to the linked datasets. An external dataset could consist of, for 
example, identifying information for patients being followed up as part of a clinical trial. 
New data are linked into the main linked databases on an annual basis, and for this reason 
the databases could not be used as an administrative system for tracking individual 
patients, as well as the probabilistic basis of the linkage techniques leading to a small 
proportion of mismatches. Records are stored together in a flat file, in chronological order, 
retaining their original unlinked format preceded by fields of linkage information such as a 
unique personal identifier for each patient group, and a marker indicating which SMR1 
records refer to the same period of continuous in-patient stay. This stay marker is useful 
since separate SMRls are completed for transfers between hospitals, specialties and 
consultants. The holding of records in patient groups is also useful for carrying out 
subject-based rather than episode-based analysis. Since the different types of records have 
different formats, they are usually accessed via FORTRAN programs.
The computer matching algorithm calculates a score for each pair of records, which is 
equivalent to the odds that they belong to the same person. The overall score is the sum of 
the scores derived from the comparison of each item of identifying information. The 
comparison scores are weighted according to the rarity of the information. For example, if 
both records have the first initial J, the score is increased by a small amount, but if both 
records have the first initial Z, the score is increased by a larger amount, reflecting the fact 
that agreement on an uncommon initial increases the probability of a match much more 
than agreement on a common initial. Similar negative weightings are applied to the level 
of disagreement between items. Items of identifying information contributing to the score 
should be statistically independent as far as possible.
The basic core of identifying information used is:
1) Surname (and it’s phonetic code to overcome differences in spelling)
2) First initial (also full forename and second initial when available)
3) Sex
4) Year, month and day of birth
5) Postcode
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The phonetic code used at SRL for the surname is the Soundex code. It has been found to 
remain unchanged in about ^  of the spelling variations observed in linked pairs of
records (Newcombe, 1967), and it sets aside only a small part of the total discriminating 
power of the full alphabetic surname, although it is less satisfactory for Oriental names. 
The Soundex coding system reduces a name to a code consisting of the leading letter 
followed by 3 digits. All vowels after the first letter are ignored, as are W and H. The 
remaining letters are coded as 1 (B,P,F,V), 3 (D,T), 4 (L), 5 (M,N), 6  (R) and 2 (all other 
consonants). If the name has fewer than 3 coded letters, trailing zeros are added. A 
Soundex weight is assigned to each code, reflecting the rarity of the Soundex code 
throughout the Scottish population as a whole. Soundex codes applying to relatively 
common surnames will have low weightings, whilst codes for rare surnames will have the 
maximum weighting of 15.00. The Soundex weight is used by the computer matching 
algorithm in the calculation of the comparison score.
Additional identifying information could be used for specific types of linkage, for 
example, hospital case reference number could be used for internal SMR1 linkages, or 
date of discharge could be compared with date of death for linkage of SMR1 and death 
records.
In order to cut down on the number of comparisons required, the records are blocked on
1) Phonetic code of surname and first initial
2) Date of birth
Full comparison is only carried out for records which agree on either of the blocking 
criteria.
A common problem is that people sometimes use their middle name for everyday 
purposes, and this is entered as forename on hospital records, so cross-comparison of first 
and second forename initials is also carried out.
Each data set has its own problems, so the distribution of scores varies for different 
linkages. The threshold (that is, the score at which the decision to link is made) is 
determined by clerical checking of a sample of pairs of records, for each linkage carried
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out, and is usually placed where the implied odds in favour of a correct match are 50:50 or 
better.
The system is designed to operate on the basis of the computer matching algorithm as far 
as possible, with minimal clerical checking. It will be described further in the next chapter, 
in the context of a practical linkage exercise involving the West of Scotland Coronary 
Prevention Study. Specific groups of records are, however, targeted for clerical 
monitoring, for example subjects with 2  death records, or with a hospitalisation occurring 
after a death record. Clerical checking of the main linked database has shown that both the 
false positive (incorrect links) and false negative (links missed) rates are around 1 per cent 
for internal ISD linkages where the national data sets are linked into patient groups. Since 
each record in a patient group will have been compared with every other record in that 
patient group, the likelihood that one or more records in the group does not correctly 
belong to that group increases as the group size increases due to the cumulative errors of 
each pairwise comparison. Clerical checking would improve the quality of the linkage 
even further, but would require much time and expense. Computerised record linkage is 
valuable if it identifies a high proportion of true events of interest, whilst keeping clerical 
checking to exclude ‘false positives’ to manageable proportions. Also, it’s cost should not 
exceed that of alternative methods of follow-up.
3.5 Record linkage outside Scotland
Canada
The earliest probability linkages were carried out as an experiment by Atomic Energy 
Canada in the 1950s, in an attempt to keep track of individuals who had been exposed to 
low-level radiation (Newcombe et al, 1959). S.J. Axford of Statistics Canada first 
suggested phonetic coding of surnames, and blocking records by surname. A decade later, 
the linkage rationale was restated and expanded into a formal mathematical theory by 
Fellegi and Sunter at Statistics Canada (Fellegi and Sunter, 1969) as described earlier. 
Close scrutiny of actual linked and unlinkable files provided insights which would have 
been missed if refinements had only been sought through developing theory. Statistics
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Canada has now developed an all-embracing system to deal with many diverse linkage 
jobs involving the Canadian mortality database which extends back to 1950. This system 
was previously known as GIRLS (Generalised Iterative Record Linkage System) and 
described in detail elsewhere (Howe and Lindsay, 1981). It is now known as CANLINK. 
This system involves iterative updates of outcome frequencies for new linkages and the 
setting of two subjective thresholds to separate links, non-links and possible links.
California
In 1981, the California Automated Mortality Linkage System (CAMLIS) was set up to 
facilitate the conduct of follow-up studies in California (Arellano et al, 1984). It uses 
probabilistic linkage decision criteria to perform mortality searches. CAMLIS offers a 
rapid, accurate and cost-effective means of accessing the California state mortality files 
and has been shown to have both reasonably high sensitivity (0.89-0.97) and specificity 
(0.93-0.99).
The Netherlands
Probability linkage has also been carried out in the Netherlands, although a formal system 
has not been set up for running linkages repeatedly. For example, an assessment was 
carried out to compare the completeness of cancer registration on the Limburg regional 
cancer registry and the GP’s centralised database, using record linkage techniques 
(Schouten et al, 1993). If the information on the 2 databases differed, it was verified using 
the source forms at the registry and by contacting the GP concerned. By combining 
information from the 2  files, it was determined which malignancies should have been 
registered. The cancer registry had recorded 307 out of 319 eligible malignancies (96.2%), 
with 5 of the 12 missed being due to systematic shortcomings in the notification 
procedures.
Oxford
The Oxford Record Linkage Study (ORLS) was founded by E.D. Acheson in 1962, as a 
pilot study to investigate the feasibility and cost of collecting records about medical 
events and linking these records, by computer, on a person and family basis, develop 
computer methods of record linkage, study applications of the files in medical and 
operational research, and if successful, promote it’s extension on a national basis
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(Acheson, 1987). Data collection began in 1963 and covered around 350,000 people. By 
1982, this had been extended to the whole of the Oxford region and part of Berkshire, 
(approximately 2.3 million people). Data are collected on general, maternity and 
psychiatric hospitalisations, births and deaths, and linked together using methods similar 
to those employed by the Scottish Record Linkage System, as described earlier. The 
linked database is particularly useful for analysis which requires unduplicated counts of 
people and studies of successive events since all the records are grouped into patient 
record sets (Goldacre, 1986), but extension to a national database has proved impractical 
in England and Wales.
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Chapter 4 
Record Linkage and WOSCOPS
4.1 Record linkage as a method of subject 
follow-up
The existence of Scottish national databases covering all deaths, incident cancers, 
hospitalisations, psychiatric hospitalisations and cardiac surgical procedures provides 
the opportunity to use record linkage techniques as an alternative method of follow-up 
for patients who have been randomised into clinical trials or are members of a screened 
cohort.
4.1.1 Clinical Trials
In a hospital based clinical trial the patients are well motivated and it is relatively easy to 
maintain contact with them and obtain information on adverse events occurring during 
the trial. Studies conducted in the community, especially primary prevention trials, often 
have very large numbers of subjects selected from a wide population base, making it 
more difficult for investigators to maintain contact with each subject. In primary 
prevention trials, the subjects are generally disease free and hence are less well 
motivated to comply with the study protocol. In many cases, follow-up is carried out 
independently of the subject’s general practitioner and thus the quality of the data 
collected substantially depends on the goodwill of the patient in attending visits and 
reporting events. Poor attendance at follow-up visits can lead to incomplete reporting of
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adverse events and study endpoints. In a clinical trial, withdrawals and defaulters will 
not necessarily be spread evenly among the study treatment arms, leading to the 
possibility of bias in the reporting of efficacy and in the adverse event profile of the 
treatments being tested in the study. Withdrawal rates can be high. For example, by the 
end of the Helsinki Heart Study (Frick et al, 1987), approximately 30% of the subjects 
had withdrawn from study medication. Although many of these subjects may have 
maintained regular contact with the study, there is clearly greater potential for 
incomplete reporting of clinical events in this group of subjects. In some countries 
(including Scotland) there are national death and cancer registries with which subjects 
can be flagged to reduce the effect of the problem of under-reporting. However, non- 
fatal events, which may be of particular interest in some studies, are not always 
available. The cost of maintaining completeness of follow-up and documentation of 
serious adverse events, particularly hospitalisations, is also a major limiting factor in the 
design of large-scale clinical trials. Any method which can reduce costs and yet retain 
adequate levels of reporting is worthy of serious consideration.
Record linkage provides an alternative, cost-effective method of subject follow-up 
using national databases, which is unaffected by the subject’s compliance with the study 
protocol, and attendance at trial visits. It does not require any further contact with the 
patient once identifying information has been recorded.
4.1.2 Epidemiology
As is the case for clinical trials, in epidemiological studies the cost of patient follow-up 
can be prohibitive, although a baseline visit for the measurement of risk factors may be 
feasible. Computerised record linkage systems can be used to search databases of 
outcome data collected for another purpose (for example, routine Health Service data in 
the case of the Scottish Record Linkage System) for the study participants, as an 
alternative to active follow-up of the individual subjects. However, this is only 
appropriate if such systems can be validated. Computerised record linkage is particularly
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cost-effective when a large number of subjects is involved, as increased number of 
subjects makes only a small difference to the costs involved in record linkage, whereas 
the costs of individual subject follow-up would increase substantially. Neutel et al 
(1991) recommend the use of record linkage procedures to reduce the cost and time 
required by follow-up studies. Cost obviously increases with the number of subjects 
involved, the duration of follow-up and the size of the area covered.
The advantages and disadvantages of using record linkage techniques in the 
epidemiological context are similar to those in the context of clinical trial follow-up.
The advantages include:
1) Cost-effectiveness - epidemiological studies frequently require data on many 
subjects, collected at different points in time. While record linkage is not cheap, it 
is considerably cheaper than the alternative methods of follow-up.
2) Fewer subjects lost to follow-up - record linkage will continue to identify 
records relating to subjects who have moved house (although the certainty of 
subject identification will be lower), or simply lost interest in the study.
3) Reduction in recall bias - since the outcome data is produced routinely by 
hospitals and does not rely on the subject’s memory.
4) Unobtrusive data collection - since direct contact with the subject is no longer 
required in order to obtain accurate information on outcomes.
5) Opportunities to consider whole populations and to obtain results quickly for 
any new hypothesis of interest, since a database covering many outcomes is 
readily available and there is no need to wait for more data to be collected.
The disadvantages include:
1) Inflexible data - since the data being linked to was originally collected for 
another purpose, it may be impossible to get information on the variables of 
interest.
2) Subjects lost to follow-up - missed linkages due to errors in identifying 
information, subjective positioning of the threshold linkage score or events not
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detected on the database being linked to (for example, events occurring outside the 
area covered by the database). This will be important if the subjects lost to follow- 
up differ in exposure and outcome from the rest of the subjects involved in the 
study.
3) Data overload - the ease of data acquisition and analysis can lead to ‘trawls’ of 
the data in a search for significant results.
4.2 Aims of this project
The primary objective of this project was to set up computerised record linkage systems 
for the WOSCOPS subjects.
The first system was to be used for the 6595 randomised subjects and encompass both 
routine linkages to the linked databases held at the Scottish Record Linkage System 
(SRL), and ad hoc linkages to unlinked databases of more recent records.
The second computerised record linkage system was to be used for the cohort of 
subjects who attended an initial screening visit for the WOSCOPS study. Although 
around 105,000 subjects were screened, only 97,165 had sufficient subject identifying 
information to make follow-up by record linkage possible.
These record linkage systems were to be set up so that it would be relatively 
straightforward to re-run the linkages repeatedly as more years of follow-up were 
accumulated. This was considered an important aspect since the more meaningful 
epidemiological data involves many years of follow-up and it’s acquisition will extend 
beyond the end of this particular project. Cancers, in particular, may take many years to 
develop.
For the clinical trial arm of the project, a comparative study was to be carried out, in 
which adverse events obtained by record linkage for the 6595 randomised subjects 
would be compared with the events on the WOSCOPS database of adverse events 
identified by individual subject follow-up. The aim was to provide an assessment of the
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effectiveness of each of these methods of subject follow-up. Further ad hoc linkages 
were to be carried out to 1994 and 1995 records where available, to provide additional 
information on events, for the WOSCOPS randomised subjects. However, only data up 
to the end of 1993 was to be included in the comparative study, in order to guarantee 
adequate time for the data to have been reported by the subject and to pass through the 
WOSCOPS reporting system.
For the epidemiological branch of the project, computerised record linkage provides the 
only feasible method by which adverse event information can be obtained for the 
WOSCOPS screened cohort. The adverse events identified by record linkage for the 
screened cohort were to be analysed in order to investigate the relationships between 
baseline risk factors and coronary heart disease, cancer, trauma and all-cause mortality 
as described in chapter 1. Analysis was to focus mainly on the group of 45-64 year old 
men who were targeted by the screening process. There was also interest in the 
screened women on their own since the majority of previous studies of coronary heart 
disease have focused on middle-aged men and it is unclear whether the same 
relationships among baseline risk factors and patterns of disease are applicable to 
women. Laboratory data such as fibrinogen levels are currently of great interest in 
relation to coronary heart disease and were to be examined for associations with 
mortality outcome determined via record linkage. Laboratory measurements are only 
available for the approximately 13,600 men who reached screening visit 3. The main 
constraint on the analysis possible for the screened cohort was the need to maintain 
subject anonymity. Adverse event data were available only by a category of baseline risk 
factors and was not identifiable at an individual subject level.
The final objective of this project was to compare the event rates observed in the 
screened cohort with the event rates observed in the general population in the area of 
screening as defined by postcode sectors.
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4.3 Author’s contribution to this project
The specific contribution made by the author to addressing the aims of this project were 
as follows:
1. Co-ordination of the postcoding exercise for the 6595 randomised subjects and the 
97,155 addresses available for the screened cohort. This involved address editing prior 
to sending a file of addresses to Greater Glasgow Health Board for postcoding, liaison 
with a postcoding bureau for the 29,310 screenee records not coded by the Health 
Board, and supervision of the manual postcoding of the records not coded by the Health 
Board or bureau (see section 4.4). All known addresses for each randomised subject 
were postcoded in order to maximise the identifying information which would later be 
available for record linkage.
2. Production of files of linking information for the randomised subjects and the 
screened cohort. A duplicate record was produced for any change in recorded 
identifying information for a randomised subject (see section 4.4).
3. Development of one-pass linkage programs (see section 4.5)
a) to take advantage of characteristics of the WOSCOPS data sets and
b) for use with other SMR records [one-pass programs had previously been used only 
for SMR1 and death records].
4. Linkage of randomised subjects to linked databases of SMR1, SMR4, SMR6  and 
Registrar General Death records until the end of 1991. These linkages were repeated for 
SMR1, SMR4, SMR6  and Death records until the end of 1992, and then for SMR1, 
SMR4 and Death records until the end of 1993, as these years of data became available. 
The randomised subjects were also linked to SMR20 records until April 1994. This was 
achieved on the first linkage run since the SMR20 database was on-line (that is, 
updated to current date). The SMR databases were described in section 3.4.1.
5. Ad hoc linkages of the randomised subjects to interim, unvalidated files to provide 
warning of events occurring in 1994 and 1995. These ad hoc linkages were carried out 
to obtain the most up-to-date information possible towards the end of the follow-up 
period for the clinical trial branch of WOSCOPS. Setting up this system involved 
modification of programs used by staff at SRL, for use with unlinked databases. 
However, a full comparison to assess the completeness of each method of follow-up was 
not carried out for these later ad hoc linkages, since the completeness of this data could 
not be guaranteed. They are thus not discussed in any detail in this thesis.
6 . Linkage of the screened cohort to the linked database of SMR Is until the end of 1993, 
deaths until the end of 1993, and SMR6 s until the end of 1992. This exercise involved 
further adaptation of the programs used at SRL, to accommodate the large number of 
subject records since there was insufficient computer memory to store all the 
WOSCOPS records at once and carry out each linkage in a single run.
7. Comparative study for the randomised subjects. The comparison of the adverse events 
identified by record linkage and by individual subject follow-up allowed an assessment 
of the advantages and disadvantages of these two methods of subject follow-up in the 
context of a clinical trial, and an assessment of the accuracy of the probabilistic record 
linkage process employed by SRL. The comparison exercise is in some ways similar to 
carrying out a second linkage exercise, linking specific events on 2  separate databases 
(WOSCOPS and SRL identified events) as opposed to linking subjects to their own 
records on the Scottish national databases as described in Chapter 3. This comparative 
study was carried out twice. Records until the end of 1991 were compared in the first 
instance (West of Scotland Coronary Prevention Study Group (in press)). The 
comparison exercise was then repeated for cancer registrations until the end of 1992, 
deaths and hospitalisations until the end of 1993 and cardiac surgery registrations until 
April 1994 (see chapter 5).
8 . Development of procedures for the investigation of events identified by linkage but 
not currently on the WOSCOPS database (in consultation with a clinical research
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associate), and keeping track of these events throughout the investigation process. These 
events were investigated to verify whether or not they did truly belong to the 
WOSCOPS subject, and , if so, whether there was any reason why the event was missed 
by WOSCOPS. It was hoped that previously unidentified adverse events, would mainly 
relate to subjects who had withdrawn from taking trial medication or who had been 
defaulting from their scheduled trial visits. Procedures were then developed for the 
documentation of new events found by linkage (in consultation with a clinical research 
associate and staff at the Data Centre). The database of adverse events identified via 
record linkage was thus used both to support and to supplement existing WOSCOPS 
adverse event reporting, so that the national databases enhanced the validity of the final 
serious adverse event report on the WOSCOPS clinical trial.
9. A comparison of the linkage quality achieved with screening visit 1 data and with 
updated prepped data (see section 5.4.1), and a comparison of the linkage quality 
achieved with postcoded and unpostcoded data, for the randomised subjects for deaths 
until the end of 1993 (see section 5.4.2).
10. Management of resolution tables for all linkage derived records brought to the Data 
Centre for the randomised subjects.
11. Production of categorisations by which the events identified by linkage for the 
screened cohort could be extracted and analysed whilst maintaining subject anonymity 
(see chapter 6 ).
12. Analysis of data for the screened cohort (see chapter 6 ). This analysis by category 
was carried out for mortality in three groups of subjects:
-  approximately 80,000 45-64 year old screened men, by a general category of CHD 
risk factors
-  approximately 14,000 screened women, by a general category of CHD risk factors
-  approximately 13,000 men who reached screening visit 3, by a category based on 
laboratory measurements.
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Analysis was also carried out for the hospitalisations and cancer registrations for the 
group of 80,000 screened men.
13. Examination of mortality rates observed in the population in the area of screening 
(as defined by postcode sectors) and calculated from data on deaths in the general 
population, obtained from the Registrar General for Scotland, along with the 1991 
census data. These mortality rates in the screening area population were compared to the 
rates observed for the screened cohort in order to address the question of how 
representative a screened cohort is of the general population, in terms of mortality rates, 
(see chapter 7).
4.4 Preparation of WOSCOPS data for 
linkage
In order to carry out record linkage, it was necessary to first produce files of identifying 
information for the 6595 randomised subjects and the 97,165 screened subjects. The 
identifying information used in the WOSCOPS linkages was
1) Surname (and it’s phonetic code - Soundex)
2) First initial (or full forename and second name depending on the file being linked to)
3) Sex
4) Day, month and year of birth
5) Postcode of home address
For the 6595 randomised subjects, these data were extracted from the computer file 
containing data entered from the WOSCOPS SCI form (see Appendix A). The file of 
linking information contained a duplicate record for each known address for a subject, 
enabling more accurate linkage to SRL records occurring at different points in time. 
Prior to producing this file, a postcoding exercise was carried out, as the postcode had
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not been obtained consistently. For the 6595 randomised subjects, every known address 
for the subject was postcoded (that is, baseline address, and any notified changes of 
address). These records were sent to Greater Glasgow Health Board where an auto­
postcoding algorithm succeeded in postcoding approximately two thirds of the 
addresses. The remainder were postcoded manually by WOSCOPS Data Centre staff.
For the cohort of 97,165 subjects who attended an initial screening visit the file of 
identifying details was based on the information recorded at this visit. As for the 
randomised subjects, a postcoding exercise was carried out for the 97,155 screenee 
records for which an address was available. 1 0  subjects had no address but were 
included in the linkage since name and date of birth information was available. On this 
occasion, Greater Glasgow Health Board succeeded in autopostcoding 67,845 records 
(approximately two thirds as before). The remaining 29,310 records were sent to 
Chester for bureau postcoding. The bureau successfully postcoded 27372 addresses, and 
provided a breakdown of the completeness of their postcoding (see Table 4.1). As a 
quality control check, the first 1 0 0  addresses which had been sent to the bureau were 
clerically checked by a member of the Data Centre staff. It was found that 91 addresses 
had been postcoded correctly, 1 had not been postcoded and 8  had been assigned a 
doubtful postcode. The 1937 UK addresses still remaining without a full postcode were 
postcoded manually by WOSCOPS Data Centre staff.
Postcode Status Number of records
Full postcode 27372
Partial postcode 951
No postcode - UK 986
No postcode - foreign country 1
Total 29310
Table 4.1 Completeness of the postcoding carried out by the bureau. This was for the 29,310 addresses 
relating to the screened cohort which had not been successfully postcoded by Greater Glasgow Health 
Board.
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4.5 Record linkage at SRL for WOSCOPS 
subjects
The computerised record linkage exercise was carried out using linkage programs written 
by staff at SRL and designed for the linkage of external data to Information and Statistics 
Division (ISD) datasets. These programs were modified to take advantage of the 
characteristics of the WOSCOPS datasets. A general account of the principles involved is 
given elsewhere (Scottish Record Linkage Team, 1995). Linkage was based on the one- 
pass method, in which the WOSCOPS records were read into memory and blocking was 
carried out using indexes, so that the records on the linked database could each be 
considered sequentially, and this huge dataset didn’t need to be re-sorted for each of the 
blocking criteria used (Scottish Record Linkage Team, 1995). Each record from the linked 
database was compared to each WOSCOPS record which agreed on the blocking criteria 
(for example, phonetic code of surname) and a linkage score was accumulated by adding 
and subtracting various adjustment weights depending on the level of agreement or 
disagreement on the items of identifying information (see chapter 3 for further details on 
the record linkage process). The file of linked pairs from which these weights were 
derived was produced at ISD using progressive refinement of the linkage algorithm. These 
weights may be amended according to features of the particular datasets being linked. For 
example, for the WOSCOPS randomised subjects, a large deduction was made for 
differences in the phonetic code of the surname since the dataset contained men only. It is 
unlikely that surname would change for men, while it usually changes for women on 
marriage. Thus, agreement on surname carries more discriminating power for men than it 
does for women. In practice, this ‘fine-tuning’ is often done fairly subjectively. A patient 
record set from the linked database cannot be linked with more than one WOSCOPS 
subject - known at SRL as the ‘best link’ principle. However, conversely, more than one 
patient record set can be linked with a given WOSCOPS subject, initially. These groups 
are then split, taking the patient record set with which the highest score is achieved and 
retaining links only when this score achieves the revised threshold score set by clerical
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checking. The best link principle is thus applied in both directions.
The main stages of the record linkage process used were:
1. Standardisation of data
-  involving assignment of Soundex codes and weights to surnames, and formatting of the 
postcode on both the WOSCOPS and the linked database records.
2. Sorting
-  of the WOSCOPS records into blocks as appropriate, for example, Soundex code order.
3. Linkage algorithm
-  the computer linkage algorithm was then run to perform the linkage. This algorithm is 
illustrated in Figure 4.1, and further details can be found in Appendix D.
4. Clerical review
-  to decide on the appropriate score at which to set the threshold for separating links and 
non-links.
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Figure 4.1 - Linking algorithm: flow diagram 
(adapted from SRL team, 1995; and used by permission of SRL)
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In general, the final score will be in the range -50 to 100, but the range may vary 
depending on the amount of identifying information available for use in the linkage 
process. For example, for the SMR6  linkage based on the items of identifying information 
available to WOSCOPS, the final score was in the range -39.4 to 57.29, with the threshold 
score set at 26 for the randomised patients linkage, while for the SMR1 linkage which uses 
only first initial rather than full forename, the final score was in the range -36.9 to 54.29, 
with the threshold score set at 25 for both the randomised and screened patients linkages.
Graphs are usually produced of the frequency of each score against the full score range 
(that is, -50 to 100) and a reduced score range (for example, 15 to 60) (See Figures 4.2 and 
4.3).
On the graph for the full range of scores (Figure 4.2), the first peak relates to comparison 
pairs (that is, pairings of WOSCOPS record and ISD record) which agree on Soundex 
code but very little else. The second peak corresponds to record pairs which agree on date 
of birth (the other blocking variable) but on little else. The later, smaller peaks correspond 
to records which have some level of agreement on both Soundex and date of birth.
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Figure 4.2 - Frequency graph of the score distribution for the full range of scores.
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Since every blocked WOSCOPS-ISD pair of records are compared, many pairs of records 
are brought together which belong to totally different people - they will have low scores as 
they will have little identifying information in common, while pairs of records which have 
a high score will usually belong to the same person, since most of the identifying 
information must be identical. The huge number of compared record pairs which belong to 
different people means that in order to see the shape of the distribution for the much 
smaller number of links, a reduced range of scores must be considered.
On the graph for the upper range of the distribution (Figure 4.3), there is a clear trough 
between the ‘good’ and ‘bad’ matches. This graph is useful in deciding on a small range of 
scores (for example, 23 to 35) in which to carry out clerical checking to decide where the 
threshold score at which record pairs will be accepted as links should be fixed. After 
clerical checking the threshold was set at 30 for this linkage. The relatively level area 
between the threshold and the point at which the frequency starts to increase again 
represents pairs where the postcode did not agree, but a match was made on the basis of 
the other identifying information (name, sex and date of birth).
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Figure 4.3 - Frequency graph of the upper range of the score distribution
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The threshold point corresponds to the crossover point of two separate distributions, the 
distribution of scores for non-links, and the distribution of scores for links, making the 
overall score frequency distribution bimodal. A strongly bimodal frequency distribution 
with a deep trough at the optimum threshold level indicates that there is good 
discriminating power, with minimal overlap between the ‘good’ and ‘bad’ matches. So not 
only is there little uncertainty concerning the best position for the threshold, but the 
numbers of potential good links and actual bad links falling on the wrong sides of the 
threshold are small, when the identifying information has good discriminating power. 
While it is desirable that both errors be kept to a minimum, these are competing aims, and 
a conscious compromise is usually required.
4.6 Possible improvements
As will be seen in chapter 5, the linkage methods currently used at SRL are very 
effective and achieve a high standard of accuracy, despite the apparent simplicity of the 
methods employed.
An alternative to the single threshold approach employed in current ad hoc linkages at 
SRL would be to set two threshold levels, one on either side of a ‘grey area’, so as to 
separate ‘good’, ‘doubtful’ and ‘bad’ linkages as described by Newcombe, 1988. 
Clerical checking could then be employed to deal with records which fall in the 
‘doubtful’ category. In the Oxford Record Linkage Study, the ‘doubtful’ category is 
further sub-divided into ‘probably good’ and ‘probably bad’ matches (Simmons, 1989).
SRL does not routinely update the frequencies contributing to the scores for new linkage 
exercises, as recommended by Newcombe in 1988. However, using scores derived 
through previous linkage exercises (with a little ad hoc ‘tweaking’) does not appear to 
have any great detrimental effect on the accuracy of results obtained.
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Although surname is commonly used as a discriminator, forename is rarely utilised, with 
only the first initial, or exact agreement on the first four letters of the forename being 
considered. SRL does in fact have a rarely used look-up table of forename weights, and 
it would be possible to phonetically code (Soundex) forenames in a similar way to 
surnames. A further method would be to use a look-up table for nicknames, a possibility 
which has been explored in Canada (Newcombe, Fair, Lalonde, 1992).
Simmons, 1989 suggested using forename as a blocking variable, but experience from 
the linkage of WOSCOPS subjects to SMR6  records suggests that it may be worth 
relaxing the current block on Soundex code of sumame+first initial to a block on 
Soundex code of surname alone. Where there are errors in date of birth (the other 
blocking variable) and the subject routinely uses a middle name, potential matches are 
not even considered due to the default blocking criteria employed at present.
Internal linkage errors (for example, when linking the SMR1 records into patient record 
sets) can lead to errors in external linkages (for example, SMRls with WOSCOPS 
subjects) when whole patient groups of records are linked if one record pair achieves the 
threshold score. The pairings with other records in the SMR1 patient record set may in 
fact fall far below the threshold score. If clerical checking is to be kept to a minimum 
then it may be worth setting a second threshold value at which individual records within 
the patient record set would be excluded from linking to the external record, even 
though at least one record in the group achieves the threshold for group linkage to the 
external record. These internal linkage errors are routinely checked for at ISD for death 
records, where it is obvious that there should be at most one record for any subject. With 
record types where multiple records are possible it is more difficult to identify patient 
record sets likely to contain errors. If ad hoc external linkages are to be carried out 
before clerical checking of the linked databases is completed, then the external records 
should only be allowed to link with a single death record, as distinct from a single 
patient record set.
However, these possible improvements relate mainly to the specifics of the linkage
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algorithm used, while the general method has been found to be straightforward and 
reliable, as will be shown in the next chapter.
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Chapter 5 
Record Linkage Comparative 
Study
5.1 Introduction
The aim of the record linkage comparative study is to compare computerised record 
linkage (CRL) with individual subject follow-up, in order to assess the advantages and 
disadvantages of these two methods of subject follow-up in the context of a clinical 
trial. The main outcome of this comparative study will be the production of tables 
containing a resolution for every adverse event record identified by either WOSCOPS 
independent follow-up or record linkage. Any records which can not be resolved as 
matching with a record on the other database will be investigated fully. The methods 
employed to carry out this comparative study are described below.
5.2 Methods
Events identified by computerised record linkage, carried out at the Scottish Record 
Linkage System (SRL), for the WOSCOPS randomised subjects, were compared with 
those recorded by the routine WOSCOPS system based on individual patient follow-up. 
Any event identified by computerised record linkage and not by the WOSCOPS system 
was followed up carefully to confirm that a WOSCOPS subject was involved and that a 
linkage mismatch had not occurred. This decision was based on direct contact with the
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appropriate physician or surgeon in the hospital where the event had been reported and 
scrutiny of the relevant medical records by a clinical research associate. This resulted in 
a great deal of manual checking to assess the degree of completeness of each set of 
records. Similarly, events identified by WOSCOPS but not by record linkage were 
examined to see if there was any reasonable explanation for the failure to find a linkage 
match.
5.2.1 Comparison
As preparation of the files of linkage derived records, any records which occurred prior 
to the individual subject’s randomisation date were removed. This was a necessary act 
since ethical permission for subject follow-up related only to the period after the subject 
had signed a consent form. It was also required for comparison purposes since 
WOSCOPS independent follow-up could only have documented events occurring after 
randomisation. SMR1 forms are completed for day case admissions as well as for 
admissions requiring overnight stays. However, day cases are not routinely documented 
by WOSCOPS, so any records with the date of admission equal to the date of discharge 
were excluded from both the WOSCOPS and linkage files. Care must be taken in the 
matching of events, particularly hospitalisations, since in the Scottish national system a 
new record is generated whenever a patient is moved between units or hospitals, even if 
being treated for the same event. Hence, on some occasions, one event in the 
WOSCOPS system is matched to a number of events on the hospital discharge database 
acquired by linkage. The SRL database contains a stay marker which indicates when 
records relate to the same episode of hospital stay. Comparisons with the WOSCOPS 
database were carried out using the first admission and the last discharge dates of the 
continuous stay in a particular hospital rather than the actual dates appearing on 
individual SMR1 records, so that separate comparisons are made for transfers between 
hospitals, but not for transfers between units or consultants within a hospital. An 
additional problem was that the WOSCOPS system, being based on patient recall, often 
contained only approximations to the dates of events.
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Each pair of files to be compared (Registrar General deaths and WOSCOPS deaths; 
SMR6 and WOSCOPS cancers; SMR1 and WOSCOPS hospitalisations) were joined on 
patient ID number (a unique number for each patient), and each combination of record 
pairs for a patient were compared (for deaths there should obviously only be one record 
pair for each subject). The comparison rules used were as follows:
1) agreement on patient ID number (always true when the patient appears in both files as 
record pair comparisons are only made within patient groups)
and some additional rules dependent on the record type.
For deaths:
2) exact agreement on date of death.
For cancer registrations:
2) agreement on year treatment commenced
3) agreement on month treatment commenced (assuming year is the same)
4) agreement on day treatment commenced (assuming month and year are the same). 
Some flexibility on the date of treatment commencing was required since this date was 
not clearly defined on the WOSCOPS independent reporting system. Records were 
considered matched if any of the components of the date agreed.
For hospitalisations:
2) date of admission or date of discharge on the WOSCOPS record contained within the 
period of the SMR1 continuous inpatient stay.
For the SMR1 record the date of admission relates to the first admission of the 
continuous inpatient stay and the date of discharge relates to the last discharge of the 
continuous inpatient stay. The variation allowed on dates was necessary because of the 
inaccuracy of patient recall in reporting these dates. Since WOSCOPS adverse event 
reporting relied primarily on patient recall, it’s dates were known to be slightly 
inaccurate at times.
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Due to the relatively small numbers of events involved, and the importance of cardiac 
events to the WOSCOPS study, all cardiac surgery registrations and psychiatric hospital 
admission records obtained via record linkage were reviewed by a clinical research 
associate, who made a subjective decision as to whether or not they matched with a 
record from the WOSCOPS individual subject follow-up.
5.2.2 Checking of comparison results
For deaths, all of the computer matched records were checked by a clinical research 
associate to verify that the cause of death agreed on both records. For hospitalisation and 
cancer registration records, a check, by the clinical research associate, on the computer 
matches ensured that the diagnoses were in agreement. If there was any discrepancy 
between the two record sources then support documentation such as death certificates, 
histology reports and hospital discharge summaries were examined to confirm the true 
diagnosis.
Any linkage derived records which did not match up with a WOSCOPS record were 
investigated by a clinical research associate to verify that they did in fact relate to the 
WOSCOPS subject. Since the 6595 WOSCOPS randomised subjects were flagged with 
the National Health Service Central Register (NHSCR) for deaths and incident cancers, 
it was likely that notification for most of these events would eventually arrive from this 
source, and these events would then be documented by WOSCOPS. However, due to 
problems with the NHSCR system, some incident cancers are not notified, and many are 
notified late. The first stage of the investigation for SMR Is, SMR4s, SMR6s and 
SMR20s was a full review of the patient’s file since it was sometimes possible to match 
the linkage SMR record with a WOSCOPS event which had dates differing by more 
than the limit for computer matching, or to find a reference to the event on another form 
in the patient’s file. Sometimes the admission constituted an extra treatment for a known 
diagnosis, for example, an extra chemotherapy session for a known cancer. The second 
stage was to obtain copies of hospital discharge summaries and histology reports from
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the appropriate consultants for any events still outstanding. These medical records 
enabled decisions to be made concerning whether the SMR records really belonged to 
the WOSCOPS subject or not.
Conversely, any WOSCOPS records which failed to match with an SMR record were 
examined to find a possible explanation. Possible explanations included stays in private 
hospitals (which are not required to submit SMR forms, although some do so 
voluntarily), admissions to hospices, or events that took place outside Scotland. 
Additional cancer records were searched for at the central Cancer Registry at ISD and at 
the West of Scotland Cancer Registry if necessary.
5.2.3 Documentation of new events
Any adverse event which was identified through record linkage but was not already 
recorded as part of the WOSCOPS independent follow-up was documented to enhance 
the validity of the final adverse event reporting of the WOSCOPS clinical trial. Since 
these events had not been reported to WOSCOPS trial centre staff by the patients in 
question, these events had to be documented at the Data Centre at Glasgow University 
and stored separately from the ‘routine’ trial documentation. The main reason for this 
was to prevent the staff at the trial centres from discussing these events with the patient, 
since it was assumed that the subject had deliberately not reported the event. Each of 
these events was investigated thoroughly by a clinical research associate, and hospital 
case notes and discharge summaries obtained where appropriate. These events were 
documented on adverse event forms similar to the routine forms described in section 2.6 
and given in Appendix B, but marked with a blue stripe (see Appendix E for an 
example) to indicate that these forms were for Data Centre use only and should be kept 
separate. These forms were coded by the Adverse Event and Endpoints Committees 
where appropriate.
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As the end of the WOSCOPS trial approached, additional linkages were carried out to 
interim files held at ISD to allow documentation of events occurring in 1994 or 1995 
which had been missed by WOSCOPS individual follow-up. These updated linkages 
were not included in this comparative study since ISD did not yet consider these interim 
files to be complete, and it could not be guaranteed that WOSCOPS clinical researchers 
always completed ‘routine’ documentation if an event which they knew to have been 
recorded on ‘blue-striped’ forms then came to light through normal channels. The 
results reported below thus consider only linkages to the main SRL databases.
5.3 Results
The results of the validation exercise are considered separately for each of the different 
databases involved in the linkage exercise - Registrar General deaths, cancer 
registrations (SMR6s), non-psychiatric hospitalisations (SMR Is), psychiatric 
hospitalisations (SMR4s), and cardiac surgery registrations (SMR20s) (see section 3.4.1 
for a description of these databases).
5.3.1 Deaths
At the time of linkage, the WOSCOPS database contained records of 165 deaths until 
the end of 1993. The computerised record linkage to the Registrar General (RG) Death 
records identified 166 deaths for the WOSCOPS subjects. 164 of these records were 
common to both files, with exact agreement on the dates of death. The causes of death 
identified by the two approaches for these 164 deaths were in agreement. There was an 
exact match on RG and WOSCOPS cause of death codes in 154 cases and a minor 
disagreement on the coding of cancer sites for 6 deaths. The remaining cases were as 
follows,
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1) the WOSCOPS database contained the primary (bronchopneumonia) and secondary 
(disease of the endocrine glands) causes of death as stated on the death certificate 
(obtained from the Registrar General for Scotland), while the SRL database had 
reversed the status of the causes of death.
2) the WOSCOPS database identified the cause of death as pulmonary embolism, 
confirmed by the death certificate and hospital notes. The SRL database stated the cause 
of death as malignant neoplasm of the trachea, bronchus and lung. The patient was 
known to suffer from cancer of the bronchus, but this information was not stated on the 
death certificate.
3) the WOSCOPS database contained only the primary cause of death (myocardial 
infarction). The death certificate also had the secondary cause of death of 
hyperlipidaemia. The SRL database had reversed the status of these two causes of death 
on the death certificate.
4) the WOSCOPS database identified the cause of death as smoke inhalation while the 
SRL database stated the cause of death to be abuse of drugs. The original death 
certificate gave the cause of death as inhalation of toxic fumes in a house fire, while a 
revised death certificate changed this to asphyxiation due to alcohol abuse.
WOSCOPS death data is confirmed from death certificates, post mortem examinations, 
hospital discharge summaries and reports from GPs when available, but the WOSCOPS 
Endpoints Committee is not always in agreement with the death certificate.
The one death identified by WOSCOPS follow-up but not by record linkage had 
occurred outside Scotland and thus did not appear on the Registrar General for 
Scotland’s file of deaths. This missed death was not due to any error in the linkage 
process.
Of the 2 deaths identified by record linkage but not by WOSCOPS independent follow- 
up, 1 was an internal linkage error on the SRL database which matched 2 deaths with 
the same subject. This type of error is corrected routinely by clerical checking at SRL 
and would not have affected the WOSCOPS linkage if the linkage exercise had been 
deferred until SRL’s internal checking had been completed. The other death was correct
107
for the WOSCOPS subject who had been assumed to be defaulting visits, and there had 
been no response to attempts at follow-up. Flagging with NHSCR had also failed to 
alert WOSCOPS staff to this death by the time of this comparison, over 2 years after the 
subject’s death.
These results are summarised in Table 5.1.
Identified by CRL
Yes No Totals
Identified by Yes 164 1 165
WOSCOPS No 1 7 1
Totals 165 1 166
Table 5.1 True deaths for the WOSCOPS subjects identified by either or both follow-up systems. 
? denotes the unknown number o f deaths missed by both follow-up methods.
5.3.2 Cancer registrations
Up until the end of 1992 the computerised record linkage and the WOSCOPS system 
identified 137 and 142 primary malignant neoplasms respectively. 131 cancers were 
common to both systems, of which 52 agreed completely on the date of treatment 
commencing, and a further 43 had the date of treatment commencing occurring in the 
same month.
6  events on the SRL system were not identified by the WOSCOPS system, of which 5 
were correct for the WOSCOPS subjects. 3 related to regular attendees and were for a 
malignant melanoma removed by the GP and 2 basal cell carcinomas removed in 
hospital. Two other events (a basal cell carcinoma and a prostatic carcinoma) not
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identified by WOSCOPS were related to subjects who had withdrawn from trial 
medication. The further additional SRL record did not relate to a WOSCOPS subject. 
This false positive linkage was due to internal linkage errors at ISD, with this record not 
achieving the threshold criteria on its own but being linked along with a higher scoring 
record in the same patient group.
Of the 11 unmatched cancer registrations on the WOSCOPS system, 2 events were not 
picked up on the SRL linkage because of errors in patient identifiers in the SRL records 
( 1  where the forename and surname were transposed, and the other where the subject 
used his middle name and there was an error on date of birth), and 9 events ( 6  of which 
were skin cancers) had not yet been reported to the Scottish Cancer Registry. With 
regard to the 6  skin cancers, basal and squamous cell skin carcinomas have always 
caused documentary problems since some physicians would not classify them as true 
cancers. Skin cancers are often dealt with by GPs and are not referred to hospital. This 
can result in a failure to register these cancers, although they should be. On account of 
this problem of poor reporting, ICD9 (International Classification of Diseases, 9th 
revision) code 173 (other malignant neoplasm of skin) is routinely excluded from 
national statistics.
These results are illustrated in Table 5.2 for cancers that truly belong to the WOSCOPS 
subjects.
Identified by CRL
Yes No Totals
Identified by Yes 131 1 1 142
WOSCOPS No 5 ? 5
Totals 136 1 1 147
Table 5.2 True cancer registrations identified for the WOSCOPS subjects by either or both systems of 
follow-up. ? denotes the unknown number of events missed by both follow-up methods
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On investigation of the support documentation for cancer registrations held by 
WOSCOPS, it was found that several events had been documented by WOSCOPS as 
cancers, in addition to the 142 primary malignant neoplasms investigated above, which 
were in fact benign ( 2  basal cell skin papillomas, 2  pituitary adenomas and 1 parotid 
adenoma), and were therefore not registered on an SMR6  form and should not have 
been documented by WOSCOPS. 7 additional WOSCOPS cancer registrations were not 
matched with an SMR6  because they related to recurrences of cancers for which an 
SMR6  had previously been completed when the cancer originally occurred, prior to the 
subject’s randomisation. WOSCOPS could only document events which had occurred 
since the subject was randomised into the study, and thus considered any cancer 
recurring after randomisation as a new cancer. These events which were not genuine 
new cancers have been omitted from these results as, strictly speaking, they should not 
have appeared in either database.
In summary, of the 147 separate non-benign, post-randomisation primary neoplasms 
relating to a WOSCOPS subject which were identified by one or other system, 136 
(93%) were picked up by SRL and 142 (96%) were eventually identified by the 
WOSCOPS system.
5.3.3 Non-psychiatric hospitalisations
The WOSCOPS database contained 2791 records for non-psychiatric, non day case 
discharges occurring before the end of 1993, and the computerised linkage generated 
3403 records which related to 2952 episodes of continuous inpatient stay. These datasets 
contained 2606 common hospitalisations. There were 2931 SMR1 records relating to 
these 2606 episodes of hospital stay. Thus, 325 of the additional SMR1 records 
corresponded to hospitalisations which were double-reported or involved transfer of the 
patient between wards or hospitals during an event which had been identified within the 
WOSCOPS system. Of these 2606 episodes of stay, 1532 (59% of the 2606 matches) 
agreed exactly on both date of admission and date of discharge on the WOSCOPS
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records and SMR1 stays, while 570 agreed exactly on one of these dates. A further 127 
were only one day out on either date of admission or date of discharge, while 23 were 
two days out on either date of admission or date of discharge. The remaining 354 SMR1 
records (including events reported late on the WOSCOPS system) were matched up 
clerically by a clinical research associate.
The additional 185 records in the WOSCOPS database were made up of 33 events 
which took place outwith Scotland, 94 events which were associated with private 
hospitals or hospices and 58 events which did not appear on the SRL database and for 
which no explanation for their absence could be identified. This group of 58 events 
would be expected to be associated with failures in the record linkage system due to 
errors in the key identifiers in one or other of the systems, or to events for which 
appropriate notification forms were not completed in the hospitals involved. These 
results for unmatched WOSCOPS records are given in Table 5.3.
Resolution Number of records
Out of Scotland 33
Private hospitals / hospices 94
Missed by linkage 58
Total 185
Table 5.3 Resolution o f WOSCOPS non-psychiatric hospitalisation records not matched with an SMR1
For computerised record linkage, 71 of the 472 unmatched records were additional 
treatments for known events (for example, additional chemotherapy sessions for a 
known cancer). Since the source events were identified in the WOSCOPS system, these 
additional treatments were not considered in this analysis to represent errors in the 
WOSCOPS system. 76 hospitalisations corresponded to adverse events which had been 
reported within the WOSCOPS system but had not been identified as a hospitalisation
I l l
due to failures in the WOSCOPS documentation procedures, but these events may have 
been detected in a review of patient files. 114 events were clearly linkage errors and had 
incorrectly been associated with WOSCOPS subjects. 210 events were confirmed as 
being previously unreported hospitalisations for WOSCOPS subjects. One more SMR1 
record could not be verified as to whether or not it related to a WOSCOPS subject, due 
to unavailability of the hospital case notes. These results for unmatched SMR1 records 
are summarised in Table 5.4.
Resolution Number of records
Events not coded as a hospitalisation 76
Additional treatments 71
New Events 2 1 0
Could not be verified 1
Linkage errors 114
Total 472
Table 5.4 Resolution of SMR1 records not matched with a WOSCOPS non-psychiatric hospitalisation
The 3077 events relating to WOSCOPS subjects identified by either system (ignoring 
double reported events, transfers and extra treatments for known events) are summarised 
in Table 5.5.
Identified by CRL
Yes No Totals
Identified by Yes 2606 185 2791
WOSCOPS No 286 7 286
Totals 2892 185 3077
Table 5.5 Distribution o f true hospitalisations identified for the WOSCOPS subjects by either or both 
systems o f follow-up. ? denotes the unknown number of events missed by both follow-up methods.
112
2791 (91%) were eventually identified within the WOSCOPS system and 2892 (94%) 
were identified by computerised record linkage. In addition, the record linkage approach 
identified one record which could not be confirmed as belonging to a WOSCOPS 
subject and wrongly associated 114 events with WOSCOPS subjects. In fact, these 114 
events related to only 42 subjects.
Calculation of the standard measures of sensitivity and specificity for the two 
approaches is difficult because there is no gold standard method which guarantees to 
identify all true events (as emphasised by the question mark in Table 5.5) and because it 
is the number of events that is being dealt with and not the number of subjects. 
However, if it is assumed that almost all events have been picked up by one or other of 
the methods then the WOSCOPS and record linkage systems will clearly have high 
sensitivities as evidenced by the 91% and 94% success rates in identifying events. In 
terms of specificity, the WOSCOPS system requires support documentation for all 
events and relies on patient reporting, so it could be considered to have a zero error rate 
in terms of wrongly identifying a subject as having had an event. In the record linkage 
approach only 114 events (on 42 subjects) were incorrectly identified, suggesting that 
the system would have a high specificity.
Of the 210 new events which were not identified by the WOSCOPS system 143 were 
associated with subjects who had either formally withdrawn from taking study 
medication or were defaulting from attending at routine study visits. For this purpose a 
defaulter was taken to be a participant who has missed at least three trial visits 
immediately following the date of event. The remaining 67 were associated with 
subjects who were regularly attending trial visits, that is, they had not withdrawn and 
were not defaulters. See Table 5.6 for further details of the default status of the subjects 
with events unreported to WOSCOPS.
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Resolution category # records # subjects
Withdrawn before event 123 8 6
Temporarily defaulting at time of event 2 0 16
Regular attendee (around time of events) 67 60
TOTAL 2 1 0 162
Table 5.6 Default status of subjects with SMR1 events not reported to WOSCOPS.
The reasons for these 210 hospitalisations were categorised by a clinical research 
associate as in Table 5.7. It is interesting that 30 of the 210 events were cardiac in nature 
and hence very important for the WOSCOPS study. In fact, three of these, for 
myocardial infarctions, turned out to be undocumented primary trial endpoints. In the 
regular attendee group there was a relatively high number of events in categories which 
patients might be more likely to conceal from trial staff (for example, urogenital 
problems and psychological problems - which included 5 overdoses).
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Diagnosis Withdrawals and defaulters Regular attenders Total
Urogenital 2 0 1 2 32
Cardiac 2 2 8 30
Gastrointestinal 19 5 24
Orthopaedic 15 7 2 2
Respiratory 9 5 14
ENT 1 2 2 14
Vascular 1 0 4 14
Psychological 5 7 1 2
Eye related 3 7 1 0
Neurological 5 4 9
Cancer 7 2 9
Skin related 4 3 7
Hernia 5 1 6
Dental 2 0 2
Endocrine 1 0 1
Miscellaneous 4 0 4
Total 143 67 210
Table 5.7 Diagnoses of events not reported to WOSCOPS. The numbers relate to the number o f SMR1 
records which formed new adverse events and were documented on blue-striped forms, for each diagnosis 
category.
5.3.4 Other uses of SMR1 information
In addition to the identification of previously undocumented events the linked computer 
records potentially provide additional information. The SMR1 records can provide 
additional flags of potentially serious events, such as the type of admission involved, or 
whether the event required transfers between units (such as ITU), consultants,
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specialties (medical or surgical) or hospitals. They can also be used as support 
documentation for adverse events which have been documented by the WOSCOPS 
follow-up system.
Type of admission
The SMR1 records contain a marker indicating the ‘type of admission’. The possible 
types of admission are:
A) deferred admission
B) waiting list admission
C) repeat admission
D) transfer
E) emergency admission for deliberate self-inflicted injury or 
poisoning
F) emergency admission for road accidents
G) emergency admission for an accident in the home
H) emergency admission for other injury
I) other emergency admission
Since accidents and suicide attempts may be important events for trials of cholesterol 
lowering drugs, these admission codes provide a useful flag on these serious events and 
an additional means of verifying how they have been coded on the WOSCOPS database. 
All SMR1 emergency admissions of types E)-H) (that is, for ‘trauma’) were cross­
checked with WOSCOPS records and hospital discharge summaries by a clinical 
research associate. Most of the 121 SMR1 emergency events identified were in 
reasonable agreement with the WOSCOPS database, but for two events, the diagnosis 
on the WOSCOPS database was recoded after closer examination of the hospital case 
notes:
1 . from ‘depression’ to ‘drug overdose’
2 . from ‘abuse alcohol’ to ‘drug overdose’
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Transfers
Separate SMR1 records are completed for all transfers between hospitals, units (such as 
intensive care), consultants and specialties (for example, general medicine, orthopaedic 
surgery or neurology, although the consultant will usually change with the specialty). 
Transfers will not usually be required for a ‘straightforward’ admission, so they can be 
used to identify potentially more serious events. Where there were more than 2 SMR1 
records relating to a single episode of continuous inpatient stay in hospital, all 
documentation for these events was reviewed by a clinical research associate. This 
minimised the possibility of missing a serious event which occurred during an 
admission for another reason.
Up until the end of 1993, there were 45 hospital stays involving 3 SMR1 records each, 
10 involving 4 SMR1 records each, 2 involving 5 records each, and 1 hospital stay 
which involved 6  SMR1 records. These were all reviewed in detail by a clinical research 
associate. Of the 191 individual SMR1 records making up these 58 episodes of stay, 52 
were admissions from home, 6  were admissions from another hospital and 133 were 
admissions from another unit within the same hospital. Correspondingly, 51 records 
related to discharges to home, 4 to discharges to another hospital, 133 to discharges to 
another unit within the same hospital and 3 to patient deaths.
Cardiac day case admissions
An SMR1 record is completed for every admission to hospital, including day case 
admissions. Although day cases were not documented as hospitalisations in the 
WOSCOPS study, it was important to obtain information on all cardiac events, which 
were documented as non-hospitalisation adverse events. Coronary arteriography (a 
secondary endpoint on the WOSCOPS study) is now often carried out on a day case 
basis.
The completion of SMR1 records for day cases allowed a review of day admissions for 
cardiac procedures by a clinical research associate, as a further check on the 
completeness of the WOSCOPS independent follow-up. There were 45 day case SMR1
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records for cardiac procedures which related to the WOSCOPS randomised subjects up 
until the end of 1993. 40 of these had already been documented by WOSCOPS. Of the 
remaining 5, 2 were referred to on other forms but the correct documentation had not 
been completed, 1 related to a ‘failed’ angiogram and did not require documentation, 
and 2 were events previously unknown to WOSCOPS.
Support documentation
WOSCOPS routinely obtains support documentation (for example, discharge summaries 
or hospital case notes) for all Trial Endpoints (deaths and serious cardiac events) and 
cancers, but not for every hospitalisation. Where a WOSCOPS hospitalisation record 
has been matched with an SMR1 record, the SMR1 record may be used as support 
documentation for the purposes of verifying that the hospitalisation occurred, since it 
isn’t feasible to obtain hospital discharge summaries for all hospitalisations. The 
difference in dates between some of the SMRls and WOSCOPS records is not a new 
problem, as the dates on hospital discharge letters currently used as support 
documentation often differ from the dates on the WOSCOPS records (which are based 
on patient recall).
5.3.5 Psychiatric hospitalisations
Since there was a very small number of psychiatric hospitalisations (documented on an 
SMR4 form, see Appendix C), they were checked clerically by a clinical research 
associate who made a subjective decision based on his experience, as to whether they 
related to a WOSCOPS subject.
The computerised linkage identified 41 non-day case, inpatient psychiatric 
hospitalisations until the end of 1993. 30 had already been identified by the WOSCOPS 
system, 7 were previously unknown events, and 4 were record linkage errors and did not 
relate to a WOSCOPS subject. Of the 7 new events discovered, 3 were for depression, 2 
relating to a regular attendee and 1 to a subject who had withdrawn from trial
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medication, while the other 4 were for alcohol dependence, 2 relating to regular 
attendees and 2  relating to subjects who had withdrawn from trial medication.
The WOSCOPS follow-up had identified 31 psychiatric hospitalisations until the end of 
1993. 28 of these matched with the 30 SMR4 records. 1 of the 3 records not found by 
linkage related to an ongoing, longstay admission for depression. Of the other 2, 1 was 
for depression and the other for alcohol abuse. These results are summarised in Table 
5.8.
Identified by CRL
Yes No Totals
Identified by Yes 28 3 31
WOSCOPS No 7 7 7
Totals 35 3 38
Table 5.8 Distribution of true psychiatric hospitalisations identified for the WOSCOPS subjects by 
either or both systems o f follow-up. ? denotes the unknown number of events missed by both follow-up 
methods.
5.3.6 Cardiac surgery registrations
While the previous linkages have all involved linked databases, the SMR20 data is held 
‘on-line’. This means that the SMR20 register being linked to is completely up to date 
(rather than only up until the end of the previous year), and that the SMR20 data is held 
as single records, not in patient groups. The SMR20 file also contains records for people 
who are on the waiting list for cardiac surgery but have not actually been admitted yet.
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Since relatively few SMR20 records are received each year, and cardiac surgery is an 
important adverse event in the WOSCOPS study, all of the SMR20 records were 
checked clerically by a clinical research associate.
6 8  events were identified by record linkage until April 1994 (when this linkage was 
carried out), 64 of which had already been documented in the WOSCOPS system or 
were in the process of being documented, and 4 which were linkage errors and did not 
relate to a WOSCOPS subject. It was reassuring to note that WOSCOPS independent 
follow-up did not appear to have missed any of these major cardiac events.
5.4 Influences on the quality of linkage
An assessment was made of the effects on the quality of linkage results of
1 ) using the patient identifying information collected at the first screening visit and 
entered directly into a database by screening centre nurses as opposed to updated data, 
prepped from forms by clerical staff
2) using unpostcoded data (as the WOSCOPS data would have been without the 
postcoding exercise carried out).
This assessment was carried out for death linkages only, as linkages to the incidence 
databases would have resulted in a lot of extra clerical checking work to be done by the 
clinical research associate, while verification of a subject’s mortality status was 
relatively simple to ascertain. These assessments have used linked death data up until 
the end of 1993.
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5.4.1 Use of linkage information collected at first 
screening visit
Death linkage was carried out for the 97,165 WOSCOPS screenees with sufficient 
identifying information in a similar way to, but completely separately from, the linkage 
for the 6595 randomised subjects as described in chapter 4. For the trial linkage, linking 
information was updated by ‘duplicate’ records, while for the screenee linkage, only a 
single baseline record obtained at screening visit 1 was available. The links identified 
for the 6595 WOSCOPS randomised subjects were extracted from the screening linked 
files, and these links were compared to the links achieved in the routine trial linkage in 
order to investigate the effects of using screening visit 1 data as opposed to data updated 
throughout the trial. The question was whether it was really worth the time and effort of 
updating patient identifying information, in terms of improved linkage quality. (It 
should be noted that not only does screening visit 1 data contain a single address, but it 
was entered directly onto the computer by screening centre nurses as the patient visit 
took place, while the trial data was entered on forms and then processed by experienced 
data clerks. This may be a factor in the quality of the data collected in addition to the 
opportunity to match being restricted to a single postcode, for screening visit 1 data, 
when the subject may have moved house.)
Until the end of 1993, routine linkage of the 6595 randomised subjects identified 166 
deaths, while screening linkage identified 165 deaths for these subjects. 157 of these 
deaths were common to both linkages (trial and screenees), with 155 of these being in 
exact agreement with the WOSCOPS independent database of deaths. One common link 
was due to an ISD internal linkage error, with 2 deaths occurring for the same subject. 
This false link to a WOSCOPS subject would not have occurred if ISD’s routine clerical 
checking program had been completed before the WOSCOPS linkages were carried out. 
The other death common to both linkages had been missed by WOSCOPS trial centre 
staff.
121
9 deaths were found by the routine trial linkage but missed by the screenee linkage. 
These deaths were in agreement with the WOSCOPS independent database. 9 missed 
deaths out of 165 deaths identified correctly for the WOSCOPS randomised subjects by 
routine linkage gives a false negative error rate (where genuine deaths for the 
WOSCOPS subjects were missed by the screenee linkage but not by the trial linkage) of 
5.4% of deaths, for the screening death linkage relative to the trial linkage.
Conversely, 8  deaths were identified by the screening linkage but missed by the routine 
trial linkage. All of these subjects have attended trial visits since their proposed date of 
death (some proposed deaths were even prior to randomisation). 7 out of these 8  links 
were admitted because the threshold score set for the screening linkage was lower than 
for the trial linkage (26 instead of 30 - the distribution of scores varies with differing 
quality of linkage information and thus the threshold score must be adjusted according 
to the characteristics of the datasets). However the other death had a linking score of 46, 
which could only be achieved by almost exact agreement on all identifying information 
(but the death could not have related to the WOSCOPS subject since the date of death 
was prior to his randomisation). So, out of the 165 deaths identified by the screening 
linkage, there was a false positive error rate of 4.8%.
The increased error rates for the screenee linkages relative to the routine trial linkages 
are likely to be greatest for the death linkages, since earlier records in patient groups 
may provide better postcode matches to the screening visit 1 data and thus link the 
whole patient record group for ‘incidence databases’, while the death record will have 
only a subject’s final address which may well be different from the address at screening. 
The potentially increased error rates resulting from use of screening visit 1 data rather 
than updated data will increase as the length of time since screening increases, but for a 
mean follow-up of 3.67 years (from randomisation date until the end of 1993), the 
linkage quality seems fairly reasonable, although not as good as the linkage using 
updated trial data which yielded virtual 100% accuracy, as described in section 5.3.1.
5.4.2 Lack of postcodes
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Death linkage was carried out for the 6595 WOSCOPS randomised subjects using 
identifying information without the postcodes, completely independently of the routine 
WOSCOPS trial linkage using baseline and updated postcodes.
The links achieved with and without postcode information were then compared, in order 
to assess the benefit arising from the WOSCOPS postcoding exercises, and thus whether 
or not it is worth postcoding addresses in general, prior to carrying out linkage exercises.
Routine trial linkage identified 166 deaths, while unpostcoded linkage identified 163 
deaths for the WOSCOPS randomised subjects.
159 death records were common to both linkages:
- 157 which were in exact agreement with the WOSCOPS independent database 
of deaths
- 1 internal linkage error - there were 2  deaths for the same subject
- 1 death which had been missed by WOSCOPS
7 deaths were found by the routine trial linkage but missed by the unpostcoded linkage - 
these deaths were all in agreement with the WOSCOPS independent database. These 7 
missed links are linkage errors due to the increased difficulty in setting a linkage 
threshold when the postcode information is unavailable. 7 missed deaths out of 165 
deaths identified correctly for the WOSCOPS randomised subjects gives a false negative 
rate of 4.2% relative to the postcoded trial linkage.
4 deaths were identified by the unpostcoded linkage but not by the routine trial linkage 
for WOSCOPS randomised subjects. All of these subjects have attended trial visits 
since their proposed date of death ( 2  proposed dates of death were even prior to the 
randomisation date for the subject in question). So out of the 163 deaths identified by 
the unpostcoded linkage there was a false positive error rate of 2.4%. These 4 deaths 
were included in the unpostcoded linkage as the threshold score for this linkage was
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only 25, while it was 30 for the routine trial linkage with postcodes. However, without 
postcode information, all of the linkage scores were lower and many more correct links 
would have been missed if the threshold had not been lowered. In fact, only 8 8  out of 
the 163 links made using the unpostcoded data achieved a linkage score greater than or 
equal to 30.
The differences in the score frequencies for the postcoded and unpostcoded linkages are 
shown in Figure 5.1. As can be seen from the graph, the threshold area is clearer for the 
postcoded linkage, with little to be lost by setting the threshold anywhere between 26 
and 31, while for the unpostcoded linkage, the threshold region is narrower (between 23 
and 25) but contains a higher frequency of record pairs at each score. The separation 
between ‘good’ and ‘bad’ matches is less distinctive, and thus the threshold is harder to 
set, for unpostcoded data. Where no postcodes are available, the subjectivity of the 
threshold setting becomes a more important factor.
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Figure 5.1 Score frequencies for postcoded and unpostcoded links
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Figure 5.1 also shows that the basic distribution of scores for linked data is similar for 
both postcoded and unpostcoded linking information, the actual scores appear to be 
simply shifted downward when there are no postcodes, closer to the distribution of 
unlinkable pairs which remains virtually the same for both linkages, as can be seen from 
the lower end of the score frequency graph in Figure 5.2.
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Figure 5.2 Score frequencies for postcoded and unpostcoded non-links
For the 158 deaths where a correct link was achieved by both methods (postcoded and 
unpostcoded), the paired scores were plotted against each other (Figure 5.3) and 
revealed a clear relationship between the two scores, with a shift upwards where 
postcodes were available (in agreement with the frequency graph in Figure 5.1) for most 
of the linked records. However, this shift does not occur for all records, and some 
additional discriminating power can be derived from use of postcodes. It should be 
noted that scores can only be plotted when they appear in both linked files. Records 
which failed to achieve the threshold score are not available for analysis and thus cannot 
be positioned on the graph.
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Figure 5.3 Unpostcoded score against postcoded score for the 158 deaths where a link was achieved by 
both linkage methods. These scores can only be plotted in this way when they appear in both linked files, 
since records not achieving the threshold score are not available for analysis and thus cannot be positioned 
on the graph. The threshold score was 30 for the postcoded linkage and 25 for the unpostcoded linkage.
For deaths until the end of 1993, unpostcoded linkage information provides a reasonable 
quality of linkage. It is expected that potential errors resulting from lower quality 
linkage information will be more frequent for the hospitalisation (SMR1) linkage than 
for the death linkage investigated here as death records contain full forenames rather 
than just first initial and the data are generally of a higher quality on a death certificate.
5.5 Discussion
1 2 6
The validation of the linkage to the Registrar General’s Deaths database was very 
encouraging, with a virtual 1 0 0 % match being achieved in terms of the deaths being 
identified by both linkage and routine WOSCOPS follow-up. The WOSCOPS system 
involved manual flagging with the Registrar General for Scotland’s death register in 
addition to individual subject follow-up, so it would be expected that these events would 
be reliably reported in the WOSCOPS system. This comparison for deaths was primarily 
an assessment of the computerised matching of linkage information. It is encouraging 
that this yielded no false positives (except for the miss-link due to failing to wait for 
completion of SRL’s checking procedures before carrying out the linkage) despite the 
fact that the linkage was based only on name, sex, date of birth and postcode.
The information obtained from the linkage on cause of death is based on death 
certificates. Concern has been expressed about the use of death certificate data 
(Alderson et al, 1983). However, others have concluded that such data are valid 
epidemiologically for most cancers and for cardiovascular and coronary heart disease 
deaths. A previous study in Scotland (Isles et al, 1986) showed that notification from the 
Registrar General was virtually complete and a comparison of coding of causes of death 
by independent physicians yielded no important discrepancies. In clinical trials, fatal 
events identified by record linkage could be fully investigated to check on the accuracy 
of the coding of cause of death, but in large epidemiological studies this would not be a 
feasible option. However, it would appear that studies based on broad classes of events 
are not subject to substantial bias.
For the hospitalisation linkage there was a much better opportunity to study the 
frequency of both false negatives and false positives. Although the SRL linkage had an 
overall false negative rate of 185 in 3077 (6 %) events identified by either system, 127 
of these events occurred either outside Scotland or in private hospitals or hospices and 
were unlikely to be identified by the linkage system. At most 58 (1.9%) of the events
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could have been missed because of linkage mismatches, although many of these were 
probably due to the failure of the hospital concerned to report the event. This was 
achieved at the expense of 114 false positives relative to the 3077 events for 
WOSCOPS subjects identified by either system. Of these 114 false positive records, 38 
individual records did not achieve the threshold score and were only linked because of 
the practice of linking a whole group of patient records on the basis of the highest score 
achieved by any record in that group. These rates compare well with the false negative 
and false positive rates (2%-3%) which SRL staff predicted on the basis of their own 
unpublished investigations. The current study provides an important independent check 
on the quality of the linkage carried out at SRL. The quoted error rates are based on 
‘clinical’ events and would be lower if transfers and additional treatments were 
included. It should also be noted that the calculations assume that all events have been 
identified and that there are at most a very small number of events which have been 
missed by both methods of follow-up. The numbers of events which have currently been 
reported and cross-checked for the other database linkages are still rather low for any 
definitive conclusions to be drawn. With the exception of skin cancers which are 
typically underreported, the cancer linkage was encouraging and it was interesting that 7 
of the 43 psychiatric hospitalisations relating to WOSCOPS subjects had not previously 
been identified by the WOSCOPS follow-up. It would appear that the ‘smaller’ linkages 
(psychiatric hospitalisation and cardiac surgery) may be less accurate than the linkages 
to larger databases. This may simply be a superficial result due to the smaller numbers 
of events involved. The fact that approximately two thirds of the previously unidentified 
hospitalisations were associated with men who had either withdrawn or were defaulting 
from trial visits confirmed preconceptions that event rates might be underreported in this 
category of subjects. It is particularly worthy of note that the SRL computerised linkage 
alone compared very favourably with the active patient follow-up system employed in 
WOSCOPS.
These results can be compared to the results obtained using linkages up until the end of 
1991 and reported by the West of Scotland Coronary Prevention Study Group (in press). 
These results may be considered to be of a potentially higher quality than the later
1 2 8
comparisons since they are uninfluenced by the effects of sorting out potential double 
documentations (that is, on both routine and blue-striped forms) which became a 
problem towards the end of the trial. It is reassuring to note that the results obtained in 
the comparison study reported in this chapter are similar to those found in 1991. For 
example, for non-psychiatric hospitalisations until the end of 1991 the results are 
summarised in Table 5.9. Of the 1246 events relating to WOSCOPS subjects, 89% were 
eventually identified within the WOSCOPS system and 95% were identified by 
computerised record linkage. In addition, record linkage wrongly associated 52 events 
with the WOSCOPS subjects. These proportions are clearly similar to those obtained in 
the later comparisons reported above. Further details of the 1991 results can be found in 
West of Scotland Coronary Prevention Study Group (in press).
Identified by CRL
Yes No Totals
Identified by Yes 1043 6 6 1109
WOSCOPS No 137 ? 137
Totals 1180 6 6 1246
Table 5.9 Distribution o f true hospitalisations identified for the WOSCOPS subjects by either or both 
systems o f follow-up until the end o f 1991. ? denotes the unknown number of events missed by both 
follow-up methods.
In summary, this comparative study demonstrated minor flaws in both systems of 
subject follow-up and showed that follow-up based on computerised linkage alone can 
be as effective as reporting based on direct contact with the patients. Active patient 
follow-up avoids the dangers of computerised linkage errors but suffers from poor 
follow-up for withdrawals and defaulters, and may under-report events for ‘sensitive’ 
diagnoses. Computerised record linkage, on the other hand, is relatively fast and cheap 
and is good for picking up events for withdrawals and defaulters. However, it only 
covers events occurring in Scotland and reporting is incomplete from private hospitals.
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Based on our experience, in contexts where computerised follow-up is feasible (such as 
a community based primary prevention study), such a system provides not only 
significant cost advantages but also potentially more complete follow-up of serious 
adverse events. It may thus be used to enhance the validity of the reporting of serious 
adverse events in clinical trials. What cannot be questioned is the fact that computerised 
linkage systems can significantly enhance the completeness of patient follow-up 
obtained by more traditional methods in clinical trials, both by providing independent 
validation of trial data and by providing additional data. Recently, the issue of fraud in 
industry and government funded clinical trials has attracted a great deal of media 
attention both in Europe and in North America. Validation of major trial outcome 
measures against independently held databases using record linkage techniques is one 
way of partially addressing this problem. If suitably validated, these systems also 
provide invaluable resources for epidemiological studies.
Previous reports of similar comparison exercises have had mixed success. A previous 
study in Scotland (Hole et al, 1981) reported a validation of computerised record linkage 
between an external data set and records held at ISD against manual tagging of subjects 
using the National Health Service Central Register (NHSCR) using the cohort of 3062 
patients involved in the Renfrew and Paisley Study. This linkage was carried out prior to 
the creation of the linked database and thus used different procedures to those currently 
employed at ISD. This study obtained sensitivities of 6 6 % and 67% for links to 
mortality and inpatient hospitalisations respectively, based on computerised record 
linkage alone, changing to 65% and 81% when clerical checking was added to their 
system. The difference between this earlier study and the current one could be due to 
improvements in the computerised record linkage system now in use at SRL, the quality 
of the data recorded on nationally held records and the quality of the recording of patient 
identifying information in the WOSCOPS trial.
A number of studies have been carried out in Canada, with the general finding that 
computerised record linkage has performed no worse than individual subject follow-up. 
In these Canadian studies, the computerised record linkage and the manual follow-up
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both dealt with the same basic death file. Statistics Canada carried out a comparison of 
individual patient follow-up with computerised record linkage to the Canadian Mortality 
Database (Shannon et al, 1989). The study sought the mortality status in 1985 for 2469 
employees, at an industrial plant in Ontario, who were alive in 1977. Where the 2 methods 
of follow-up gave a different outcome, further investigation was carried out and the 
individual patient follow-up was, surprisingly, found to be in error for most of these cases. 
It was thus found that computerised record linkage gave accurate information and was 
relatively cheap for large studies (>1000 cases suggested). It would be preferable to 
compare both methods of follow-up to the absolute tme mortality status (unknown), but 
investigation was only carried out where the 2  methods gave a different outcome, and it is 
possible that both were mistaken in some cases. A similar study involving uranium 
workers in Eldorado (Newcombe et al, 1983) found that not only was the computer 
more successful at finding matches than the manual searchers, but it was also less likely 
to yield false linkages with death records not related to the study population.
The comparative study reported in this chapter has thus achieved results which compare 
well with previous studies. This may be due to the extensive ‘cleaning’ exercise which 
has been carried out on the WOSCOPS database, yielding a high quality of patient 
identifying information to be used in the record linkage process. The techniques 
employed in record linkage have improved over the years since the previous Scottish 
study was carried out and this may therefore not be a fair comparison. However, in 
agreement with this study, the Canadian studies achieved highly accurate results for 
linkages to mortality databases. The main drawback of the Canadian system compared 
to the Scottish system used here was that the Canadian system involves only the 
mortality database, while the Scottish system makes use of all records which form part 
of the National Health Service databases. The Scottish system can thus give much more 
versatile and complete information for subjects to be followed up. On the whole, the 
Scottish Record Linkage System compares favourably with other linkage systems and is 
more accurate than the system available in the early 1980s.
Chapter 6 
Analysis of linkage data for the 
WOSCOPS cohort
6.1 Introduction
The WOSCOPS screening exercise was of great interest in its own right in a part of the 
world where coronary heart disease death rates are consistently among the highest in the 
international league tables of cause specific mortality (see section 1.2.5).
Full informed consent was not available to link the WOSCOPS screened subjects to 
their computerised medical records on an individual case basis. However, permission 
was obtained from the Scottish Record Linkage System (SRL) to hold the identifying 
information for these subjects in Edinburgh, to link them to the SRL databases and to 
make tabulations of frequencies of events, defined by cross-classifications of risk factors 
collected during screening, available to WOSCOPS researchers. For instance, a table of 
the frequency of coronary heart disease death could be obtained broken down by 
smoking status and quintiles of age, total cholesterol and diastolic blood pressure. In this 
way, analyses of the relationships between outcome and the various risk factors were 
possible.
6.2 Methods
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6.2.1 Data available
In the screening phase of WOSCOPS 105,383 subjects were screened for coronary 
heart disease risk factors. The information collected on each subject was described in 
chapter 2  and the detailed characteristics of these subjects have been reported elsewhere 
(section 2.5 and West of Scotland Coronary Prevention Study Group, 1995). For the 
97,165 subjects who attended screening visit 1, and had sufficient identifying 
information to allow linkage to be carried out, data were available on demographic 
parameters and coronary heart disease risk factors (Table 2.1).
The postcoding exercise which was carried out (section 4.3) not only enhanced the 
quality of the linkage to SRL databases (section 4.4), but also allowed assignment of 
Carstairs deprivation scores (Carstairs and Morris, 1991). These deprivation scores were 
derived from the 1991 census data, and were assigned to WOSCOPS subjects on the 
basis of postcode sector. The Carstairs score is based on proportions of car ownership, 
male unemployment, low social class and overcrowding (Carstairs and Morris, 1991; 
McLoone, 1994). The range of deprivation scores possible is from -9 to +13, and these 
are grouped into 7 deprivation categories known as DEPCATs. In this analysis, the 
DEPCATs have been grouped into 3 blocks - DEPCATs 1 and 2, DEPCATs 3, 4 and 5, 
and DEPCATs 6  and 7, with ‘affluent’ defined to be a Carstairs deprivation score less 
than -3, ‘middle’ as a score between -3 and 3, and ‘deprived’ as a score greater than 3 
(McLoone and Boddy, 1994).
For the restricted group of approximately 13,600 middle-aged men who attended a third 
screening visit, data were also available from a full biochemical and haematological 
profile, as well as measurements of lipids, fibrinogen and plasma viscosity (section 2.4).
Event data obtained from SRL came from the database of Registrar General deaths, 
hospital discharges (SMRls) and cancer registrations (SMR6 s). SMR6 s were only
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available until the end of 1992, while deaths and SMRls were available until the end of 
1993. These national data sets have been described in section 3.4.1.
All events which were identified between initial screening (October 1988) and the end 
of 1993 were included. This resulted in between 3 and 5 years of follow-up on each 
subject, depending on when the subject was screened. Analysis considered only the 
subjects who had sufficient identifying information to allow follow-up by record linkage 
techniques (97,165 out of the total 105,383 subjects).
6.2.2 Categorisation
To maintain subject anonymity, and thus meet the conditions of the linkage approval at 
SRL, it was necessary to construct categorisations of the data available for the 
WOSCOPS subjects, on the basis of which morbidity and mortality data would be 
released by SRL. Each contributing continuous variable was categorised. Each cell in 
the cross-classification of the categorical variables was required to be of a reasonable 
size. ‘Reasonable’ was generally taken to mean that there were at least 5 subjects in each 
cell. Event records extracted at SRL were then identified only by a cell number, and 
were not identifiable at an individual subject level.
Many cross-classifications were considered. This thesis will discuss only three, one for 
each of the subgroups of subjects as given below:
1. A cross-classification of CHD risk factors for middle-aged men at screening visit 1: 
This cross-classification involved 2 levels of age (45-54 and 55-64), 3 levels of 
smoking status (never, ex and current), 5 levels of cholesterol (quintiles), 7 levels of 
alcohol consumption (0, 1-20, 21-30, 31-40, 41-50, 51-60 and >60 units per week), 2 
levels of DBP (split at the median value), 2 levels of BMI (split at the median value), 
and 3 levels of DEPCAT (affluent, middle and deprived). This cross-classification 
was selected since cholesterol and alcohol were the main factors of interest, and it 
was thus desirable to incorporate as many levels of them as possible.
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2. A cross-classification based on CHD risk factors for women attending screening visit 
1: This cross-classification involved 4 levels of age (<45, 45-54, 55-64 and >64), 3 
levels of smoking (never, ex and current), 5 levels of cholesterol (quintiles), 3 levels 
of alcohol (0, 1-10 and >10), 2 levels of DBP (split at the median value), 2 levels of 
BMI (split at the median value), and 3 levels of DEPCAT (affluent, middle and 
deprived). This cross-classification was selected to allow an analysis comparable to 
that already carried out for middle-aged men. Fewer levels of alcohol were possible 
since only a small number of women consumed large amounts each week.
3. A cross-classification involving laboratory measurements for men who reached 
screening visit 3: This cross-classification involved 2 levels of age (45-54 and 55- 
64), 3 levels of smoking (never, ex and current), 2 levels of DBP (split at the median 
value), 2 levels of LDL cholesterol (split at the median value), 3 levels of HDL 
cholesterol (tertiles), 3 levels of plasma viscosity (tertiles), and 5 levels of fibrinogen 
(quintiles). Fibrinogen and viscosity were the main factors of interest in this cross­
classification. Smoking was an important factor since it is known to be related to 
fibrinogen levels.
The need to maintain subject anonymity placed severe restrictions on the number of 
factors and the number of levels of each factor which could be included in a cross­
classification. These cross-classifications were selected by a trial and error process. This 
process involved experimenting with tabulations in order to identify cross­
classifications which allowed the maximum number of factors and levels whilst 
achieving reasonable cell sizes.
6.2.3 Analysis for each cross-classification
The first stage in each analysis involved tabulations of the number of deaths for various 
causes of death. The main outcomes of interest were CHD, cancer and injury/poisoning, 
since some studies have found the incidence of cancer and injury/poisoning to be related 
to cholesterol level measured at a previous screening visit.
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Formal analysis was carried out using logistic regression since the outcome was binary 
(event / no event), and individual survival times were not available (due to the need to 
preserve subject anonymity). Alternatives to this method of analysis will be discussed 
later.
Univariate logistic models were fitted first, to examine the relationship between 
outcome and each variable on its own. The next stage was to fit logistic regression main 
effects models, simultaneously including all variables involved in the cross­
classification, to assess the contribution of each explanatory variable after the others 
were included in the model. In addition to p-values for the significance of each variable, 
‘contrasts’ among different levels of the risk factors were studied to investigate in more 
detail the relationships between the factors and mortality risk. A Bonferroni correction 
was used within each risk factor to adjust for multiple comparisons. Pairwise contrasts 
were considered significant if the p-value was less than 0.0167 for factors with 3 levels 
(such as DEPCAT and smoking), less than 0.005 for factors with 5 levels (such as 
cholesterol) and less than 0.0024 for factors with 7 levels (such as alcohol).
Finally, interactions were investigated. Interaction terms were added into the logistic 
model in a forward stepwise manner, in which higher order terms were only allowed 
once their constituent lower order terms had been included. For example, the age*BMI 
interaction could only be considered once the age and BMI main effects had been 
included in the model. Tabulations of the observed relative frequencies of deaths and the 
expected relative frequencies of deaths based on the logistic main effects model were 
constructed to investigate the nature of any significant interaction effects. The 
significance of the parameters fitted in the final models (following stepwise logistic 
regression), for contrasts between levels of the main effects and interactions, were also 
examined, to provide further information on the nature of the effects. The coefficient 
divided by the standard error, for each contrast, is an approximate z-statistic. The 
exponential of the coefficient provides an estimate of the odds ratio for the levels being 
contrasted. Plots of residuals against fitted values were constructed to investigate model 
fit. Large residuals indicate observations which are poorly accounted for by the model 
(Pregibon, 1981). Chi-square goodness-of-fit statistics and dispersion parameters were 
also examined to provide some measure of the appropriateness of the fitted model.
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6.2.4 Additional analysis for middle-aged men
More detailed analyses were carried out for the group of middle-aged men who were 
systematically invited to screening visit 1 (see section 2 .2 ), since it had a far larger 
sample size than any of the other groups considered. The following analyses were 
carried out.
1) Hospital discharge data were analysed as described in section 6.2.3 for mortality data 
(that is, univariate logistic regression, multivariate main effects model, forward stepwise 
logistic regression allowing interactions, tabulations of significant interactions, and 
model checking). For hospital discharge data there was a sufficient number of events to 
allow consideration of attempted suicide as a separate analysis outcome. Care was 
required in the analysis of the SMR1 dataset, since a new SMR1 record is generated 
every time a subject is hospitalised or moved to another unit (within an episode of stay). 
The data were analysed on a subject rather than event basis. A subject may be admitted 
for many different diagnoses. For each diagnosis category, a subject was counted only 
once in that diagnosis group, no matter how many admissions he had for that diagnosis. 
A subject could, of course, be included in more than one of the diagnosis groups.
2) Cancer deaths, hospitalisations and registrations were analysed in relation to the 
cross-classification of CHD risk factors. This was of interest due to the concerns about 
potential increased cancer risk associated with low cholesterol discussed in section 1.4. 
Analyses were carried out for ‘All malignant neoplasms’ and for ‘lung neoplasms’ - 
lung being the most common cancer site. For each of these contexts, logistic models 
were investigated as described in section 6.2.3.
3) Other studies have suggested that the relationship between cholesterol and cancer 
may be due to undetected disease, which causes the lowering of cholesterol. If this was 
true, the relationship would diminish with increased length of subject follow-up. To 
investigate this, the cancer data were analysed as in section 6.2.3, and this was repeated 
with the first year of follow-up excluded, and then with the first 2  years of follow-up 
excluded. Although a longer period of follow-up would be required to obtain more
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meaningful results (follow-up was only for between 3 and 5 years), this gives an 
indication of the relationship between cholesterol and cancer once the early years have 
been excluded. Events which are diagnosed later are less likely to have been pre-existing 
at baseline.
4) Analysis was also carried out for cancer deaths, with deaths from non-cancer causes 
excluded, to see whether this strengthened the relationships between the risk factors and 
outcome. This was only done for total cancer mortality. 1205 subjects died from cancer 
until the end of 1993. In this analysis, these subjects were considered relative to the 
70,909 subjects who had not died from a non-cancer cause. Analysis thus considered 
factors associated with deaths due to cancer, within the subjects who had not died from 
other causes.
6.3 Men age 45-64 at screening visit 1
6.3.1 Results
The data for the men age 45-64 were used for the most extensive analyses, since this 
was the group targeted for possible inclusion in the WOSCOPS clinical trial, and thus 
made up the largest subgroup screened. There were 74,576 men age 45-64 in the group 
of 97,165 subjects who were screened and had sufficient identifying information to 
allow follow-up by record linkage. The mean period of follow-up for the 74,576 middle- 
aged men was 4.0 years (298,548 subject years in total) until the end of 1993.
6.3.1.1 Preliminary examination of mortality data
The deaths identified by record linkage for the 74,576 men age 45-64 are given in Table 
6 .1 , broken down by cause of death.
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Cause of death Number of deaths
Malignant neoplasms 1230
Coronary heart disease 1333
Cerebrovascular 190
Other circulatory 145
Respiratory 186
Digestive 144
Injury / poisoning 131
Endocrine / nutritional 47
Nervous system 33
Mental disorders 2 1
Urogenital 1 0
Infectious disease 5
Blood disorders 5
Other causes 13
Total deaths 3493
Table 6.1 Numbers o f deaths from various causes for the men age 45-64 at screening visit 1
Table 6.2 contains the frequencies and rates of death for the 74,576 male screenees aged 
45-64, broken down by 10-year age band (45-54 and 55-64), smoking status (never, ex 
or current), cholesterol level (quintiles - 0-4.93, 4.94-5.55, 5.56-6.11, 6.12-6.80 or >6.80 
mmol/1), alcohol consumption (0, 1-20, 21-30, 31-40, 41-50, 51-60, or >60 units per 
week), diastolic blood pressure (< or > the median pressure of 84 mmHg), body mass 
index (< or > the median of 25.46 kg/m2) and DEPCAT (affluent, middle or deprived) 
for all-cause mortality and death due to coronary heart disease, malignant neoplasms and 
injury/poisoning. The death rates are calculated based on the number of subject years of 
follow-up accrued within each level of each factor.
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Variable Levels Number
of
subjects
Deaths
(All-causes)
Deaths
(CHD)
Deaths
(Cancer)
Deaths 
(Injury / 
poisoning)
Age
(years) 45-54 37289 887 (5.98) 345 (2.33) 293 (1.97) 52 (0.35)
55-64 37287 2606 (17.35) 988 (6.58) 937 (6.24) 79 (0.53)
Smoking
never 20855 529 (6.38) 212(2.56) 170(2.05) 27(0.33)
ex-smoker 20773 942(11.29) 377(4.52) 308(3.69) 30(0.36)
current
smoker
32947 2022(15.29) 744(5.63) 752(5.69) 74(0.56)
Cholesterol
(mmol/1) <4.93 14904 838(14.08) 217(3.65) 343(5.76) 37(0.62)
4.93-5.55 15029 615(10.29) 217(3.63) 233(3.90) 25(0.42)
5.56-6.11 14890 653(11.00) 253(4.26) 246(4.15) 25(0.42)
6.12-6.80 14821 618(10.41) 263(4.43) 199(3.35) 13(0.22)
>6.80 14905 768(12.69) 383(6.33) 208(3.44) 31(0.51)
Alcohol
(units/week) 0 15813 929(14.48) 375(5.85) 311(4.85) 32(0.50)
1 - 2 0 43569 1862(10.72) 724(4.17) 675(3.88) 73(0.42)
21-30 7567 295(9.78) 102(3.38) 118(3.91) 8(0.26)
31-40 3065 138(11.27) 46(3.76) 46(3.76) 6(0.49)
41-50 1584 80(12.6) 26(4.10) 26(4.10) 2(0.32)
51-60 961 60(15.56) 20(5.18) 16(4.15) 6(1.56)
>60 1270 83(16.35) 23(4.53) 24(4.73) 3(0.59)
DBP
(mmHg) <84 35978 1613(11.18) 570 (3.95) 620 (4.30) 71 (0.49)
>84 38590 1880(12.17) 763 (4.94) 610 (3.95) 60 (0.39)
BMI
(kg/m2) <25.46 37236 1946(13.01) 665 (4.44) 764 (5.11) 81 (0.54)
>25.46 37308 1545 (10.37) 667 (4.48) 465 (3.12) 50 (0.34)
DEPCAT
affluent 10874 320(7.76) 118(2.86) 125(3.03) 1 1 (0 .2 2 )
middle 42615 1870(10.87) 733(4.26) 665(3.86) 71(0.41)
deprived 20453 1264(15.27) 472(5.70) 430(5.19) 45(0.54)
Table 6.2: Number o f deaths (events/1000 years o f follow-up) for middle-aged, male screenees broken 
down by each o f the risk factors. It should be noted that due to a small amount o f missing data for each 
variable the total numbers o f subjects are not consistent across the variables.
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The results in Table 6.2 parallel those presented in other epidemiological studies, with 
increased risk of CHD death in smokers (Parish et al, 1995) and in older subjects with 
raised cholesterol level or blood pressure (see Table 1.1; Smith et al, 1989; Stokes et al, 
1987; Martin et al, 1986). Increased risk of death due to cancer or external causes was 
associated with current smoking and low cholesterol or alcohol consumption in other 
studies also (Muldoon et al, 1990; Isles et al, 1989; Law et al, 1994). Elevated death 
rates were also found in other studies to be associated with the group who reported zero 
alcohol consumption (Friedman et al, 1986), and the group categorised as deprived 
(Pocock et al, 1987).
6.3.1.2 Logistic models for mortality
Main effects models
The relationship between mortality and the factors listed above was considered for the
73,110 men age 45-64 who had no missing values on the explanatory variables and 
could thus be used in fitting models. Main effects logistic regression models were fitted 
for deaths prior to the end of 1993. The odds ratios (of having an event relative to not 
having an event) and p-values obtained from the univariate (unadjusted) and 
multivariate (adjusted for all other factors) main effects models are given in table 6.3 for 
all-cause mortality, table 6.4 for CHD mortality, table 6.5 for cancer mortality and table 
6 . 6  for trauma mortality. It should be noted that the odds ratios are calculated relative to 
the highest level of each factor and the p-values relate to the overall significance of each 
factor.
141
Variable Levels
Univ< 
Odds Ratio
ariate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.32 0.32
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.40 0.42
ex-smoker 0.73 0.70
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 1 . 1 0 1.04
4.93-5.55 0.79 0.78
5.56-6.11 0.85 0.84
6.12-6.80 0.81 0.79
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 0.89 0.94
1 - 2 0 0.64 0.69
21-30 0.58 0.62
31-40 0.67 0.72
41-50 0.76 0.77
51-60 0.95 1 . 0 1
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 0.92 0.89
>84 1 . 0 0 0.0156 1 . 0 0 0 . 0 0 1 2
BMI
(kg/m2) <25.46 1.28 1 . 2 0
>25.46 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DEPCAT
affluent 0.46 0.57
middle 0.70 0.76
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Table 6.3. Odds ratios and p-values for the univariate and multivariate models for all-cause mortality. All
odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f the factor.
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Variable Levels
Univ. 
Odds Ratio
ariate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.35 0.35
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.45 0.44
ex-smoker 0.80 0.73
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 0.57 0.56
4.93-5.55 0.56 0.57
5.56-6.11 0 . 6 6 0.67
6.12-6.80 0.70 0.69
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 1.35 1.36
1 - 2 0 0.94 0.97
21-30 0.76 0.77
31-40 0.85 0.85
41-50 0.93 0.89
51-60 1.18 1.16
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 0.80 0.81
>84 1 . 0 0 0 . 0 0 0 1 1 . 0 0 0.0003
BMI
(kg/m2) <25.46 1 . 0 1 1 . 0 1
>25.46 1 . 0 0 0.0916 1 . 0 0 0.9225
DEPCAT
affluent 0.48 0.54
middle 0.76 0.76
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Table 6.4. Odds ratios and p-values for the univariate and multivariate models for CHD mortality. All
odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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Variable Levels
Univ. 
Odds Ratio
mate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.30 0.31
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.36 0.38
ex-smoker 0.65 0.65
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 1 . 6 8 1.53
4.93-5.55 1 . 1 2 1.06
5.56-6.11 1 . 2 0 1.13
6.12-6.80 0.97 0.95
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 1.06 1.08
1 - 2 0 0.83 0 . 8 8
21-30 0.83 0 . 8 8
31-40 0.80 0 . 8 6
41-50 0 . 8 8 0.87
51-60 0.89 0.96
>60 1 . 0 0 0.0300 1 . 0 0 0.1165
DBP
(mmHg) <84 1 . 1 0 1 . 0 0
>84 1 . 0 0 0.1845 1 . 0 0 0.9645
BMI
(kg/m2) <25.46 1.61 1.48
>25.46 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DEPCAT
affluent 0.55 0.70
middle 0.76 0.84
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 0.0008
Table 6.5. Odds ratios and p-values for the univariate and multivariate models for cancer mortality. All
odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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Variable Levels
Univj 
Odds Ratio
iriate
p-value
Multi'' 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0 . 6 6 0.61
55-64 1 . 0 0 0.0081 1 . 0 0 0.0070
Smoking
never 0.56 0 . 6 6
ex-smoker 0.63 0.70
current 1 . 0 0 0.0239 1 . 0 0 0.1070
smoker
Cholesterol
(mmol/1) <4.93 1.19 1.09
4.93-5.55 0.79 0.79
5.56-6.11 0.80 0.84
6.12-6.80 0.42 0.45
>6.80 1 . 0 0 0.0490 1 . 0 0 0.0806
Alcohol
(units/week) 0 0.84 0.89
1 - 2 0 0.70 0.72
21-30 0.44 0.48
31-40 0.82 0 . 8 8
41-50 0.53 0.55
51-60 2.62 2.78
>60 1 . 0 0 0.0328 1 . 0 0 0.0458
DBP
(mmHg) <84 1.24 1.18
>84 1 . 0 0 0.1915 1 . 0 0 0.3669
BMI
(kg/m2) <25.46 1 . 6 8 1.42
>25.46 1 . 0 0 0.0129 1 . 0 0 0.0619
DEPCAT
affluent 0.46 0.55
middle 0.76 0.85
deprived 1 . 0 0 0.066 1 . 0 0 0.2176
Table 6.6. Odds ratios and p-values for the univariate and multivariate models for trauma mortality. All
odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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To help interpret the data, Bonferroni adjusted 95% confidence intervals for all the 
pairwise contrasts among the levels of the risk factors were computed. The results are 
summarised in Table 6.7.
Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Trauma
mortality
Age
Smoking
DBP
BMI
Cholesterol
Alcohol
DEPCAT
1 2  
1 2  3
1  2
2  1
2 4 3 5 1 
3 2 4 5 6 7  1 
1 2  3
1  2  
1 2  3 
2  1 
2  1  
4 5 2 3 1 
2 3 5 4 6 7 1  
1 2 3
1  2  
1 2  3 
1  2  
2  1 
1 2 3 4 5 
2 3 4 5 7 6  1 
1 2  3
1  2  
1 2 3 
2  1 
2  1 
4 2 3 5 1 
3 5 2 1 4 7 6  
1 2 3
Table 6.7. Significance o f pairwise contrasts among levels o f the risk factors in the main effects logistic 
models for men age 45-64. Levels o f each risk factor are given in order o f increasing risk from low to 
high. Levels which are joined by a line were not significantly different from each other after adjusting for 
multiple comparisons by means of a Bonferroni correction.
Stepwise modelling
The next stage of the analysis was to allow interaction terms to be brought into the 
logistic model, in a stepwise manner, bringing in the most significant term at each step, 
given the terms already included. Higher order interactions were considered only when 
the lower order terms contributing to them had been brought into the model.
For all-cause mortality, this forward stepwise process included all main effects and 
introduced four interaction terms - smoking*DEPCAT (p=0.003), smoking*BMI 
(p=0.004), smoking*age (p=0.005) and age*DBP (p=0.024). The parameter estimates 
obtained by fitting this logistic model are given in Appendix J 1, and may be used in
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conjunction with the covariance matrix in Appendix FI to examine any contrast 
between levels of the factors.
For CHD mortality, the forward stepwise model fitting dropped the BMI main effect and 
brought in four interaction terms - age*smoking (p=0.004), smoking*DBP (p=0.023), 
smoking*alcohol (p=0.021) and smoking*DEPCAT (p=0.034).
The parameter estimates, approximate z-statistics (coefficient / standard error) and 
estimated odds ratios (exponential(coefficient)) obtained by fitting this logistic model 
are given in Appendix J2. These parameter estimates may be used in conjunction with 
the covariance matrix given in Appendix F2 to examine any contrast among levels of 
the factors.
For cancer mortality, the stepwise process dropped the main effects for alcohol and 
DBP. None of the interaction terms were significant although DEPCAT*age (p=0.0639) 
and alcohol*BMI (p=0.0637) were borderline. For trauma deaths, only the main effects 
for age and alcohol consumption were included by the stepwise model fitting.
The parameter estimates, approximate z-statistics (coefficient / standard error) and 
estimated odds ratios (exponential(coefficient)) obtained by fitting the final logistic 
model are given in Appendix J3 for cancer mortality and Appendix J4 for trauma 
mortality. These parameter estimates may be used in conjunction with the covariance 
matrices given in Appendices F3 and F4 to examine any contrast between levels of the 
factors.
Tabulations of the observed and expected proportions of deaths/subjects in each 
category were constructed to help investigate the nature of the interaction effects (see 
Appendix G).
For all-cause mortality, each of the main effect terms was significant. Mortality risk 
increased with increasing age, blood pressure and deprivation category. Current smokers 
were at greater risk than ex-smokers, who were, in turn, at greater risk than subjects who 
had never smoked. Mortality risk was greater with lower levels of BMI. For cholesterol,
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the lowest and the highest quintiles were at significantly greater risk than the three 
middle quintiles. The highest risk alcohol group was consumption of more than 50 units 
per week, with the second highest risk being for the group consuming 0  units per week. 
The mortality risk for these groups was only significantly greater than the risk for the 
groups consuming 1-30 units per week. Significant interaction terms, brought in by the 
stepwise logistic modelling, were smoking*DEPCAT, smoking*BMI, smoking*age and 
age*DBP. Mortality risk increased with smoking category (never/ex/current) at each 
level of DEPCAT, BMI and age (see Appendix G nos 1-4). It increased with DEPCAT 
and with age at each level of smoking. However, the risk increased with BMI for those 
who had never smoked but decreased for current and ex-smokers. It increased with DBP 
for each age group, and increased with age for each DBP category.
CHD mortality was significantly related to each of the main effect terms except BMI. 
Mortality risk increased with increasing age, blood pressure, cholesterol and 
deprivation. Risk also increased with smoking status (never/ex/current). The group 
claiming consumption of 0  units of alcohol per week was at significantly greater risk 
than the groups consuming 1-30 units per week. Significant interaction terms brought in 
by the stepwise modelling were age*smoking, smoking*DBP, smoking*alcohol and 
smoking*DEPCAT. CHD mortality risk increased with smoking category at each level 
of alcohol consumption, age, DEPCAT and DBP. It generally decreased with alcohol 
and increased with age, DBP and DEPCAT for each smoking category (see Appendix G 
nos 5-8).
Cancer mortality was not significantly related to DBP or alcohol consumption. 
However, cancer risk did increase with increasing age, deprivation and smoking status 
(never/ex/current). Cancer risk was also greater for lower BMI, and for the lowest 
quintile of cholesterol. No interaction terms were significant for cancer mortality.
Trauma mortality was significantly related to only age and alcohol consumption, with 
increased risk for the older age group, and the higher levels of alcohol consumption, 
although none of the pairwise contrasts between levels of alcohol consumption were 
significant. No interaction terms were significant for trauma mortality.
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As a further means of investigating the interaction effects, plots were constructed for the 
fitted values at relevant cross-tabulations of factors. This was done using the final 
stepwise models with factors not involved in the interaction of interest kept at baseline 
levels. This gives a pictorial representation of the nature of the interaction effect.
For all-cause mortality, the smoking*DEPCAT interaction is illustrated in Figure 6.1, 
the smoking*BMI interaction in Figure 6.2, the smoking*age interaction in Figure 6.3 
and the age*DBP interaction in Figure 6.4.
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Figure 6.1. Fitted values from the final stepwise model for all-cause mortality at cross-tabulations o f  
smoking*DEPCAT.
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Figure 6.2. Fitted values from the final stepwise model for all-cause mortality at cross-tabulations o f  
smoking*BMI.
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Figure 6.3. Fitted values from the final stepwise model for all-cause mortality at cross-tabulations o f
smoking*age.
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Figure 6.4. Fitted values from the final stepwise model for all-cause mortality at cross-tabulations o f  
age*DBP.
The significant interaction between DEPCAT and smoking for all-cause mortality may 
relate to lower smoking rates among affluent compared to deprived subjects. There is 
higher mortality in middle and deprived ex-smokers than would have been expected 
(Figure 6.1). The age*smoking interaction is due to a wider diference in mortality for 
smokers compared to non and ex-smokers (Figure 6.3). The age*DBP interaction seems 
to be picking up a very small effect, with the graph showing little of real interest (Figure 
6.4). Mortality risk increased with BMI for the subgroup of men who had never smoked, 
but decreased with BMI for current and ex-smokers (Figure 6.2). This interaction may 
be due to current smokers being at greater risk of lung cancer which is also related to 
low BMI. Thus, obesity appears to be a risk factor in the absence of smoking, but 
smoking is a more important factor and is related to low BMI.
For CHD mortality, the smoking*age interaction is illustrated in Figure 6.5, the 
smoking*DBP interaction in Figure 6 .6 , the smoking*alcohol interaction in Figure 6.7 
and the smoking*DEPCAT interaction in Figure 6 .8 .
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Figure 6.5. Fitted values from the final stepwise model for CHD mortality at cross-tabulations of 
smoking*age.
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Figure 6.6. Fitted values from the final stepwise model for CHD mortality at cross-tabulations o f
smoking*DBP.
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Figure 6.7. Fitted values from the final stepwise model for CHD mortality at cross-tabulations of 
smoking*alcohol.
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Figure 6.8. Fitted values from the final stepwise model for CHD mortality at cross-tabulations o f
smoking*DEPCAT.
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The difference between ex-smokers and men who have never smoked was 
approximately the same in each of the age groups (see Appendix G no 5). However, the 
CHD mortality rate observed for the current smokers was around three times that in the 
never smokers for the younger age group but only around twice that observed for never 
smokers for the older age group. The graph shows similar trends (Figure 6.5). For the 
DBP*smoking interaction, there was little DBP difference for never and ex-smokers, 
while for current smokers there was greater mortality risk for subjects with high DBP. 
For alcohol and smoking, current smokers consuming 21-30 units of alcohol per week 
were at substantially greater risk of CHD mortality than subjects at any other level of 
these risk factors. The difference between the levels of DEPCAT are similar for current 
smokers and men who have never smoked. However, the differences are much larger for 
the group of ex-smokers. The proportion of CHD deaths for ex-smokers in the middle 
DEPCAT is approximately twice that for affluent ex-smokers, while the proportion for 
deprived ex-smokers is around three times that for affluent ex-smokers (see Appendix G 
no 8 ).
The fit of the final models was checked by means of plots of residuals against fitted 
values, which were expected to show a random scatter around 0. As an example of the 
model fit achieved, the residual plot for the outcome of all-cause mortality is given in 
Appendix H. Chi-square goodness-of-fit tests leading to estimates of the dispersion 
parameters were also examined (see Appendix H) but did not indicate that there were 
any problems with model fit.
6.3.1.3 Logistic models for hospitalisation
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An approach to the analysis of morbidity was to use the SMR1 (hospital discharge) 
database which went up to the end of 1993. The numbers of 45-64 year old men 
identified by record linkage as being hospitalised for various events are given in Table 
6 .8 . It should be noted that the diagnosis of ‘mental disorders’ will usually be recorded 
on the SMR4 (psychiatric hospital admission) form rather then an SMR1 form.
Main effects models
As for mortality, to give an overview, logistic main effects models were fitted for the
73,110 men age 45-64 who had sufficient identifying information to allow follow-up by 
record linkage and no missing values for any of the explanatory variables contributing to 
the categorisation. The odds ratios (of having an event relative to not having an event) 
and p-values obtained from the univariate (unadjusted) and multivariate (adjusted for all 
other factors) main effects models are given in table 6.9 for all-cause hospitalisation, 
table 6.10 for CHD hospitalisation, table 6.11 for cancer hospitalisation, table 6.12 for 
trauma hospitalisation and table 6.13 for suicide hospitalisation. It should be noted that 
the odds ratios are calculated relative to the highest level of each factor and the p-values 
relate to the overall significance of each factor.
155
Reason for hospitalisation Number of SMR1 
records
Number of subjects
Malignant neoplasms 8765 2626
Other neoplasms 1647 1209
Coronary heart disease 9722 4037
Cerebrovascular 1298 906
Other circulatory 6439 3783
Respiratory 2967 1984
Digestive 9007 6010
Injury / poisoning 3571 2103
Endocrine / nutritional 1130 475
Nervous system 2992 2118
Mental disorders 410 298
Urogenital 5331 3530
Infectious disease 174 132
Blood disorders 602 303
Congenital 134 115
Musculoskeletal 3432 2490
Skin disease 2234 1722
Miscellaneous 10994 7534
Total 70849 26693
Table 6.8 Numbers o f hospitalisations from various causes for the men age 45-64. The miscellaneous 
category related to a primary diagnosis o f a ‘symptom’ or a ‘supplementary’ code o f factors influencing 
contact with health services and thus did not represent events which were meaningful in themselves. It 
should be noted that the total number of subjects is not equal to the sum o f the column since subjects may 
be included in more than one diagnosis group.
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Variable Levels
Univi 
Odds Ratio
iriate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.95 0.63
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.72 0.72
ex-smoker 0.94 0.92
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 0.98 0.98
4.93-5.55 0 . 8 8 0 . 8 8
5.56-6.11 0.90 0.90
6.12-6.80 0.91 0.91
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 1.04 1.04
1 - 2 0 0.80 0.82
21-30 0.77 0.79
31-40 0.81 0.82
41-50 0.75 0.74
51-60 0.92 0.94
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 1 . 0 0 1 . 0 0
>84 1 . 0 0 0.9048 1 . 0 0 0.8991
BMI
(kg/m2) <25.46 1 . 0 1 0.99
>25.46 1 . 0 0 0.4599 1 . 0 0 0.6047
DEPCAT
affluent 0.67 0.73
middle 0.84 0.87
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Table 6.9. Odds ratios and p-values for the univariate and multivariate models for all-cause
hospitalisation. All odds ratios are calculated relative to the highest level o f each factor and p-values relate
to the overall significance of each factor.
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Variable Levels
Univ< 
Odds Ratio
iriate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.57 0.60
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.55 0.53
ex-smoker 0.99 0 . 8 8
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 0.39 0.41
4.93-5.55 0.53 0.55
5.56-6.11 0 . 6 8 0.70
6.12-6.80 0.75 0.76
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 2 . 0 0 2.03
1 - 2 0 1.44 1.45
21-30 1 . 1 0 1.09
31-40 1.28 1.25
41-50 1 . 0 0 0.95
51-60 1.13 1 . 1 0
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 0 . 8 6 0.90
>84 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 0 . 0 0 2 2
BMI
(kg/m2) <25.46 0.74 0.76
>25.46 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DEPCAT
affluent 0.63 0 . 6 8
middle 0 . 8 8 0.87
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Table 6.10. Odds ratios and p-values for the univariate and multivariate models for CHD hospitalisation.
All odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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Variable Levels
Univ. 
Odds Ratio
iriate
p-value
Multi'' 
Odds ratio
/ariate
p-value
Age
(years) 45-54 0.32 0.32
55-64 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Smoking
never 0.51 0.52
ex-smoker 0.79 0.76
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 1.33 1.28
4.93-5.55 1.03 1 . 0 1
5.56-6.11 1 . 0 0 0.99
6.12-6.80 0.94 0.93
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Alcohol
(units/week) 0 0.92 0 . 8 6
1 - 2 0 0.78 0.76
21-30 0.74 0.74
31-40 0.81 0.83
41-50 0 . 6 8 0.65
51-60 0.91 0.94
>60 1 . 0 0 0.0051 1 . 0 0 0.0351
DBP
(mmHg) <84 1.04 1 . 0 1
>84 1 . 0 0 0.3672 1 . 0 0 0.7697
BMI
(kg/m2) <25.46 1.31 1 . 2 1
>25.46 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DEPCAT
affluent 0.73 0.89
middle 0.77 0.85
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 0 . 0 0 1 0
Table 6.11. Odds ratios and p-values for the univariate and multivariate models for cancer hospitalisation.
All odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance of each factor.
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Variable Levels
Univj 
Odds Ratio
iriate
p-value
Multr 
Odds ratio
/ariate
p-value
Age
(years) 45-54 1.13 1.08
55-64 1 . 0 0 0.0072 1 . 0 0 0.0744
Smoking
never 0.65 0.76
ex-smoker 0.62 0.71
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 1.36 1.25
4.93-5.55 1.06 1 . 0 2
5.56-6.11 1 . 0 2 1 . 0 0
6.12-6.80 0.98 0.98
>6.80 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 0.0007
Alcohol
(units/week) 0 0.32 0.38
1 - 2 0 0.33 0.39
21-30 0.42 0.48
31-40 0.50 0.54
41-50 0.54 0.58
51-60 0.73 0.78
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 1 . 0 2 0.98
>84 1 . 0 0 0.6113 1 . 0 0 0.5823
BMI
(kg/m2) <25.46 1.40 1.31
>25.46 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DEPCAT
affluent 0.44 0.50
middle 0.70 0.76
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
Table 6.12. Odds ratios and p-values for the univariate and multivariate models for trauma hospitalisation.
All odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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Variable Levels
Univ 
Odds Ratio
ariate
p-value
Multi1 
Odds ratio
y ariate 
p-value
Age
(years) 45-54 1.46 1.37
55-64 1 . 0 0 0 . 0 1 1 2 1 . 0 0 0.0357
Smoking
never 0.29 0.36
ex-smoker 0.39 0.49
current 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
smoker
Cholesterol
(mmol/1) <4.93 1.34 1.13
4.93-5.55 1 . 0 1 0.94
5.56-6.11 1.06 1.03
6.12-6.80 1.16 1.15
>6.80 1 . 0 0 0.6476 1 . 0 0 0.8982
Alcohol
(units/week) 0 0.30 0.42
1 - 2 0 0.16 0 . 2 2
21-30 0.42 0.52
31-40 0.41 0.47
41-50 0.30 0.34
51-60 0.30 0.34
>60 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 <0 . 0 0 0 1
DBP
(mmHg) <84 1.38 1.26
>84 1 . 0 0 0.0294 1 . 0 0 0.1223
BMI
(kg/m2) <25.46 1.79 1.50
>25.46 1 . 0 0 0 . 0 0 0 1 1 . 0 0 0.0098
DEPCAT
affluent 0.29 0.39
middle 0.54 0.64
deprived 1 . 0 0 <0 . 0 0 0 1 1 . 0 0 0.007
Table 6.13. Odds ratios and p-values for the univariate and multivariate models for suicide hospitalisation.
All odds ratios are calculated relative to the highest level o f each factor and p-values relate to the overall
significance o f each factor.
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To see which levels of the risk factors were related to increased risk of a subject being 
hospitalised, the pairwise contrasts among the levels of each risk factor were computed. 
A Bonferroni correction was applied within each risk factor to adjust for multiple 
comparisons with results as in Table 6.14.
Risk factor All-cause CHD Cancer Trauma Suicide
Age 1 2 1 2 1 2 2  1 2  1
Smoking 1 2  3 1 2  3 1 2  3 2  1 3 1 2  3
DBP 2  1 1 2 2  1 1 2 2  1
BMI 1 2 1 2 2  1 2  1 2  1
Cholesterol 2 3 4 1 5 1 2 3 4 5 4 3 5 2 1 4 3 5 2 1 2 5 3 1 4
Alcohol 5 3 2 4 6 7 1 5 3 7 6 4 2  1 5 3 2 4 6 7  1 1 2 3 5 4 6 7 265  1 4 3 7
DEPCAT 1 2 3 1 2 3 2 1 3 1 2 3 1 2 3
Table 6.14 Significance o f pairwise contrasts among levels o f the risk factors for multivariate main 
effects logistic models for subjects hospitalised. Levels o f each risk factor are given in order o f increasing 
risk from low to high. Levels which are joined by a line were not significantly different from each other, 
after adjusting for multiple comparisons by means o f a Bonferroni correction.
Stepwise modelling
The next stage of the analysis was to allow interaction terms to be brought into the 
logistic model, in a stepwise manner, bringing in the most significant term at each step 
given the terms already included. Higher order interactions were considered only when 
the lower order terms contributing to them had all been brought into the model.
For all-cause hospitalisation, this forward stepwise process dropped the DBP and BMI 
main effects and introduced two interaction terms - DEPCAT*age (p=0.0002) and 
smoking*age (p=0.026).
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The parameter estimates, approximate z-statistics (coefficient / standard error) and odds 
ratios (exponential(coefficient)) obtained by fitting the final logistic model for 
hospitalisation from any cause are given in Appendix J5 and may be used in conjunction 
with the covariance matrix given in Appendix F5 to examine any contrast between 
levels of the factors.
For CUD hospitalisation, the final model resulting from the forward stepwise model 
fitting included all the main effects and four interaction terms - age*smoking (p<0 .0 0 1 ), 
age*DBP (p=0.008), age*cholesterol (p=0.016) and age*DEPCAT (p=0.049).
The parameter estimates, approximate z-statistics (coefficient / standard error) and odds 
ratios (exponential(coefficient)) obtained by fitting the final logistic model for CHD 
hospitalisation are given in Appendix J6  and may be used in conjunction with the 
covariance matrix given in Appendix F6  to examine any contrast between levels of the 
factors.
For cancer hospitalisation, none of the interaction terms were significant and the final 
model contained only the main effects of age, smoking, BMI, cholesterol, DEPCAT and 
alcohol. The parameter estimates, approximate z-statistics (coefficient / standard error) 
and odds ratios (exponential(coefficient)) obtained by fitting the final logistic model for 
cancer hospitalisation are given in Appendix J7 and may be used in conjunction with the 
covariance matrix given in Appendix F7 to examine any contrast between levels of the 
factors.
For hospitalisations for injury or poisoning, the stepwise process dropped the terms for 
the age and DBP main effects and brought in two interaction terms - BMI*DEPCAT 
(p=0.007) and BMI*smoking (p=0.028).
The parameter estimates, approximate z-statistics (coefficient / standard error) and odds 
ratios (exponential(coefficient)) obtained by fitting the final logistic model for trauma 
hospitalisation are given in Appendix J 8  and may be used in conjunction with the
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covariance matrix given in Appendix F8  to examine any contrast between levels of the 
factors.
For hospitalisations for attempted suicide, the final stepwise model dropped the main 
effects of cholesterol and DBP and introduced the smoking*DEPCAT interaction 
(p=0.039). The parameter estimates, approximate z-statistics (coefficient / standard 
error) and odds ratios (exponential(coefficient)) obtained by fitting the final logistic 
model for hospitalisation for attempted suicide are given in Appendix J9 and may be 
used in conjunction with the covariance matrix given in Appendix F9 to examine any 
contrast between levels of the factors.
Tabulations of the observed and expected proportions of deaths/subjects in each 
category were carried out to investigate the nature of the interaction effects.
Risk of hospitalisation for any cause was not significantly related to DBP or BMI. Risk 
increased with increasing age, deprivation and smoking status (never/ex/current). The 
highest risk for cholesterol was for the lowest and highest quintiles, and the greatest risk 
associated with alcohol was for consumption of 0  or more than 60 units per week. 
Significant interaction terms brought in by the stepwise modelling were age*DEPCAT 
and age*smoking. Risk increased with age for each DEPCAT and smoking category, 
and increased with DEPCAT and smoking category for each age group (see Appendix G 
nos 9 and 10).
Hospitalisation for CHD was significantly related to each of the main effect terms fitted. 
Risk increased with increasing age, blood pressure, BMI, cholesterol, deprivation and 
smoking status (never/ex/current). The group who claimed to have an alcohol 
consumption of 0  units per week were at significantly greater risk than any of the other 
alcohol groups. The interaction terms brought in by the stepwise modelling were for 
age*smoking, age*DBP, age*cholesterol and age*DEPCAT. CHD risk increased with 
age for each category of smoking, DEPCAT, DBP and cholesterol. It also increased with 
DBP, cholesterol, DEPCAT and smoking category for each age group (see Appendix G 
nos 11-14).
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Cancer hospitalisation was not significantly related to DBP. However, cancer risk did 
significantly increase with increasing age and smoking status. Risk was greater for lower 
levels of BMI, and for the lowest quintile of cholesterol. The most deprived group was 
at significantly greater risk than the ‘middle’ group, and the highest alcohol risk was 
with consumption of 0  units per week, although none of the pairwise contrasts between 
levels of alcohol consumption were significant. No interaction terms were significant for 
cancer hospitalisation.
Trauma (injury or poisoning) risk was not significantly related to age or blood pressure. 
Risk increased with increasing deprivation and alcohol consumption. There was 
increased risk associated with current smokers, low BMI, and the lowest quintile of 
cholesterol. Stepwise modelling brought in the interaction terms BMI*DEPCAT and 
BMI*smoking. Risk decreased with BMI in each DEPCAT and smoking category and 
increased with DEPCAT and smoking category for each level of BMI (see Appendix G 
nos 15 and 16).
Hospitalisation for attempted suicide was not significantly related to DBP or cholesterol. 
Risk was greater for the younger age group, the current smokers, the group with lower 
BMI and the most deprived group. There was no clear pattern in the risk associated with 
alcohol consumption, although the lowest risk group was for a consumption of 1 - 2 0  
units per week. There was also a significant interaction between smoking and DEPCAT. 
Suicide risk increased with smoking category in the middle and deprived categories of 
DEPCAT while there was no clear trend in the affluent group. In a similar way, risk 
increased with DEPCAT for current and ex-smokers but did not show this trend for the 
group of subjects who had never smoked (see Appendix G no 17).
As a further means of investigating the interaction effects, plots were constructed for the 
fitted values at relevant cross-tabulations of factors. This was done using the final 
stepwise models with factors not involved in the interaction of interest kept at baseline 
levels. This gives a pictorial representation of the nature of the interaction effect.
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For all-cause hospitalisation, the DEPCAT*age interaction is illustrated in Figure 6.9 
and the smoking*age interaction in Figure 6.10.
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Figure 6.9. Fitted values from the final stepwise model for all-cause hospitalisation at cross-tabulations o f  
DEPCAT*age.
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Figure 6.10. Fitted values from the final stepwise model for all-cause hospitalisation at cross-tabulations 
of smoking*age.
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The trends across DEPCAT for each age group are similar (Figure 6.9) and the 
age*DEPCAT interaction seems to be picking up a very small effect. Similarly, the 
smoking*age interaction seems to be a marginal effect, although there is higher than 
expected risk in the older ex-smokers - possibly due to having accumulated more years 
of smoking before they stopped (Figure 6.10).
For CHD hospitalisation, the age*smoking interaction is illustrated in Figure 6.11, the 
age*DBP interaction in Figure 6.12, that age*cholesterol interaction in Figure 6.13 and 
the age*DEPCAT interaction in Figure 6.14.
50 -  45-54
~  "55-64
40 -
ooo
30 -<D
CLQ)
5 20 -
10 -
non-smoker ex-smoker smoker
Figure 6.11. Fitted values from the final stepwise model for CHD hospitalisation at cross-tabulations of 
age*smoking.
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Figure 6.12. Fitted values from the final stepwise model for CHD hospitalisation at cross-tabulations o f  
age*DBP.
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Figure 6.13. Fitted values from the final stepwise model for CHD hospitalisation at cross-tabulations of
age*cholesterol.
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Figure 6.14. Fitted values from the final stepwise model for CHD hospitalisation at cross-tabulations o f  
age*DEPCAT.
For the age*smoking interaction, the pattern was the same as for all-cause 
hospitalisation (Figure 6.11). The differences between ex-smokers and never smokers 
and between current smokers and never smokers were larger in the 45-54 year old age 
group (2 and 2.5 times as big) than in the 55-64 year old group (1.5 and 1.4 times as big 
- see Appendix G no 11). This is in agreement with a recently published case-control 
study (Parish et al, 1995) which found that at ages 30-49 the rate of myocardial 
infarction in smokers was about five times that in non-smokers, while at ages 50-59 the 
rate was only around three times as big, and at ages 60-79 it was only around twice as 
large as that in non-smokers. For age*DBP, the difference between the blood pressure 
groups is slightly larger in the younger age group (Figure 6.12). For the interaction 
between age and cholesterol, the differences in mortality risk are wider for the older age 
group than the younger (Figure 6.13). The final interaction for CHD hospitalisation 
related to age and DEPCAT. This seems to be picking up a small effect with the trend 
lines being reasonably parallel (Figure 6.14).
For trauma hospitalisation, the DEPCAT*BMI interaction is illustrated in Figure 6.15 
and the smoking*BMI interaction in Figure 6.16.
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Figure 6.15. Fitted values from the final stepwise model for trauma hospitalisation at cross-tabulations of 
DEPCAT*BMI.
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Figure 6.16. Fitted values from the final stepwise model for trauma hospitalisation at cross-tabulations of 
smoking*BMI.
The proportion of subjects hospitalised for injury or poisoning decreased with BMI but 
increased with DEPCAT and smoking, each of which had significant interactions with 
BMI. So, thin men who smoked, and came from the deprived group, were at the highest
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risk of hospitalisation for injury or poisoning. For the BMI*DEPCAT interaction, there 
was little difference in BMI risk for the affluent and middle groups, while for deprived 
subjects there was much greater risk with low BMI (Figure 6.15). Greater risk was 
related to high BMI for non-smokers, but low BMI for ex and current smokers (Figure 
6.16).
For suicide hospitalisation, the smoking*DEPCAT interaction is illustrated in Figure 
6.17. There was a much greater risk difference among the deprivation levels for current 
smokers than for never and ex-smokers, with the middle deprivation group being at 
highest suicide risk for smokers, and the deprived group being at the highest risk for 
never and ex-smokers.
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Figure 6.17. Fitted values from the final stepwise model for suicide hospitalisation at cross-tabulations of 
smoking*DEPCAT.
The fit of the final models was examined by the construction of residual plots and 
consideration of estimates of the dispersion parameters (see Appendix H). There were 
no indications that there was a problem with model fit.
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6.3.1.4 Comparison of results from mortality, registration and 
hospitalisation databases
For cancers, there was an alternative database at SRL which provided information on 
incidence - the Cancer Registration (SMR6 ) database, which may potentially provide 
better incidence information than consideration of hospital discharges, since each cancer 
will be registered only once, at the time of diagnosis. However, cancer registrations only 
went up to the end of 1992 on the linked database at SRL. Based on cancer registrations 
until the end of 1992, there were 1510 registrations for the middle-aged men. Of these 
1510 cancers, the most common cancer sites were as in Table 6.15.
Cancer Site Frequency
Lung 362
Skin 204
Bladder 99
Colon 93
Rectum 78
Prostate 76
Stomach 67
Oesophagus 56
Table 6.15 Frequency of cancer sites for men age 45-64 from SMR6s until the end o f 1992
Since skin neoplasms (with the exception of malignant melanomas) are often less 
serious, and are known to be inconsistently registered, lung was the only site with 
sufficient numbers to be worth consideration on its own at this stage. Further 
consideration was given to cancers, comparing the results for mortality and incidence, 
where incidence data were derived from both the SMR1 and SMR6  databases. The 
number of events accumulated on each record type are given in Table 6.16. Results may 
differ between the SMR6  and SMR1 analyses since hospitalisation will be required for
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the more serious cancers, with ‘minor’ skin neoplasms being removed by GPs and not 
appearing on an SMR1. It is also possible that the SMR1 database will contain further 
treatment admissions for cancers which were diagnosed prior to subject screening, and 
should thus not be included in prospective follow-up, but these events cannot be 
distinguished from the information available.
Men age 45-64 73,110
Cancer deaths until the end of 1993 1205
Cancer registrations until the end of 1992 1510
Subjects hospitalised for cancer until the end of 1993 2626
Table 6.16 Numbers of cancer events for men age 45-64
Logistic main effects models were fitted for the categorised records for the diagnosis of 
all malignant neoplasms for each of the record types and gave the results in Table 6.17.
Risk factor Deaths SMR6 s SMRls
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
DBP 0.9645 0.4759 0.7697
BMI <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Cholesterol <0 . 0 0 0 1 0.0605 <0 . 0 0 0 1
Alcohol 0.1165 0.0439 0.0351
DEPCAT 0.0008 0 . 0 0 0 1 0 . 0 0 1 0
Table 6.17. P-values from logistic main effects models for all cancers recorded on each o f the databases. 
P-values relate to the significance o f the factor once all other terms have been included.
Stepwise logistic regression for each of the three record types resulted in the models 
given in Table 6.18.
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Explanatory Deaths SMR6 s SMRls
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
BMI <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
DEPCAT <0 . 0 0 0 1 0 . 0 0 0 1 0 . 0 0 1 1
Alcohol - 0.042 0.0376
Cholesterol <0 . 0 0 0 1 0.068 <0 . 0 0 0 1
Alcohol * Cholesterol - 0.0168 -
Table 6.18 P-values for models arising out of stepwise logistic regression for all malignant neoplasms. 
The p-values are for each effect once all other terms have already been included.
While the results from analysis of the three databases are similar, there are some 
differences, which will be discussed in section 6.3.2.
The above analysis for each database was repeated for the restricted outcome of lung 
cancer, for which there were 461 deaths until the end of 1993, 362 registrations until the 
end of 1992, and 633 subjects hospitalised until the end of 1993. Lung cancer thus
accounted for approximately ^  of the total cancer events. Logistic main effects models 
including all factors were fitted, and resulted in the p-values given in Table 6.19.
Risk Factor Deaths SMR6 s SMRls
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
DBP 0.6490 0.9901 0.7583
BMI <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Cholesterol 0.0833 0.0078 0.0356
Alcohol 0.4643 0.7391 0.6687
DEPCAT 0.0073 0.0146 0.0014
Table 6.19 P-values from logistic main effects models for lung cancer. The p-values are for each factor 
once all other terms have been included.
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When stepwise logistic regression was carried out, no interaction terms were brought 
into the model. Lung cancer gave results which were similar to those for all cancers, 
although some differences appeared for cholesterol, alcohol and DEPCAT. For total 
cancers, cholesterol was significant for deaths and SMRls but not for SMR6 s. In 
contrast, for lung cancer, cholesterol was not significant for deaths, but was for SMRls 
and SMR6 s. Alcohol was not a significant risk factor for lung cancer whereas it had 
been significant for total cancer incidence. DEPCAT remained significant for each 
database, with the affluent group being at the lowest risk, and the deprived group at the 
highest.
6.3.1.5 Exclusion of early years of follow-up
In order to investigate the hypothesis that low cholesterol is caused by pre-clinical 
cancer and the relationship between low cholesterol and cancer would thus disappear 
after a few years of follow-up, the first two years of subject follow-up were excluded, to 
see whether the strength of the relationship diminished. Only the first two years were 
excluded since WOSCOPS only had between 3 and 5 years of follow-up until the end of 
1993. Total cancer mortality was the outcome considered in this analysis, since specific 
cancer sites would have had insufficient numbers of events once the early years were 
excluded.
Logistic main effects models including all factors were fitted for:
1) the 1205 cancer deaths occurring in the 73,110 men age 45-64 (as considered earlier)
2) the 1033 deaths occurring after the first year for the 72,938 men age 45-64 who were 
followed up for more than one year
3) the 752 deaths occurring after two years of follow-up for the 72,657 men age 45-64 
who were followed up for more than two years.
The resulting p-values were as in Table 6.20.
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Risk factor Full follow-up Year 1 excluded Years 1 & 2 excluded
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
DBP 0.9645 0.6131 0.9816
BMI <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Cholesterol <0 . 0 0 0 1 0.0008 0.0693
Alcohol 0.1165 0.2013 0.8712
DEPCAT 0.0008 0.0008 0.0314
Table 6.20 P-values from additive models for total cancer mortality with exclusion o f years o f follow-up
The results remained similar when the early years of follow-up were excluded, with the 
exception of cholesterol which became statistically non-significant after excluding the 
first two years. It was possible that this was simply due to a widening of the confidence 
intervals for the difference between the levels of cholesterol, caused by the decrease in 
the number of subjects included in the analysis. For each of the three models fitted, the 
lowest cholesterol risk was associated with quintile 4, and the highest risk was
associated with quintile 1 of cholesterol levels. The differences ( pj — p4) and the
I /  /V /V \  /A  a  \  /  A A A A \
standard errors ( J v a r m j - p 5) + varm 4 - P 5 J - 2 covm 1 — P5 , p 4 - P 5 J) for this 
comparison are given in Table 6.21.
Model Effect Standard error
Full follow-up 0.4801 0.0914
Year 1 excluded 0.4014 0 . 1 0 0 0
Years 1 and 2 excluded 0.3181 0.1171
Table 6.21 Differences and standard errors for comparison o f cholesterol quintiles 1 and 4 for each model
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It has been stated elsewhere (Salmond et al, 1985) that if the magnitudes of relative risk 
estimates are not reduced when deaths in the first few years of follow-up are excluded 
then it is unlikely that cancer causes low cholesterol shortly before diagnosis. The odds 
ratios observed here for total cancer mortality for cholesterol quintile 1 to quintile 4
were:- 1.62 when all data was included
1.49 when the first year of follow-up was excluded
1.37 when the first two years of follow-up were excluded.
These odds ratios showed a trend consistent with a reduced effect, as the early years of 
follow-up were excluded, but this decrease cannot be confirmed due to the large 
standard errors (Table 6.21).
6.3.1.6 Exclusion of competing causes of death
A further point of interest was to see whether the relationships between the risk factors 
and the outcome of total cancer mortality were strengthened by excluding all deaths 
from non-cancer causes, as described in section 6.2.4. The resulting p-values are shown 
in Table 6.22.
Risk factor All subjects Excluding non-cancer deaths
Age <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1
DBP 0.9645 0.9136
BMI <0 . 0 0 0 1 <0 . 0 0 0 1
Cholesterol <0 . 0 0 0 1 <0 . 0 0 0 1
Alcohol 0.1165 0.0626
DEPCAT 0.0008 0.0003
Table 6.22 P-values for multivariate main effects models for total cancer mortality with exclusion of
competing causes of death.
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The results remained very similar after excluding these competing causes of death. The 
only factor on which this exclusion had any appreciable effect was alcohol consumption. 
When all 73,110 men were included in the analysis, alcohol consumption had a p-value 
of 0.1165 and there were no significant pairwise differences (with Bonferroni 
correction) between levels of alcohol. However, when men dying from non-cancer 
causes were excluded from the model fitting, there was a significant difference between 
levels 1 and 2  of alcohol (that is, 0  units and 1 - 1 0  units) with men consuming 0  units per 
week being at significantly higher risk of dying from cancer than men consuming 1 - 1 0  
units of alcohol per week. The overall p-value for the alcohol effect was not quite 
significant though (p=0.0626), and this was really a very small effect.
6.3.2 Discussion
Middle-aged men were targeted for screening (as described in section 2.2) with around 
80,000 attending for screening, although there was only an approximately 50% response 
rate with around 160,000 men being invited by letter. They were the only group 
screened in a systematic fashion. Consideration of this group of men thus gives a study 
of the people who are likely to come along to public health screening.
For mortality, the older age group was at increased risk for each of the Causes of Death 
considered (all-cause, CHD, cancer and trauma). Smoking also, predictably, was related 
to increased mortality risk from each of the major outcomes, although not from trauma. 
High blood pressure was associated with CHD mortality risk but not risk of cancer or 
trauma. Low BMI was related to increased risk of cancer and all-cause mortality, 
possibly due to weight loss induced by the cancer process. Cholesterol was a significant 
risk factor for each of the outcomes except trauma, for which it was only borderline 
significant, probably due to the small number of trauma events observed. Cholesterol 
showed the same trends reported elsewhere (see chapter 1) - the U-shaped curve for all­
cause mortality being reflected by the lowest and highest quintiles being at significantly 
higher risk than the middle three quintiles. The risk in the highest quintile was 
associated with coronary causes, with risk of CHD increasing in order from quintile 1 up
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to quintile 5. The risk in the lowest quintile was mainly associated with cancer. Alcohol 
was significant for each outcome except cancer. Trauma risk increased with alcohol 
consumption, but the highest risk of CHD mortality was for the group consuming 0 
units of alcohol per week. DEPCAT also showed interesting relationships with the 
major causes of death - the most deprived group being at the highest risk. These results 
(see Table 6.7) are in agreement with the findings of other studies, as discussed in 
Chapter 1. However, the main effects model becomes difficult to interpret when 
significant interaction terms are included in the model.
The greatest risks of hospitalisation from any of the outcomes were for the older age 
group, the current smokers, and the deprived group (see Table 6.14). High BMI was 
related to increased risk of CHD, but lower risk of cancer. Cholesterol also remained 
consistent to the mortality result already seen - highest all-cause risk for quintiles 1 and 
5, graded relationship with CHD with highest risk in quintile 5, and highest cancer risk 
in quintile 1. Alcohol showed the expected pattern with trauma hospitalisation, that is 
higher risk with higher consumption, but the CHD risk was significantly higher for 
consumption of 0 units per week. For hospitalisation from any cause, the categories of 0 
and >60 units of alcohol per week were at significantly higher risk than the intermediate 
categories. These results are thus similar to those obtained for mortality in 45-64 year 
old men.
The final models arrived at in this study were identified using forward stepwise logistic 
regression techniques, which seem to have given plausible results. However, it is 
possible that a backward stepwise or an all-subsets method could have resulted in 
different models which fitted the data equally well. The main reason for sticking with 
the forward stepwise method was the reduction in computer run time, avoidance of 
problems with array sizes (for storage of the design matrix), and simplicity. The models 
which were identified using the forward stepwise method were checked for fit by means 
of a plot of residuals against fitted values and examination of the dispersion parameters. 
These checks revealed no problems in model fit. Only one example of the resulting 
residual plots and dispersion parameters is given in this thesis (see Appendix H).
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For the comparison of cancer events on the three types of record, the main differences 
among the results observed were for cholesterol and alcohol. Cholesterol was highly 
significant for the deaths and hospitalisations, but not for the SMR6 s. This may be due 
to the lower number of incidence records for the SMR6 s which only go up to 1992, but 
there was still a larger number of SMR6 s until 1992 than there were deaths until 1993, 
so this explanation seems unlikely. It is possible that cholesterol may be more strongly 
related to the more serious cancers requiring hospital treatment and frequently causing 
death, whilst having a weaker relationship when ‘minor’ skin neoplasms are included in 
the analysis. A further plausible explanation would be that cholesterol lowering is more 
apparent with ‘advanced’ cancers, as appearing in the deaths and hospitalisations, but 
less clear for cancers which have been diagnosed recently, as documented on cancer 
registration forms (SMR6 s). This would provide some support for the hypothesis that 
cholesterol lowering is an effect of existing cancer and not a causal effect in itself. 
Alcohol was not a significant risk factor for cancer mortality, but was for cancer 
incidence using either SMRls or SMR6 s. As for mortality, the highest cancer incidence 
risk was for the categories of >50 or 0 units of alcohol per week. This difference in 
results could be explained by the cumulation of more events for incidence than for 
mortality, enabling better detection of significant effects.
The exclusion of early years of follow-up had little effect on the relationships between 
the risk factors and cancer mortality, with the exception of cholesterol. Cholesterol 
became marginally non-significant after the exclusion of the first two years of follow- 
up. While the difference between the lowest (quintile 4) and the highest (quintile 1) risk 
groups decreased as years were excluded, the standard error for this difference increased 
slightly. The odds ratios for mortality for quintile 1 to quintile 4 showed a downward 
trend as years were excluded, but the excess risk in quintile 1 relative to quintile 4 had 
not disappeared after excluding the first two years. This supports the findings of other 
studies (see section 1.4) which have suggested that the relationship between cancer and 
low cholesterol may be a short term effect of undiagnosed disease which disappears 
once the first few years of follow-up are excluded. Although insufficient years have 
been excluded to remove the apparent effect in this study, the trend is heading that way 
and this should be examined again once more years of follow-up have been 
accumulated.
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It is interesting to note that the exclusion of competing causes of death had little effect 
on the results obtained from the logistic regression models. Alcohol came close to 
overall significance for cancer mortality when alternative causes of death were 
excluded, so this may be worth re-examining once further years of follow-up have been 
accumulated.
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6.4 Women who attended screening visit 1
6.4.1 Results
The mean period of follow-up for women who attended screening visit 1 was 4.6 years 
(68646 subject years in total) until the end of 1993. The deaths identified by record 
linkage for these 14,950 women are given in Table 6.23, broken down by cause of 
death.
Cause of death Number of deaths
Malignant neoplasms 155
Coronary heart disease 8 6
Cerebrovascular 33
Other circulatory 29
Respiratory 13
Digestive 8
Injury / poisoning 6
Other cause 8
Total 338
Table 6.23 Numbers o f deaths for women screened
Table 6.24 contains the frequencies and rates of death for the 14,950 women screened 
broken down by age group (<45, 45-54, 55-64 or >64 years), smoking status (never 
smoked, ex-smoker or current smoker), diastolic blood pressure (< or > the median 
pressure of 80 mmHg), body mass index (< or > the median of 24.5 kg/m ), cholesterol 
(quintiles - <4.97, 4.97-5.67, 5.68-6.33, 6.34-7.16 or >7.16 mmol/1), alcohol (0, 1-10 or 
>10 units per week) and DEPCAT (affluent, middle or deprived). The death rates are 
calculated based on the number of subject years of follow-up accrued in each level of 
each factor.
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Variable Levels Number
of
subjects
Deaths
(All-causes)
Deaths
(CHD)
Deaths
(Cancer)
Deaths 
(Injury / 
poisoning)
Age
(years) <45 3422 10 (0.64) 0  (0 .0 0 ) 7 (0.45) 0  (0 .0 0 )
45-54 4950 48 (2.12) 7(0.31) 24 (1.06) 1 (0.04)
55-64 4818 144 (6.50) 43(1.94 65 (2.93) 4(0.18)
>64 1749 136 (16.83) 36 (4.45) 59 (7.30) 1 (0 .1 2 )
Smoking
Never 7976 135 (3.68) 33 (0.90) 61 (1 .6 6 ) 4(0.11)
Ex-smoker 2927 80 (5.94) 21 (1.56) 38 (2.82) 0  (0 .0 0 )
Current 4045 123 (6.64) 32(1.73) 56 (3.02) 2 (0 .1 1 )
Cholesterol
(mmol/1) <4.97 2885 32 (2.44) 4 (0.30) 17 (1.30) 0  (0 .0 0 )
4.97-5.67 2960 6 8  (5.04) 12 (0.89) 32 (2.37) 1 (0.07)
5.68-6.33 3016 71 (10.24) 18 (2.60) 32 (4.62) 1 (0.14)
6.34-7.16 3012 6 6  (4.76) 21 (1.51) 30 (2.16) 0  (0 .0 0 )
>7.16 3069 101 (7.07) 31 (2.17) 44 (3.08) 4 (0.28)
Alcohol
(units/week) 0 6750 193 (6.19) 53 (1.70) 83 (2.66) 3 (0.10)
1 - 1 0 7118 126 (3.87) 30 (0.92) 63 (1.94) 2  (0.06)
> 1 0 753 12(3.51) 2 (0.58) 6(1.75) 0  (0 .0 0 )
DBP
(mmHg) <80 8653 169 (4.26) 41 (1.03) 77(1.94) 4(0.10)
>80 6291 169 (5.84) 45 (1.55) 78 (2.69) 2 (0.07)
BMI
(kg/m2) <24.5 7539 170 (4.91) 37(1.07) 83 (2.40) 2  (0.06)
>24.5 7398 167 (4.92) 48(1.41) 72 (2.12) 4(0.12)
DEPCAT
Affluent 1536 23 (3.28) 6  (0 .8 6 ) 9(1.28) 1 (0.14)
Middle 10529 255 (5.24) 65 (1.33) 124 (2.54) 2 (0.04)
Deprived 2805 60 (4.76) 15(1.19) 22(1.75) 3 (0.24)
Table 6.24: Number o f deaths (events/1000 years o f follow-up) for women attending screening visit 1 
broken down by each o f the risk factors. It should be noted that due to a small amount o f missing data for 
each variable the total numbers of subjects are not consistent across the variables.
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The women show lower mortality rates than the middle-aged men considered in section 
6.3. In many of the categories, the female mortality rate is approximately half that in the 
corresponding category for middle-aged men. On the whole, the trends appear similar to 
those observed for men.
Main effects models
Logistic regression main effects models were fitted for these categorised deaths. There 
were 14,517 women who had no missing values on the variables contributing to the 
category and could thus be used in fitting models. The p-values obtained when each 
variable was fitted on its own are given in Table 6.25, and the p-values obtained for 
each variable once all the other factors in the category were included are given in Table 
6.26.
Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 0.0048 0.0275
DBP 0.0033 0.0317 0.0564
BMI 0.0219 0.4905 0.2364
Cholesterol <0 . 0 0 0 1 0.0481 0.0015
Alcohol <0 . 0 0 0 1 0.1076 0.0083
DEPCAT 0.0310 0 . 0 2 2 1 0.4139
Table 6.25 P-values for univariate logistic models for female mortality
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Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 0.0007 0.0018
DBP 0.3383 0.2985 0.6268
BMI 0.2420 0.1768 0.6436
Cholesterol 0.0675 0.4381 0.6684
Alcohol 0.0711 0.7313 0.2378
DEPCAT 0.0837 0.0344 0.5754
Table 6.26 P-values for multivariate main effects logistic models for female mortality. P-values are for 
each variable once all the other factors have already been fitted.
The pairwise contrasts between the levels of each factor (Bonferroni corrected) gave an 
indication of the direction of increased mortality risk with results as in Table 6.27.
Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age 1 2  3 4 1 2  3 4 1 2  3 4
Smoking 1 2  3 1 2 3 1 2 3
DBP 1 2 1 2 1 2
BMI 2  1 2  1 1 2
Cholesterol 4 1 5  3 2 4 5 3 1 2 1 4 2 3 5
Alcohol 2 3 1 3 2 1 3 2 1
DEPCAT 1 3 2 1 3 2 3 1 2
Table 6.27 Significance o f pairwise contrasts in multivariate logistic main effects models for female 
mortality. Levels o f each risk factor are given in order of increasing risk. Levels which are joined by a line 
were not significantly different from each other after adjusting for multiple comparisons by means o f a 
Bonferroni correction.
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Stepwise modelling
The next stage of the analysis was to allow interaction terms to be brought into the 
logistic model, in a forward stepwise manner as has been described earlier.
For all-cause mortality, only the main effects of age and smoking were brought into the 
model. The parameter estimates, approximate z-statistics (coefficient / standard error) 
and odds ratios (exponential(coefficient)) obtained by fitting the final logistic model for 
all-cause mortality are given in Table 6.28. These parameter estimates may be used in 
conjunction with the covariance matrix given in Appendix F10 to examine any contrast 
between levels of the factors.
TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(45-54 /  <45) 1.20 0.35 3.44 3.31
(55-64 / <45) 2.34 0.33 7.12 10.4
(>64 /< 4 5 ) 3.4 0.33 10.4 31.2
smoking(ex/never) 0.32 0.15 2.19 1.37
(current/never) 0.80 0.13 6.08 2.22
CONSTANT -6.16 0.32 -18.9 0.00
Table 6.28 Parameter estimates for the contrasts in the final model for all-cause mortality in the women 
screened. The coefficient divided by the standard error (SE) o f the coefficient gives an approximate z- 
statistic, and the exponential o f the coefficient gives the estimated odds ratio for each contrast.
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For cancer mortality, the main effects of age, smoking and DEPCAT were brought into 
the model. The parameter estimates, approximate z-statistics (coefficient / standard 
error) and odds ratios (exponential(coefficient)) obtained by fitting the final logistic 
model for cancer mortality are given in Table 6.29. These parameter estimates may be 
used in conjunction with the covariance matrix given in Appendix FI 1 to examine any 
contrast between levels of the factors.
TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(45-54 /  <45) 0.87 0.43 2.02 2.38
(55-64 /  <45) 1.92 0.40 4.80 6.79
(>64 /  <45) 2.85 0.40 7.06 17.3
smoking(ex/never) 0.38 0.21 1.83 1.47
(current/never) 0.74 0.19 3.89 2.11
depcat(middle/affluent) 0.72 0.37 1.97 2.06
(deprived/affluent) 0.29 0.42 0.68 1.33
CONSTANT -7.10 0.52 -13.6 0.00
Table 6.29 Parameter estimates for the contrasts in the final model for cancer mortality in the women 
screened. The coefficient divided by the standard error (SE) o f the coefficient gives an approximate z- 
statistic, and the exponential o f the coefficient gives the estimated odds ratio for each contrast.
For CHD mortality, age, smoking and the age*smoking interaction were brought into 
the model. The parameter estimates, approximate z-statistics (coefficient / standard 
error) and odds ratios (exponential(coefficient)) obtained by fitting the final logistic 
model for CHD mortality are given in Table 6.30. These parameter estimates may be 
used in conjunction with the covariance matrix given in Appendix F I2 to examine any 
contrast between levels of the factors.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(45-54 /< 4 5 ) 2.38 2.54 0.94 10.8
(55-64 /  <45) 4.50 2.37 1.90 89.7
(>64 /  <45) 6.52 2.35 2.77 680.
smoking(ex/never) 0.00 4.98 0.00 1.00
(current/never) 0.00 3.92 0.00 1.00
Age45-54(Ex/Never smoker) /  
Age<45(Ex/Never smoker)
1.065 5.18 0.206 2.90
Age55-64(Ex/Never smoker) /  
Age<45 (Ex/Never smoker)
1.26 5.00 0.25 3.51
Age>64(Ex/Never smoker) /  
Age<45 (Ex/Never smoker)
-0.39 5.00 -0.08 0.67
Age45-54(Current/Never smoker) 
/ Age<45(Current/Never smoker)
2.15 4.07 0.53 8.59
Age55-64(Current/Never smoker) 
/  Age<45 (Current/Never smoker)
1.66 3.94 0.42 5.27
Age>64(Current/Never smoker) /  
Age<45 (Current/Never smoker)
-0.31 3.95 -0.08 0.73
CONSTANT -10.20 2.34 -4.35 0.00
Table 6.30 Parameter estimates for the contrasts in the final model for CHD mortality in the women 
screened. The coefficient divided by the standard error (SE) o f the coefficient gives an approximate z- 
statistic, and the exponential o f the coefficient gives the estimated odds ratio for each contrast.
The observed proportions of deaths at each level of the interaction are tabulated in Table 
6.31, and the expected proportions are tabulated in Table 6.32.
Observed Never smoker Ex-smoker Current smoker
Age <45 0 . 0 0 0 0 0 . 0 0 0 0 0 . 0 0 0 0
Age 45-54 0.0004 0 . 0 0 1 2 0.0034
Age 55-64 0.0032 0.0115 0.0170
Age >64 0.0236 0.0166 0.0176
Table 6.31 Observed risk of death for each level o f age crossed with smoking
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Expected Never smoker Ex-smoker Current smoker
Age <45 0 . 0 0 0 0 0 . 0 0 0 0 0 . 0 0 0 0
Age 45-54 0 . 0 0 1 0 0.0014 0.0023
Age 55-64 0.0061 0.0086 0.0143
Age >64 0.0160 0.0226 0.0371
Table 6.32 Expected risk o f death for each level o f age crossed with smoking, based on the logistic main 
effects model for CHD mortality
The proportion of deaths / subjects increased with age for each smoking category, and 
increased with smoking category for each age group except age <45 in which there were 
no deaths. The nature of the interaction will be considered further in the discussion 
(section 6.4.2).
6.4.2 Discussion
The women screened represent a more diverse population than the men considered 
earlier. They were not invited to screening, but they were included since screening was 
initially open to everyone. However, in the later stages of the screening process, women 
were not included. Many of the women screened had accompanied their husbands to 
their first screening visit. However, despite the difficulties in clearly defining this 
population, the women screened are of great interest since most of the previous studies 
(see Chapter 1) have concentrated on middle-aged men, with relatively few of them 
considering women. For these women, there was only a small number of deaths, with 
the proportion of subjects dying being only approximately half that observed in the 
middle-aged men.
While many variables appear to be significantly related to each of the outcomes at a 
univariate level (see Table 6.25), once all the risk factors are included only age and 
smoking remain significant (see Table 6.26), although other factors showed patterns 
which were similar to those for men (see Table 6.27). For example, the highest risk (for 
each outcome) is for an alcohol consumption of 0  units per week, although alcohol was
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not significant overall for any outcome. However, it should be noted that 46% of the 
women had a reported alcohol consumption of 0 units per week. For the women, there 
was a wide age range, and age-specific mortality rates for women tend to be lower than 
those for men, so that insufficient events were observed for this cohort of women to 
clearly detect relationships between baseline risk factors and mortality. The pairwise 
contrasts may also be affected by the differing numbers of women in the various levels. 
For example, the majority of women were in level 2 of DEPCAT and this may lead to 
difficulty in detecting differences between levels 1 and 3. However, it is clear that the 
most outstanding modifiable risk factor for women was smoking, with cholesterol level 
being of much less importance. Cholesterol was almost significant for all-cause 
mortality, with quintile 2 being at significantly higher risk than quintile 4, but it was far 
from significant for any of the more specific outcomes. It is possible that, for women, 
cholesterol may be partially confounded with age. The only significant interaction term 
was age*smoking, for CHD mortality, again in agreement with the recent case-control 
study (Parish et al, 1995) which was discussed in section 6.3.2. These two interacting 
variables had multiplicative effects. None of the contrasts estimated to help interpret this 
interaction came close to significance (see Table 6.30), so this significant overall 
interaction may be due to sensitivity in picking up very small effects. Each of the 
models was checked by means of a plot of residuals against fitted values and 
consideration of the dispersion parameters (as described in Appendix H). There were no 
indications that there was a problem with model fit.
Consideration of incidence may yield higher event rates, and more power to detect 
differences. However the low event rate for CHD is due to the relatively young age of 
the women, since, in general, CHD occurs at an older age in women than men (see 
section 1 .1 .2 ), so that consideration of incidence is unlikely to yield a sufficient 
frequency of CHD events. More events will be accumulated with further years of 
follow-up and an ageing cohort.
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6.5 Men who reached screening visit 3
6.5.1 Results
The deaths identified by record linkage for the 13,559 men who reached screening visit 
3 are given in Table 6.33.
Cause of death Number of deaths
Malignant neoplasms 135
Coronary heart disease 205
Cerebrovascular 23
Other circulatory 1 1
Respiratory 17
Digestive 14
Injury / poisoning 18
Other cause 39
Total 462
Table 6.33 Numbers of deaths for men who reached screening visit 3
Table 6.34 contains the frequencies and rates of death for the 13,559 men who reached 
screening visit 3 broken down by age (45-54 or 55-64 years), smoking status (never 
smoked, ex-smoker or current smoker), diastolic blood pressure (< or > the median 
pressure of 85 mmHg), LDL cholesterol (< or > the median of 4.75 mmol/1), HDL 
cholesterol (tertiles - <1.50, 1.05-1.2 or >1.2 mmol/1), fibrinogen (quintiles - <3.59, 
3.59-3.99, 4.0-4.40, 4.41-4.92, or >4.92 g/dl) and viscosity (tertiles - <1.29, 1.29-1.37 or 
>1.37 mPa.s). The death rates are calculated based on the number of subject years of 
follow-up accrued within each level of each factor.
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Variable Levels Number
of
subjects
Deaths
(All-causes)
Deaths
(CHD)
Deaths
(Cancer)
Deaths 
(Injury / 
poisoning)
Age
(years) 45-54 6784 122 (4.47) 61 (2.24) 24 (0.88) 10(0.37)
55-64 6653 336 (12.34) 142 (5.21) 109 (4.00) 8  (0.29)
Smoking
Never 3720 67 (4.47) 29(1.93) 18(1.20) 2(0.13)
Ex-smoker 3999 113(6.94) 52 (3.19) 30(1.84) 3(0.18)
Current 4719 282(11.94) 124 (5.25) 87 (3.68) 13 (0.55)
DBP
(mmHg) <85 6785 193 (7.41) 71 (2.73) 69 (2.65) 9 (0.34)
>85 6743 269 (9.32) 134 (4.64) 6 6  (2.29) 9(0.31)
LDL chol
(mmol/1) <4.75 6408 206 (7.89) 90 (3.45) 67 (2.57) 8(0.31)
>4.75 7120 256 (8.89) 115 (3.99) 6 8  (2.36) 10(0.35)
HDL chol
(mmol/1) < 1.05 4769 190 (9.88) 96 (4.99) 58 (3.01) 6(0.31)
1.05-1.2 3180 150 (7.52) 65 (3.26) 37(1.85) 7 (0.35)
> 1 . 2 5579 122 (7.77) 44 (2.80) 40 (2.55) 5 (0.32)
Viscosity
(mPa.s) < 1.29 5298 106 (4.97) 51 (2.39) 30(1.41) 4(0.19)
1.29-1.37 4858 147 (8.24) 57 (3.20) 48 (2.69) 8  (0.45)
>1.37 3372 191 (12.13) 8 8  (5.59) 54 (3.43) 5 (0.32)
Fibrinogen
(g/dl) <3.59 2963 62 (5.01) 26 (2 .1 0 ) 24(1.94) 2(0.16)
3.59-3.99 2581 57 (5.39) 24 (2.27) 14(1.32) 4 (0.38)
4.0-4.40 2686 78 (6.94) 35 (3.11) 24(2.13) 2(0.18)
4.41-4.92 2630 91 (8.82) 45 (4.36) 25 (2.42) 4 (0.39)
>4.92 2668 161 (15.46) 6 8  (6.53) 46 (4.42) 6  (0.58)
Table 6.34: Number o f deaths (events/1000 years o f follow-up) for men who reached screening visit 3 
broken down by each o f the risk factors. It should be noted that due to a small amount o f missing data for 
each variable the total numbers of subjects are not consistent across the variables.
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The men who reached screening visit 3 had lower mortality rates than the large cohort of 
men at screening visit 1 considered earlier. The rates for this sub-cohort were 
approximately two thirds of those observed for all middle-aged men for all-cause 
mortality, and about half those observed for cancer mortality. The rates were similar, 
although still slightly lower, for mortality from CHD or trauma.
Main effects models
Logistic main effects models were fitted for these categorised deaths. There were 12,864 
men who had no missing values on the variables contributing to the category and could 
thus be used in fitting models. The p-values obtained when each variable was fitted on 
its own are given in Table 6.35, and the p-values obtained for each variable once all the 
other factors were included are given in Table 6.36.
Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Fibrinogen <0 . 0 0 0 1 0.0006 <0 . 0 0 0 1
HDL 0.0089 0.0528 0.0018
LDL 0.2509 0.6201 0.3083
Viscosity <0 . 0 0 0 1 0.0016 <0 . 0 0 0 1
DBP 0.0050 0.3985 <0 . 0 0 0 1
Table 6.35 P-values for univariate logistic models for mortality in men who reached screening visit 3
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Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Smoking <0 . 0 0 0 1 <0 . 0 0 0 1 <0 . 0 0 0 1
Fibrinogen 0.0094 0.1595 0.3888
HDL 0.1943 0.1502 0.0305
LDL 0.9603 0.2591 0.7191
Viscosity 0.0033 0.0573 0.0855
DBP 0.0094 0.3342 0 . 0 0 0 1
Table 6.36 P-values for multivariate main effects logistic models for mortality in men who reached 
screening visit 3. P-values are for each variable once all the other factors have already been fitted.
The pairwise contrasts between the levels of each factor (Bonferroni corrected) gave an 
indication of the direction of increased mortality risk, with results as in Table 6.37.
Risk factor All-cause
mortality
Cancer
mortality
CHD
mortality
Age i  2 i  2 i  2
Smoking 1 2 3 1 2 3 1 2 3
Fibrinogen 2 3 4 1 5 2 4 3 5 1 2 1 3  4 5
HDL 2 3 1 2 3 1 3 2 1
LDL 2  1 2  1 1 2
Viscosity 1 2 3 1 2 3 1 2 3
DBP 1 2 2  1 1 2
Table 6.37 Significance o f pairwise contrasts in multivariate main effects logistic models for mortality. 
Levels o f each risk factor are listed in order of increasing risk. Levels which are joined by a line were not 
significantly different from each other after adjusting for multiple comparisons by means o f  a Bonferroni 
correction.
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Stepwise modelling
The next stage of the analysis was to allow interaction terms to be brought into the 
logistic model, in a forward stepwise manner as has been described earlier.
For all-cause mortality, the final model resulting from this forward stepwise process 
dropped the HDL and LDL main effects and introduced the age*smoking interaction 
(p=0.038).
The parameter estimates, approximate z-statistics (coefficient / standard error) and odds 
ratios (exponential(coefficient)) obtained by fitting the final logistic model for all-cause 
mortality are given in Table 6.38. These parameter estimates may be used in conjunction 
with the covariance matrix given in Appendix F I3 to examine any contrast between 
levels of the factors.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 /  45-54) 1.03 0.11 9.27 2.81
smoking(ex/never) 0.64 0.40 1.63 1.91
(current/never) 1.44 0.37 3.90 4.21
viscosity(medium/low) 0.31 0.14 2.27 1.36
(high/low) 0.49 0.14 3.53 1.64
fibrinogen(q2/ql) -0.35 0.50 -0.71 0.70
(q3/q l) 0.19 0.43 0.45 1.21
(q4/q l) 0.62 0.41 1.51 1.86
(q5/q l) 1.04 0.41 2.56 2.83
dbp(high/low) 0.26 0.10 2.56 1.29
Ex-sm oker(q2/ql) /  Never 
sm oker(q2/ql)
0.11 0.61 0.18 1.12
Ex-sm oker(q3/ql) /  Never 
sm oker(q3/ql)
0.17 0.56 0.30 1.18
Ex-sm oker(q4/ql) /  Never 
sm oker(q4/ql)
-0.65 0.56 -1.16 0.52
Ex-sm oker(q5/ql) /  Never 
sm oker(q5/ql)
-0.22 0.49 -0.44 0.81
Current sm oker(q2/ql) /  Never 
sm oker(q2/ql)
-0.49 0.52 -0.95 0.61
Current smoker(q3/ql) /  Never 
sm oker(q3/ql)
-0.91 0.47 -1.93 0.40
Current smoker(q4/ql) /  Never 
sm oker(q4/ql)
-0.46 0.49 -0.94 0.63
Current smoker(q5/ql) /  Never 
sm oker(q5/ql)
-0.97 0.45 -2.14 0.38
CONSTANT -5.37 0.33 -16.0 0.00
Table 6.38 Parameter estimates for the contrasts in the final model for all-cause mortality in males age 45- 
64 at screening visit 3. The coefficient divided by the standard error (SE) o f the coefficient gives an 
approximate z-statistic, and the exponential o f the coefficient gives the estimated odds ratio for each 
contrast.
The observed proportions (deaths/subjects) are tabulated in Table 6.39. The risk of death 
increased with smoking category for each level of fibrinogen, but showed no clear trend 
with fibrinogen in each smoking category. The expected proportions are given in Table 
6.40.
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Fibrinogen level Never smoked Ex-smoker Current smoker
0-3.58 g/dl 0.0105 0.0215 0.0421
3.59-3.99 g/dl 0.0084 0.0190 0.0375
4.0-4.40 g/dl 0.0162 0.0170 0.0463
4.41-4.92 g/dl 0.0271 0.0329 0.0395
>4.92 g/dl 0.0447 0.0589 0.0663
Table 6.39 Observed risk o f death for each level o f fibrinogen crossed with smoking
Fibrinogen level Never smoked Ex-smoker Current smoker
0-3.58 g/dl 0.0179 0.0249 0.0462
3.59-3.99 g/dl 0.0151 0 . 0 2 1 0 0.0377
4.0-4.40 g/dl 0.0175 0.0243 0.0436
4.41-4.92 g/dl 0.0183 0.0254 0.0455
>4.92 g/dl 0.0266 0.0364 0.0635
Table 6.40 Expected risk o f death for each level o f fibrinogen crossed with smoking, based on the logistic 
main effects model for all-cause mortality
For cancer mortality, the main effects of age, smoking and viscosity were brought into 
the model. The parameter estimates, approximate z-statistics (coefficient / standard 
error) and estimated odds ratios (exponential(coefficient)) obtained by fitting the final 
logistic model for all-cause mortality are given in Table 6.41. These parameter estimates 
may be used in conjunction with the covariance matrix given in Appendix F14 to 
examine any contrast between levels of the factors.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64/45-54) 1.58 0.23 6.82 4.86
smoking(ex/never) 0.36 0.30 1.19 1.44
(current/never) 1.13 0.27 4.19 3.08
viscosity(medium/low) 0.49 0.24 2.07 1.64
(high/low) 0.60 0.23 2.54 1.81
CONSTANT -6.7 0.34 -19.7 0.00
Table 6.41 Parameter estimates for the contrasts in the final model for cancer mortality in males age 45-64  
at screening visit 3. The coefficient divided by the standard error (SE) o f the coefficient gives an 
approximate z-statistic, and the exponential o f the coefficient gives the estimated odds ratio for each 
contrast.
For CHD mortality, age, smoking, DBP, viscosity and HDL were brought into the 
model. The parameter estimates, approximate z-statistics (coefficient / standard error) 
and estimated odds ratios (exponential(coefficient)) obtained by fitting the final logistic 
model for all-cause mortality are given in Table 6.42. These parameter estimates may be 
used in conjunction with the covariance matrix given in Appendix F15 to examine any 
contrast between levels of the factors.
TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64/45-54) 0.84 0.16 5.29 2.31
smoking(ex/never) 0.47 0.24 1.94 1.60
(current/never) 1.03 0.22 4.70 2.81
dbp(high/low) 0.63 0.16 4.06 1.88
viscosity(medium/low) 0.10 0.20 0.52 1.11
(high/low) 0.54 0.18 2.97 1.71
HDL chol(medium/low) -0.35 0.17 -2.07 0.71
(high/low) -0.49 0.19 -2.58 0.61
CONSTANT -5.71 0.28 -20.1 0.00
Table 6.42 Parameter estimates for the contrasts in the final model for CHD mortality in males age 45-64  
at screening visit 3. The coefficient divided by the standard error (SE) o f the coefficient gives an 
approximate z-statistic, and the exponential o f the coefficient gives the estimated odds ratio for each 
contrast.
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Each of the models was checked by means of a plot of residuals against fitted values, 
and examination of the dispersion parameters (as described in Appendix H). There were 
no indications of a problem with model fit.
6.5.2 Discussion
The men who reached screening visit 3 represented a more homogeneous population 
than those who attended screening visit 1. The men who were invited to screening visit 
1 were identified on the basis of age and sex. By the time they got to screening visit 3, 
this subgroup of men had additional characteristics. These included no history of 
symptomatic myocardial infarction, a raised total cholesterol level (> 6.5 mmol/1 at 
screening visit 1), and an elevated LDL cholesterol level ((> 4.0 mmol/1 at screening 
visit 2). Further details of the screening process can be found in Chapter 2.
The main interest in this analysis was in the laboratory measurements of fibrinogen and 
plasma viscosity which other recent studies have shown to be potentially important risk 
factors for CHD (see section 1.1.4). Both of these variables were significantly related to 
each of the three outcomes (all-cause, CHD and cancer mortality) when considered at a 
univariate level. However, once all other main effect terms were included they were 
only significant for all-cause mortality. The univariate pairwise contrasts revealed that 
risk of any of the outcomes increased with plasma viscosity. Fibrinogen showed patterns 
similar to cholesterol in that the highest cancer risk was in quintile 1 and the highest 
CHD risk was in quintile 5. It was worthy of note that LDL cholesterol was not 
significantly related to any of the outcomes, and HDL cholesterol was related only to 
CHD mortality, for which the highest risk was with the lowest HDL levels. The only 
interaction term which was introduced by forward stepwise modelling was 
smoking*fibrinogen for all-cause mortality. The only significant contrast estimated to 
help interpret this interaction was for the difference between quintiles 1 and 5 of 
fibrinogen for current and never smokers (see Table 6.38). The contrast between 
quintiles 1 and 3 of fibrinogen for current and never smokers was close to significance. 
The proportion of deaths in the highest fibrinogen quintile was over four times that in
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the lowest quintile for never smokers, but was only 1 . 6  times that in the lowest quintile 
for current smokers (see Table 6.39). Fibrinogen level thus seems to be a much more 
important factor in predicting all-cause mortality in the absence of smoking. However, 
this interaction could be an artefact of the varying distribution of fibrinogen levels in 
smokers and non-smokers. While fibrinogen levels are split into quintiles, the number of 
subjects in each cell when these quintiles are cross-tabulated by smoking category show 
differing patterns (see Table 6.43). The mean and median values in the highest quintile 
(which has no upper limit) are also slightly higher with higher levels of smoking (see 
Table 6.44), which may provide another explanation of the significant interaction effect.
Fibrinogen quintile Never smoker Ex­
smoker
Current smoker
<3.59 998 913 764
3.59-3.99 861 820 914
4.0-4.40 769 858 1166
4.41-4.92 607 684 1304
>4.92 424 658 1569
Table 6.43. Numbers o f subjects at levels o f fibrinogen*smoking.
Fibrinogen quintile Never smoker Ex­
smoker
Current smoker
<3.59 3.23 / 3.32 3.23/3.31 3.23/3.34
3.59-3.99 3.80/3.81 3.80/3.81 3.80/3.81
4.0-4.40 4.19/4.18 4.20/4.20 4.20/4.20
4.41-4.92 4.64/4.63 4.66 / 4.67 4.67/4.66
>4.92 5.57/5.36 5.62/5.40 5.63/5.46
Table 6.44. Mean/Median values o f fibrinogen in each cell o f fibrinogen*smoking.
6.6 Overview
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This prospective follow-up study raised a number of ethical issues. If individual patient 
records are to be accessed by study investigators, it is important that full informed 
consent is obtained from the trial participants prior to the study. Ideally, the patients 
should be aware that, by giving an investigator access to their medical records, the 
investigator will be able to access both hardcopy and computerised versions of their 
records. In the epidemiological follow-up of WOSCOPS screenees there was no full 
informed consent from the screenees to access their medical records. The data which 
have been accessed by record linkage are routinely published in summary form and are 
likewise made available to bona fide investigators in the form of small-area statistics, all 
without the permission of the individual patients. It is argued that use of the Scottish 
Record Linkage System to link screening data to national databases of medical records, 
in order to obtain output in the form of summary statistics, does not breach any rules of 
confidentiality and is comparable with routine uses for such data. Investigators should 
be aware that access will be denied to certain sensitive medical information even if 
informed consent is available. For example, in this study no access was given to any 
information which would reveal the HIV status of the subjects. For linkages carried out 
at the Scottish Record Linkage System, each study is considered in detail by a Privacy 
Advisory Committee and must be approved by them before any linkages can be carried 
out.
The analysis involving CHD risk factors in men age 45-64 confirmed that WOSCOPS 
was in agreement with the trends reported in other studies (see Chapter 1). It was 
reassuring to note that smoking and increasing age were found to be related to increased 
risk of all-cause, CHD and cancer mortality or hospitalisation. The most socially 
deprived group, as defined by DEPCAT groupings, were also at increased risk of these 
outcomes. The analysis reported in section 6.3 was repeated using systolic instead of 
diastolic blood pressure, yielding similar results. Cholesterol showed the U-shaped 
relationship with all-cause mortality, caused by high CHD risk with high cholesterol and 
high cancer risk with low cholesterol which has been reported elsewhere (Sorlie and 
Feinleib, 1982; Blackwelder et al, 1980). It was also interesting to identify a U-shaped
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risk curve with alcohol consumption, with the highest risk category being 0  units per 
week, which has also been reported by other studies (Friedman and Kimball, 1986; 
Marmot et al, 1981). Analysis of the WOSCOPS cohort found that the association 
between low cholesterol and cancer mortality diminished with time and became non­
significant when the first two years of follow-up were excluded. The odds ratio 
decreased from 1.62 to 1.37 when the first two years were excluded. It would thus seem 
likely that this relationship is due, at least in part, to the cholesterol lowering effects of a 
developing malignancy.
The results for women provided some interesting contrasts with those for men. For all­
cause mortality, only age and smoking were significant for women, while all seven risk 
factors were significant for the middle-aged men. Similarly, for CHD, only age and 
smoking were significant for female mortality, while all except BMI were significant for 
the men. For cancer mortality, age, smoking and DEPCAT were significant for women, 
while age, smoking, DEPCAT, BMI and cholesterol were significant for men. Some of 
these differences in results may be due to the fact that, for men, analysis was restricted 
to the 45-64 year age group, while, for women, the full range of ages were included. 
The differences may also be due to the fact that, in general, women have lower age- 
specific death rates than men, and thus insufficient numbers of events to detect 
differences have been observed for women, and, probably more importantly, many 
fewer women were studied.
The results for the men who reached screening visit 3 provide an interesting supplement 
to the earlier results, with the WOSCOPS results reflecting those in other studies.
Obviously there is huge potential for analyses of alternative diagnoses for the screened 
cohort. While there has been insufficient length of follow-up to detect some effects, this 
preliminary analysis gives clear indications of factors of interest for future work.
The main restriction on the analysis so far has been the use of categorised data. While 
many variables can be examined in this way, potential cross-classifications have been 
abandoned due to small cell sizes caused by correlations between variables. The full 
potential of this data set has thus not been utilised. Use of the original data set (with
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continuous explanatory variables) in the analysis would enhance the power to detect 
associations between risk factors and outcome and allow consideration of combinations 
of variables which have been impossible so far. However, analysis using the original 
data set would involve identifying each patient and their event records with the same ID 
number, and thus break the requirements of subject anonymity.
An alternative to analysis by categorical versions of the baseline variables would be to 
construct a logistic score function from the logistic regression coefficients of models 
involving continuous explanatory variables. Since these coefficients are unavailable for 
the WOSCOPS screened cohort (NB individual subject data not available due to privacy 
restrictions), the alternative would be to use coefficients from models fitted in other 
published studies, for example, MRFIT or Framingham. A categorisation of this score 
could be used to adjust for some variables, and thus allow further factors to be examined 
in a categorical analysis, without compromising subject anonymity.
Problems with this method of analysis arise in:
1) choice of which published study to obtain logistic regression coefficients from. The 
study used should, ideally, relate to a population similar to the one currently under 
investigation.
2) which variables to adjust for in the score. It would be necessary to adjust for all the 
variables contributing to the published model, some of which may not be available for 
WOSCOPS, or some of which may be of interest in their own right. The published 
coefficients are affected by each variable in the model, and thus all should be included.
3) the outcome for the model fitted. The logistic score will be correlated with the 
particular outcome for the model from which the fitted coefficients came, and may not 
be appropriate for consideration of other outcomes.
This method may be worthy of further exploration in the future.
An alternative to logistic regression analysis would have been to fit some sort of 
survival curve for mortality against subject years of follow-up. This was impossible due 
to the format of the data - by category, and not identifiable at an individual subject level.
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Chapter 7 
Comparison of screenee and 
population event rates
7.1 Introduction
The relationship between event rates in the group of subjects who are willing to attend 
for health screening and that in the local community is of particular interest for the 
planning of public health initiatives. The main aim of this chapter is to compare event 
rates in the WOSCOPS screened cohort with those in the general population, in order to 
provide an assessment of how representative the screened cohort is of the population 
from which it comes. This will give an indication of the appropriateness of applying the 
results achieved for the screened cohort in chapter 6  to the general population. 
Consideration will once again focus on the 45-64 year old men since they make up the 
largest subgroup in the cohort screened, and were the only group screened in a 
systematic fashion.
7.2 Preliminary comparison of screenee and 
trial events to the Scottish population
Table 7.1 below contains the frequencies and rates of death for the WOSCOPS screened 
subjects, with follow-up until the end of 1993, for various ranges of ICD codes. For 
comparison, the corresponding death rates for the WOSCOPS randomised subjects and
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for the whole of Scotland in 1991 (as given in the Registrar General’s Annual Report for 
1991) are also quoted. The year of 1991 was selected since it lay in the middle of the 
follow-up period and was the year in which the census was carried out. These rates 
relate to men age 45-64.
Type of event ICD9 codes Scottish 
death rates 
in 1991
Number of deaths 
for the 74,576 
WOSCOPS 
screenees 
(death rates)
Number of deaths 
for the 6595 
WOSCOPS 
randomised 
subjects 
(death rates)
All causes 11.72 3493(11.70) 166 (6.85)
Cardiovascular 390-459 5.42 1668 (5.59) 8 6  (3.55)
-CHD 410-414 4.23 1333 (4.46) 74 (3.05)
- stroke 430-438 0.7 190 (0.64) 8  (0.33)
Malignant
neoplasm
140-208 3.8 1230(4.12) 57 (2.35)
-lung 162 1.39 474(1.59) 2 0  (0.82)
External causes E800-E999 0 . 6 131 (0.44) 6  (0.25)
- suicide E950-E959 0 . 2 51 (0.17) 1 (0.04)
Respiratory 460-519 0.76 186 (0.62) 5 (0.21)
Digestive 520-579 0.46 144 (0.48) 4(0.16)
Other causes 0 . 6 8 134 (0.45) 7 (0.29)
Table 7.1 Numbers o f deaths and mortality rates for men age 45-64 broken down by various causes of 
death. The rates quoted are numbers o f events per 1000 subject years.
There is broad agreement between the rates for the Scottish population and the 
WOSCOPS screenees across the range of causes of death considered, with rates for 
WOSCOPS randomised subjects being lower. It is clear that the death rates for the 
WOSCOPS randomised subjects, despite being selected as a high risk group for 
coronary heart disease, are lower than in the screened cohort as a whole, in each of the 
categories of cause of death, although these rates may not be statistically significantly
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lower in all categories due to small numbers of events for some of the cause of death 
outcomes.
The preliminary data reported on the epidemiological prospective study of WOSCOPS 
screenees matches well with Scottish national death rates. It would be expected that 
subjects who are willing to attend for population screening will be more healthy than 
those in the general population. Subjects who are seriously ill and subjects in areas of 
social deprivation, where mortality rates are typically highest, are the least likely to 
attend health screening clinics. Acting in the opposite direction is the fact that screening 
was conducted in areas with high death rates relative to Scotland as a whole.
The low cause-specific death rates in the randomised subjects, as compared to the 
screenee group, serves as a reminder of the dangers of using population data to project 
event rates in clinical trials. Although inclusion criteria for the trial (including raised 
LDL cholesterol) would serve to select a group at higher risk for coronary heart disease, 
this would probably be compensated for by exclusion criteria (such as, no previous 
myocardial infarction, no recent evidence of coronary heart disease and no current 
serious illness). The danger of using population data to project event rates is particularly 
clear in the non-coronary death rates, where there would be little expectation of the trial 
medication lowering rates of death.
7.3 Population comparisons
Some initial comparisons were carried out to investigate the similarity between the 
population in the screening area and the Scottish population as a whole, and to look at 
variation within the screening area population.
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7.3.1 Comparison of the screening area population 
with the Scottish national population
Mortality rates for the screening area population were calculated using data supplied by 
the Registrar General for Scotland. The screening area population was defined to be the 
general population resident in the postcode sectors in which screening was carried out. 
These postcode sectors are listed in Appendix I, and cover the four health board areas 
involved in the study - Greater Glasgow Health Board, Argyll and Clyde Health Board, 
Lanarkshire Health Board and Dumfries and Galloway Health Board. The Registrar 
General provided date of death and causes of death by sex, age and postcode sector, for 
all deaths occurring in the area of screening (as defined by postcode sectors) between 
1988 and 1993. The Registrar General also provided the population size broken down 
by sex and 5-year age band based on the 1991 census. The relative frequency of deaths 
per annum for the screening area was calculated as x/6 n where x was the number of 
deaths occurring in the 6 -year period from 1988 until 1993, and n was the number of 
subjects according to the 1991 census.
The relative frequencies of deaths in the screening population and the whole of Scotland 
were compared for all-cause mortality in men age 45-64. The Scottish national death 
rate (as given in the Registrar General’s Annual Report for 1991) was 11.7 deaths/1000 
subject years. The all-cause mortality rate for the population of men age 45-64 in the 
area of screening was 13.6 deaths/1000 subject years. In the formal comparison of the 
two ‘populations’, the true proportions of number of deaths divided by number of 
subjects (from which the mortality rates are derived) were used. Deaths for these two 
populations were compared as two binomial proportions, using the formula
screening area over the 6  year period as defined above. This led to a 95% confidence 
interval of (-2.6, -1.9) deaths per 1000 years for the difference between the two
where pi was the relative frequency of
mortality in the whole of Scotland and p2  was the relative frequency of mortality in the
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proportions. Thus we could reject the hypothesis that the underlying mortality rate was 
the same for the two populations.
Similarly, for coronary heart disease, the Scottish national mortality rate was 4.2/1000 
years and the screening area population rate was 4.9/1000 subject years, with the 
confidence interval for the difference being (-1 .0 , -0 .6 ) deaths per 1 0 0 0  subject years, 
and for cancer deaths the national rate was 3.8/1000 subject years and the screening area 
rate was 4.2/1000 subject years, with a confidence interval of (-0.75, -0.35) deaths per 
1000 years for the difference between them. The assumption that the population 
mortality rate in the screening area was the same as that in Scotland as a whole was thus 
rejected for these causes of death also. It can be concluded from this that the population 
mortality rates in the screening area are significantly higher than the rates in Scotland as 
a whole.
The above formula for a confidence interval for the difference between two proportions 
assumes, among other things, that the two proportions being compared relate to 
independent samples. This assumption is not valid since the screening area population is 
contained within the Scottish national population, and thus these confidence intervals 
are only approximate. The Scottish national population is around three times the size of 
the screening area population.
7.3.2 Comparisons within the screening area 
population
The Carstairs deprivation score (as discussed in section 6.2.1) was assigned to records 
on the basis of postcode sector. These deprivation scores are based on the 1991 census 
data. The deprivation scores were grouped into seven categories, known as DEPCATs, 
as suggested by Carstairs and Morris (1991). The DEPCATs were used to divide the 
screening area into subpopulations to be compared. To make the seven subpopulations 
more comparable, the mortality rates were age standardised against the total screening 
area population. Both the crude and age-standardised mortality rates for each of the
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DEPCATs are given in Table 7.2. This analysis was restricted to men age 45-64. The 
crude mortality rates were calculated as in the previous section. The age-standardised 
mortality rates were calculated in an analogous fashion based on the age distribution in 
the standard population. The standard population was taken to be all men age 45-64 in 
the screening area (based on the 1991 census), and the study populations were taken to 
be the DEPCAT groups which together made up the standard population.
DEPCAT Crude mortality rate Age-standardised mortality rate
1 6.30 6.83
2 7.44 7.72
3 8.56 8.61
4 10.39 10.54
5 11.58 11.50
6 13.45 13.14
7 16.87 16.50
Table 7.2 Crude and age-standardised population mortality rates (events per 1000 years) for each o f the 
DEPCAT areas within the screening area. Standardisation is against the total population in the screening 
area.
The age-standardised mortality rates were similar to the crude mortality rates in each of 
the DEPCATs. It can be seen that the more affluent areas (low DEPCATs) had lower 
mortality rates than the deprived areas (high DEPCATs), as has been found in other 
studies (McLoone and Boddy, 1994).
7.4 Mortality trends in the screened cohort
Trends in screenee death rates were examined by looking at the mortality rate in each 3 
month block of follow-up. Until the end of 1993, the screened subjects were followed
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up for between 33 and 63 months, depending on when they were screened. Life tables 
were constructed for all-cause mortality in the 3 month blocks of follow-up for males, 
and for females, in each of six age categories - <45 / 45-49 / 50-54 / 55-59 / 60-64 / >64.
d t
The proportion dying during the 3 month block, pt = —  where dt is the number of
n t
deaths occurring in block t and nt is the number of subjects at risk at the start of the 3 
month block of follow-up.
t
The proportion surviving, St = l-pt and the survivor function, S(t) = .
i= l
It should be noted that the only screenee death information released by the Scottish 
Record Linkage System (SRL) was a cross-tabulation of 3 month blocks of ‘number of 
days from screening till 1.1.94’ and ‘number of days from screening till death’, thus 
preserving subject anonymity as discussed in chapter 6 .
Plots of the survivor function S(t), such as Figure 7.1, showed, as expected, that 
survival times were larger for females than for males in each age group.
1.00 -
o>c•5E3
C/5 _ __f  0.99 
o '■e 
oQ.
Female
2
Q_
20100
Time period (3 month block of follow-up)
Figure 7.1 Survivor function for 45-49 year old male and female screenees
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A similar plot of the survivor function for males, Figure 7.2, showed that survival times 
were longer for the younger age groups, as expected. The plot for females revealed a 
similar pattern.
1.00 - <45
45-49o>
•§ 0.95 - 50-54
‘1 . 55-59
O 0.90 -
-"i_,
0.85 -
0 10 20
Time period (3 month block of follow-up)
Figure 7.2 Survivor function for male screenees by age group
7.5 Comparison of the screening area 
population with the screened cohort
The main objective of this chapter is the comparison of mortality rates in the screened 
cohort with mortality rates in the population in the area of screening. To carry out this 
comparison, certain assumptions have been made. These include a constant population 
size (since we have used the population size from the 1991 census for each of the six 
years from 1988 to 1993), and a lack of any trends in the population or screened cohort 
mortality rates during the time period considered. The analysis will focus on men aged 
45-64.
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Initially, consider the first year of subject follow-up for each of the screened men age 
45-64. This avoids the problems of an ageing cohort. For the first year, the age group 
specified for the cohort will be directly comparable to the age group specified for the 
population. In later years, the cohort will be older, and some subjects will have moved 
into an older age group. However, screened subjects can only be identified by their age 
group at screening visit 1, so no adjustment can be made for this ageing. Screening took 
place between 1988 and 1991. For this reason, the death rate in 1991 was used as the 
population rate, since it was close to the mid-point of follow-up, and the census data 
were collected in 1991.
For the first year of follow-up, 95% confidence intervals were produced for all-cause 
mortality for the difference between the cohort and population mortality rates, in each of 
the five year age-bands - 45-49 / 50-54 / 55-59 / 60-64. Ages <45 or >64 years were not 
considered for the calculation of confidence intervals due to the difficulty in defining 
subgroups which would be directly comparable in the screened cohort. The results were 
as in Table 7.3.
Age group 95% Cl for males 95% Cl for females
45-49 -3.52 to -1.52 -3.82 to -1.23
50-54 -5.01 to -2.36 -5.50 to -3.62
55-59 -7.30 to -3.95 -8.75 to -5.06
60-64 -10.16 to -5.49 -11.95 to -5.04
Table 7.3 95% confidence intervals for the difference in screenee and population all-cause mortality rates 
(events/1000 subject years) for 45-64 year old males and females.
None of the confidence intervals in Table 7.3 contains zero, with the population rate 
being significantly larger than the screenee rate for men and women age 45-64. This 
supports the hypothesis that it is more healthy subjects who are willing and or able to 
come for screening.
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However, in later years of follow-up, the population mortality rate may not be 
significantly higher than the mortality rate in the screened cohort, since subjects who are 
healthy and willing to come for screening one year may not necessarily still be healthy a 
year later.
The year 2 mortality rate was calculated as the number of deaths in year 2 divided by the 
number of subjects at risk at the start of year 2. This approach was also used to calculate 
the screenee all-cause mortality rates for year 3. The rates calculated by this method are 
given in Table 7.4.
Sex Age Year 1 
death rates
Year 2 
death rates
Year 3 
death rates
Male <45 1 . 6 2 . 8 2 . 6
45-49 2.98 3.98 4.89
50-54 5.53 7.14 8.46
55-59 8.91 12.35 14.08
60-64 16.72 21.35 24.92
>64 21.19 37.51 37.31
Female <45 0 0.58 1.17
45-49 0 . 8 6 8 1.74 1.74
50-54 0.378 2.27 2.65
55-59 1.92 5.38 5.02
60-64 6.34 5.01 9.62
>64 9.15 15.0 18.75
Table 7.4 Screenee mortality rates in each year o f follow-up broken down by sex and age group at 
screening. The death rates are the number of deaths per 1000 subject years.
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While the screenee mortality rates do in general increase across the years of follow-up 
(for the first 3 years at least), it must be remembered that the cohort is also ageing. The 
group of subjects who were age 45-49 in the first year of follow-up were age 46-50 in 
the second year of follow-up. In Figure 7.3, a five year age band is taken as reflecting an 
interval represented by one unit. The mortality rates are plotted against the midpoint of 
the interval, and the increasing age of the cohort is adjusted for by moving along the 
axis by 0.2 of an interval (representing 1 year) for each of the years of follow-up. This 
gave a plot for males as in Figure 7.3, with females showing a similar pattern although 
the actual rates were lower.
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Figure 7.3 Male population and screenee mortality rates (events per 1000 subject years) against age group
It can be seen that the ‘shifted’ rates are similar for years 2 and 3, while year 1 is slightly 
lower. The population rate was clearly higher than the screenee rates, even after 3 years 
of follow-up. While it is not surprising that the screened cohort was more healthy than 
the population in the first year or two after screening, it is interesting that the rate does 
not appear to have increased to the population level 3 years after screening.
Since the screening process concentrated on males in the 45-64 year old age group, there 
was a much smaller group of men aged <45 or >64. These age groups were also defined
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differently for the screened cohort and the population. For the screened cohort, any man 
outwith the 45-64 year age group was included in one of these categories, but for the 
population these bands were restricted to age 40-44 and age 65-69. These two age bands 
were thus excluded, and analysis focused on the 45-64 year old group.
When a logistic transform (loge—^— ) is applied to each of the all-cause mortality rates,
1 -p
the trends become reasonably linear for males, as can be seen in Figure 7.4. For females 
the trends with age are more erratic, possibly due to the smaller sample size of women 
screened.
PofxJation 
Scr year 1 
Scryear2 
Scr year 3
45-49 50-54 55-59 60-64
Years (age group)
Figure 7.4 Logistic transform of the relative frequencies o f all-cause mortality for males in the population 
and screened cohort against age group.
Logistic regression was used to model the probability of death given age and group. 
Group 1 related to the screening area population mortality rates for 1991 since the 
census data were collected in that year, group 2  to the cohort of subjects available for 
the first year of follow-up, group 3 to the cohort of subjects available for the second year 
of follow-up, and group 4 to the cohort of subjects available for a third year of follow- 
up. The term fitted for the age*group interaction was not significant (p=0.1520), so 
there was no evidence to reject the assumption that each of the groups showed the same
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trend with age. Fitting a main effects logistic model showed that age and group were 
both highly significant (pcO.OOl for both). Estimated coefficients for the contrasts 
among the probabilities of death for the different groups are given in Table 7.5. The 
estimated coefficients divided by standard errors can be considered as z-statistics. It can 
be seen that the mortality rates in each year of follow-up for the screened cohort were 
significantly lower than the mortality rates in the screening area population in 1991. 
Consideration of the population deaths in other years (1990 and 1992) made little 
difference to this result.
Comparison Coefficient Standard error 
of coefficient
Coeff / standard 
error
Screenee year 1 - Population -0.464 0.044 -10.4
Screenee year 2 - Population -0.295 0.040 -7.33
Screenee year 3 - Population -0.245 0.038 -6.38
Table 7.5 Coefficients, standard errors and z-statistics (coefficient divided by standard error) for the 
comparison o f screenees in each year o f follow-up with the population in the screening area.
7.6 Discussion
The main difficulty in comparing the WOSCOPS screened cohort with the general 
population in the area of screening has been the need to preserve subject anonymity in 
the screened cohort. This has meant that subjects were identifiable only by sex and age 
group at screening. As length of follow-up increased, the cohort was ageing and thus 
subjects would have moved into a higher age group and the youngest age group would 
have progressively decreased in size. However, with no knowledge of the age 
distribution of subjects who died within each five year age group, it was impossible to 
accurately adjust for this source of bias. This problem has been partially addressed by 
consideration of ‘shifted’ mortality rates in the logistic models. It was interesting to note
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that the mortality rates in the screened cohort were still lower than those in the general 
population in the third year of follow-up. It had been expected that in the first year of 
follow-up, the mortality rates would have been lower due to healthier people attending 
for screening. However, the mortality rates in the screened cohort did not become closer 
to those in the general population in the later years of follow-up. This may be a 
reflection of the fact that subjects who volunteer for public health screening are more 
health conscious, and the effects of this persist for a long period of time. The length of 
follow-up considered here may be too short to overcome the ‘healthy screenee’ effect.
A further source of bias is the fact that groups being compared are not independent since 
the screened cohort is contained within the population in the screening area. It is hoped 
that this will not be too major a source of error since the screening area population is 
larger than the screened cohort (the cohort makes up approximately 35% of the 
population of men age 45-64 in the screening area). However, this correlation would, if 
anything, make the groups more alike.
Overall, the screened cohort does not appear to be very representative of the population 
from which it came, at least for a short period of follow-up, and thus there does seem to 
be a particular group of healthier people who attend population screening initiatives.
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Chapter 8 
Summary and future work
8.1 Summary
One of the main findings of this thesis has been the feasibility and accuracy of using 
record linkage techniques as a means of subject follow-up in clinical trials. The 
comparative study (dealt with in Chapter 5) for the subjects randomised into the clinical 
trial branch of WOSCOPS found that record linkage for deaths achieved very high 
accuracy compared to the individual subject follow-up routinely employed in 
WOSCOPS. The only death which was missed by record linkage was one which 
occurred after the patient had moved out of Scotland. While the linkage quality was 
lower for the incidence databases (hospitalisations and registrations), it was nonetheless 
still of a reasonably high standard. For example, assuming that all non-psychiatric 
hospitalisations were identified by one or other system, record linkage identified 94% of 
events while WOSCOPS individual follow-up identified 91%. Record linkage thus 
appears to be more successful at identifying adverse events than individual subject 
follow-up. However, events identified by record linkage should be validated since 
probabilistic linkage may identify events which do not really belong to the WOSCOPS 
subjects. Comparisons of the events identified by record linkage using fully postcoded 
and updated data against unpostcoded data and data recorded at an initial screening visit 
have found that while linkage quality is reasonable for each data file, it is of a higher 
standard when updated, postcoded data is used. While the difference in linkage quality 
with no postcodes and screening visit 1 records is not large at this stage, this difference 
will increase as the length of subject follow-up increases.
Having established that linkage based on data collected at screening visit 1 gave a 
reasonable level of accuracy, linkage was used to identify adverse events for all subjects
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who attended an initial screening visit. Record linkage provided the only feasible 
method by which such a large cohort (97,165 subjects with identifying information 
available) could be followed-up. While analysis was limited by the need to maintain 
subject anonymity, quite extensive analysis was carried out using categories of the 
baseline risk factors (see Chapter 6 ).
The first group studied was the 74,576 men aged 45-64 at screening visit 1- the group 
targeted by the screening exercise. Analysis by a cross-classification of coronary heart 
disease risk factors identified the U-shaped relationship between cholesterol and all­
cause mortality which has been found in other studies (see Chapter 1 ), with high 
cholesterol being associated with risk of coronary heart disease and low cholesterol 
being associated with risk of cancer mortality. A further point of interest was the higher 
mortality risk associated with an alcohol consumption of zero units per week. This 
relationship was also in agreement with other studies. However, the observed 
relationships become more difficult to interpret once interaction terms are included in 
the model. These were discussed in more detail in Chapter 6 . The relationships observed 
among risk factors for mortality in these middle-aged men also appeared when 
hospitalisation was the outcome considered.
It was interesting to note the differences in the results for cancer outcomes when each of 
the three possible databases (cancer mortality, registration and hospitalisation) were 
considered. It was reassuring to note that the exclusion of competing causes of death had 
little effect on the results. The exclusion of the early years of follow-up also had little 
effect on the results, with the exception of cholesterol, for which the excess risk in the 
lowest cholesterol quintile decreased as years were excluded. Both these analyses 
support the suggestion that the relationship between cancer and low cholesterol may, at 
least in part, be a short term artefact of undiagnosed disease. For fuller discussion of this 
conclusion see sections 6.3.1.4 and 6.3.1.5.
The second group studied was the cohort of 14,950 women who attended screening visit 
1. Consideration of female mortality resulted in trends similar to the analysis of middle- 
aged men, although the factors fitted were often not statistically significant due to the 
low event rate in this group of subjects.
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The third group studied was the cohort of 13,559 middle-aged men with raised 
cholesterol who reached screening visit 3. These men were analysed by a cross­
classification based on laboratory measurements made at this third screening visit. The 
main finding of this analysis was that plasma fibrinogen exhibited the same U-shaped 
curve with mortality as total cholesterol, with the highest quintile being associated with 
coronary heart disease mortality and the lowest quintile with cancer mortality. However, 
fibrinogen was not significantly related to coronary heart disease or cancer mortality, 
once other factors had been taken into account.
Having obtained these results for the screened cohort, it was then of interest to consider 
how applicable these conclusions are to the general population in the area of screening. 
From the analysis in Chapter 7, it would appear that the screened cohort of men age 45- 
64 have lower mortality rates than the population of 45-64 year old men in the screening 
area. It was expected that it would be more healthy subjects who were able to attend for 
screening in the first instance, but that this effect would disappear as follow-up 
continued. However, the screened cohort is still different from the population after three 
years of follow-up. This persistent difference may be due to subjects who volunteer for 
public health screening being generally more health-conscious, or it may be a residual 
effect of the fact that these subjects were well enough to be able to attend for screening 
in the first instance.
8.2 Future work
While interesting relationships have been established between risk factors such as 
cholesterol, alcohol and DEPCAT and mortality from cancer and violence as well as 
cardiovascular causes, it would be of interest to look at relationships between other risk 
factors and mortality. Other factors of interest could be use of educational and 
occupational status in place of DEPCAT which is a non subject specific generalisation 
across each postcode sector. The relationships may change when alternative covariates 
have been accounted for in the analysis. It may also be of interest to restrict analysis to 
screened subjects who have no history of coronary heart disease, although this would
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reduce the number of factors which could be included in the cross-classification. While 
some other cross-classifications have been looked at (although not discussed in this 
thesis), there is clearly huge potential for further analysis.
The main drawback in the analysis of the screened cohort presented in this thesis was 
the need to preserve subject anonymity. If analysis using the original data, with 
continuous variables, was possible then this would enhance the power of the analysis to 
detect relationships. This would be especially helpful in the consideration of screened 
women, for whom the event rate was much lower than for the men. This may be 
possible by requesting that an internal analysis be carried out at the Scottish Record 
Linkage System, so that only the output from the analysis would be released and no data 
would be given to WOSCOPS researchers. Since there would then be no constraints on 
the data available for analysis, it would also be possible to carry out survival analysis 
using the time from screening until event. It may be argued that there would be no 
ethical problem with this analysis since no release of data would be involved.
The power to identify associations between baseline risk factors and outcome will 
increase with increasing years of follow-up. This will be particularly important for 
certain subgroups of the cohort being examined, for example, women, non-smoking 
males or diabetics, and for less common outcomes such as mortality for specific cancer 
sites.
For the comparison of mortality rates for the screened cohort with rates for the 
population in the screening area, it would be interesting to repeat the comparison with 
further years of follow-up included. This would give an indication of the length of time 
for which the ‘healthy screenee’ effect persists. In the public health context, this would 
also provide an indication of the regularity required in screening exercises if subjects at 
high risk are to be identified.
8.3 Implications of this thesis
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This thesis has provided the first external check on the quality of linkage achieved at the 
Scottish Record Linkage System for linking patient files to the data held at SRL. This 
study has shown that a high standard of linkage is possible with only a few subject 
identifiers (name, sex, date of birth and postcode). This thesis has shown that the 
linkage quality may be enhanced through the postcoding of all addresses for study 
subjects and periodic updating of identifying information recorded. These points may be 
of relevance to any other studies which aim to use computerised record linkage to detect 
events for subject follow-up.
This thesis has also given indications of interesting relationships between baseline risk 
factors and mortality which agree with previous studies and should be re-examined once 
sufficient numbers of events have been accumulated. The population comparisons 
should also be re-examined to see how many years of follow-up are required before the 
event rate in the screened cohort becomes the same as the event rate in the population in 
the screening area.
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A: WOSCOPS subject identification form
SC1
Form Type [______
Visit No. | 0 ( Q j
0
P a t ie n t  ld e n t if ic a t io n R andom No.!" 
F o rm  ^
Patient No. j
Ti»l I ! I i
UD1190 n
Date of Visit | | j j I I
0  0  M  M Y Y
Patient Initials
SECTION 1 Patient and G.P. Information
1. Patient Surname _________________
Forename__________________
Date of Birth
Address
NHS No.
Sex Q ]  M [ 2 ] F
n
Patient
Telephone.
2. G.P. Dr.
Centre
Address
SECTION 2 Additional Flagging Details
Patient Surname at Birth__________
Place of Birth __________
Maiden Name ______________    t»f applicable)
Address on  29th SEPTEMBER 1939
SECTION 3 Dietary Counselling
Has the patient been g :ven dietary counselling? [T] Yes [Tj No
SECTION 4 Lipoprotein Analysis
Has the patient fastec  overnight? [TJ Yes (Tj No
I n v e s t i g a t o r  s  Init ial s N a m e  o f  P e r s o n  C o m p l e t i n g  F o r m C a t e  o f  C o m p l e t i o n
224
B: Examples of WOSCOPS adverse event forms
Serial No. 1 I I I 1 1
Form Type | 7 j l |
Visit No. I 1 1
A d verse Event 
Sum m ary
UD1 290
Random No.( 
Patient No. [
Date of Visit I I t I I I Patient Initials.
0  0  M M Y Y
SECTION 1 Adverse Events 
Summarise illness or event
NB. If more space is required in any section please attach an OC13
Relevant Past Medical History
Relevant Laboratory Date: Date Test Result Normal Range N/A
Concomitant Medications & Dates
Clinical Impression__________________________________________________________________
In your estimation is the event related to trial medication? Yes ( j j  No j |
(Please tick the appropriate box.)
Answer ail following questions by circling as appropriate Yes No
(1) —.................................................  - ........... Did patient die? jT] [2]
(2) —.............. - ............    Was adverse event life threatening? QJ [2]
(3) —   Did event require or prolong in-patient hospitalisation ? [7] [2]
(4) —...................................................     Was event permanently disabling? Q ] [2 ]
(5 )  ...... - ........................— .................................. Was event cancer, or overdose ? (TJ [2]
(6 ) .......... — ........................................    Was therapy permanently withdrawn? [Tj [2]
(?) — .....     — Was this event a Cerebro-Vascular AcddentfTIA? [Tj [2]
(If answer to question 7 is yes, complete form OC14)
SECTION 2 TO BE COMPLETED BY THE ADVERSE EVENTS COMMITTEE
Primary Diagnosis_____________ _______ _ ______________________________________________
Secondary Diagnosis____________________________________________ ______ ______________
s n tw rr r  k u o c m  to t m m  m u g  t m m . onug status
ICO COOE(S) " HU Mltw i Sm i  Wall— M l  U—  U»mm«a* WMwM W— aM WMXrn—n 11111 0 a a bid 0 0 0 0 0
□ri 1111 mati] o’ a a 0 o a a
Has this event been referred to the End-Points Committee? Yes Q j  No (Tj
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j
Serial No.
Form Type 
Visit No. [  
Date of Reportf
5 2
H ospitalisation Random No.| I I le i I 1 FI
Report ,
U01-ai Patient No. I I I |e | I I T1
Patient Initials.
o  o  M M Y Y
Was the patient hospitalised for this event?
(If 'YES' complete Section 1)
SECTION 1 To be completed by Trial Physician
1. Date of admission to hospital
2. Date of discharge from hospital
3. Hospital. 
Address.
Consultant.
4. In your clinical opinion what is the main reason for hospitalisation?
Comments.
Yes [Tj No [2]
I I I I T  I I
0  0  M M Y Y
I I I I I I I
0  D U M Y  Y
5. Did the main reason/symptoms of this 
condition exist prior to randomisation?
Yes Q j No [2] Unknown |~3~|
SECTION 2 To be completed by Trial Monitor
1. Main reason for hospitalisation
2. Other illnesses or events during hospitalisation
3. Treatment or surgical procedure during hospitalisation
4. Is the event thought to be cardiac related? 
If 'Yes' ECGs should be attached
CATEGORY
-  m
-  m
-  m
-  m
COOES
TI T I I I
nm c 
m  c  m rrmn
Yes Q ]  No [ | ]
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0019
Serial No. f 1 1 1 I
Form Type [%lH
visit no. \ in
Oat* of Visit \ 1 1  I
Cancer Form
UD1S91
Random No.[ j [ ~ |#(~ 
P atien t No. j ( | ]*f~
o 0 M M Y V Patien t Initials
SECTION 1
1. Data treatment commenced I l l l I l I
0  0  M M Y Y
2. Site of Tumour — - -
3. Histology
"3;ve full details of biopsy report)
ICO Cod. | | | | | 
ICO Cod. I I I I I
4. (a) Oid the patient have any illness or symptoms prior to randomisation of relevance to this event?
Yes Q] No [7] Unknown [5] 
<t>) If 'Yes', please give details -  . . _________________________________
5. Is this form accompanied by a Cancer Registration Abstract Card? Yes C D  no [T]
SECTION 2
To be completed by Adverse Events Committee 
Qinicai Diagnosis
ICO Code i l l  j |
S*q<vitvK« lor Advert* 
Events Committee
Name ot N n o n  C o m p ilin g  form Oaie
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Serial No. 
Form Type 
Visit No.
Date of Report
4 8
A n giop lasty  Form R andom  No.|
UD1-691
P atien t  No. I
O O M M Y Y
P atien t  Initials.
If not already completed for this event, please prepare Form SQ1.
SECTION 1 Coronary Angioplasty 
1. Enter date of PTCA n
0  O M M Y V
Location
(Record hospital where procedure was performed.)
Q] GRI v [ | ]  WIG [J] Other 
Consultant _________________
(Specify).
3. Vessel dilation Vessels Attempted Successful
(Please circle all responses
as appropriate) Yes No Yes No
Left mainstream a a a a
Left anterior descending m a a a
Left circumflex a a a a
Right coronary artery m a a a
Other a a a a
(Specify)
4. Record outcome
(Please circle all responses
as appropriate) Yes No Yes No
Successful reperfusion [T] a Repeat PTCA a a
Ml - Q] a Unstable angina a a
Emergency CABG Q] a Death a a
Elective |Tj a O ther (specify)
Investigator's Initials Name of Person Completing Form Oate ol Completion
C: Scottish Morbidity Record forms
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SMR1:
Scotland • Inpatient and Day Case Records Summary Sheet SMR1 Medical In Confidence
Hospital Hospital Cod# (hospi 
Hospital Case Reference No.(CBN)
Surname m 
Fast
Tim# of sdmusiorWanefer
Previously attended »*s hospital? YES/NO 
MYESsa
Next o f Un (fW aionahip)
GP Practice Code iqppc)
GPGMC Number iopc)
Data placed on Waiting List (owu
Dale o f Admission #XM)
Dais of Discharge <oooi 
Time of Discharge
Provisional Diagnosis on Admission
' 7J- Consultant Code173 (CONC)To be completed by doctor on discharge of patient
Main Condition <ooi) (OQtd
Other Conditions (DOS)
(003)
(004)
(1)
(2)
(3)
(4)
Main Operation (OPi)
Other Operations tone
(OBJ)
(OP*)
(0P1C)
(CPJO
(OPJC)
- - ;- - ri i ? 1 i ? i
■ _ U  .t !
. ! !.. i 'i i
. ! L t M r. l i t !
Date of Main Operation <oopi) Oats of Main Operation (oobi)
ERROR REPORT COMMENT: (COM|
Local
Additional notes: National
SMR4:
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i
i m p o r t a n t  o n l y  t o  b e  u s e o  f o b  i n f o r m a l  p a t i e n t s
M E D I C A L  IN C O N F I O E N C E  M E N T A L  H E A L T H  S T A T I S T I C S  SC O T L A N D  S M R 4
P a rt  1 — IN P A T IE N T  A O M IS S IO N  (to  t>a r t tu r n a d  in ra a o a c t o f aa ch  in o a tia n t  ad m iss io n  o r  tra n s ta r  to  tfta c a ra  o f  a  P sy ch ia tris t)  
O n  ad m iss io n  c o m p ia ta  P a rt 1 a n d  san d  to o  c o o v  to  th a  In fo rm a tio n  S arv tcaa O Knsion
R EVISED  l 1 8 6
C A R O  TYPE
h o s p i t a l  n a m e
593039□
I 6
h o s p i t a l  c o o e
O A T S  O P AO M ISSIO N
S U R N A M E
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MEDICAL IN CONFIDENCE
COPY 1 
Form S«nal No.
Scottish Cardiac Surgery Register: Registration Form
A General Information
1 SCSR Number
2 Surname
3 First Name
4 Other Initial n  * S*X  (1 » MMfcS •  A m * .
•  •  Qmm.9 •  rnmtnmmu □
6 Date ofBirth
7 NHS Number*
Maiden Nam*
9m mmt wt nui— I »*  MO Wit  —
8 Home Address ___________
9 Postcode
B Administrative Data
14 Accepting Hospital Code
15 Accepting 
Case Ref. No.
16 Date Accepted for Surgery
O aM U aM n fM riO K
20 Urgency Code (1 • Emwgancy.2 •  Urg««.
1 « Rouans.4 ■ O atm ol
21 Revised Urgency Code
22 Oate of Revision
C Clinical Data 
Cardiac Diagnosis
23(i) ___________
24(H)
25(fii)
Procedure<s) required
27(0
28(ii)
□
□
D Exit from Waiting List 
29 Reason
0 •  M M  m  f m f M y  • n« on VMIng UM
1 rntmmmtm t w ee— yton wnnq tie
□
4 .C
im f
it
TmUmTrn
30 Date of Exit from Waiting List
E Details of Stay in Hospital
31 Name of Consultant Surgeon
32 Date of First Operation
Procedural*) Performed and Procedure Category 
l . c i i m  a>
33 (I)
34 (ii)
Additional Procedures Performed
35 (i)
Date of this procedure
36 (ii)
Date of this procedure
37 (iii)
Date of this procedure
38 Oate of Oischarge from 
Cardiac Surgery Unit
F Disposal from Cardiac Surgery Unit 
41 Destination
1 .  Hkoma 3 > 0 * arH M (M *
2 ■ OSmt Unit M4 Hoaptfe ••Owd » -0 * w
□
G Follow Up 
44 Date of Death
H Option Boxes
45 National
46 Local
Wj&;fe s o
p m i m p m m r n m ■
P L E A SE  NOTE: COMPLETION O F SHADED B O X E S IS OPTIONAL
D: Linkage algorithm
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The details of the linkage algorithm used in the SRL are as follows:
1. Locate Soundex code and Soundex weight for each surname in a look-up table 
and append to the WOSCOPS record.
2. Read the WOSCOPS patient identifying information into an array.
3. Block the array on Soundex code and first initial, and date of birth, storing the 
position in the WOSCOPS array at which each Soundex code and first initial, and 
date of birth occurs.
4. Read in records from the ISD linked database, a patient record set at a time, where 
a patient record set contains all the records linked together for a given patient.
5. If the Soundex code and first initial, or the date of birth is present in the blocking 
array, then compare each record in the patient record set with each of the 
WOSCOPS records in this block, and calculate a comparison score for each pair of 
records.
6 . Store the highest score achieved.
7. If this highest score is above the nominal threshold score (total weight), then link 
the entire patient record set to the WOSCOPS subject with which this highest score 
is achieved.
8 . If more than one WOSCOPS subject achieves the same high score with a patient 
record set, then link the patient record set with the first WOSCOPS subject to 
achieve this highest score.
9. Read in the next patient record set.
The specific details of the bonuses and deductions used for the WOSCOPS linkages are as 
follows:
1. Initialise the matching score to 0.
2. If the Soundex code agrees, add the Soundex weight to the score, where the 
Soundex weights reflect the rarity of the surname, else make a deduction of 3.0.
233
3. If the first initial agrees then add a bonus to the score according to the look-up 
array of first initial bonuses, else make a deduction of 4.9.
4. If the first 4 letters of the forename agree, add a bonus of 3.0 to the score, else 
make a deduction of 2.5 [for death, SMR6  and SMR20 records where full forename 
is available].
5. If the sex does not agree, make a deduction of 6.5.
6 . If the first 8  characters of the surname do not agree, make a deduction of 2.0.
7. If the year of birth agrees, add a bonus of 6.3. Else make a deduction according to 
the size of the difference (from a look-up array) up to 2 0  years, at which the 
deduction is 7.0.
8 . If the month of birth agrees, add a bonus of 3.56, else make a deduction according 
to the size of the difference (from a look-up array).
9. If the day of birth agrees, add a bonus of 4.9, else make a deduction according to 
the size of the difference (from a look-up array).
10. Compare the postcode. Add different weights depending on how many 
characters of the postcode agree and how common each area is (for example, EH 
gets a larger bonus than G, reflecting the fact that a Glasgow postcode is more 
common than an Edinburgh one, for the Scottish population as a whole). However, 
make no deduction for differing postcodes.
11. If the score is between 15 and 35, compare the full surname character by 
character, and make a further deduction of 2.5 if there are two differences in the 
name.
12. Add and subtract these individual weights to give the Total Weight on the basis 
of which a linkage decision is made.
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E: Example of a WOSCOPS adverse event form 
for an event identified only by record linkage
These forms were identical to the standard W OSCOPS adverse event forms, except that 
they were marked with blue stripes to indicate that they were for Data Centre use only.
SECTION 2 To be o o m p M t d b y
1. Mam reason
2. Other ij ;events
WEST OF SCOTLAND 
CORONARY PREVENTION STUDY
Hospitalisation R andom  No. 
Report
ARL2/OC10 
Serial No. 
Form Type 
Visit No.
Date of Report Patient Initial)
SECTION 1 To be co m p le te d  by th e  Triai P h ysic ian
1. Oate of admission to hospital
2. Date of discharge from hospital
3. Hospital
Address
Consultant
4. in your clinical opinion what is the mam rei ipitalisation7
Comments
In v e s tig a to r 's  Initials N a m e ot P e r s o n  C o m p le tin g  Form  Oate ot Completion
Trial Monitor
during hospitalisation
5 . Did the  m am  r e a s o n / symtoms of th is  Yes IT! No T ' Unknown 13]
conai tion exis t o no r  to random isation 7 ~  —  —
CATEGORY CODES
- m  r r r r n
or surgical procedure during hospitalisation
F: Covariance matrices
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The covariance matrices produced when the final models are fitted may be used in 
conjunction with the parameter estimates, given in Chapter 6 , to examine any possible 
contrast between levels of the factors. The ‘final models’ are those arrived at via stepwise 
logistic regression. For each of these models, the covariance matrices were as follows.
1. All-cause mortality in the 73,110 men aged 45-64 at screening visit 1
age smok(l) smok(2) dep(l) dep(2) alc(l) alc(2) alc(3) alc(4)
age 0.01335
smok(l) 0.00814 0.04068
smok(2) 0.00831 0.01967 0.02796
dep(l) -0.00023 0.01102 0.01103 0.01533
dep(2) -0.00046 0.01065 0.01066 0.01155 0.01869
alc(l) 0.00012 -0.00011 -0.00002 0.00007 0.00011 0.00177
alc(2) 0.00019 -0.00027 -0.00027 0.00006 -0.00000 0.00121 0.00491
alc(3) 0.00015 -0.00020 -0.00031 -0.00002 -0.00009 0.00121 0.00126 0.00919
a]c(4) 0.00020 -0.00024 -0.00039 0.00002 0.00000 0.00121 0.00126 0.00127 0.01475
alc(5) 0.00018 -0.00018 -0.00038 -0.00002 -0.00012 0.00121 0.00126 0.00129 0.00128
alc(6) 0.00017 -0.00017 -0.00041 0.00000 -0.00016 0.00121 0.00128 0.00131 0.00131
chol(l) 0.00001 -0.00007 -0.00003 -0.00000 0.00003 -0.00003 -0.00001 -0.00002 0.00002
chol(2) -0.00004 -0.00007 -0.00009 0.00002 0.00005 -0.00005 -0.00001 -0.00003 0.00001
chol(3) -0.00005 -0.00009 -0.00009 -0.00002 0.00003 -0.00004 -0.00002 -0.00002 0.00002
chol(4) -0.00005 -0.00013 -0.00016 -0.00004 0.00007 -0.00003 -0.00001 -0.00000 0.00002
bmi -0.00006 0.00426 0.00426 -0.00055 -0.00097 0.00002 -0.00006 -0.00006 -0.00010
dbp 0.00279 -0.00006 0.00022 -0.00002 -0.00004 -0.00006 -0.00016 -0.00026 -0.00016
B*C(1) 0.00022 -0.02575 -0.01103 -0.01532 -0.01154 0.00002 0.00003 0.00002 0.00005
B*C(2) 0.00023 -0.01102 -0.01773 -0.01533 -0.01154 -0.00006 -0.00003 -0.00008 0.00003
B*C(3) 0.00044 -0.02528 -0.01066 -0.01154 -0.01867 0.00003 0.00008 -0.00000 0.00001
B*C(4) 0.00044 -0.01065 -0.01736 -0.01154 -0.01867 -0.00006 -0.00002 -0.00006 -0.00007
B*F(1) 0.00009 -0.00664 -0.00424 0.00055 0.00097 0.00000 0.00005 0.00001 0.00006
B*F(2) 0.00002 -0.00425 -0.00518 0.00055 0.00096 0.00003 0.00014 0.00016 0.00019
A*G -0.00380 0.00004 -0.00028 0.00001 0.00003 0.00001 0.00004 0.00018 -0.00003
A*B(1) -0.01116 -0.01430 -0.00818 0.00022 0.00044 -0.00005 -0.00001 -0.00002 -0.00002
A*B(2) -0.01137 -0.00817 -0.00994 0.00022 0.00043 -0.00008 -0.00005 0.00001 -0.00003
CONSTANT -0.00984 -0.01946 -0.01965 -0.01105 -0.01073 -0.00120 -0.00106 -0.00093 -0.00099
alc(5) alc(6) chol(l) chol(2) chol(3) chol(4) bmi dbp B*C(1)
alc(5) 0.02018
alc(6) 0.00133 0.01525
chol(l) -0.00002 0.00008 0.00311
chol(2) -0.00002 0.00009 0.00134 0.00303
chol(3) 0.00002 0.00008 0.00135 0.00136 0.00313
chol(4) -0.00001 0.00011 0.00135 0.00136 0.00137 0.00282
bmi -0.00013 -0.00004 -0.00006 -0.00008 -0.00009 -0.00014 0.00844
dbp -0.00024 -0.00028 -0.00003 -0.00007 -0.00009 -0.00013 -0.00021 0.00489
B*C(1) -0.00001 0.00003 0.00006 -0.00000 0.00003 0.00002 0.00055 0.00001 0.03223
B*C(2) -0.00004 -0.00008 0.00004 0.00005 0.00005 0.00006 0.00054 0.00004 0.01532
B*C(3) 0.00002 -0.00002 0.00005 0.00002 0.00002 0.00003 0.00096 0.00004 0.02651
B*C(4) -0.00009 -0.00015 0.00006 0.00010 0.00012 0.00010 0.00096 0.00005 0.01154
B*F(1) 0.00006 -0.00001 0.00003 0.00004 0.00004 0.00003 -0.00840 0.00009 -0.00073
B*F(2) 0.00021 0.00015 -0.00001 -0.00004 -0.00008 -0.00008 -0.00840 -0.00002 -0.00055
A*G 0.00014 0.00014 -0.00001 0.00002 0.00003 0.00006 0.00004 -0.00486 0.00002
A*B(1) -0.00006 -0.00005 -0.00004 0.00001 -0.00002 -0.00001 0.00003 0.00000 -0.00039
A*B(2) 0.00006 0.00015 -0.00002 0.00004 0.00005 0.00006 0.00003 -0.00028 -0.00023
CONSTANT -0.00092 -0.00099 -0.00128 -0.00124 -0.00119 -0.00114 -0.00407 -0.00256 0.01099
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B*C(2) B*C(3) B*C(4) B*F(1) B*F(2) A*G A*B(1) A*B(2)
B*C(2) 0.02313
B*C(3) 0.01154 0.03718
B*C(4) 0.01830 0.01867 0.02683
B*F(1) -0.00055 -0.00116 -0.00097 0.01308
B*F(2) -0.00055 -0.00097 -0.00091 0.00840 0.01078
A*G -0.00001 0.00000 -0.00002 -0.00010 0.00004 0.00658
A*B(1) -0.00022 -0.00073 -0.00044 -0.00001 -0.00003 0.00004 0.01887
A*B(2) -0.00029 -0.00044 -0.00054 -0.00004 0.00001 0.00040 0.01114 0.01376
CONSTANT 0.01101 0.01059 0.01061 0.00416 0.00425 0.00273 0.00822 0.00837 0.02280
2. CHD mortality in the 73,110 men aged 45-64 at screening visit 1
age smok(l) smok(2) chol(l) chol(2) chol(3) chol(4) dep(l) dep(2)
age 0.03066
smok(l) 0.02422 0.12935
smok(2) 0.02423 0.06432 0.09128
chol(l) 0.00001 -0.00020 -0.00012 0.00963
chol(2) -0.00008 -0.00016 -0.00028 0.00484 0.00896
chol(3) -0.00010 -0.00017 -0.00042 0.00485 0.00486 0.00887
chol(4) -0.00006 -0.00030 -0.00063 0.00485 0.00487 0.00488 0.00768
dep(l) -0.00057 0.02893 0.02894 -0.00003 0.00003 -0.00008 -0.00012 0.03826
dep(2) -0.00127 0.02856 0.02855 0.00005 0.00013 0.00007 0.00015 0.02909 0.04690
alc(l) 0.00159 0.01609 0.01610 -0.00008 -0.00012 -0.00016 -0.00015 0.00089 0.00158
alc(2) 0.00417 0.01673 0.01675 -0.00012 -0.00011 -0.00018 -0.00032 0.00094 -0.00088
alc(3) 0.00483 0.01479 0.01480 -0.00018 -0.00029 -0.00045 -0.00017 -0.00121 -0.00338
alc(4) 0.00337 0.01511 0.01516 -0.00003 0.00005 -0.00032 -0.00064 0.00026 -0.00097
alc(5) 0.00518 0.01443 0.01447 -0.00008 -0.00004 -0.00038 -0.00055 -0.00150 -0.00398
alc(6) 0.00544 0.01556 0.01555 -0.00018 -0.00007 0.00001 -0.00002 -0.00061 -0.00562
dbp -0.00113 0.01056 0.01057 -0.00011 -0.00017 -0.00019 -0.00025 -0.00025 -0.00038
A*B(1) -0.03066 -0.04018 -0.02423 -0.00007 0.00003 -0.00000 0.00002 0.00057 0.00127
A*B(2) -0.03066 -0.02423 -0.02866 -0.00002 0.00014 0.00021 0.00025 0.00057 0.00127
B*F(1) 0.00113 -0.01616 -0.01055 0.00009 0.00012 0.00002 0.00003 0.00025 0.00038
B*F(2) 0.00113 -0.01055 -0.01357 -0.00001 -0.00003 -0.00004 -0.00004 0.00025 0.00038
B*E(1) -0.00159 -0.02569 -0.01607 0.00001 -0.00003 -0.00005 -0.00005 -0.00088 -0.00158
B*E(2) -0.00159 -0.01609 -0.02216 -0.00000 0.00001 0.00012 0.00016 -0.00089 -0.00158
B*E(3) -0.00417 -0.02694 -0.01673 -0.00001 -0.00011 -0.00002 0.00011 -0.00094 0.00088
B*E(4) -0.00417 -0.01673 -0.02294 0.00014 0.00017 0.00023 0.00044 -0.00094 0.00089
B*E(5) -0.00483 -0.02381 -0.01476 -0.00001 0.00011 0.00015 -0.00028 0.00122 0.00337
B*E(6) -0.00483 -0.01480 -0.02079 0.00018 0.00029 0.00055 0.00035 0.00121 0.00338
B*E(7) -0.00337 -0.02453 -0.01514 -0.00013 -0.00019 0.00021 0.00037 -0.00026 0.00096
B*E(8) -0.00338 -0.01512 -0.02111 0.00015 0.00004 0.00050 0.00094 -0.00027 0.00097
B*E(9) -0.00517 -0.02321 -0.01443 0.00009 -0.00037 0.00025 0.00010 0.00151 0.00396
B*E(10) -0.00519 -0.01444 -0.02066 0.00002 0.00008 0.00060 0.00076 0.00150 0.00398
B*E(11) -0.00544 -0.02400 -0.01553 -0.00001 -0.00021 -0.00052 -0.00018 0.00061 0.00562
B*E(12) -0.00545 -0.01558 -0.02150 0.00056 0.00052 0.00051 0.00055 0.00061 0.00563
B*D(1) 0.00058 -0.07124 -0.02893 0.00015 0.00001 0.00007 0.00005 -0.03826 -0.02909
B*D(2) 0.00057 -0.02893 -0.04650 0.00010 0.00014 0.00013 0.00016 -0.03826 -0.02909
B*D(3) 0.00127 -0.07096 -0.02857 0.00016 0.00009 0.00008 0.00009 -0.02909 -0.04689
B*D(4) 0.00126 -0.02857 -0.04610 0.00016 0.00027 0.00031 0.00027 -0.02910 -0.04689
CONSTANT -0.02418 -0.06413 -0.06401 -0.00472 -0.00467 -0.00452 -0.00441 -0.02889 -0.02864
alc(l) alc(2) alc(3) alc(4) alc(5) alc(6) dbp A*B(1) A*B(2)
alc(l) 0.02332
alc(2) 0.01397 0.09256
alc(3) 0.01392 0.01469 0.26794
alc(4) 0.01393 0.01449 0.01466 1.02039
alc(5) 0.01392 0.01481 0.01521 0.01484 0.52480
alc(6) 0.01386 0.01488 0.01526 0.01471 0.01542 1.02370
dbp 0.00003 -0.00138 -0.00237 -0.00236 -0.00293 -0.00134 0.02060
A*B(1) -0.00159 -0.00417 -0.00483 -0.00337 -0.00518 -0.00544 0.00113 0.05019
A*B(2) -0.00160 -0.00418 -0.00483 -0.00340 -0.00520 -0.00544 0.00112 0.03066 0.03722
B*F(1) -0.00003 0.00140 0.00238 0.00239 0.00295 0.00134 -0.02060 -0.00147 -0.00113
alc(l) alc(2) alc(3) alc(4) alc(5) alc(6) dbp A*B(1)
2 3 7
A*B(2)
B*F(2) -0.00003 0.00140 0.00238 0.00238 0.00295 0.00134 -0.02059 -0.00113 -0.00131
B*E(1) -0.02331 -0.01396 -0.01391 -0.01391 -0.01390 -0.01386 -0.00002 0.00224 0.00159
B*E(2) -0.02332 -0.01397 -0.01391 -0.01394 -0.01393 -0.01386 -0.00003 0.00159 0.00184
B*E(3) -0.01397 -0.09255 -0.01468 -0.01448 -0.01480 -0.01488 0.00139 0.00608 0.00417
B*E(4) -0.01397 -0.09257 -0.01469 -0.01450 -0.01482 -0.01488 0.00138 0.00417 0.00490
B*E(5) -0.01391 -0.01467 -0.26793 -0.01461 -0.01517 -0.01526 0.00239 0.00669 0.00482
B*E(6) -0.01392 -0.01470 -0.26795 -0.01468 -0.01523 -0.01525 0.00237 0.00483 0.00590
B*E(7) -0.01393 -0.01448 -0.01465 -1.02037 -0.01482 -0.01471 0.00236 0.00493 0.00339
B*E(8) -0.01394 -0.01450 -0.01466 -1.02043 -0.01487 -0.01471 0.00235 0.00337 0.00404
B*E(9) -0.01391 -0.01479 -0.01520 -0.01480 -0.52477 -0.01542 0.00295 0.00706 0.00518
B*E(10) -0.01392 -0.01482 -0.01522 -0.01488 -0.52483 -0.01541 0.00292 0.00518 0.00647
B*E(11) -0.01385 -0.01488 -0.01523 -0.01470 -0.01540 -1.02370 0.00135 0.00714 0.00543
B*E(12) -0.01387 -0.01490 -0.01528 -0.01475 -0.01545 -1.02370 0.00132 0.00544 0.00680
B*D(1) -0.00089 -0.00094 0.00121 -0.00024 0.00152 0.00061 0.00025 -0.00105 -0.00058
B*D(2) -0.00089 -0.00094 0.00121 -0.00025 0.00151 0.00061 0.00025 -0.00057 -0.00079
B*D(3) -0.00158 0.00088 0.00337 0.00095 0.00397 0.00562 0.00038 -0.00208 -0.00127
B*D(4) -0.00159 0.00087 0.00336 0.00094 0.00395 0.00562 0.00037 -0.00126 -0.00163
CONSTANT -0.01598 -0.01657 -0.01458 -0.01490 -0.01421 -0.01551 -0.01041 0.02423 0.02411
B*F(1) B*F(2) B*E(1) B*E(2) B*E(3) B*E(4) B*E(5) B*E(6) B*E(7)
B*F(1) 0.03192
B*F(2) 0.02060 0.02640
B*E(1) -0.00044 0.00003 0.03689
B*E(2) 0.00002 -0.00028 0.02331 0.03178
B*E(3) -0.00252 -0.00140 0.02249 0.01397 0.13532
B*E(4) -0.00140 -0.00200 0.01396 0.01995 0.09256 0.11653
B*E(5) -0.00352 -0.00238 0.02239 0.01390 0.02337 0.01466 0.61196
B*E(6) -0.00238 -0.00301 0.01391 0.01991 0.01469 0.02081 0.26792 0.30124
B*E(7) -0.00385 -0.00238 0.02242 0.01394 0.02318 0.01449 0.02335 0.01467 1.36630
B*E(8) -0.00239 -0.00324 0.01391 0.01993 0.01448 0.02061 0.01459 0.02082 1.02039
B*E(9) -0.00397 -0.00295 0.02236 0.01392 0.02347 0.01479 0.02394 0.01521 0.02352
B*E(10) -0.00296 -0.00358 0.01390 0.01992 0.01480 0.02097 0.01516 0.02145 0.01485
B*E(11) -0.00283 -0.00134 0.02227 0.01385 0.02361 0.01487 0.02414 0.01522 0.02354
B*E(12) -0.00133 -0.00218 0.01386 0.01985 0.01489 0.02108 0.01525 0.02154 0.01473
B*D(1) -0.00026 -0.00025 0.00164 0.00089 0.00179 0.00094 -0.00125 -0.00121 0.00095
B*D(2) -0.00025 -0.00016 0.00088 0.00095 0.00094 0.00109 -0.00122 -0.00156 0.00025
B*D(3) -0.00021 -0.00038 0.00281 0.00158 -0.00017 -0.00088 -0.00433 -0.00337 -0.00086
B*D(4) -0.00038 -0.00027 0.00158 0.00181 -0.00088 -0.00092 -0.00338 -0.00387 -0.00094
CONSTANT 0.01050 0.01058 0.01610 0.01602 0.01672 0.01652 0.01480 0.01452 0.01503
B*E(8) B*E(9) B*E(10) B*E(11) B*E(12) B*D(1) B*D(2) B*D(3) B*D(4)
B*E(8) 1.07354
B*E(9) 0.01482 0.79013
B*E(10) 0.02108 0.52479 0.61054
B*E(11) 0.01469 0.02430 0.01538 1.28840
B*E(12) 0.02099 0.01543 0.02180 1.02368 1.09079
B*D(1) 0.00024 -0.00189 -0.00152 -0.00024 -0.00060 0.08527
B*D(2) 0.00042 -0.00152 -0.00166 -0.00062 -0.00084 0.03826 0.05849
B*D(3) -0.00095 -0.00528 -0.00397 -0.00789 -0.00561 0.07135 0.02910 0.09719
B*D(4) -0.00117 -0.00397 -0.00461 -0.00564 -0.00670 0.02909 0.04674 0.04689 0.06829
CONSTANT 0.01476 0.01440 0.01412 0.01573 0.01514 0.02887 0.02883 0.02848 0.02837
CONSTANT
CONSTANT 0.06789
3. Cancer mortality in the 73,110 men aged 45-64 at screening visit 1
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age smok(l) smok(2) bmi chol(l) chol(2) chol(3) chol(4) dep(l)
age 0.00469
smok(l) -0.00030 0.00957
smok(2) 0.00002 0.00619 0.00774
bmi 0.00002 -0.00014 0.00052 0.00376
chol(l) -0.00005 -0.00009 -0.00003 -0.00015 0.00761
chol(2) -0.00003 -0.00010 -0.00003 -0.00026 0.00308 0.00742
chol(3) -0.00003 -0.00017 -0.00004 -0.00037 0.00309 0.00311 0.00834
chol(4) 0.00001 -0.00029 -0.00020 -0.00049 0.00310 0.00312 0.00314 0.00811
dep(l) -0.00013 -0.00041 -0.00063 -0.00009 0.00008 0.00011 0.00004 -0.00000 0.00990
dep(2) -0.00022 -0.00045 -0.00100 -0.00007 0.00021 0.00034 0.00032 0.00037 0.00838
CONSTANT -0.00334 -0.00541 -0.00574 -0.00142 -0.00306 -0.00311 -0.00300 -0.00286 -0.00777
dep(2) CONSTANT
dep(2) 0.01091
CONSTANT -0.00771 0.01791
4. Trauma mortality in the 73,1 10 men aged 45-64 at screening visit 1
age alc(l) alc(2) alc(3) alc(4) alc(5) alc(6) CONSTANT
age 0.03417
alc(l) 0.00202 0.04595
alc(2) 0.00479 0.03160 0.15697
alc(3) 0.00584 0.03166 0.03213 0.19932
alc(4) 0.00410 0.03156 0.03189 0.03202 0.53222
alc(5) 0.00640 0.03169 0.03221 0.03241 0.03208 0.20030
alc(6) 0.00684 0.03172 0.03227 0.03248 0.03214 0.03260 0.36684
CONSTANT -0.02336 -0.03270 -0.03459 -0.03531 -0.03412 -0.03569 -0.03599 0.04729
5. Hospitalisation for any cause for the men aged 45-64 at screening visit 1
age smok(l) smok(2) alc(l) alc(2) alc(3) alc(4) alc(5) alc(6)
age 0.00230
smok(l) 0.00045 0.00103
smok(2) 0.00041 0.00049 0.00077
alc(l) 0.00002 -0.00002 -0.00001 0.00038
alc(2) 0.00003 -0.00004 -0.00004 0.00027 0.00088
alc(3) 0.00004 -0.00004 -0.00005 0.00027 0.00028 0.00176
alc(4) 0.00001 -0.00003 -0.00006 0.00027 0.00028 0.00028 0.00319
alc(5) 0.00004 -0.00003 -0.00006 0.00027 0.00028 0.00029 0.00029 0.00483
alc(6) 0.00002 -0.00003 -0.00008 0.00027 0.00029 0.00029 0.00029 0.00029 0.00369
dep(l) 0.00085 -0.00004 -0.00007 0.00001 0.00001 -0.00001 -0.00001 -0.00002 -0.00002
dep(2) 0.00083 -0.00004 -0.00012 0.00002 -0.00000 -0.00003 -0.00002 -0.00003 -0.00008
chol(l) -0.00000 -0.00000 0.00000 -0.00000 -0.00000 -0.00000 -0.00000 -0.00001 0.00001
chol(2) -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 -0.00000 -0.00001 0.00001
chol(3) -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 -0.00000 0.00001
chol(4) -0.00001 -0.00002 -0.00002 -0.00001 -0.00001 -0.00001 -0.00001 -0.00001 0.00002
A*D(1) -0.00169 0.00004 0.00007 0.00000 0.00000 0.00001 0.00002 0.00001 0.00002
A*D(2) -0.00165 0.00004 0.00012 -0.00001 0.00001 0.00001 0.00002 0.00000 0.00005
A*B(1) -0.00086 -0.00102 -0.00049 -0.00001 -0.00000 -0.00001 -0.00001 -0.00001 -0.00001
A*B(2) -0.00080 -0.00049 -0.00076 -0.00001 -0.00001 -0.00000 -0.00001 0.00001 0.00002
CONSTANT -0.00118 -0.00042 -0.00039 -0.00027 -0.00026 -0.00024 -0.00024 -0.00024 -0.00024
dep(l) dep(2) chol(l) chol(2) chol(3) chol(4) A*D(1) A*D(2) A*B(1)
dep(l) 0.00113
dep(2) 0.00091 0.00138
chol(l) 0.00000 0.00001 0.00060
chol(2) 0.00000 0.00002 0.00030 0.00060
chol(3) 0.00000 0.00002 0.00030 0.00030 0.00060
chol(4) -0.00000 0.00002 0.00030 0.00030 0.00030 0.00059
A*D(1) -0.00113 -0.00091 0.00000 0.00000 -0.00000 0.00000 0.00220
A*D(2) -0.00090 -0.00138 -0.00000 0.00001 0.00000 0.00000 0.00179 0.00265
A*B(1) 0.00004 0.00004 -0.00000 0.00000 -0.00000 0.00000 -0.00009 -0.00009 0.00183
A*B(2) 0.00007 0.00012 -0.00000 0.00001 0.00001 0.00002 -0.00014 -0.00024 0.00094
CONSTANT -0.00086 -0.00086 -0.00030 -0.00029 -0.00029 -0.00028 0.00085 0.00084 0.00046
A*B(2) CONSTA
NT
A*B(2) 0.00149
CONSTANT 0.00042 0.00160
6 . CHD hospitalisation for the men aged 45-64 at screening visit 1
chol(l) chol(2) chol(3) chol(4) alc(l) alc(2) alc(3) alc(4) alc(5)
chol(l) 0.01140
chol(2) 0.00621 0.00966
chol(3) 0.00622 0.00624 0.00944
chol(4) 0.00623 0.00625 0.00627 0.00852
alc(l) -0.00002 -0.00003 -0.00002 -0.00002 0.00145
alc(2) -0.00001 -0.00001 -0 .0 0 0 0 0 -0.00001 0.00099 0.00442
alc(3) 0.00001 -0 .0 0 0 0 0 0.00003 0.00004 0.00099 0.00103 0.00843
alc(4) -0.00002 -0.00001 -0.00004 -0.00002 0.00099 0.00103 0.00104 0.01880
alc(5) -0.00002 0.00001 0.00001 -0.00006 0.00099 0.00103 0.00105 0.00104 0.02742
alc(6) 0.00014 0.00013 0.00018 0.00022 0.00099 0.00105 0.00107 0.00106 0.00108
age 0.00624 0.00616 0.00610 0.00595 0.00012 0.00018 0.00015 0.00007 0.00017
smok(l) -0.00002 -0.00008 -0.00010 -0.00020 -0.00007 -0.00017 -0.00015 -0.00013 -0.00011
smok(2) 0 .0 0 0 0 0 -0.00009 -0.00013 -0.00027 -0.00005 -0.00017 -0.00023 -0.00021 -0.00024
bmi -0.00007 -0.00012 -0.00015 -0.00019 0.00002 0.00001 0.00001 0.00002 -0 . 0 0 0 0 0
dep(l) 0.00005 0.00007 0.00006 -0.00001 0.00004 0.00004 -0.00006 -0.00003 -0.00004
dep(2) 0.00019 0.00023 0.00023 0.00030 0.00010 0.00001 -0.00011 -0.00009 -0.00011
C*D(1) 0.00002 0.00009 0.00010 0.00021 -0.00004 -0.00001 -0.00002 -0.00003 -0.00005
C*D(2) -0.00001 0.00007 0.00011 0.00024 -0.00006 -0.00005 0.00001 -0.00005 0.00004
dbp -0.00009 -0.00018 -0.00024 -0.00031 -0.00005 -0.00013 -0.00022 -0.00015 -0.00018
C*G 0.00009 0.00019 0.00026 0.00033 0.00001 0.00004 0.00014 -0.00001 0.00010
C*A(1) -0.01140 -0.00621 -0.00621 -0.00622 -0 .0 0 0 0 0 -0.00001 -0.00005 0.00003 -0.00001
C*A(2) -0.00621 -0.00965 -0.00623 -0.00624 -0.00002 -0.00002 -0.00004 0.00001 -0.00007
C*A(3) -0.00621 -0.00623 -0.00943 -0.00625 -0.00003 -0.00004 -0.00010 0.00005 -0.00002
C*A(4) -0.00622 -0.00624 -0.00625 -0.00850 -0.00003 -0.00003 -0.00010 0 .0 0 0 0 0 0.00002
C*F(1) -0.00005 -0.00007 -0.00005 0.00001 0.00001 0.00001 0.00003 0 .0 0 0 1 1 0.00001
C*F(2) -0.00019 -0.00023 -0.00023 -0.00030 -0.00003 0.00001 0.00003 0.00009 -0.00003
CONSTANT -0.00620 -0.00609 -0.00602 -0.00585 -0.00099 -0.00091 -0.00078 -0.00079 -0.00079
alc(6) age smok(l) smok(2) bmi dep(l) dep(2) C*D(1) C*D(2)
alc(6) 0.02343
age 0.00018 0.02495
smok(l) -0.00012 0.00417 0.00732
smok(2) -0.00030 0.00407 0.00451 0.00579
bmi 0.00003 -0.00005 -0.00005 0.00012 0.00114
dep(l) -0.00008 0.00668 -0.00023 -0.00038 -0.00003 0.00815
dep(2) -0.00032 0.00674 -0.00023 -0.00065 -0.00002 0.00696 0.00933
C*D(1) -0.00007 -0.00612 -0.00731 -0.00450 0.00002 0.00023 0.00022 0.01067
C*D(2) 0.00007 -0.00603 -0.00451 -0.00576 0.00004 0.00037 0.00065 0.00666 0.00889
dbp -0.00023 0.00148 0.00001 0.00016 -0.00016 -0.00001 -0.00002 0.00001 -0.00017
C*G 0.00012 -0.00244 0.00000 -0.00017 0.00002 0.00001 0.00002 0.00002 0.00028
alc(6) age smok(l) smok(2) bmi dep(l) dep(2) C*D(1) C*D(2)
C*A(1) -0.00013 -0.00949 0.00002 -0.00000 0.00003 -0.00005 -0.00019 -0.00006 0.00000
C*A(2) -0.00009 -0.00945 0.00009 0.00008 0.00005 -0.00007 -0.00023 -0.00012 -0.00005
C*A(3) -0.00019 -0.00931 0.00010 0.00012 0.00006 -0.00005 -0.00024 -0.00017 -0.00009
C*A(4) -0.00022 -0.00911 0.00021 0.00026 0.00008 0.00001 -0.00030 -0.00033 -0.00029
C*F(1) 0.00010 -0.01032 0.00023 0.00037 -0.00001 -0.00815 -0.00696 -0.00041 -0.00063
C*F(2) 0.00018 -0.01043 0.00023 0.00065 -0.00002 -0.00696 -0.00932 -0.00041 -0.00106
CONSTANT -0.00084 -0.01646 -0.00410 -0.00408 -0.00049 -0.00669 -0.00679 0.00420 0.00411
dbp C*G C*A(1) C*A(2) C*A(3) C*A(4) C*F(1) C*F(2) CONSTANT
dbp 0.00294
C*G -0.00291 0.00464
C*A(1) 0.00009 -0.00014 0.01702
C*A(2) 0.00019 -0.00026 0.00944 0.01498
C*A(3) 0.00026 -0.00035 0.00944 0.00946 0.01460
C*A(4) 0.00033 -0.00045 0.00945 0.00948 0.00949 0.01336
C*F(1) 0.00001 0.00000 0.00010 0.00013 0.00004 -0.00003 0.01268
C*F(2) 0.00003 -0.00001 0.00029 0.00040 0.00037 0.00047 0.01076 0.01452
CONSTANT -0.00137 0.00146 0.00623 0.00615 0.00609 0.00593 0.00668 0.00676 0.01727
7. Cancer hospitalisation in the men aged 45-64 at screening visit 1
age smok(l) smok(2) bmi chol(l) chol(2) chol(3) chol(4) alc(l)
age 0.00213
smok(l) -0.00015 0.00370
smok(2) -0.00000 0.00225 0.00307
bmi 0.00001 -0.00007 0.00024 0.00169
chol(l) -0.00002 -0.00004 -0.00002 -0.00007 0.00369
chol(2) -0.00002 -0.00005 -0.00002 -0.00013 0.00163 0.00376
chol(3) -0.00002 -0.00008 -0.00002 -0.00017 0.00163 0.00164 0.00389
chol(4) 0.00000 -0.00014 -0.00010 -0.00023 0.00164 0.00165 0.00166 0.00378
alc(l) 0.00009 -0.00014 -0.00014 0.00003 -0.00004 -0.00007 -0.00006 -0.00004 0.00238
alc(2) 0.00024 -0.00027 -0.00034 0.00001 -0.00003 -0.00003 -0.00004 -0.00003 0.00169
alc(3) 0.00031 -0.00026 -0.00037 0.00000 -0.00004 -0.00005 -0.00004 -0.00002 0.00169
alc(4) 0.00019 -0.00025 -0.00043 -0.00000 0.00001 0.00000 0.00001 0.00001 0.00169
alc(5) 0.00034 -0.00025 -0.00038 -0.00002 -0.00005 -0.00005 0.00001 -0.00003 0.00169
alc(6) 0.00040 -0.00026 -0.00042 0.00002 0.00008 0.00010 0.00008 0.00011 0.00168
dep(l) -0.00007 -0.00018 -0.00028 -0.00005 0.00004 0.00005 0.00001 -0.00001 0.00006
dep(2) -0.00012 -0.00019 -0.00043 -0.00004 0.00010 0.00015 0.00014 0.00016 0.00012
CONSTANT -0.00156 -0.00176 -0.00192 -0.00073 -0.00159 -0.00158 -0.00153 -0.00148 -0.00167
alc(2) alc(3) alc(4) alc(5) alc(6) dep(l) dep(2) CONSTANT
alc(2) 0.00599
alc(3) 0.00174 0.01143
alc(4) 0.00174 0.00175 0.02352
alc(5) 0.00175 0.00177 0.00176 0.02969
alc(6) 0.00176 0.00179 0.00178 0.00181 0.02122
dep(l) 0.00007 -0.00007 0.00007 -0.00006 -0.00003 0.00383
dep(2) 0.00002 -0.00016 -0.00006 -0.00023 -0.00032 0.00311 0.00439
CONSTANT -0.00163 -0.00154 -0.00156 -0.00154 -0.00165 -0.00288 -0.00288 0.00833
241
8 . Hospitalisation for injury or poisoning for men aged 45-64 at screening visit 1
dep(l) dep(2) alc(l) alc(2) alc(3) alc(4) alc(5) alc(6) smok(l)
dep(l) 0.01167
dep(2) 0.01008 0.01236
alc(l) 0.00008 0.00017 0.00350
alc(2) 0.00011 0.00004 0.00259 0.00678
alc(3) -0.00003 -0.00015 0.00258 0.00263 0.01151
alc(4) 0.00006 -0.00009 0.00259 0.00264 0.00266 0.01858
alc(5) -0.00005 -0.00017 0.00258 0.00263 0.00265 0.00266 0.02279
alc(6) -0.00003 -0.00034 0.00257 0.00265 0.00267 0.00269 0.00268 0.01435
smok(l) -0.00047 -0.00060 -0.00016 -0.00034 -0.00031 -0.00034 -0.00030 -0.00030 0.00954
smok(2) -0.00073 -0.00120 -0.00017 -0.00049 -0.00056 -0.00066 -0.00061 -0.00065 0.00480
bmi 0.00946 0.00920 0.00000 -0.00012 -0.00016 -0.00022 -0.00023 -0.00017 0.00427
chol(l) 0.00004 0.00014 -0.00005 -0.00003 -0.00003 -0.00001 -0.00007 0.00011 -0.00006
chol(2) 0.00005 0.00019 -0.00007 -0.00004 -0.00005 -0.00001 -0.00005 0.00010 -0.00009
chol(3) 0.00005 0.00022 -0.00006 -0.00004 -0.00002 -0.00004 -0.00002 0.00011 -0.00014
chol(4) 0.00001 0.00023 -0.00005 -0.00004 -0.00000 -0.00002 -0.00008 0.00016 -0.00018
b*d(l) -0.01167 -0.01006 0.00001 -0.00003 -0.00005 -0.00004 -0.00001 -0.00001 0.00048
b*d(2) -0.01006 -0.01231 -0.00000 -0.00001 0.00002 0.00005 -0.00004 0.00002 0.00061
s*b(l) 0.00047 0.00060 0.00001 0.00008 0.00010 0.00014 0.00013 0.00009 -0.00952
s*b(2) 0.00073 0.00121 0.00004 0.00021 0.00026 0.00035 0.00034 0.00031 -0.00477
CONSTANT -0.00955 -0.00945 -0.00253 -0.00228 -0.00211 -0.00213 -0.00204 -0.00212 -0.00403
smok(2) bmi chol(l) chol(2) chol(3) chol(4) b*d(l) b*d(2) s*b(l)
smok(2) 0.00626
bmi 0.00395 0.02695
chol(l) 0.00001 -0.00008 0.00452
chol(2) 0.00000 -0.00012 0.00200 0.00463
chol(3) 0.00001 -0.00013 0.00201 0.00202 0.00475
chol(4) -0.00007 -0.00020 0.00201 0.00203 0.00205 0.00472
b*d(l) 0.00074 -0.02129 0.00000 -0.00001 -0.00006 -0.00005 0.02579
b*d(2) 0.00123 -0.02095 -0.00007 -0.00007 -0.00014 -0.00012 0.02224 0.02823
s*b(l) -0.00477 -0.00787 0.00004 0.00005 0.00009 0.00004 -0.00085 -0.00089 0.01757
s*b(2) -0.00621 -0.00731 -0.00002 -0.00007 -0.00010 -0.00015 -0.00126 -0.00205 0.00869
CONSTANT -0.00374 -0.01256 -0.00199 -0.00197 -0.00196 -0.00188 0.00948 0.00927 0.00420
s*b(2) CONST
s*b(2) 0.01293
CONSTANT 0.00393 0.01602
9. Hospitalisation for attempted suicide in men aged 45-64 at screening visit 1
age smok(l) smok(2) bmi alc(l) alc(2) alc(3) alc(4) alc(5)
age 0.02255
smok(l) -0.00198 1.09111
smok(2) -0.00028 0.16742 0.33470
bmi 0.00026 -0.00179 0.00131 0.02368
alc(l) 0.00112 -0.00255 -0.00121 0.00034 0.03438
alc(2) 0.00296 -0.00538 -0.00461 0.00009 0.02075 0.05172
alc(3) 0.00362 -0.00414 -0.00455 0.00015 0.02076 0.02140 0.09896
alc(4) 0.00274 -0.00426 -0.00541 0.00054 0.02075 0.02136 0.02156 0.22238
alc(5) 0.00396 -0.00391 -0.00540 0.00008 0.02077 0.02149 0.02174 0.02169 0.35655
alc(6) 0.00461 -0.00414 -0.00479 0.00090 0.02074 0.02166 0.02198 0.02197 0.02219
dep(l) -0.00064 0.16706 0.16690 -0.00151 0.00095 0.00047 -0.00067 -0.00037 -0.00088
dep(2) -0.00146 0.16742 0.16718 -0.00291 0.00207 -0.00094 -0.00211 -0.00089 -0.00335
B*E(1) -0.00039 -1.09038 -0.16704 0.00040 0.00064 0.00146 0.00080 0.00104 0.00015
B*E(2) -0.00009 -0.16702 -0.33385 0.00145 -0.00044 0.00014 -0.00039 0.00057 0.00017
age smok(l) smok(2) bmi
B*E(3) -0.00048 -1.09066 -0.16710 0.00207
B*E(4) 0.00024 -0.16727 -0.33381 0.00356
CONSTANT -0.00941 -0.16340 -0.16591 -0.00929
alc(6) dep(l) dep(2) B*E(1)
alc(6) 0.10067
dep(l) -0.00060 0.26683
dep(2) -0.00373 0.16730 0.29319
B*E(1) 0.00084 -0.26665 -0.16697 1.26148
B*E(2) -0.00047 -0.26675 -0.16712 0.26668
B*E(3) 0.00142 -0.16702 -0.29250 1.09036
B*E(4) -0.00084 -0.16717 -0.29273 0.16699
CONSTANT -0.01709 -0.16660 -0.16606 0.16638
alc(l)
0.00102
-0.00069
-0.02109
0.44832
0.16706
0.33416
0.16661
alc(2)
0.00304
0.00093
-0.01853
1.27170
0.29256
0.16538
alc(3)
0.00120
0.00022
-0.01746
0.47747
0.16571
alc(4)
0.00119
-0.00056
-0.01741
242
alc(5)
0.00252
0.00114
-0.01697
0.18740
10. All-cause mortality in the 14,950 women screened
age(l)
age(l) 0.12143
age(2) 0.10037
age(3) 0.10039
smok(l) -0.00045
smok(2) -0.00009
CONSTANT -0.10024
age(2)
0.10790
0.10062
-0.00099
0.00060
-0.10048
age(3)
0.10935
-0.00152
0.00255
-0.10131
smok(l)
0.02119
0.00780
-0.00681
smok(2) CONSTANT
0.01724
-0.00925 0.10570
11. Cancer mortality in the 14,950 women screened
age(l) age(2) age(3) smok(l) smok(2) dep(l) dep(2) CONSTANT
age(l) 0.18518
age(2) 0.14330 0.15912
age(3) 0.14329 0.14375 0.16320
smok(l) -0.00106 -0.00219 -0.00336 0.04408
smok(2) -0.00031 0.00113 0.00469 0.01669 0.03662
dep(l) 0.00037 -0.00106 -0.00087 0.00215 -0.00151 0.13507
dep(2) -0.00106 -0.00243 -0.00035 0.00095 -0.00325 0.12680 0.17541
CONSTANT -0.14307 -0.14220 -0.14404 -0.01643 -0.01757 -0.12603 -0.12456 0.27248
12. CHD mortality in the 14,950 women screened
age(l) age(2) age(3) smok(l) smok(2) a*s(l) a*s(2) a*s(3) a*s(4)
age(l) 6.44741
age(2) 5.49018 5.61559
age(3) 5.49018 5.49018 5.53475
smok(l) 5.49018 5.49018 5.49018 24.83957
smok(2) 5.49018 5.49018 5.49018 5.49018 15.36703
a*s(l) -6.44741 -5.49018 -5.49018 -24.83957 -5.49018 26.79729
a*s(2) -5.49018 -5.61559 -5.49018 -24.83957 -5.49018 24.83957 25.04929
a*s(3) -5.49018 -5.49018 -5.53475 -24.83957 -5.49018 24.83957 24.83957 25.01127
a*s(4) -6.44741 -5.49018 -5.49018 -5.49018 -15.36703 6.44741 5.49018 5.49018 16.52495
a*s(5) -5.49018 -5.61559 -5.49018 -5.49018 -15.36703 5.49018 5.61559 5.49018 15.36703
age(l) age(2) age(3) smok(l) smok(2) a*s(l) a*s(2)
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a*s(3) a*s(4)
a*s(6)
CONSTANT
-5.49018
-5.49018
-5.49018
-5.49018
-5.53475
-5.49018
-5.49018 -15.36703
-5.49018 -5.49018
5.49018
5.49018
5.49018
5.49018
5.53475
5.49018
15.36703
5.49018
a*s(5) a*s(6) CONSTANT
a*s(5)
a*s(6)
CONSTANT
15.54090
15.36703
5.49018
15.61529
5.49018 5.49018
13. All-cause mortality in the 13,559 men who reached screening visit 3
age smok(l) smok(2) visc(l) visc(2) fibr(l) fibr(2) fibr(3) fibr(4)
age 0.01242
smok(l) -0.00080 0.15565
smok(2) 0.00019 0.10142 0.13561
visc(l) -0.00005 -0.00041 0.00027 0.01840
visc(2) -0.00051 -0.00042 0.00010 0.01196 0.01951
fibr(l) -0.00069 0.10153 0.10139 -0.00220 -0.00198 0.24621
fibr(2) -0.00127 0.10161 0.10136 -0.00359 -0.00409 0.10203 0.18766
fibr(3) -0.00164 0.10168 0.10134 -0.00473 -0.00585 0.10224 0.10298 0.16824
fibr(4) -0.00157 0.10171 0.10134 -0.00513 -0.00882 0.10242 0.10349 0.10435 0.16455
dbp -0.00004 0.00032 0.00027 -0.00042 -0.00097 -0.00005 -0.00018 -0.00020 -0.00056
s*f(l) 0.00023 -0.15561 -0.10144 0.00028 -0.00020 -0.24589 -0.10144 -0.10142 -0.10132
s*f(2) 0.00050 -0.10146 -0.13557 0.00012 0.00004 -0.24592 -0.10151 -0.10154 -0.10155
s*f(3) 0.00040 -0.15563 -0.10143 0.00085 0.00015 -0.10153 -0.18666 -0.10159 -0.10149
s*f(4) 0.00100 -0.10149 -0.13556 0.00010 0.00026 -0.10152 -0.18671 -0.10167 -0.10175
s*f(5) 0.00044 -0.15562 -0.10142 0.00071 -0.00022 -0.10151 -0.10151 -0.16617 -0.10136
s*f(6) 0.00097 -0.10147 -0.13556 -0.00005 -0.00038 -0.10148 -0.10150 -0.16617 -0.10147
s*f(7) -0.00019 -0.15557 -0.10142 0.00070 0.00013 -0.10149 -0.10150 -0.10151 -0.16021
s*f(8) 0.00016 -0.10141 -0.13557 -0.00027 -0.00054 -0.10140 -0.10137 -0.10134 -0.16005
CONSTANT -0.00779 -0.10091 -0.10181 -0.00741 -0.00593 -0.09996 -0.09874 -0.09786 -0.09711
dbp s*f(l) s*f(2) s*f(3) s*f(4) s*f(5) s*f(6) s*f(7) s*f(8)
dbp 0.01010
s*f(l) -0.00047 0.36841
s*f(2) 0.00026 0.24587 0.31194
s*f(3) -0.00051 0.15564 0.10144 0.31377
s*f(4) 0.00054 0.10142 0.13565 0.18653 0.24128
s*f(5) -0.00012 0.15563 0.10145 0.15565 0.10145 0.26768
s*f(6) 0.00074 0.10142 0.13565 0.10144 0.13570 0.16614 0.22147
s*f(7) 0.00008 0.15559 0.10143 0.15561 0.10142 0.15562 0.10143 0.24261
s*f(8) 0.00086 0.10140 0.13562 0.10140 0.13564 0.10144 0.13567 0.16019 0.20521
CONSTANT -0.00564 0.10150 0.10092 0.10118 0.10041 0.10103 0.10045 0.10127 0.10099
CONSTANT
CONSTANT 0.11298
14. Cancer mortality in the 13,559 men who reached screening visit 3
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age smok(l) smok(2) visc(l) visc(2)
age 0.05386
smok(l) -0.00215 0.09328
smok(2) 0.00139 0.05951
visc(l) -0.00110 -0.00017
visc(2) -0.00367 -0.00261
CONSTANT -0.04259 -0.05660
0.07224
-0.00147 0.05662
-0.00470 0.03505 0.05473
-0.05831 -0.03310 -0.02857
15. CHD mortality in the 13,559 men who reached screening visit 3
age smok(l) smok(2) dbp visc(l) visc(2) hdl(l)
age 0.02505
smok(l) -0.00153 0.05950
sinok(2) 0.00089 0.03907 0.04834
dbp -0.00011 0.00015 0.00167 0.02423
visc(l) -0.00076 -0.00002 -0.00104 -0.00091 0.03865
visc(2) -0.00259 -0.00172 -0.00302 -0.00208 0.02061 0.03284
hdl(l) -0.00054 0.00030 0.00201 0.00014 0.00044 0.00172 0.02823
hdl(2) -0.00119 0.00041 0.00289 -0.00016 0.00095 0.00174 0.01157
CONSTANT -0.01547 -0.03750 -0.04069 -0.01607 -0.01906 -0.01622 -0.01330
CONSTANT
0.11668
hdl(2) CONSTANT
0.03654
-0.01341 0.08093
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G: Tabulations to investigate interaction effects 
for men age 45-64
These tabulations relate to the significant interactions in the models fitted for the 73,110 
men aged 45-64 at screening visit 1.
1. For all-cause mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the DEPCAT*smoking interaction were as follows.
Observed Never smoked Ex-smoker Current smoker
Affluent 0 . 0 2 2 0 0.0231 0.0433
Middle 0.0237 0.0442 0.0569
Deprived 0.0324 0.0617 0.0744
Expected Never smoked Ex-smoker Current smoker
Affluent 0.0188 0.0321 0.0457
Middle 0.0267 0.0448 0.0626
Deprived 0.0339 0.0571 0.0797
2. For all-cause mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the BMI*smoking interaction were as follows.
Observed Never smoked Ex-smoker Current smoker
BMI <25.46 kg/m2 0.0231 0.0514 0.0670
BMI >25.46 kg/m2 0.0272 0.0411 0.0535
Expected Never smoked Ex-smoker Current smoker
BMI < 25.46 kg/m2 0.0290 0.0489 0.0688
BMI >25.46 kg/m2 0.0249 0.0420 0.0580
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3. For all-cause mortality the tabulations of the observed and expected proportions of
deaths/subjects for the age*smoking interaction were as follows.
Observed Never smoked Ex-smoker Current smoker
Age 45-54 0.0116 0.0189 0.0341
Age 55-64 0.0407 0.0655 0.0916
Expected Never smoked Ex-smoker Current smoker
Age 45-54 0.0140 0.0233 0.0333
Age 55-64 0.0410 0.0676 0.0948
4. For all-cause mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the age*DBP interaction were as follows.
Observed DBP < 84 mmHg DBP > 84 mmHg
Age 45-54 0 . 0 2 2 0 0.0256
Age 55-64 0.0696 0.0701
Expected DBP < 84 mmHg DBP > 84 mmHg
Age 45-54 0.0225 0.0249
Age 55-64 0.0654 0.0723
5. For CHD mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the age*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
Age 45-54 0.0043 0.0073 0.0134
Age 55-64 0.0167 0.0264 0.0327
247
Expected Never smoked Ex-smoker Current smoker
Age 45-54 0.0052 0.0084 0.0115
Age 55-64 0.0145 0.0234 0.0320
Contrasts Coeff / s.e.
Age45-54(Ex-Never smoked) - Age55-64(Ex-Never smoked) 
Age45-54(Current-Never smoked) - Age55-64(Current-Never smoked)
-0.788
-2.80
6 . For CHD mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the DBP*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
DBP < 84 mmHg 0.0093 0.0177 0.0185
DBP > 84 mmHg 0.0109 0.0185 0.0268
Expected Never smoked Ex-smoker Current smoker
DBP < 84 mmHg 0.0085 0.0143 0.0194
DBP > 84 mmHg 0.0106 0.0174 0.0237
7. For CHD mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the alcohol*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
0  units alcohol / week 0.0139 0.0302 0.0281
1 - 2 0  units / week 0.0088 0.0161 0.0223
21-30 units / week 0.0087 0.0138 0.0149
31-40 units / week 0.0070 0.0038 0.0228
41-50 units / week 0.0036 0.0077 0.0243
51-60 units / week 0.0114 0.0171 0.0242
>60 units / week 0.0050 0.0140 0 . 0 2 2 2
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Expected Never smoked Ex-smoker Current smoker
0  units alcohol / week 0.0130 0 . 0 2 1 2 0.0289
1 - 2 0  units / week 0.0093 0.0152 0.0208
21-30 units / week 0.0074 0 . 0 1 2 1 0.0166
31-40 units / week 0.0082 0.0136 0.0184
41-50 units / week 0.0086 0.0146 0.0196
51-60 units/ week 0 . 0 1 1 1 0.0190 0.0256
>60 units / week 0.0097 0.0162 0.0218
8 . For CHD mortality the tabulations of the observed and expected proportions of 
deaths/subjects for the DEPCAT*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
Affluent 0.0085 0.0080 0.0160
Middle 0.0098 0.0174 0.0218
Deprived 0.0127 0.0263 0.0259
Expected Never smoked Ex-smoker Current smoker
Affluent 0.0066 0 . 0 1 1 1 0.0150
Middle 0.0095 0.0155 0.0213
Deprived 0.0123 0.0203 0.0266
9. For all-cause hospitalisation the tabulations of the observed and expected proportions of 
deaths/subjects for the age*DEPCAT interaction were as follows:
Observed Affluent Middle Deprived
Age 45-54 0.2635 0.3010 0.3551
Age 55-64 0.3678 0.4211 0.4455
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Expected Affluent Middle Deprived
Age 45-54 0.2718 0.3064 0.3385
Age 55-64 0.3711 0.4123 0.4487
10. For all-cause hospitalisation the tabulations of the observed and expected proportions 
of deaths/subjects for the age*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
Age 45-54 0.2624 0.3045 0.3414
Age 55-64 0.3721 0.4314 0.4434
Expected Never smoked Ex-smoker Current smoker
Age 45-54 0.2680 0.3167 0.3345
Age 55-64 0.3673 0.4233 0.4436
11. For CHD hospitalisation the tabulations of the observed and expected proportions of 
deaths/subjects for the age*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
Age 45-54 0.0213 0.0423 0.0522
Age 55-64 0.0520 0.0774 0.0748
Expected Never smoked Ex-smoker Current smoker
Age 45-54 0.0228 0.0374 0.0412
Age 55-64 0.0384 0.0612 0.0676
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12. For CHD hospitalisation the tabulations of the observed and expected proportions of
deaths/subjects for the age*DBP interaction were as follows:
Observed DBP < 84 mmHg DBP > 84 mmHg
Age 45-54 0.0357 0.0458
Age 55-64 0.0677 0.0713
Expected DBP < 84 mmHg DBP > 84 mmHg
Age 45-54 0.0324 0.0355
Age 55-64 0.0539 0.0588
13. For CHD hospitalisation the tabulations of the observed and expected proportions of 
deaths/subjects for the age*cholesterol interaction were as follows:
Observed Age 45-54 Age 55-64
Choi < 4.94 mmol/1 
4.94-5.55 mmol/1 
5.56-6.11 mmol/1 
6.12-6.80 mmol/ 1  
>6.80 mmol/ 1
0.0223
0.0275
0.0423
0.0461
0.0655
0.0445
0.0612
0.0703
0.0768
0.0957
Expected Age 45-54 Age 55-64
Choi < 4.94 mmol/1 
4.94-5.55 mmol/1 
5.56-6.11 mmol/1 
6.12-6.80 mmol/ 1  
>6.80 mmol/ 1
0.0206
0.0273
0.0351
0.0379
0.0484
0.0352
0.0456
0.0578
0.0623
0.0805
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14. For CHD hospitalisation the tabulations of the observed and expected proportions of
deaths/subjects for the age*DEPCAT interaction were as follows:
Observed Affluent Middle Deprived
Age 45-54 0.0258 0.0414 0.0484
Age 55-64 0.0571 0.0698 0.0753
Expected Affluent Middle Deprived
Age 45-54 0.0279 0.0339 0.0392
Age 55-64 0.0470 0.0558 0.0647
15. For hospitalisation for injury or poisoning the tabulations of the observed and expected 
proportions of deaths/subjects for the BMPDEPCAT interaction were as follows:
Observed Affluent Middle Deprived
BMI < 25.46 kg/m2 0.0185 0.0300 0.0484
BMI >25.46 kg/m2 0.0161 0.0242 0.0281
Expected Affluent Middle Deprived
BMI < 25.46 kg/m2 0.0299 0.0415 0.0449
BMI >25.46 kg/m2 0.0298 0.0349 0.033
16. For hospitalisation for injury or poisoning the tabulations of the observed and expected 
proportions of deaths/subjects for the BMP smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
BMI <25.46 kg/m2 0.0236 0.0258 0.0416
BMI >25.46 kg/m2 0.0238 0.0204 0.0277
252
Expected Never smoked Ex-smoker Current smoker
BMI <25.46 kg/m2 0.0390 0.0388 0.0386
BMI >25.46 kg/m2 0.0348 0.0370 0.0382
17. For hospitalisation for attempted suicide the tabulations of the observed and expected 
proportions of deaths/subjects for the DEPCAT*smoking interaction were as follows:
Observed Never smoked Ex-smoker Current smoker
Affluent 0.0015 0.0009 0.0018
Middle 0.0003 0 . 0 0 1 1 0.0036
Deprived 0.0017 0.0038 0.0053
Expected Never smoked Ex-smoker Current smoker
Affluent 0 . 0 0 1 0 0.0013 0.0028
Middle 0.0017 0.0023 0.0047
Deprived 0.0026 0.0036 0.0074
H: Logistic model checking
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While model checking was carried out for each model fitted, only one example is given 
here. The results for each model were similar.
Plot of residuals against fitted values
These plots of residuals against fitted values were constructed to investigate model fit. 
Large residuals indicate observations which are poorly accounted for by the model. Raw 
residuals (the difference between the observed and predicted values) were used here, 
although the chi residuals (the square root of the contribution for the observation to the 
Pearson chi-square) and deviance residuals (the square root of the deviance contribution 
for the observation, with sign equal to the sign of the residual) could also have been used 
(SAS Institute Inc., 1993).
This residual plot relates to the final model for all-cause mortality in middle-aged men at 
screening visit 1, in which interaction terms were included. It shows that while there may 
be one outlying observation, most points are reasonably accounted for by the fitted model.
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Dispersion parameters
X w i ( y i - m f  2
The Pearsons chi-square statistic, % 2  = —------- — -------- , and its scaled version, —
4>
(distributed as %2 (n-p) under the null hypothesis), where is the dispersion parameter, can 
be used as an approximate guide to the goodness of fit of a given model (SAS Institute 
Inc., 1993). The chi-square statistic and it’s degrees of freedom can be used to give an
v 2
estimate of the dispersion parameter ({) = —— . For a good fitting model, the dispersion
n -p
parameter should be close to one. The data may be overdispersed if the dispersion estimate 
is greater than one or underdispersed if the dispersion estimate is less than one.
For each of the models fitted, the dispersion parameter was close to one, indicating no 
problems with model fit. In the example illustrated above for all-cause mortality in 
middle-aged men at screening visit 1, %2 =2201.5 with 2245 degrees of freedom, leading to
<j) =0.981, which is clearly close to one.
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I: Postcode districts making up the screening area
The following postcode districts have been used to define the area in which screening was 
carried out for WOSCOPS. They are divided into five postcode areas.
1. North Glasgow
G l, G2, G3, G4, Gi l ,  G12, G13, G14, G15, G20, G21, G22, G23, G31, G32, G33, G34, 
G60, G61, G62, G63, G64, G65, G6 6 , G67, G6 8 , G69, G81, G82, G83, G84.
2. South Glasgow
G5, G40, G41, G42, G43, G44, G45, G46, G51, G52, G53, G71, G72, G73, G76, G77, 
G78.
3. East Kilbride and Lanarkshire
G74, G75, ML1, ML2, ML3, ML4, ML5, ML6 , ML7, ML8 , ML9, ML10, ML11, ML12.
4. Renfrew, Paisley and Greenock
PA1, PA2, PA3, PA4, PA5, PA6 , PA7, PA8 , PA9, PA10, PA11, PA12, PA13, PA14, 
PA 15, PA 16, PA 17, PA18, PA19.
5.Dumfries and Galloway
DG1, DG2, DG5, DG6 , DG7, DG8 , DG9, DG10, DG11, DG12.
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J: Parameter estimates from stepwise models
Parameter estimates are given here for the contrasts in the final models. The coefficient divided 
by the standard error (SE) of the coefficient gives an approximate z-statistic, and the 
exponential of the coefficient gives the estimated odds ratio for each contrast.
1. The final model for all-cause mortality in males age 45-64.
TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 /45-54) 1.38 0.12 12.0 3.99
smok(Ex/Never) 0.13 0.20 0.65 1.14
(current/never) 1.08 0.17 6.43 2.93
depcat(middle/affluent) -0.00 0.12 -0.01 1.0
(deprived/affluent) 0.30 0.14 2.19 1.35
alcohol(l-20  / 0) -0.31 0.04 -7.30 0.74
(2 1 -3 0 /0 ) -0.42 0.07 -6.02 0.66
(3 1 -4 0 /0 ) -0.28 0.10 -2.88 0.76
(4 1 -5 0 /0 ) -0.20 0.12 -1.66 0.82
(5 1 -6 0 /0 ) 0.06 0.14 0.44 1.06
(>60 /  0) 0.05 0.12 0.42 1.05
cholesterol(q2/q 1) -0.29 0.06 -5.16 0.75
(q3/q l) -0.22 0.06 -3.95 0.80
(q4/q l) -0.27 0.06 -4.83 0.76
(q5/q i) -0.04 0.05 -0.75 0.96
bmi(high/low) 0.09 0.09 1.0 1.10
dbp(high/low) 0.25 0.07 3.60 1.29
middle(ex/never) /  
affluent(ex/never smoked)
0.64 0.18 3.58 1.90
middle(current/never) / 
affluent(current/never smoked)
0.24 0.15 1.56 1.27
deprived(ex/never) /  
affluent(ex/never smoked)
0.65 0.19 3.39 1.92
deprived(current/never) /  
affluent(current/never smoked)
0.17 0.16 1.06 1.19
exsmoker(high/low BMI) /  
never smoked(high/low BMI)
-0.34 0.11 -2.95 0.71
current smoker(high/low BMI) / 
never smokedhigh/low BMI)
-0.33 0.10 -3.15 0.72
age55-64(high/low DBP) /  
age45-54(high/low DBP)
-0.18 0.08 -2.25 0.83
age55-64(ex/never) /  
age45-54(ex/never smoked)
-0.00 0.14 -0.01 1.00
age45-54(current/never) /  
age55-65(current/never smoked)
-0.27 0.12 -2.33 0.76
CONSTANT -4.36 0.15 -28.8 0.01
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2. The final model for CHD mortality in males age 45-64.
Main effects contrasts:
TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 /  45-54) 1.42 0.18 8.10 4.13
smok(Ex/Never) 0.16 0.36 0.44 1.17
(current/never) 0.78 0.30 2.58 2.18
depcat(middle/affluent) 0.04 0.20 0.20 1.04
(deprived/affluent) 0.33 0.22 1.51 1.39
alcohol(l-20 /  0) -0.36 0.15 -2.35 0.70
(2 1 -3 0 /0 ) -0.29 0.30 -0.96 0.75
(3 1 -4 0 /0 ) -0.46 0.52 -0.90 0.63
(4 1 -5 0 /0 ) -1.25 1.01 -1.24 0.29
(5 1 -6 0 /0 ) -0.03 0.72 -0.04 0.97
(>60 /  0) -0.81 1.01 -0.80 0.44
cholesterol(q2/q 1) 0.03 0.10 0.34 1.03
(q3/q l) 0.20 0.10 2.09 1.22
(q4/q l) 0.23 0.09 2.42 1.26
(q5/ql) 0.60 0.09 6.84 1.82
dbp(high/low) 0.06 0.14 0.45 1.07
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Interaction contrasts:
TERM COEFFICIENT SE COEF/SE ODDS RATIO
affluent (ex/never) / 
middle(ex/never smoked)
0.69 0.29 2.36 1.99
affluent(current/never) / 
middle(current/never smoked)
0.24 0.24 0.99 1.27
affluent(ex/never) / 
deprived(ex/never smoked)
0.83 0.31 2.65 2.29
affluent(current/never) / 
deprived(current/never smoked)
0.15 0.26 0.56 1.16
never smoked(high/low DBP) / 
exsmoker(high/low DBP)
-0.05 0.18 -0.30 0.95
never smoked(high/low DBP) / 
current smoker(high/low DBP)
0.28 0.16 1.72 1.32
exsmoker(l-2010)/ 
never smoker(l-20 / 0)
-0.19 0.19 -0.99 0.83
exsmoker(21-30 / 0) / 
never smoker(21-30 / 0)
0.16 0.18 0.88 1.17
exsmoker(31-40 / 0) / 
never smoker(31-40 / 0)
-0.33 0.37 -0.89 0.72
exsmoker(41-50 / 0) / 
never smoker(41-50 / 0)
-0.28 0.34 -0.81 0.76
exsmoker(51-60 / 0) / 
never smoker(51-60 / 0)
-1.54 0.78 -1.97 0.21
exsmoker(>60 / 0) / 
never smoker(>60 / 0)
0.36 0.55 0.66 1.44
current smoker(l-20 / 0) / 
never smoker(l-20 / 0)
-0.03 1.17 -0.03 0.97
current smoker(21-30 /0) / 
never smoker(21-30 / 0)
1.16 1.04 1.12 3.18
current smoker(31 -40 / 0) / 
never smoker(31-40 / 0)
-0.47 0.89 -0.53 0.62
current smoker(41-50 / 0) / 
never smoker(41-50 / 0)
0.06 0.78 0.07 1.01
current smoker(51-60 / 0) / 
never smoker(51-60 / 0)
0.08 1.14 0.07 1.09
current smoker(>60 / 0) / 
never smoker(>60 / 0)
0.71 1.04 0.68 2.03
age45-54(ex/never) / 
age55-64(ex/never smoked)
-0.18 0.22 -0.79 0.84
age45-54(current/never) / 
age55-65(current/never smoked)
-0.54 0.19 -2.80 0.58
CONSTANT -5.61 0.26 -21.5 0.00
3. Cancer mortality in males age 45-64.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 /  45-54) 1.19 0.07 17.4 3.30
smoking(ex/never smoked) 0.54 0.10 5.51 1.71
(current/never smoked) 0.96 0.09 10.9 2.61
bmi(high/low) -0.39 0.06 -6.31 0.68
cholesterol(q2/q 1) -0.38 0.09 -4.30 0.69
(q3/q i) -0.31 0.09 -3.56 0.74
(q4/q l) -0.48 0.09 -5.31 0.62
(q5/q l) -0.43 0.09 -4.78 0.65
depcat(middle/affluent) 0.20 0.10 1.96 1.22
(deprived/affluent) 0.37 0.10 3.57 1.45
CONSTANT -5.26 0.13 -39.3 0.01
4. Trauma mortality in males age 45-64.
TERM COEFFICIENT SE COEF/SE ODDS RATIO
a g e (5 5 -6 4 /45-54) 0.49 0.18 2.66 1.64
alcohol(l-20  /  0) -0.22 0.21 -1.01 0.80
(2 1 -3 0 /0 ) -0.58 0.40 -1.46 0.56
(3 1 -4 0 /0 ) 0.05 0.45 0.12 1.06
(4 1 -5 0 /0 ) -0.41 0.73 -0.57 0.66
(5 1 -6 0 /0 ) 1.23 0.45 2.74 3.41
(>60 / 0) 0.26 0.61 0.43 1.30
CONSTANT -6.50 0.22 -29.9 0.00
5. All-cause hospitalisation in males age 45-54.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64/45-54) 0.48 0.05 10.0 1.62
smoking(ex/never) 0.21 0.03 6.61 1.24
(current/never) 0.35 0.03 12.6 1.42
alcohol(l-20 / 0) -0.24 0.02 -12.4 0.79
(21-30/0) -0.28 0.03 -9.40 0.76
(31-40/0) -0.24 0.04 -5.66 0.79
(41-50/0) -0.34 0.06 -6.01 0.71
(51-60/0) -0.11 0.07 -1.54 0.90
(>60/0) -0.05 0.06 -0.79 0.95
depcat(middle/affluent) 0.14 0.03 4.30 1.16
(deprived/affluent) 0.36 0.04 9.61 1.43
cholesterol(q2/ql) -0.10 0.02 -3.98 0.91
(q3/qi) -0.08 0.20 -3.23 0.92
(q4/ql) -0.07 0.02 -2.83 0.93
(q5/ql) 0.02 0.02 1.01 1.03
age55-64(middle/affluent) / 0.04 0.05 0.92 1.04
age45-54(middl e/affluent)
age55-64(deprived/affluent) / -0.09 0.05 -1.66 0.92
age45-54(deprived/affluent)
age55-64(ex/never smoked)/ 0.04 0.04 1.01 1.04
age45-54(ex/never smoker)
age55-64(current/never smoked) / -0.06 0.04 -1.48 0.94
age45-54(current/never smoked)
CONSTANT -0.96 0.04 -24.1 0.38
6. CHD hospitalisation in males age 45-64.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
cholesterol(q2/q 1) 0.21 0.11 1.97 1.23
(q3/q l) 0.62 0.10 6.36 1.87
(q4/q l) 0.69 0.10 7.15 2.00
(q5/q l) 1.03 0.09 11.1 2.79
a lcohol(l-20  /  0) -0.33 0.04 -8.63 0.72
(2 1 -3 0 /0 ) -0.62 0.07 -9.30 0.54
(3 1 -4 0 /0 ) -0.49 0.09 -5.31 0.61
(4 1 -5 0 /0 ) -0.75 0.14 -5.50 0.47
(5 1 -6 0 /0 ) -0.62 0.17 -3.75 0.54
(>60 / 0) -0.71 0.15 -4.67 0.49
a g e (5 5 -6 4 /45-54) 1.27 0.16 8.04 3.56
smoking(ex/never) 0.67 0.08 7.81 1.95
(current/never) 0.92 0.08 12.1 2.52
bmi(high/low) 0.27 0.03 7.87 1.30
depcat(middle/affluent) 0.40 0.09 4.39 1.49
(deprived/affluent) 0.56 0.10 5.83 1.76
age55-64(ex/never smoked) /  
age45-54(ex/never smoked)
-0.25 0.10 -2.38 0.78
age55-64(current/never smoked)/ 
age45-54(current/never smoked)
-0.47 0.09 -4.96 0.63
dbp(high/low) 0.21 0.05 3.93 1.24
age55-64(high/low DBP)/ 
age45-54(high/low DBP)
-0.18 0.07 -2.66 0.83
age55-64(q2/q l)/
age45-54(q2/ql)
0.12 0.13 0.94 1.13
age55-64(q3/q l)/
age45-54(q3/q l)
-0.14 0.12 -1.13 0.87
age55-64(q4/q l)/
age45-54(q4/ql)
-0.12 0.12 -1.01 0.89
age55-64(q5/q l)/
age45-54(q5/q l)
-0.23 0.12 -1.97 0.80
age55-64(middle/affluent)/
age45-54(middle/affluent))
-0.24 0.1 -2.14 0.78
age55-64(deprived/affluent)/
age45-54(deprived/affluent)
-0.29 0.12 -2.40 0.75
CONSTANT -4.72 0.13 -35.9 0.00
7. Cancer hospitalisation in males age 45-64.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 / 45-54) 1.14 0.05 24.7 3.14
smoking(ex/never) 0.38 0.06 6.22 1.46
(current/never) 0.65 0.06 11.7 1.91
bmi(high/low)
-0.19 0.04 -4.65 0.83
cholesterol(q2/q 1) -0.24 0.06 -3.97 0.79
(q3/q l) -0.26 0.06 -4.25 0.77
(q4/q l) -0.32 0.06 -5.04 0.73
(q5/q l) -0.25 0.06 -4.01 0.78
alcohol(l-20  /  0) -0.13 0.05 -2.58 0.88
(2 1 -3 0 /0 ) -0.15 0.08 -1.96 0.86
(3 1 -4 0 /0 ) -0.04 0.11 -0.35 0.96
(4 1 -5 0 /0 ) -0.28 0.15 -1.86 0.75
(5 1 -6 0 /0 ) 0.08 0.17 0.49 1.09
(>60 /  0) 0.15 0.15 1.03 1.16
depcat(middle/affluent) -0.04 0.06 -0.73 0.96
(deprived/affluent) 0.12 0.07 1.82 1.13
CONSTANT -4.06 0.09 -44.5 0.02
8. Trauma hospitalisation in males age 45-64.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
depcat(middle/affluent) 0.43 0.11 3.91 1.53
(deprived/affluent) 0.82 0.11 7.33 2.26
alcohol(l-20  /  0) 0.26 0.06 0.44 1.03
(2 1 -3 0 /0 ) 0.23 0.08 2.79 1.26
(3 1 -4 0 /0 ) 0.35 0.11 3.27 1.42
(4 1 -5 0 /0 ) 0.42 0.14 3.08 1.52
(5 1 -6 0 /0 ) 0.72 0.15 4.76 2.05
(>60 /  0) 0.97 0.12 8.07 2.63
smoking(ex/never) 0.02 0.10 0.24 1.02
(current/never) 0.40 0.08 5.14 1.50
bmi(high/low) 0.06 0.16 0.38 1.06
cholesterol(q2/q 1) -0.20 0.07 -2.95 0.82
(q3/q l) -0.22 0.07 -3.23 0.80
(q4/q l) -0.24 0.07 -3.51 0.78
(qS/ql) -0.22 0.07 -3.14 0.81
high BMI(middle/affluent)/ -0.02 0.16 -0.14 0.98
low BMI(middle/affluent)
high BMI(deprived/affluent)/ -0.32 0.17 -1.88 0.73
low BMI(deprived/affluent)
exsmoker(high/low BMI)/ -0.20 0.13 -1.50 0.82
never smoker(high/low BMI)
current smoker(high/low BMI)/ -0.30 0.11 -2.66 0.74
never smoker(high/low BMI)
CONSTANT -4.06 0.13 -32.1 0.02
9. Hosptalisation for attempted suicide in males age 45-64.
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TERM COEFFICIENT SE COEF/SE ODDS RATIO
age(55-64 / 45-54) -0.33 0.15 -2.19 0.72
smoking(ex/never) -1.47 1.04 -1.40 0.23
(current/never) 0.04 0.58 0.07 1.04
bmi (high/low) -0.44 0.15 -2.86 0.64
alcohol(l-20 / 0) -0.64 0.18 -3.48 0.52
(21-30/0) 0.18 0.23 0.78 1.19
(31-40/0) 0.07 0.32 0.23 1.08
(41-50/0) -0.23 0.47 -0.49 0.80
(51-60/0) -0.26 0.60 -0.43 0.78
(>60/0) 0.83 0.32 2.62 2.30
depcat(middle/affluent) -0.53 0.52 -1.03 0.59
(deprived/affluent) 0.15 0.54 0.28 1.16
exsmoker(middle/affluent)/ 
never smoker(middle/affluent)
1.79 1.12 1.59 5.97
exsmoker(depri ved/affluent)/ 
never smoker(deprived/affluent)
1.36 0.67 2.02 3.88
current smoker(middle/affluent)/ 
never smoker(middle/affluent)
2.21 1.13 1.96 9.13
current smoker(deprived/affluent)/ 
never smoker(depri ved/affluent)
0.93 0.69 1.34 2.53
CONSTANT -5.85 0.43 -13.5 0.00
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